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Clozapine is the only antipsychotic that has been repeatedly shown to be effective in 
treatment-resistant schizophrenia.  Despite this, it is underused.  This thesis investigates 
prescribing patterns of clozapine in a large NHS Trust in South East London.  Retrospective 
clinical note review found a mean theoretical delay to clozapine prescription of 3.93 
years.  The length of delay to clozapine use was not affected by age, ethnicity or 
diagnosis.  In a survey of clinical staff, the majority were familiar with clozapine prescribing 
guidelines and how to prescribe the drug, and felt that barriers to prescribing were 
predominantly patient concerns about tolerability or compliance with blood testing.  Almost 
half of patients surveyed had never heard of clozapine.  A narrow majority (57%) of patients 
said that blood testing would not stop them taking clozapine, with less than half being 
concerned about side effects.  Being admitted to hospital for clozapine initiation was a barrier 
to treatment for patients.  I found that taking clozapine reduces the number of days spent as 
an inpatient per year.  The length of delay to starting clozapine had no effect on the eventual 
clinical benefit, as measured by inpatient admissions, although younger patients did derive 
more benefit.  The majority of patients in my cohort remained compliant with clozapine for 
the duration of the study.  Those that discontinued were more likely to be male, but no other 
factors affected the likelihood of stopping clozapine.  Patients that discontinued clozapine 
gained less benefit in clinical outcomes that those that continued taking it.  My research 
shows that clozapine should be introduced as early as possible in the treatment 
pathway.  Not only do younger people benefit more in terms of reductions in time spent in 
psychiatric institutions, but for all patients clinical and economic savings continue to accrue 
over time.  Strategies that may enable earlier introduction of clozapine should focus on 
reducing blood testing requirements or making blood testing a less unattractive prospective 
to patients.  Making patients more familiar with clozapine earlier in their illness may help to 
reduce the fear of side effects, which if they occur must be treated swiftly and 
robustly.  Dedicated and accessible day hospital beds for clozapine initiation may be helpful 
for some.  Every effort should be made to allow patients to remain compliant with clozapine 
– male patients may especially require support.  
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First described by Kraepelin in 1893 and named by Bleuler in 1908 (1), schizophrenia is a 
severe and enduring psychotic disorder.  It is characterised by symptoms that may include 
hallucinations, delusions, disorganised speech and behaviour, and a flattened affect (2).  The 
World Health Organisation International Statistical Classification of Diseases and Related 
Health Problems (ICD-10) (3) describes the main psychopathological phenomena as thought 
echo, thought insertion or withdrawal, thought broadcasting, delusional perceptions and 
delusions of control, passivity phenomena, auditory hallucinations, thought disorders and 
negative symptoms.  Affecting about 5 in 1000 people in the UK (4) and with a worldwide 
incidence of 0.1 – 0.4 per 1000 population (5), it impacts significantly on social and 
occupational functioning.     
Schizophrenia is a costly illness.  Whilst the disease itself is not fatal, suffering from it 
significantly increases mortality (6).  Life expectancy may be reduced by almost 15 years (7), 
not only due to increased risk of suicide or violent death, but also because of the association 
between serious mental illness and cardiovascular disease, cancer and diabetes.  
Additionally damaging to quality of life is the associated social dysfunction, which can occur 
even in the absence of psychotic symptoms.  Self-care, occupational functioning, and 
functioning in personal and community settings are affected (8).  The social stigma attached 
to mental illness is still, despite the efforts of government and charity campaigners, a 
significant problem (9).   
Poorly or incompletely treated schizophrenia imposes costs not just on the individual but also 
on wider society.  Increased bed stay and more frequent and lengthy contact with medical, 
social, housing and criminal justice services all represent direct costs to the taxpayer.  There 
are also indirect costs which arise when a patient, or carer, is rendered unable or less able 
to contribute to the workforce.  The sum of these excess costs has been estimated at almost 
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£12 billion per year in the UK (10), and over $62 billion per annum in the USA (11, 12).  
Clearly, there is much to be gained if schizophrenia can be treated faster and more 
effectively. 
 Pharmacological treatment of schizophrenia 
Kraepelin described the deteriorating course of his patient’s ‘dementia praecox’ as being 
progressive and severe (13, 14), with active symptoms requiring continuous hospitalisation.  
This is in contrast to other observations of a more relapsing and remitting disease state, 
where periods of illness may be interspersed with at least partial remission.  Modern 
definitions describe the course of schizophrenia as either continuous, episodic with 
progressive or stable deficits, or one or more episodes of complete or incomplete remission 
(3).  Further, the diagnosis itself may be defined more precisely as a particular ‘type’ of 
schizophrenia; paranoid, hebephrenic, catatonic, undifferentiated, residual, simple or 
otherwise unspecified (3).  Regardless of the label, the mainstay of pharmacological 
treatment is a group of drugs termed ‘antipsychotics’. 
The first antipsychotic was discovered serendipitously in 1951, when the antihistamine 
chlorpromazine was found to have beneficial effects on psychotic symptoms when tested in 
patients with psychosis (15).  The discovery of chlorpromazine led to work that found the key 
mechanism of action in relief of psychosis to be blockade of dopamine receptors in the brain.  
As new antipsychotic agents were synthesised, it was recognised that they all appeared not 
only to improve psychotic symptoms, but also to cause ‘neurolepsis’ – a slowing of motor 
response, quiescence and behavioural indifference (16).  Despite the frequently severe 
movement disorders, the arrival of antipsychotic medications on psychiatric hospital wards 
was transformative.  Other drugs, all with a similar pharmacology to chlorpromazine (that is, 
predominantly dopamine receptor blockade) were produced.  This group are commonly 
referred to as ‘conventional’, ‘typical’ or ‘first-generation’ antipsychotics, of which the British 
National Formulary (BNF) lists 16 currently available in the UK (17). 
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In the mid 20th century, psychopharmacologists believed that the antipsychotic benefits and 
movement disorder side effects of neuroleptic drugs went hand in hand.  The prevailing 
opinion was that without the often physically and socially disabling emergence of movement 
disorders such as tardive dyskinesias and extra-pyramidal side effects (EPSEs) an 
antipsychotic would lack therapeutic effect.  The synthesis of clozapine in 1959 marked a 
turning point.  Clozapine was the first antipsychotic to demonstrate therapeutic effect in the 
treatment of psychosis, but with no accompanying EPSEs.  Ironically, this fact meant it was 
largely dismissed as a viable treatment option as clinicians considered the possibility of a 
drug that could treat schizophrenia but not cause movement disorders literally unbelievable 
(18).  As a result, clozapine was not marketed for schizophrenia treatment until 1972.  
Clinicians found clozapine to be effective and well tolerated, and its use gathered pace until 
1975, when 9 cases of fatal blood dyscrasias secondary to clozapine were reported in 
Finland (19).  Following this, clozapine was withdrawn from the market.    
 Treatment-resistant schizophrenia 
In the absence of clozapine, it was apparent that for a significant proportion of patients the 
available ‘typical’ antipsychotics were either ineffective, or intolerable.  These ‘treatment-
resistant’ patients were defined by Kane in 1988 and 1989 (20, 21) as: patients (with a 
diagnosis of schizophrenia) who had had at least three periods of treatment in the preceding 
five years with neuroleptic agents (from at least two different chemical classes) at dosages 
equivalent to or greater than 1000mg/day of chlorpromazine for a period of six weeks, each 
without symptomatic relief, and no period of good functioning within the preceding five years 
(20).   
Prior to its removal from the market clozapine had started to show promise in clinical settings 
for the treatment of these patients.  Seven trials form the foundation on which evidence for 
the efficacy and tolerability of clozapine in treatment-resistant schizophrenia has been laid.  
In 1987, Claghorn and colleagues (22) compared clozapine therapy to chlorpromazine in the 
treatment of patients who were suffering with tardive dyskinesias or EPSEs induced by 
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antipsychotic medications.   Clozapine was demonstrably superior to chlorpromazine not only 
in amelioration of EPSEs, but also in magnitude of therapeutic efficacy, and the speed at 
which this was achieved.   
This result was repeated in 1988 (20) and 1989 (21) by Kane et al.  For patients with 
schizophrenia that was unresponsive to at least 3 other antipsychotic trials (and to pre-trial 
testing with a mean of 61mg/day haloperidol), clozapine provided symptom relief after 6 
weeks in 30% of cases, compared with 5% of patients who were given chlorpromazine (20).   
Honigfeld et al. (23) produced a strikingly similar result in comparison with haloperidol – 
therapeutic benefit was demonstrated in 31% of the clozapine group, compared with 10% of 
the haloperidol-receiving patients. 
In 1986 Kuha and colleagues (24) published the first review to demonstrate clozapine’s long 
term efficacy.  In a retrospective review over 7 years, patients (all of whom had previously 
failed to adequately respond to other antipsychotics, and had a mean duration of illness of 
15 years) experienced symptom improvement in 33% of cases.  The longer studies 
conducted by Povlsen et al. (25) and Lindstrom et al. (26), both retrospective studies over 12 
year periods, showed symptom improvement on clozapine in 51% and 40% of patients 
respectively. 
This compelling evidence that clozapine was uniquely effective in treatment-resistant 
schizophrenia, did not cause movement disorders, and continued to provide symptom relief 
for many years fuelled enthusiasm for its reinstitution in the psychiatrist’s formulary.  Close 
analysis of the individual cases of agranulocytosis and neutropaenia reported in Finland in 
1975 suggested that in most cases, the reaction was reversible (on stopping clozapine) and, 
if detected early and before infection had taken hold, survivable (27).  This recognition of 
clozapine-induced blood dyscrasias being detectable and the risk modifiable, the lack of any 
comparable successor to clozapine being identified in the intervening years, and, crucially, 
the work of Kane and colleagues in the late 1980s, led to its re-introduction to the market in 
1990. 
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After clozapine was retrieved from the pharmaceutical sin bin, it was hoped that as well as 
improving the symptom control of many patients for whom the conventional antipsychotics 
had failed, it would also lead to the discovery of other antipsychotics that would be effective 
for the treatment of this neglected group of patients (28).  Clozapine has been repeatedly 
shown to be superior to typical antipsychotics in treatment-resistant schizophrenia (20-26, 
29, 30).  Following the success of clozapine, other antipsychotics were synthesised (often 
referred to as ‘atypical’ or ‘second generation’ drugs) that aimed to mimic clozapine’s effect 
on psychotic symptoms, and its lack of EPSEs.  Risperidone was the first of these newer 
antipsychotics to the market in 1994, followed by olanzapine in 1996 and quetiapine in 1997 
(31).  As these atypical antipsychotics were introduced, their potential as haematologically-
safer alternatives to clozapine in treatment-resistant schizophrenia was proposed.  
Randomised trials of risperidone (32, 33) found it to be effective in 33% of treatment-resistant 
patients.  However, switching the risperidone non-responsive patients to clozapine provided 
symptom relief for a further 56%.  Short trials found risperidone to be non-inferior but faster 
acting (34, 35), but longer trials demonstrated superiority for clozapine (36, 37).  Non-
inferiority studies of olanzapine in treatment-resistant schizophrenia found it effective (38), 
but others found clozapine remained superior (39).  Studies where clozapine responders 
were switched to olanzapine were inconclusive – some showing response to olanzapine in 
90% of cases (40), others decompensation for 58% of patients (41).  It is worth noting that 
several of these trials were sponsored by the companies marketing the new atypical 
medication, used low comparator clozapine doses, or included treatment ‘intolerant’ patients, 
as well as truly ‘treatment-resistant’ patients (42).  These factors, as well as the now near-
impossibility of conducting a truly blinded trial of clozapine as its distinctive side-effect pattern 
is well known, means that interpretation of the results of any clozapine trial after Kane’s 
rigorous 1988 study should proceed cautiously.  This is illustrated by the finding of Samara 
and colleagues in their network meta-analysis that clozapine is no more effective than any 
other antipsychotic in treatment-resistant schizophrenia (43).  Rather than clinical 
observations, and the data presented by Kane and others being untrue, it is more likely that 
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this result reflects the fact that the biases inherent to many clozapine comparator studies are 
insufficiently controlled (44). 
 Schizophrenia treatment guidelines 
In the face of what was considered overwhelming evidence for clozapine being the gold 
standard treatment for neuroleptic-resistant schizophrenia, guidelines in the USA (45-47), 
UK (48, 49), and internationally (50, 51) were developed.  All recommend the use of clozapine 
after two failed trials of other antipsychotics. 
Despite published evidence, and national and international guidelines advising the use of 
clozapine in treatment-resistant psychosis, prescription rates are almost universally low.  It 
is generally thought that around one third of patients suffering with schizophrenia will have a 
treatment-resistant illness (52).  Given that clozapine is the only recommended treatment for 
these patients, prescriptions of clozapine within a population with schizophrenia should be 
around 30% of all antipsychotics.  Several large reviews of antipsychotic use in outpatients 
in the USA have found clozapine to represent just 2% of the total antipsychotic prescriptions 
(53), with 5.5% of patients with treatment-resistant schizophrenia receiving clozapine (54).  
Although it is true that clozapine may not be appropriate for all patients, taking into account 
medical complications precluding treatment, this still presumably leaves more than 90% of 
patients taking non-clozapine therapies for treatment-resistant schizophrenia that are not 
evidence-based.  Juarez-Reyes and colleagues looked at this in more detail (55), assessing 
293 patients in the USA for eligibility for clozapine.  They found that 42.9% were eligible, but 
were not prescribed clozapine. 
Similarly low clozapine use has been reported in Israel (2% of all antipsychotic prescriptions) 
(56), Quebec (6.7% of all antipsychotic prescriptions) (57), South Africa (10% of all 
antipsychotic prescriptions) (58) Canada (16% of all antipsychotic prescriptions) (59) and 
Australia (8.4% of prescriptions in treatment-resistant schizophrenia) (60).  In Europe, rates 
vary from very low in Italy (1.3 – 1.5% of all antipsychotic prescriptions) (61) and France 
(1.2% of all antipsychotic prescriptions) (62), 10.5% in Denmark (63), 17.2% in inpatients in 
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Germany (64) to 36% in Sweden (65).  Prevalence of clozapine appears to be higher in New 
Zealand (32.8% of all antipsychotic prescriptions) (66), China (40.3%) (67) and Taiwan 
(26.9%) (67).  Data suggest that in most countries, clozapine use has increased in recent 
years (52), but clearly substantial global variation in prescribing prevalence remains. 
Not only is the prevalence of clozapine generally lower than would be expected if guidelines 
for prescribing were being followed, but for those who are given clozapine the journey to this 
point seems to have been, for the most part, a long one.  Using the commonly accepted Kane 
criteria (20) as the diagnostic standard for treatment-resistance, the minimum amount of time 
taken to reach a prescription of clozapine, from first antipsychotic prescription, is probably 12 
weeks.  This may be shorter if one of the two drugs tried is not tolerated for a full 6 week trial, 
or longer if the time taken to reach therapeutic dose is taken into consideration.  This also 
assumes that patients are clearly ‘treatment-resistant’ from the outset of illness – i.e. each of 
the two antipsychotics trialled fail within the first 6 weeks.  An alternative pathway is one of 
‘developing’ treatment-resistance – that is, one or both of the pre-clozapine antipsychotics 
work for a while, but efficacy ‘wears off’ as treatment-resistance sets in during the treatment 
course.  Either way, it is clear that using sequential non-clozapine antipsychotics to treat 
continuing psychotic symptoms after two antipsychotics have failed to do so is almost certain 
to be ineffective.  Kinon et al. (68, 69) found that a third antipsychotic trial conferred less than 
a 7% chance of response in patients who had already failed to respond to two prior 
antipsychotics.  Similarly, Agid et al.’s trial of 244 patients in their first episode of 
schizophrenia found that 75% responded to the first flexibly dosed treatment of risperidone 
or olanzapine.  The remaining non-responding 25% were switched to the antipsychotic they 
didn’t try in the first phase, and of these just 17% responded.  Following this, non-responders 
to the second antipsychotic trial were switched to clozapine, with a 75% success rate (70). 
Where the time to first prescription of clozapine has been reported, the data vary widely.  In 
their retrospective chart review of 467 outpatients in Canada, Alessi-Severini and colleagues 
reported the time from first presentation to psychiatric services to first receiving clozapine 
was an average of 8.9 years for men, and 7.7 years for women (59).  In the UK, Taylor et al. 
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found a delay to receiving clozapine (that is, time from diagnosis of treatment-resistant 
schizophrenia to clozapine prescription) of 5 years, although the range was wide (0 – 11.1 
years) (71).  This finding was echoed by Najim et al. ten years later in their study of 42 
outpatients taking clozapine in England, who on average took 5 years to reach clozapine 
after a diagnosis of treatment-resistance, with a range of 0.2 – 16.1 years (72).  In New 
Zealand, Wheeler and colleagues found the time from first presentation to psychiatric 
services until prescription of clozapine to be 5.3 years (6.5 years in a corresponding UK 
cohort) (73) - something of an improvement on similar data from just 3 years before this, 
which described an average of 9.7 years in services before receiving clozapine (66).  In the 
New Zealand group, 37% of patients had started clozapine within the first 5 years of contact 
with services.  In Denmark in 1996, this figure was just 10.4%, and actually reduced to 3.4% 
by 2003 (63). 
Pharmacological strategies employed in treatment-resistant schizophrenia instead of 
clozapine are frequently ineffective and harmful.  Antipsychotics may be prescribed in doses 
above those that have been licensed (‘high dose’ prescribing), or in combination with other 
antipsychotics (‘polypharmacy’).  Neither of these options is without risk.  The compounding 
of side effects such as sedation, weight gain or other metabolic effects, increased serum 
prolactin or akathisia is inevitable.  Despite these risks, and the availability of a treatment 
with proven efficacy in refractory schizophrenia, use of non-clozapine treatment strategies in 
treatment-resistant schizophrenia is widespread.  Although it is known to be ineffective (69), 
prescribing multiple successive non-clozapine antipsychotics rather than the evidence-based 
two prior to clozapine is common.  In Canada, 68% of patients eventually prescribed 
clozapine received 3 or more antipsychotics first (59).  In New Zealand, the average is also 
3 antipsychotics pre-clozapine (73), whilst in the UK the mean has been reported as 5.5, with 
a huge range of 1 – 13 (71).  Polypharmacy is also common, with 65% of patients in Taylor 
et al.’s 2003 study receiving multiple concurrent antipsychotics prior to clozapine (71).  In the 
same area of South East London, Thompson and colleagues found that 13.6% of patients in 
their study were taking multiple antipsychotics immediately prior to clozapine being 
prescribed (74). 
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 Explaining practice 
Several demographic descriptors are reported by many authors to be associated with a 
higher likelihood of being prescribed clozapine.  These include being male (54, 75, 76), young 
(53, 54, 63, 71, 72, 75, 76), white (53, 54, 75) and having a higher illness severity (53, 54, 
76).  Others, however, have found no effect of gender (63, 66, 67, 77), age (67, 77) or 
symptom acuity (77).  The reason for the demographic influences found by some groups is 
not immediately apparent.  It is probable that patients with non-white backgrounds are more 
likely to have congenitally lower levels of white blood cells, unrelated to clozapine use, and 
this may preclude, or at least complicate, starting clozapine.  It has been suggested that men 
have a more severe illness course, and that for younger patients prescribers are more keen 
to prevent long-term disability, both factors making clozapine prescribing perhaps more likely 
(54). 
Factors relating to the prescribing culture surrounding the clinician and patient also appear 
to affect clozapine prescribing patterns.  Prescribing of clozapine in treatment-resistant 
schizophrenia seems to remain something of a postcode lottery.  In 2000, Purcell and Lewis 
reviewed the prescribing practices of 12 UK NHS Trusts, and found a 34 fold variation in 
rates of clozapine prescribing between institutions (78).  A repeat study in 2003 (79) showed 
some improvement, but still a 16 fold variation remained.  More recently, Downs and Zinckler 
compared data from 45 NHS Trusts, finding a persistent 5 fold variation in prescribing (80).  
Variations in individual clinical practice, including the relative experience of psychiatrists in 
prescribing clozapine has also been suggested to influence prescription rates by other 
authors – Nielsen et al. (63) proposed that younger prescribers working in outpatient settings 
would be less likely to have the required experience and confidence in prescribing clozapine.  
Wide variations in prescribing within the same country or area (and therefore subject to the 
same clozapine guidelines and restrictions) but between institutions or individual prescribers 
would seem to support this view.  A review of clozapine prescribing frequency in the USA 
found that the proportion of clozapine prescribed by individuals, as a percentage of their total 
prescriptions, ranged from 0 – 89%, and that those who prescribed the highest volumes of 
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medications were more likely to prescribe clozapine, suggesting that a lack of experience 
may indeed hinder prescribing (81).   
Clinician concerns over what patients are likely to tolerate or comply with are often listed as 
barriers to clozapine prescribing.  Fears that patients will not comply with the compulsory 
blood testing probably contribute not only to the lower prescription rates in those with 
comorbid substance abuse disorders (53, 54), but in also patients without these 
complications (71, 82). 
Finally, it is undoubtedly the case that clozapine is a more costly drug to initiate than any 
other antipsychotic, given the blood monitoring requirements, increased intensity of physical 
monitoring, additional administrative time and multidisciplinary team activities.  Despite this 
‘front-loading’ of costs, clozapine has proven cost-effectiveness when balanced against the 
reduction in expensive re-admissions.  In a study conducted by Essock et al. (83), eligible 
patients were switched to clozapine from their previous antipsychotic.  Those that received 
clozapine had a 3% readmission rate, those that didn’t a 29% rate.  Many other groups have 
also demonstrated the relative cost-effectiveness of clozapine (84-90), even when clozapine 
was still within patent protection and therefore significantly more expensive than it is now.  
This message seems to have had an impact on the influence of cost as a barrier to 
prescribing, with few recent studies citing this is a likely issue, although in some countries 
this may still be relevant (private medical insurance requirements in the USA may make 
clozapine unavailable for some (52), and conversely, the minimal cost of clozapine compared 
to other atypical antipsychotics in China means that it is actually the most commonly 
prescribed medication for schizophrenia (91)). 
 Patient opinions 
Even the most effective, evidence-based medications are of no use if the patient does not 
take them.  There can be little doubt that taking clozapine is a particularly arduous process, 
with attendant pre- and on-therapy regular blood tests, intensive physical health monitoring 
during initiation, lengthy periods of dose escalation and titration, and an intimidating list of 
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acute and chronic side effects.  It is not surprising that health care professionals may expect 
patients to at least dislike the idea of clozapine for these reasons, and not unreasonable to 
fear non-compliance or outright refusal of treatment.   
However, despite the obvious inconveniences, patients who are prescribed clozapine are 
actually found to be adherent to treatment for longer than their counterparts taking non-
clozapine antipsychotics (92).  When asked directly for their opinions on clozapine, patients 
who are taking the drug are almost all very positive about their experiences.  In a large study 
of 1126 patients in Australia, of those taking clozapine just 5.3% thought the drug hadn’t been 
helpful (93).  Wolfson et al. asked 35 patients who had been taking clozapine for more than 
6 months directly about their experience, and found 82% to report benefitting overall from 
the treatment (94).  Where patients experienced side effects, they still preferred clozapine 
over their previous medications (which were typical antipsychotics – this study was done in 
1996), and the majority of patients didn’t mind the blood tests either at all, or only a little.  This 
nonchalance about the burden of blood testing was also found by Taylor et al. at few years 
later; 87% of clozapine patients in this survey felt that the advantages of clozapine 
outweighed the disadvantage of blood testing (95), with 86% of patients feeling better on 
clozapine than their previous treatment, and 89% wishing to remain on therapy.  This desire 
to keep taking clozapine was echoed in Waserman and co-worker’s interviews of patients 
prescribed clozapine (96), where improved mood, social and activity levels and a better 
quality of life meant patients were more satisfied with clozapine treatment than their previous 
medications, and wanted to continue taking it.  The willingness to continue with treatment 
seems to improve with time – in a study of 80 patients taking clozapine at discharge from 
inpatient services, Angermeyer et al. found 44% believed they would relapse if they stopped 
taking the medication when interviewed at discharge, but this increased to 55% six months 
later (97).  In a recent survey of Japanese patients taking clozapine, not only did 66% of 
those interviewed find clozapine to be effective or extremely effective for them, but 68% also 
felt it was a safe or extremely safe drug (98).   
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The obvious bias in all of these studies is of course the selection of patients already 
successfully established on clozapine treatment, for whom the drug is presumably effective 
(at least sufficiently to allow participation in research interviews or completion of 
questionnaires).  The views of patients who have experienced therapeutic failure or 
intolerable side effects with clozapine have not been studied.  Similarly uncharacterised in 
the literature are the opinions of patients who were offered clozapine but did not wish to take 
it, or those who might be eligible to take it, but have never been given the opportunity to do 
so. 
 Non-prescribing and non-compliance  
Despite being apparently well disposed to clozapine when taking it, it is true that not all 
patients remain adherent with clozapine therapy indefinitely.  It is also true that despite an 
apparent knowledge of the clinical guidelines and benefits of clozapine (discussed below), 
not all psychiatrists choose to prescribe it in a timely manner.  The consequence of a delay 
in clozapine prescription is not widely studied.  In a retrospective review of 402 patients in 
New Zealand, Harrison et al. found an average patient journey from first presentation to 
psychiatric services to clozapine prescription of 2.8 years - and the shorter this period was, 
the fewer subsequent hospitalisations patients experienced (99).  This finding was 
statistically non-significant however, and only included patients who had been taking 
clozapine for more than 3 years.  In their 2015 study of 162 Turkish patients taking clozapine, 
Ucok and colleagues also found a better response to clozapine if the prescribing delay was 
shorter (their patient cohort had an average 29 month delay between diagnosis of treatment-
resistance and clozapine prescription), the illness duration was shorter, and the patient was 
younger (100).  Most recently, Yoshimura’s group in Japan studied 90 patients who had been 
on clozapine for at least 3 months, and found prescription delay to be a predictor of response 
to clozapine (101).  They describe a ‘critical treatment window’ (the time from diagnosis of 
treatment-resistance to clozapine prescription) of 2.8 years, demonstrating a response rate 
of 82% if patients received clozapine within this window, but 31% if treatment fell outside it.  
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Once the decision to prescribe clozapine has been made, and the patient has agreed to 
accept treatment, it is unfortunately the case that not all patients are able to remain adherent 
with it for as long as their clinical team might wish.  Reports of discontinuation rates for 
clozapine vary, and meaningful comparisons are difficult because outcomes may depend on 
the study length, degree of support provided to patients, diversity of patient groups (including 
ethnicity, as this may affect likelihood of discontinuation due to neutropaenia), and definitions 
of ‘discontinuation’ (this is usually not clearly described, and where it is varies from 4 day 
treatment interruptions to ‘snapshot’ data collection at defined time points).  Despite these 
differences in reporting, most studies found clozapine discontinuation rates to be between 
20 and 50%, with the greater proportion of discontinuers doing so in within the first year (56, 
60, 77, 90, 102-114).  Higher rates of 57% discontinuation were found by Davis et al. in their 
15 year retrospective study of 320 patients on clozapine (this group had a strictly defined 
discontinuation definition of anything over 4 days without clozapine) (102), 55% by Atkinson 
et al. (106), 53% by Ciaparrelli et al. (107) and 51% by both Vella et al. (60) and Krivoy et al. 
(56).  Lower discontinuation rates were reported by Taylor et al. (18%) (113) and Rascati et 
al. (16%) (112).  Regardless of discontinuation rate, the majority of studies found patients 
who discontinued treatment were most likely to do so within the first year.  Studies that looked 
at this in more detail found the risk to be front loaded into this year – Davis, Pai, Hayhurst, 
Kelly, and Rascati and colleagues (90, 102, 108, 112, 115) all found discontinuation of 
clozapine to be most likely in the first 6 months.  Where reported, two main themes of non-
adherence (56, 102, 104, 106, 107, 112-115) and side-effects (102, 104, 105, 107, 109, 112, 
114, 116, 117) are given as the reasons for discontinuation.  Demographic factors that 
contribute to the likelihood of discontinuation have been found to include older age (56, 102-
104) and being African-Caribbean (77, 102, 103, 105, 108, 111, 118), although other authors 
have also failed to demonstrate these associations (111, 112).  It is important to note that 
patients are in fact more likely to remain compliant with clozapine than with other 
antipsychotics.  The landmark Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE) trials found 74% of patients discontinued non-clozapine antipsychotics within the 
first year (119), and in the large Schizophrenia Outpatient Health Outcome (SOHO) trials, 
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79.5% of patients allocated to clozapine were still taking it at 12 months, a higher 
concordance rate than for any other antipsychotic medication (120). 
Given the evidence for the efficacy of clozapine in most treatment-resistant patients, and the 
fact that antipsychotic medications are not curative, it would seem obvious that not continuing 
to comply with treatment would be harmful.  Indeed, Atkinson et al. showed that Global 
Assessment of Functioning (GAF) scores were lower after stopping clozapine (106), and 
Hayhurst and colleagues (90) found that clozapine discontinuers had more, and longer 
hospital admissions.  Interestingly, some groups report that non-improvement in symptoms 
was a reason for discontinuing clozapine (112, 114, 116), and this seems not only 
unfortunately predictable (clozapine is not effective in all patients) but also clinically 
challenging, since the ineffectiveness of any other medication is also predictable in this 
circumstance.  The scrabble for symptom control after stopping clozapine is reflected in 
Atkinson et al.’s finding that 74% of patients had two or more antipsychotics prescribed in 
the year after discontinuation, with 44% of patients receiving polypharmacy (106). 
 Improving practice 
Audit and feedback of adherence to guidelines go some way to improving practice 
(increasing clozapine prescribing from a 21% baseline rate to 35% following audit in one 
study (75)), but underuse of clozapine remains commonplace.  The UK’s National Institute 
for Health and Care Excellence (NICE) states that in 2002, just 21% of patients diagnosed 
with treatment-resistant schizophrenia were receiving clozapine (121).  By 2010, this figure 
had increased to 54% (122), leaving 46% of patients without the one treatment proven to 
work in their condition.  An audit by the Royal College of Psychiatrists in 2012 echoed this 
statistic, finding that 43% of treatment-resistant patients had not been offered clozapine 
(123), and that stark differences in prescribing practices between clinicians remained. 
Several authors have suggested that a lack of knowledge is the principal barrier to 
prescribing in line with evidence-based recommendations (124).  In 1994 Kissling presented 
a cohort of psychiatrists with clinical scenarios and asked them to make treatment 
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recommendations (125).  Vastly different answers were received, many of them outside 
prescribing guidelines of the time.  A lack of prescriber knowledge of recommendations was 
blamed.  Patel et al. (126) extended this theory to depot medication, showing that a poor 
knowledge of aspects of medication prescribing results in poor attitudes to the drug, and 
lower levels of prescribing. 
More recent surveys have shown that knowledge of guidelines seems to be improving, with 
88% of psychiatrists recognising that clozapine should be commenced after two failed trials 
of other antipsychotics (127).  Despite this, within the same cohort of prescribers a clear 
reluctance to prescribe clozapine remained; 99% of doctors said they would use clozapine 
for treatment-resistant schizophrenia, and yet 64% would rather co-prescribe two other 
antipsychotics instead of starting clozapine.  Guidelines are clearly only responsible for one 
part of the prescribing decision.  Personal experiences, local context, prescribing cultures, 
and patient characteristics are all involved (128).  Lloyd et al. (129) analysed attitudes to 
prescribing within the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study 
(CUtLASS) in 2005, and found guidelines to constitute only 8% of the prescribing decision, 
compared with review articles or randomised controlled trials (35%), or clinician experience 
(17%). 
There are few studies of guideline adherence, and where studied it is shown to be poor (130, 
131).  This also seems to be influenced by the demographics of the patient  - Weinmann et 
al. (132) demonstrated that patients with chronic illness are at higher risk of not receiving 
care in line with guidelines.  This is borne out specifically in relation to clozapine prescribing; 
Wheeler et al. (75) found that older patients were less likely to be prescribed clozapine, and 
Taylor and colleagues (71) showed that the delay to starting clozapine was increased for 
those over the age of 30.  It also appears to hold true for speaking to patients about 
medication; Hamann et al. (133) showed that psychoeducation tended to be reserved for 
younger patients with a shorter duration of illness and fewer inpatient admissions.  This is 
despite evidence that talking to patients about their treatment plans improves outcomes 
(134). 
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A lack of communication between prescriber and patient may in part explain the repeated 
findings that the views of patients of clozapine differ markedly from what prescribers think 
their views are.   A study by Hodge et al. (135) found that 81% of patients considered the 
side effect profile of clozapine to be better than that of the antipsychotics they had been 
taking previously.  Just 17% of their clinicians thought this to be the case.  48% of prescribers 
thought that patients wouldn’t mind about having their blood monitored whilst on therapy – in 
fact, 81% of patients said they didn’t mind.  Few clinicians (30%) thought clozapine would be 
a patient’s favourite drug.  When asked, 85% of patients preferred clozapine over any other 
antipsychotic.  Day and colleagues also demonstrated this mismatch of opinions in their 
survey of patients with schizophrenia and psychiatrists (136).  They found clinicians 
frequently overestimated the magnitude of distress associated with a variety of side effects 
compared with that reported by the patients, showing an apparent lack of understanding by 
psychiatrists of the adverse effects their patients are worried about. 
For patients at South London and the Maudsley NHS Foundation Trust (SLaM), treatment 
delay to clozapine in 2001 was an average of 5 years (71).  The authors at the time 
hypothesised several possible reasons for this; patient reluctance to comply with blood tests, 
clinician fears over probable non-compliance with medication or the development of 
agranulocytosis or other side effects, cost, lack of experience in prescribing clozapine, and 
lack of clinician confidence in the clinical effectiveness of clozapine in treatment-resistant 
schizophrenia.  These theories were not tested at the time.  As yet, no research group has 
clarified the barriers to prescribing clozapine as perceived by clinicians working directly with 
patients with schizophrenia, with a view to generating potential solutions. 
 Aims 
The aim of this thesis is to first examine whether there remains a delay to clozapine 
prescribing for patients at SLaM.  A retrospective review of clinical data looks at prescribing 
strategies before clozapine initiation and the length of time between diagnosis of treatment-
resistance and clozapine prescription.  Secondly, I report a questionnaire study that probes 
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the attitudes and experience of clinicians working within the same Trust towards clozapine.  
This aims to reveal barriers to clozapine prescribing, and put forward solutions for improving 
access to the drug.  Following this, I describe the results from interviews conducted with 
patients eligible for, but not taking clozapine in order to study the extent to which the opinions 
of medical teams tally with those of their patients regarding clozapine initiation.  
Retrospective clinical data collection is used to conduct a mirror-image study to observe the 
effect of any delay to clozapine prescribing on patient outcomes.  Finally, the data are 
interrogated for detailed information about those patients that discontinue clozapine, 
appraising the effect of stopping clozapine on clinical outcomes, and elucidating predictors 
for clozapine discontinuation. 
 Ethics 
All studies described in this thesis were approved by the Trust Drug and Therapeutics 
Committee.  Research Ethics Committee approval was not required for the studies described 
in chapters 2, 5 and 6 as the research was considered a clinical audit, designed to answer 
whether the service reaches predetermined prescribing standards.   They involved analysis 
of existing data and no allocation of treatment or randomisation was carried out.  Research 
Ethics Committee approval was not required for the study described in chapter 3 as the 
research involved NHS and social care staff recruited as research participants by virtue of 
their professional roles. The survey of patient attitudes to clozapine outlined in chapter 4 did 
not require Research Ethics Committee approval as this study was considered a service 
evaluation or quality improvement project, conducted to define clinical care and answer ‘what 
standard does this service achieve’.  It did not involve allocation of treatment or 
randomisation.  
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2 Is there a delay to clozapine use? 
 Introduction 
In about one in three patients with schizophrenia, the condition is treatment-resistant (122, 
137, 138).  This has been defined as an inadequate response to sequential treatment with 
two different antipsychotics at adequate dose, duration and adherence (48, 138).  Clozapine 
is the only drug treatment currently licensed for patients with treatment-resistant 
schizophrenia, and is associated with lower rehospitalisation rates compared with other 
antipsychotics (138, 139).  However, long delays in initiating clozapine in routine clinical 
practice have been reported (66, 71, 99, 108).  In 2001, research showed that patients at 
SLaM experienced a mean delay of 5 years to receive clozapine (71).  Since this study, 
clinical guidelines from NICE and other organisations have been published recommending 
that clozapine be offered at the earliest opportunity for treatment-resistant patients (49, 140).  
Whilst there is little clear benefit over other antipsychotics of clozapine as a first-line treatment 
(141) a study of patients presenting to services for the first time found that 75% of patients 
who failed to respond to sequential 4 week treatment trials with two different antipsychotics 
then responded to clozapine (142). 
Guidelines issued by NICE and other organisations also state that there is little evidence to 
support the use of antipsychotic doses above the licensed maximum dose or for antipsychotic 
polypharmacy (other than for short periods during cross-tapering) and recommend that these 
strategies should be used only in exceptional cases (49, 140).  The aim of this study is to 
determine if prescribing practice at SLaM followed NICE clinical guidelines.  Specifically, I 
sought to determine the time taken to initiate clozapine after a patient had completed 
adequate treatment with two different antipsychotic drugs, and the frequency of antipsychotic 
polypharmacy and high dose antipsychotic treatment prior to clozapine initiation. 
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 Objectives 
 To describe the pre-clozapine antipsychotic prescribing histories of a cohort of patients 
who received clozapine. 
 To calculate the theoretical delay to clozapine use for these patients. 
 To establish whether the duration of the psychotic illness, the age of the patients, their 
ethnicity, gender or diagnosis affects the theoretical delay to clozapine prescribing. 
 Method 
A list of all patients who commenced clozapine under the care of SLaM between 1st January 
2006 and 15th April 2010 was obtained from the Zaponex Treatment Access System (ZTAS) 
patient monitoring database.  The list was inclusive of outpatients, inpatients, and those being 
treated by tertiary referral services.  The clinical records of these patients were interrogated 
for the following demographic data: 
 Gender 
 Age (defined as the date of birth to the end date of the study) 
 Primary diagnosis (ICD-10 criteria) 
 Self-reported ethnicity (categorised as White British/other, Black British/other, Asian 
British/other, or mixed) 
Clinical data were extracted by hand-searching of the clinical notes.  The following were 
recorded: 
 Duration of illness (defined as the time from the first recording of the diagnosis of a 
psychotic illness by a clinician to the end date of the study) 
 Antipsychotic treatment history 
Antipsychotic treatment episodes were recorded and categorised in the following way: 
 Adequate treatment episode: 
o Atypical drug 
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o Typical drug 
o Depot drug 
 Inadequate treatment episode:  
o Due to duration <6 weeks 
o Due to non-therapeutic dose 
o Due to duration <6 weeks and non-therapeutic dose 
Therapeutic doses of oral antipsychotics were determined in accordance with the Maudsley 
Prescribing Guidelines (138).  Minimum therapeutic doses of depot medications were as 
defined by Taylor in his 2009 paper (143).  Where minimum doses were not available from 
these sources, expert pharmacists were consulted and a consensus reached.  The following 
table sets out the doses used to define adequate treatment doses during data collection. 
Table 2-1 Minimum effective doses of antipsychotics 
Antipsychotic First episode (mg) Subsequent episodes (mg) 
Typical antipsychotics 
Chlorpromazine 200 300 
Haloperidol 2 >4 
Sulpiride 400 800 
Trifluoperazine 10 15 
Atypical antipsychotics 
Amisulpride 400 800 
Aripiprazole 10 10 
Asenapine 10 10 
Iloperidone 4 8 
Olanzapine 5 10 
Quetiapine 150 300 
Risperidone 2 3 
Sertindole 12 12 
Ziprasidone 80 80 
Depot antipsychotics 
Flupenthixol decanoate 60 every 2 weeks 60 every 2 weeks 
Fluphenazine decanoate 50 every 2 weeks 50 every 2 weeks 
Haloperidol decanoate 100 every 2 weeks 100 every 2 weeks 
Perphenazine decanoate 150 every 2 weeks 150 every 2 weeks 
Pipothaizine palmitate 50 every 2 weeks 50 every 2 weeks 
Zuclopenthixol decanoate 300 every 2 weeks 300 every 2 weeks 
Olanzapine palmoate 300 every 2 weeks 300 every 2 weeks 
Risperidone microspheres 37.5 every 2 weeks 37.5 every 2 weeks 
Pro Re Nata (PRN, ‘as required’) antipsychotic doses were not recorded as treatment 
episodes.  Continuous administration of an antipsychotic for at least 24 hours was required 
for consideration as a separate treatment episode.  Where adherence to medication was 
 61 
clearly documented as poor or non-existent, the episode was designated ‘inadequate’. 
Multiple treatment episodes of the same drug were counted as different episodes if they were 
separated by at least 6 weeks.  Polypharmacy was recorded if two antipsychotics were 
prescribed concurrently, both at adequate doses, for more than 6 weeks.  Supra-maximal 
doses of antipsychotics were recorded and defined by the licensed maximum doses for drugs 
published in the BNF 61st edition (144).  Where polypharmacy occurred, the total combined 
dose was calculated and determined as above or within BNF limits as outlined in the 
Prescribing Observatory for Mental Health (POMH) audit guidelines (145). 
Data were then extracted as follows: 
 Total number of antipsychotic treatment episodes prior to the first use of clozapine 
 Number of different antipsychotic drugs used before the first use of clozapine 
 Number of adequate antipsychotic treatment episodes before first clozapine use 
 Number of adequate treatment episodes of different antipsychotics before first 
clozapine use 
 Number of antipsychotic treatment episodes with different atypical drugs before first 
starting clozapine 
The primary outcome measure was the maximum theoretical delay in clozapine initiation.  
This was defined as: the date of the end of the second adequate treatment episode (6 weeks 
at an adequate dose) to the date of the first prescription of clozapine.  The period before 
January 1990 was excluded as clozapine was not then available in the UK.  Where data were 
missing either for duration of treatment episodes or doses of drugs, the episode was 
excluded from analyses of adequate trials, but counted for the purposes of the total number 
of antipsychotic treatment episodes.  Every effort was made to gather complete prescribing 
histories for all patients, but where this was not possible, demographic data were gathered 
and these patients designated ‘excluded’. 
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 Statistical analysis 
Data were analysed using Microsoft Excel 2010 and IBM SPSS Statistics 21.  Bias was tested 
using z-scores.  Possible sources of bias in the data are outlying data scores, and violations 
of assumptions (normality and homoscedasticity or homogeneity of variance).  Outliers can 
bias both parameter estimates and the errors associated with those estimates, and so should 
be identified if present.  z-scores can be used to find outliers, as they express the data in 
terms of a distribution with a mean of 0 and a standard deviation of 1.  In a normal distribution, 
approximately 5% of the z-scores would be expected to be greater than 1.96, 1% to have 
values greater than 2.58, and none to be greater than 3.29 (146).   Where required, z-score 
testing was followed up with normality testing, using the Kolomogorov-Smirnov and Shapiro-
Wilk tests to compare the z-scores of the data sample to a normally distributed set of scores 
with the same mean and standard deviations.  If the tests are non-significant (p > 0.05), the 
distribution of the sample is considered to be normal.   
The variance of the data affects the estimation of the parameters in the model when using 
the method of least squares, and also the null hypothesis significance testing (test statistics 
assume the variance to be equal across different values of the predictor variable).  For 
accuracy of these results, it is therefore important to assume homoscedasticity, or 
homogeneity of variance.  Levene’s test was used to test the null hypothesis that the 
variances in different groups are equal.  If Levene’s test is significant (p < 0.05), the null 
hypothesis is incorrect and the variances are significantly different – that is, the assumption 
of homogeneity of variances has been violated.  
In order to reduce the impact of this bias to the data, four methods can be employed; trimming 
the data, winsorising, bootstrapping, or transforming.  Trimming the data (deleting the 
patients who contribute outlying scores) is not appropriate, since the sample is entirely drawn 
from the target population.  Winsorising (changing outlying data scores to the next highest 
score that is not an outlier) is also inappropriate for the same reason.  Bootstrapping the data 
is considered the most robust way of dealing with bias in this sort of data set, as it applies 
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tests that are unaffected by outliers, and does not rely on the assumption of normally 
distributed data.  This is the technique that will be used for the following statistical tests.  
In order to assess differences between included and excluded patients, an independent 
samples t-test was used.  Each patient was either included or excluded and could not be a 
member of both groups at different times, so a paired-samples t-test was not appropriate.  
The t-test is carried out by comparing the sample means for each set of data (in this case, 
included versus excluded patients).  If the samples come from the same population, the 
means are expected to be roughly equal.  As the t-test uses numerical sample means, it can 
only be applied to continuous variables (in this data set, age and the duration of illness).   
To test for differences between included and excluded patients in terms of the categorical 
variables, chi-square tests were carried out.  Pearson’s chi-square test compares the 
frequencies observed in certain categories compared to those expected to occur in those 
categories by chance.  For this data set, the test analyses how many patients from each 
group (included or excluded) fall into each category (for gender, the categories are male or 
female; for ethnicity the categories are white, mixed race, Asian – and so on) – this is the 
frequency.  For variables with two categories (i.e. gender; the categories are male or female), 
the expected frequency of values in each category must be more than 5.  For variables with 
3 or more categories (i.e. ethnicity and diagnosis), the expected frequency of values in each 
category must be greater than 1, and no more than 20% of the expected counts should be 





Table 2-2 Patient demographics 
 Total 







= 75  
p 
Age (years), mean (range) 37 (15 – 75) 34 (15 – 75) 43 (22 – 75) <0.0001 
Gender Male, n (%) 142 (63.4) 102 (68.5) 40 (53.3) 0.027 
Female, n (%) 82 (36.6) 47 (31.5) 35 (46.70) 
Ethnicity White, n (%) 106 (47.3) 61 (40.9) 45 (60.0) 0.026 
Black, n (%) 81 (36.2) 61 (40.9) 20 (26.7) 
Asian, n (%) 12 (5.4) 7 (4.7) 5 (6.7) 
Mixed, n (%) 14 (6.3) 12 (8.1) 2 (2.7) 
Other, n (%) 11 (4.9) 8 (5.4) 3 (4.0) 
Diagnosis Schizophrenia, 
n (%) 
165 (73.7) 116 (77.9) 49 (65.3) 0.012 
Schizoaffective 
disorder, n (%) 
36 (16.1) 24 (16.1) 12 (16.0) 
Bipolar 
disorder, n (%) 
17 (7.6) 8 (5.4) 9 (12.0) 




 11 (1 – 45) 9 (1 – 30) 16 (1 – 45) <0.0001 
 Bias 
Assessment of bias in the data set shows that the sample includes outlying data that may 
influence the results, and also that the sample values may not be normally distributed, and 
homogeneity of variance cannot be assumed for all variables.   
The frequency of z-scores in this data set are shown in Appendix A (Table 7-1).  For this data 
set, 2% of the cases were above 3.29 (extreme cases), 2.7% were greater than 2.58 (more 
than the expected 1% for probable outliers), and 7.4% had values greater than 1.96 (potential 
outliers).  The remaining cases constitute 92.6% of the values, and these lie within the normal 
range.  Therefore the data are not consistent with what would be expected from a normal 
distribution, where 95% of the data would be expected to fall with the normal range. 
It is important to establish the normality of the data set, as significance tests relating to the 
parameters of the data model depend on normality of the distribution.  The central limit 
theorem, which is generally accepted to apply to sample sizes over 30 (as presented here), 
means that normality can usually be assumed for large data sets (where outliers have more 
of an influence).  As the z-scores showed a problem with outlying data scores in this sample, 
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I performed tests for normality.  The results from these tests are presented for included and 
excluded patients in Appendix A (Table 7-2).  The tests for age, sex, ethnicity, primary 
diagnosis, duration of illness and theoretical delay for included patients were all highly 
significant, D(149), p < 0.0005.  This indicates that these distributions are not normal.  The 
tests for age, sex, ethnicity and primary diagnosis for excluded patients were also highly 
significant, D(75), p < 0.05, again indicating a non-normal distribution. 
The results for Levene’s test are presented in Appendix A (Table 7-3).  The test can be based 
on differences between scores and the mean or the median (both are shown in the table).  
The latter is preferable as it is less affected by outlying data, which the z-scores discussed 
earlier demonstrate are present in this data set.  For the variable of age, the variances were 
equal for included and excluded patients, F(1, 217), p = 0.074, showing no significant 
difference for patients in each group based on this variable.  For gender, the variances were 
unequal for included and excluded patients, F(1, 217), p = 0.025, indicating a significant 
difference between included and excluded patients within this variable.  For ethnicity, the 
variances were equal for included and excluded patients, F(1, 217), p = 0.105, showing no 
significant difference for patients in each group based on this variable.  For diagnosis, 
variances were unequal for included and excluded patients, F(1, 217), p = 0.005.  For 
duration of illness, variances were unequal for included and excluded patients, F(1,217), p < 
0.0005, indicating a significant difference between included and excluded patients within both 
these final variables. 
 Comparison of included and excluded patients 
The characteristics of the patients who were included were compared to those who were 
excluded from data analysis, to ensure no differences in demographics were present that 
would indicate a bias in the selection of the patient population.  In order to assess differences 
between these two groups of patients, an independent samples t-test was used.  Excluded 
patients tended to be older, and this difference, -8.8, BCa 95% CI [-12.2, -5.4] was significant 
t(217) = -5.4, p = <0.0005).  Excluded patients also tended to have a longer duration of 
illness, and this difference, -7.8 BCa 95% CI [-10.0, -5.8] was significant t(217) = -6.6, p 
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<0.0005.  Based on the odds ratio, the likelihood of being included in the analysis was 1.9 
times higher if the patient was male than if the patient was female.  The excluded patient 
group was made up of a higher proportion of white patients and a lower proportion of black 
patients than the included group.  Patients were 3.71 times more likely to be excluded from 
the analysis if they had a diagnosis other than schizophrenia or schizoaffective disorder.  The 
results of the independent samples t-test for the continuous variables, along with the 
corresponding bootstrapping test results (as discussed above) are presented in Appendix A 
(Table 7-4 and Table 7-5) and described in more detail below.   
The data from Levene’s test, carried out previously but repeated here as part of the t-test, 
show that the assumption of homogeneity of variance for both variables has been violated 
(Levene’s test is significant at p = 0.042 for age, and p < 0.0005 for duration of illness).  Equal 
variances should therefore not be assumed.  The two-tailed value of p is < 0.0005 for both 
variables, and so I conclude that there is a significant difference between the means of the 
two groups for both age and illness duration.  The bootstrapping procedure re-estimates the 
standard error of the mean difference, and shows the difference between the group mean 
ages as -8.8, with a confidence interval of -12.2 to -5.4.  This confidence interval implies that 
the difference between the means in the population is negative (the interval range is 
negative) and cannot be zero (the interval range does not cross zero).  The bootstrap 
procedure therefore confirms that there is a significant difference in mean age between the 
two groups of patients.  The same applies to the duration of illness variable, where 
bootstrapping shows the difference between the group mean illness durations as -7.8, with 
a confidence interval of -10.0 to -5.8.   
The results of the chi-square test for the differences in gender distribution across the included 
and excluded patient groups are presented in Appendix A (Table 7-6).  The test shows that 
no combination of categories contained less than 5 expected counts, and so this assumption 
is met and no further data manipulation is required.  The chi-square test demonstrates that 
there is a significant association between gender and whether or not a patient was included 
in the analysis χ2 (1) = 4.917, p = 0.027.  The odds of male patients being included in the 
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study can be calculated by dividing the number of male patients that were included in the 
analysis (102) by the number of male patients that were excluded from the analysis (40) = 
2.55.  The same odds can be calculated for female patients, by dividing the number of female 
patients that were included in the analysis (47) by the number of female patients that were 
excluded from the analysis (35) = 1.34.  The odds ratio is the odds of male patients being 
included in the study (2.55) divided by the odds of female patients being included in the study 
(1.34) = 1.90.   
The results of the chi-square test for the differences in ethnicity distribution across the 
included and excluded patient groups are presented in Appendix A (Table 7-7).  The test 
shows that 5 combinations of categories contained less than 5 expected counts.  As this 
variable consists of more than two categories (white, mixed race, Asian and Asian British, 
Black or Black British, other, not stated) it is not possible to use Fisher’s exact test to correct 
this violation.  Instead, it is necessary to either collect more data (which is not possible), 
accept the loss of statistical power (which is not desirable), or collapse the categories within 
the variable (i.e. merge some categories together).  The detailed breakdown of the expected 
counts for each category within the variable are shown in the crosstabulation table in 
Appendix A (Table 7-8).  This table shows that the expected counts are less than 5 for the 
categories of mixed race, Asian or Asian British, other, and ‘not stated’.  By combining these 
categories together into one larger ‘other’ category, this allows the expected frequencies in 
all categories to be more than 5 (data shown in the second crosstabulation table presented 
in Appendix A, Table 7-9).  The new categories within the ethnicity variable are therefore 
white, black, and ‘other’. 
The results of the chi-square test for the differences in ethnicity distribution across the 
included and excluded patient groups, with the new categories within this variable are 
presented in Appendix A (Table 7-10).  The test demonstrates that there is a significant 
association between ethnicity and whether or not a patient was included in the analysis, χ2 
(2) = 7.333, p = 0.026.  The odds of white patients being included in the study can be 
calculated by dividing the number of white patients that were included in the study (61) by 
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the number that were excluded (45) = 1.36.  The same odds can be calculated for black 
patients; 61/20 = 3.05, and for those in the other ethnic groups; 27/10 = 2.7.  The 
crosstabulation table shows that of all the patients that were excluded, 60% were white.  Of 
the patients that were included, 40.9% were white.  These proportions are significantly 
different (at p > 0.05), as denoted by different subscript letters in the table.  The proportions 
of black patients in each group also differ significantly, with 26.7% of excluded patients and 
40.9% of included patients being black.  For those in the ‘other ethnicity’ category, 13.3% 
were excluded, and 18.1% were included.   
The results of the chi-square test for the differences in primary diagnosis distribution across 
the included and excluded patient groups are also presented in Appendix A (Table 7-11).  As 
for ethnicity, the test shows that assumptions have been violated with 2 combinations of 
categories containing less than 5 expected counts.  The detailed breakdown for the expected 
counts for each category within the variable are shown in the crosstabulation table in 
Appendix A (Table 7-12).  The table shows the expected counts for schizophrenia and 
schizoaffective disorder to be above 5, but those for the ‘other’ diagnosis category to fall 
below this minimum level.  The expected counts for bipolar disorder are lower than those for 
the other diagnoses, but within the required parameters.  Combining the ‘other’ and bipolar 
disorder categories is a sensible approach, and this new crosstablulation table is also 
presented in Appendix A (Table 7-13).  The new categories for the diagnosis variable are 
now schizophrenia, schizoaffective disorder, and ‘other’.  Treating the data in this way allows 
all expected counts to be above 5. 
The results of the chi-square test for the differences in diagnosis distribution across the 
included and excluded patient groups, with the new categories within this variable are 
presented in Appendix A (Table 7-14).  The test demonstrates that there is a significant 
association between diagnosis and whether or not a patient was included in the analysis χ2 
(2) = 8.808, p = 0.012.  The crosstabulation table shows that the proportions of patients in 
each group differed significantly for schizophrenia and ‘other’ diagnoses (indicated by 
different subscript letters).  The proportions of patients with schizoaffective disorder did not 
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differ significantly across the included and excluded groups.  The odds of a patients being 
excluded from the study if their diagnosis was schizophrenia can be calculated by dividing 
the number that had a diagnosis of schizophrenia and were excluded (49) by the number 
with this diagnosis that were included (116) = 0.42.  The odds of a patient being excluded 
from the study if their diagnosis was ‘other’ can be calculated by dividing the number that 
had an ‘other’ diagnosis and were excluded (14) by number that had an ‘other’ diagnosis but 
were included (9) = 1.56.  The odds ratio for exclusion from the study can be calculated by 
dividing the odds of being excluded if the diagnosis was ‘other’ (1.56) by the odds of being 
excluded if the diagnosis was schizophrenia (0.42) = 3.71.   
 Treatment episodes 
The characteristics of the pre-clozapine antipsychotic trials as gathered by interrogation of 
the clinical notes are given in the table below (Table 2-3).  The total number of antipsychotic 
prescriptions prior to clozapine commencing ranged from 1 to 20, with a mean of 5.62.  This 
included all prescriptions prescribed regularly for more than 24 hours (i.e. excluding the use 
of PRN antipsychotics).  Of these antipsychotic trials, some were repeated prescriptions (at 
different time points but for the same patient) of the same antipsychotic.  Excluding these 
episodes of a subsequent use of a previously prescribed antipsychotic, the number of 
different antipsychotics used in the population prior to clozapine was a mean of 3.89, with a 
range of 1 to 10.  Excluding inadequate trials of antipsychotics, the total number of different 
antipsychotics prescribed before clozapine (at therapeutic doses and for at least 6 weeks) 
ranged from 0 to 8, with a mean of 2.81.  There was a mean of 0.63 episodes per patient of 
polypharmacy (range 0 – 6), defined as the prescription of two or more antipsychotics for 
more than 6 weeks concurrently.  The number of depot antipsychotics prescribed in the pre-
clozapine period ranged from 0 – 8, with a mean of 1.28 per patient.  The total number of 
atypical antipsychotics prescribed ranged from 0 to 5, with a mean of 2.51.  When only 
adequate trials (in terms of dose and duration) were considered, the range reduced to 0 to 
4, and the mean to 1.97. 
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Table 2-3 Treatment episodes 
 Minimum Maximum Mean Std. 
Deviation 
Total number of 'regular' antipsychotic 
prescriptions before clozapine, at any dose 
for >24h 
1 20 5.62 3.521 
Number of different antipsychotics used prior 
to clozapine 
1 10 3.89 1.860 
Number of documented episodes of 
adequate trial (>6 weeks) 
0 12 3.72 2.351 
Number of different antipsychotics given 
adequate trial 
0 8 2.81 1.486 
Polypharmacy (two or more antipsychotics 
>6 weeks) 
0 6 0.63 1.074 
Number of atypicals given adequate trial 0 4 1.97 0.930 
Total number of atypicals used (adequate 
AND inadequate trials) 
0 5 2.51 1.037 
Number of episodes of depot antipsychotic 
use 
0 8 1.28 1.607 
Details of the reasons for classification of the antipsychotic trials as inadequate are given in 
the table below (Table 2-4).  In total, patients received a mean of 1.88 inadequate trials of 
medication prior to clozapine initiation, with a range of 0 – 10.  Of these inadequate trials, a 
mean of 0.56 were due to dosing below that considered therapeutic (range 0 – 6).  A mean 
of 0.59 trials were inadequate due to a duration of less than 6 weeks (range 0 – 5).  A 
combination of both of these factors accounted for the inadequacy of a mean of 0.12 trials 
(range 0 – 3), and for a mean of 0.61 of the trials (range 0 – 7) the information available in 
the clinical notes was not available to classify further. 
Table 2-4 Inadequate treatment episodes 
 Minimum Maximum Mean Std. Deviation 
Inadequate dose 0 6 0.56 0.982 
Inadequate duration 0 5 0.59 0.908 
Inadequate dose and duration 0 3 0.12 0.434 
Unavailable information 0 7 0.61 1.044 
Total 0 10 1.88 2.043 
  Regression analysis 
In order to establish whether any of the variables associated with the data (duration of illness, 
age, ethnicity, gender or diagnosis) affect the theoretical delay to clozapine initiation, 
regression analysis was used.  For the continuous variables of age and illness duration, 
simple linear regression was employed.  As age and illness duration may also be expected 
to influence each other (increased age at the time of clozapine initiation would be likely to be 
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associated with an increased duration of illness up to this point), multiple regression analysis 
was then used to establish any confounding relationship between these variables and the 
effect on the theoretical delay to clozapine use.   
For the purpose of this analysis, age was defined as the time from the date of birth to the 
point at which the criteria for diagnosis of refractory illness were met, and duration of illness 
as the time from the onset of psychosis to the point at which the criteria for diagnosis of 
refractory illness were met.  This avoids including the clozapine delay time period in these 
time spans; without doing so, the theoretical delay and age or duration of illness would be 
inherently related to each other and any independent relationship would be masked.  This 
problem is known as ‘part-whole correlation’, where one variable is derived from the other 
and an inherent correlation may exist between the two (147).  For both variables, where a 
diagnosis of refractory illness was not met, this date was taken as the date at which clozapine 
was commenced.   
The effect of the categorical variables of gender, ethnicity and diagnosis on the theoretical 
clozapine delay was examined using one-way analysis of variance (ANOVA) (where there 
were more than two categories within the variable – as for ethnicity and diagnosis) or 
independent t-test (where there were only 2 categories, as for gender). 
 Illness duration 
The scatterplot showing the relationship between the theoretical delay to clozapine initiation 
and the duration of the illness is presented in Appendix A (Figure 7-1).  The pattern of the 
data shows that a negative relationship exists between the variables, whereby the longer the 
duration of the illness, the shorter the theoretical delay to clozapine use.  The equation of the 
regression line, annotated on the scatterplot as y = 45.02 + -0.05 x, means that the theoretical 
delay to clozapine use (in months) can be calculated by: 45.02 + -0.05 times the duration of 
the illness (in months). 
The summary of the regression model is shown in Appendix A (Table 7-15 Regression model 
summary).  The table shows that R = 0.037, and because there is only one predictor (duration 
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of illness), this value is representative of the correlation between theoretical delay to 
clozapine initiation and the duration of the psychotic illness.  The value of R2 = 0.001; the R2 
represents the amount of variance in the outcome explained by the model, in terms of a 
proportion.  Therefore the duration of illness can account for 0.1% of the variation in the 
theoretical delay.  This means that 99.9% of the variation in the theoretical delay to clozapine 
use cannot be explained by the duration of illness alone, and there must be other variables 
that are influencing the outcome. 
Next, I conducted an ANOVA, in order to establish whether the regression model presented 
above results in a significantly better prediction of the theoretical delay to clozapine use than 
if the mean theoretical delay was used alone.  The results of this are presented in Appendix 
A (Table 7-16 ANOVA).  The table provides the sum of squares with associated degrees of 
freedom (df), and the average sum of squares (noted in the table as mean square, calculated 
by dividing the sum of squares by the associated degrees of freedom).  The F-ratio is 
calculated by dividing the value of the mean squares for the model by the residual mean 
squares, and for these data F is 0.206, which is non-significant at a p value of 0.651. 
Therefore the regression model does not predict theoretical delay significantly well (no better 
than using the mean value of the theoretical delay alone). 
The model parameters (coefficients) give an indication of the individual contribution of 
variables in the model, and are presented in Appendix A (Table 7-17 Model coefficients).  
The value b0 is the Y intercept of the scatterplot discussed earlier.  The table shows that b0 
(the constant) is 45.051, therefore when theoretical delay is zero (the intercept of the X axis 
on the scatterplot), the expected duration of illness is 45.051 months.  The data table also 
shows the value of b1 (the gradient of the regression line) as -0.048.  This value represents 
the change in the outcome associated with a unit change in the predictor, therefore for each 
extra month of illness, the theoretical delay to clozapine is decreased by 0.048 months.  The 
value of the regression coefficient (b) should be different from zero if the duration of illness 
has a significant impact on the ability of the model to predict the theoretical delay to clozapine 
use.  This is tested using t-test, the results of which (and associated p values) are given in 
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the final two columns of the table.  The result of the t-test for the duration of illness is non-
significant at a p value of 0.651, meaning that the regression coefficient (b) for this variable 
is not significantly different from zero.  Therefore in the case of the duration of illness, this 
makes no significant contribution (p = 0.651) to predicting the length of delay to clozapine 
initiation. 
As explained previously, these data may not conform to normality assumptions and so I 
carried out bootstrapping procedures for the model parameters.  The results from this are 
given in Appendix A (Table 7-18 ).  The bootstrap confidence intervals indicate that the 
population value for b (the value of the regression coefficient) for the duration of illness is 
likely to fall between -0.227 and 0.243.  As this interval includes zero, there is no relationship 
between theoretical delay and duration of illness in the population.  Additionally, the 
significance associated with this confidence interval is p = 0.635, which is non-significant. 
 Age 
The scatterplot showing the relationship between the theoretical delay to clozapine initiation 
and age is presented in Appendix A (Figure 7-2).  The pattern of the data shows that a 
negative relationship exists between the variables, whereby the older the age of the patient, 
the shorter the theoretical delay to clozapine use.  The equation of the regression line, 
annotated on the scatterplot as y = 66.06 + -0.07 x, means that the theoretical delay to 
clozapine use (in months) can be calculated by: 66.06 + -0.07 times the age of the patient 
(in months). 
The summary of the regression model is shown in Appendix A (Table 7-19).  The table shows 
that R = 0.147, and because there is only one predictor (age), this value is representative of 
the correlation between theoretical delay to clozapine initiation and the age of the patient.  
The value of R2 = 0.022, therefore the age of the patient can account for 2.2% of the variation 
in the theoretical delay.  This means that 97.8% of the variation in the theoretical delay to 
clozapine use cannot be explained by age of the patient alone, and there must be other 
variables that are influencing the outcome. 
 74 
Next, I conducted an ANOVA, in order to establish whether the regression model presented 
above results in a significantly better prediction of the theoretical delay to clozapine use than 
if the mean theoretical delay was used alone.  The results of this are presented in Appendix 
A (Table 7-20).    The F-ratio = 3.238, which is not significant at a p value of 0.074.  Therefore 
the regression model does not predict theoretical delay significantly well (no better than using 
the mean value of the theoretical delay alone). 
The model parameters (coefficients) give an indication of the individual contribution of 
variables in the model, and are presented in Appendix A (Table 7-21).  The value b0 is the Y 
intercept of the scatterplot discussed earlier.  The table shows that b0 (the constant) is 66.055, 
therefore when theoretical delay is zero (the intercept of the x axis on the scatterplot), the 
expected age of the patient at the time of starting clozapine is 66.055 months.  The data table 
also shows the value of b1 (the gradient of the regression line) as -0.067.  This value 
represents the change in the outcome associated with a unit change in the predictor, 
therefore for each extra month of age, the theoretical delay to clozapine is decreased by 
0.067 months.  The value of the regression coefficient (b) should be different from zero if the 
age of the patient has a significant impact on the ability of the model to predict the theoretical 
delay to clozapine use.  This is tested using t-test, the results of which (and associated p 
values) are given in the final two columns of the table.  The result of the first t-test is significant 
at a p value of < 0.0005.  The result of the second t-test is non-significant at a p value of 
0.074.  The non-significant result for the b for the age of the patient means that this regression 
coefficients is not significantly different from zero, and so in the case of the age of the patient, 
this does not make a significant contribution (p = 0.074) to predicting the length of delay to 
clozapine initiation. 
As explained previously, these data may not conform to normality assumptions and so I 
carried out bootstrapping procedures for the model parameters.  The results from this are 
given in Appendix A (Table 7-22).  The bootstrap confidence intervals indicate that the 
population value for b (the value of the regression coefficient) for the age of the patient is 
likely to fall between -0.126 and -0.011.  As this interval does not include zero, there is a 
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genuine negative relationship between theoretical delay and the age of the patient in the 
population.  Additionally, the significance associated with this confidence interval is p = 0.016, 
suggesting that there may be a significant relationship between the variables – but the result 
from the t-test described above contradicts this. 
 Multiple regression analysis 
As outlined above, the two variables of age and duration of illness are likely to influence each 
other.  The linear regression analysis showed that neither variable alone has an effect on the 
theoretical delay to clozapine initiation.  However, the linear regression procedure does not 
control for the other potentially confounding variable when assessing the impact of the 
variable of interest on the outcome.  Additionally, bootstrap confidence intervals for the 
relationship between the age of the patient and the theoretical delay to clozapine use 
suggested that there may be a significant correlation.  In order to establish whether the 
combination of age and duration of illness affect the delay in clozapine prescribing, multiple 
regression analysis is required.  Multiple regression analysis allows a model to be built that 
has several predictor variables; in this case, age and duration of illness. 
As the linear regression showed that neither variable had an effect on the outcome, I did not 
use hierarchical (blockwise entry) to build the multiple regression models.  I also did not use 
the stepwise method (automatic linear modelling), where the variables are entered into the 
model based on mathematical criterion, because of the risk of overemphasis of correlation 
of the two variables and over- or under-fitting the model.  Instead, forced entry (putting both 
predictors into the model simultaneously) was appropriate as the data suggest that the 
influence of each variable on the outcome is the same.   
For the first model, the predictor variable was the age of the patient.  The second model used 
both the duration of the illness and the age of the patient as predictors.  For both models, the 
dependent variable was the theoretical delay to clozapine prescription.  The results from 
these models are presented in Appendix A (Table 7-23).  The table shows the R value (the 
multiple correlation coefficients between the predictor and the outcome variable) for model 
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1, where only age was included as a predictor, to be 0.147.  As expected, this is the same R 
as found in the simple linear regression calculated earlier.  The R2 for this variable is 0.532, 
which as explained previously is a measure of how much of the variability in the outcome is 
accounted for by the predictor.  For this first model, the R2 is 0.022, so the age of the patient 
accounts for 2.2% of the variation in the duration of the illness.  However, when the other 
predictor of duration of illness is included in model 2, this value remains the same, at 0.022 
or 2.2% of the variance in delay to clozapine use.  Therefore, the inclusion of the new 
predictor of duration of illness explains none of the remaining 97.8% of the variation in the 
delay to clozapine prescription. 
The model summary table also shows the adjusted R2, and this gives an indication of the 
generalisability of the model.  This value should ideally be as close as possible to the value 
of R2.  For model 1, the adjusted R2 is 0.015, with the difference between the values being 
0.007, or 0.7%.    This means that if the model were derived from the whole population rather 
than the sample included in this study, then it would account for approximately 0.7% less 
variance in the outcome.  The change statistics are explored further in the next columns in 
this table.  The R2 change column shows that model 1 causes R2 to change from 0 to 0.022, 
and this change in the amount of variance explained results in an F-ratio of 3.238, which is 
not significant at a probability of 0.074.  In model 2, where the duration of the illness has been 
added as a predictor, the R2 does not change (the R2 change is 0), so the R2 of this model is 
0.022.  The F-ratio for this is 0.015, which is non-significant at a p of 0.902.  Finally, the 
Durbin-Watson statistic is given in the last column of the table.  This tests whether 
correlations exist between errors (or residuals) in the data.  Violation of this assumption 
invalidates the confidence intervals and significance tests.  In order for the assumption of 
independent errors to remain tenable, this value should be between 1 and 3 (and as close to 
2 as possible).  The value for this model is 1.740, showing that this assumption has been 
met. 
I have so far presented the results from the one-way ANOVA for each continuous variable, 
which showed that neither age nor duration of illness have an effect on the delay to clozapine 
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use, although bootstrap confidence intervals for age hinted at a possibly significant negative 
relationship for this variable.  I then combined these variables in a multiple regression 
analysis to establish their influence on the outcome variable when considered individually.  
This analysis suggested that the influence on the delay to clozapine use (if there is any 
significant influence) lies in the age, rather than the duration of illness of the patient.  Both 
these continuous variables, having an influence on the dependent variable of delay to 
clozapine use, can be called covariates and therefore included in an analysis of covariance 
(ANCOVA).  I am using the ANCOVA test here to eliminate the possibility of confounding of 
the results by either variable, as the test looks at the difference between the group means 
adjust for the covariates (age and duration of illness).  The output data for the ANCOVA 
analyses are shown in Appendix A. 
The first ANCOVA defines the dependent variable as the delay to clozapine use, the 
independent variable as the duration of the illness, and the covariate (the possible 
confounding variable) as the age of the patient at the point of clozapine initiation.   The results 
for Levene’s test of equality of error variances for this ANCOVA is presented in Appendix A 
(Table 7-24).  Levene’s test is significant at p = 0.001, indicating that the assumption of 
homogeneity of variances has been violated.  However, the ANCOVA is a linear model, and 
so it is homogeneity of the residuals that matters, which is not tested by Levene’s test.  This 
is important to note however, and any significant results from the subsequent ANCOVA 
should ideally be bootstrapped to account for this. 
The results table for the ANCOVA is shown in Appendix A (Table 7-25).  From the 
significance values, it is evident that the covariate (age) has no significant effect on the 
outcome (theoretical delay), as the p = 0.411.  When the effect of age is removed, the 
duration of illness also does not significantly affect the theoretical delay, at p = 0.968.  
Therefore, the theoretical delay is not influenced by the duration of the illness or by the age 
of the patient.   
The second ANCOVA again uses the delay to clozapine treatment as the dependent variable, 
but this time the independent variable is set as the age of the patient, and the covariate 
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(confounding variable) as the duration of the illness.  The results for Levene’s test of equality 
of error variances for this ANCOVA is presented in Appendix A (Table 7-26).  Levene’s test 
is again significant at p = 0.002, indicating that the assumption of homogeneity of variances 
has been violated, but as discussed previously this may be of less importance as the 
ANCOVA is a linear test. 
The results table for this ANCOVA is presented in Appendix A (Table 7-27).  The significance 
values show that when duration of the illness is set as the covariate, it has no significant 
effect on the delay to clozapine use, at a p value = 0.806.  The independent variable of age 
also has no effect on the outcome, at a p of 0.488.  Removing the effect of the duration of 
illness from the age of the patient has no effect on the result, indicating no influence of age 
on the theoretical delay. 
 Gender 
In order to establish the effects of the categorical variable of gender on the delay to clozapine 
prescribing, I used an independent samples t-test.  The independent samples t-test expects 
(under the null hypothesis) that both samples (i.e. male and female patients) come from the 
same population, and therefore that their means (of delay to clozapine use) will be 
approximately equal.  The results of the t-test for gender are given in Table 2-5. 
Table 2-5 Independent samples t-test summary (gender) 
 Statistic Bootstrap 
Bias Std. 
Error 
BCa 95% Confidence 
Interval 
Lower Upper 
Male n 102  
Mean clozapine 
delay (months) 
35.93 -0.20 4.18 28.52 43.60 
Std. Deviation 42.726 -0.719 5.162 33.031 50.975 
Std. Error Mean 4.231  
Female n 47  
Mean clozapine 
delay (months) 
60.47 -0.26 9.06 43.99 78.19 
Std. Deviation 62.698 -1.058 6.614 49.958 72.314 
Std. Error Mean 9.145  
The table shows that men have a shorter mean delay to clozapine use than women.  As the 
confidence intervals for the two groups do not overlap, this suggests that they may not be 
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from the same population. 
The main test statistics for the independent samples t-test for gender are presented in 
Appendix A (Table 7-28).  As discussed previously, Levene’s test shows whether the 
variances are different between the different groups.  Levene’s test is significant for these 
data at p < 0.0005, therefore the assumption of homogeneity of variances has been violated 
and the test statistics in the row labelled ‘equal variances not assumed’ should be used.  The 
mean difference between the groups is -24.537, with a standard error of the sampling 
distribution of differences of 10.077.  The t statistic (calculated by dividing the mean 
difference by the standard error) is -2.435.  The degrees of freedom (calculated by adding 
the two sample sizes and then subtracting the number of samples) is 66.408.  The value of t 
is compared to the value of t expected if the null hypothesis is correct (that both the samples 
have the same mean), based on the calculated degrees of freedom.  The value of t is 0.018, 
which is significant at p < 0.05.  This shows that there is a significant difference in the mean 
delay to clozapine use when comparing male and female patients. 
The results of the bootstrapping are also given in Appendix A (Table 7-29).  The 
bootstrapping re-estimates the standard error of the mean difference, which is now estimated 
at 9.849 rather than 10.077.  The difference between the means is -24.537, and the 
bootstrapped confidence interval for this ranges from -44.502 to -5.927.  This confidence 
interval range is entirely negative and does not include zero.  This shows that the true 
difference between the means is negative, and cannot be zero (i.e. the means are not the 
same).  The bootstrap confidence interval therefore confirms the result outlined above; on 
average, females had a longer theoretical delay (mean = 60.47 months, SE = 9.15) than 
males (mean = 35.93 months, SE = 4.23).  This difference, -24.54, BCa 95% CI [-44.502, -
5.927] was significant t(66.41) = -2.44, p = 0.018. 
 Ethnicity 
I used one-way ANOVA to examine the effect of the categorical variable of ethnicity on the 
theoretical delay to clozapine use.  ANOVA analysis was required rather that the t-test used 
 80 
for the categorical variable of gender described previously as the ethnicity variable contains 
more than two categories; the ANOVA is also a linear model, but allows the comparison of 
the means of more than 2 groups.  
The descriptive statistics for the one-way ANOVA for the ethnicity variable are shown in Table 
2-6.  Black patients have a slightly higher mean delay than white patients, but the lowest 
mean delay is for patients in the ‘other’ ethnicity category.  
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Table 2-6 Descriptive statistics for one-way ANOVA (ethnicity) 






White n 61 0 6 51 71 
Mean clozapine delay (months) 43.75 0.38 7.10 29.62 59.24 
Std. Deviation 55.794 -0.713 7.515 39.681 68.521 
Std. Error 7.144  
95% Confidence 









Black n 61 0 6 50 73 
Mean clozapine delay (months) 47.20 -0.46 6.29 35.95 57.85 
Std. Deviation 50.736 -1.372 6.000 39.651 58.459 
Std. Error 6.496  
95% Confidence 









Other n 27 0 5 19 34 
Mean clozapine delay (months) 35.52 0.02 7.38 22.33 50.80 
Std. Deviation 39.613 -1.272 6.827 27.150 49.206 
Std. Error 7.624  
95% Confidence 









Total n 149 0 0 0 0 
Mean 43.67 <0.005 4.08 35.69 51.86 
Std. Deviation 50.975 -0.468 4.195 43.212 57.433 
Std. Error 4.176  
95% Confidence 









Next, Levene’s test of the difference in variance between the three groups is shown in 
Appendix A (Table 7-30).  The test is non-significant at a p of 0.486, showing that the 
homogeneity of variances can be assumed and there is no requirement to transform the data.  
The ANOVA output data table is presented in Appendix A (Table 7-31).  The data are divided 
into between groups effects, which are the effects due to the model (the experimental effects) 
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and the within-group effects, which are the effects due to unsystematic variation of the data.    
For the between groups effect, the sum of squares is 2553.194, with a degrees of freedom 
of 2, and a mean square of the model of 1276.597.  The sum of squares and mean squares 
represent the experimental effect.  The within groups model has a sum of squares (the 
residual sum of squares, as it corresponds to the amount of unsystematic variation in the 
data) of 382023.692, and a mean square of 2616.601 (the average amount of unsystematic 
variation).  The F-ratio shows whether the group means are the same.  The ratio is 0.488, 
with a significance of 0.615 (this significance is the probability of calculating an F ratio this 
size if there was no difference between the means in the populations).  This significance 
shows that there is a 61.5% chance that the F ratio would be calculated if in reality there was 
no effect.  As this significance is > 0.05, the ANOVA shows that there is no difference in the 
means between the different ethnicity categories. 
As I had no specific hypothesis that any particular ethnicity category would be expected to 
have an effect on the theoretical delay to clozapine use, I carried out post-hoc tests to 
compare all the groups of participants with each other.  The results of Tukey’s test (known 
as Tukey’s Honestly Significant Difference, or HSD), Gabriels’ pairwise test procedure and 
the Games-Howell procedure are shown in Appendix A (Table 7-32).  Tukey’s test controls 
for type 1 errors, and is used because I have no reason to think that the population variances 
are unequal.  For this test, each group participant is compared to all the remaining groups, 
as can be seen in the table.  For each pair of groups, the difference between the means, the 
standard error of the difference, the significance level of the difference and the 95% 
confidence intervals are given.  For all comparisons, the differences between the means are 
non-significant at p > 0.05.  I have used Gabriel’s pairwise test procedure as the sample sizes 
in the three categories are different.  It again controls for type 1 errors and as for Tukey’s 
HSD, finds that the differences between the means for each pair group are non-significant.  
Finally, the Games-Howell procedure is the most powerful test of the three presented, and 
supports the other results in also finding no significant differences between the group means.  
Overall, there was no significant effect of ethnicity on theoretical delay to clozapine, F(2, 146) 
= 0.688, p = 0.505. 
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 Diagnosis 
I applied the same procedures to analysis of the effect of diagnosis on the theoretical delay 
to clozapine, as similarly to ethnicity, this variable contained more than 2 categories.  The 
descriptive statistics for the one-way ANOVA for the diagnosis variable are shown in Table 
2-7.  
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Table 2-7 Descriptive statistics for one-way ANOVA (diagnosis) 
  Bootstrap 




Schizophrenia n 116 0 5 106 125 
Mean clozapine delay 
(months) 
41.94 0.15 5.13 32.56 52.53 
Std. Deviation 52.830 -0.255 5.406 42.050 62.614 














n 24 0 4 16 32 
Mean clozapine delay 
(months) 
41.21 0.28 8.11 27.44 57.69 
Std. Deviation 39.715 -1.110 6.960 27.315 49.806 












Other n 9 0 3 5 14 
Mean clozapine delay 
(months) 
72.56 -0.32 16.78 45.37 107.05 
Std. Deviation 49.156 -5.456 13.800 25.195 61.362 












Total n 149 0 0 0 0 
Mean clozapine delay 
(months) 
43.67 0.14 4.30 35.80 52.36 
Std. Deviation 50.975 -0.117 4.414 42.175 59.139 












Table 2-7 shows that the mean theoretical delay to clozapine use was longest for those with 
a diagnosis in the ‘other’ category.  Patients with schizoaffective disorder had the shortest 
delay. 
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Next, Levene’s test of the difference in variance between the three groups is shown in 
Appendix A (Table 7-33).  The test is non-significant at a p of 0.452, showing that the 
homogeneity of variances can be assumed and there is no requirement to transform the data.  
The ANOVA output data table is presented in Appendix A (Table 7-34).  The F-ratio is 1.551, 
with a significance of 0.215.  This significance shows that there is a 21.5% chance that the F 
ratio would be calculated if in reality there was no effect.  As this significance is > 0.05, the 
ANOVA shows that there is no difference in the means between the different diagnosis 
categories. 
As for the ethnicity variable described previously, I carried out post-hoc tests for the diagnosis 
variable to compare all the groups of participants with each other.  The results of Tukey’s 
test, Gabriels’ pairwise test procedure and the Games-Howell procedure are shown in 
Appendix A (Table 7-35).  All three tests found no significant differences between the group 
means at p >0.05.  Overall, there was no significant effect of diagnosis on theoretical delay 
to clozapine, F(2, 146) = 1.608, p = 0.226. 
 Summary 
This study retrospectively examined the clinical notes of patients commencing clozapine over 
a 4 year period at SLaM to establish antipsychotic prescribing histories before clozapine was 
prescribed.  In total, 149 patients were included in the analysis and 75 were excluded.  
Patients were excluded from the data analysis where their prescribing histories could not be 
established from the clinical notes.   Excluded patients tended to be older, and this difference, 
-8.764, BCa 95% CI [-12.217, -5.379] was significant t(217) = -5.436, p = <0.0001).  Excluded 
patients also tended to have a longer duration of illness, and this difference, -7.837 BCa 95% 
CI [-10.00, -5.752] was significant t(217) = -6.612, p <0.0001.  Gender also affected the 
likelihood of being excluded from the analysis (χ2 (1) = 4.917, p = 0.027), with male patients 
being more likely to be included in the study, with an odds ratio of 1.90.  The ethnicity of 
patients also differed significantly between the included and excluded groups (χ2 (2) = 7.333, 
p = 0.026), with the excluded patient group made up of a higher proportion of white patients 
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and a lower proportion of black patients than the included group.  There was also a significant 
difference in diagnosis across the two groups (χ2 (2) = 8.808, p = 0.012), with patients 3.71 
times more likely to be excluded from the analysis if they had a diagnosis other than 
schizophrenia or schizoaffective disorder.  Overall, excluded patients were more likely to be 
older, have a longer duration of illness, be female, white, and have a diagnosis of something 
other than schizophrenia or schizoaffective disorder. 
I found a mean theoretical delay to clozapine prescription of 43.38 months (3.6 years, SE = 
4.18 months).  This delay was not influenced by the duration of the psychotic illness or the 
age of the patient.  Gender did have an effect on the delay to clozapine use, with female 
patients having a longer theoretical delay (mean = 60.47 months, SE = 9.15) than male 
patients (mean = 35.93 months, SE = 4.23).  This difference, -24.54, BCa 95% CI [-44.502, 
-5.927] was significant t(66.41) = -2.44, p = 0.018.  The ethnicity of the patient had no effect 
on the delay to clozapine (F(2, 146) = 0.688, p = 0.505), and neither did the diagnosis (F(2, 
146) = 1.608, p = 0.226). 
 Publications arising from this study 
See Appendix I: Oliver Howes, Francis Vergunst, Siobhan Gee, Philip McGuire, Shitij Kapur, 
David Taylor (2012) Adherence to treatment guidelines in clinical practice: a study of 
antipsychotic prescription prior to clozapine initiation.  British Journal of Psychiatry, 201:481-
485.  
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3 Practitioner attitudes to clozapine initiation 
 Introduction 
Despite clear recommendations for the use of clozapine, I have shown in chapter 2 that 
patients experience lengthy delays in prescribing. In 2001, the mean theoretical delay to 
clozapine prescribing (the time from the end of the second failed antipsychotic trial, after 
which clozapine should be initiated, to the time when clozapine was actually started) was 5 
years (71). At the same Trust in 2010, this delay had reduced but still stood at almost 4 years 
(148). 
At the time of the 2001 study, several possible reasons for the prescribing delays were 
suggested; patient reluctance to comply with blood tests, clinician fears over probable non-
compliance with medication or the development of agranulocytosis or other side effects, cost, 
lack of experience in prescribing clozapine, and lack of clinician confidence in the clinical 
effectiveness of clozapine in treatment-resistant schizophrenia. These theories were not 
tested at the time. 
This study aims to clarify the barriers to prescribing of clozapine in treatment-resistant 
schizophrenia where clozapine initiation is indicated, as perceived by clinicians directly 
involved in the care of such patients. 
 Objectives 
 To establish how familiar clinicians feel with clozapine prescribing guidelines and 
procedures. 
 To investigate how effective clinicians feel clozapine is, compared with other 
antipsychotics. 
 To elucidate factors clinicians feel are likely to delay prescribing clozapine. 
 To elucidate factors clinicians feel are likely to reduce the delay to prescribing clozapine. 
 To examine differences in the above outcome measures between professional groups. 
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 Method 
A questionnaire suitable for electronic and hard-copy completion was formulated and piloted 
to a convenience sample of 10 members of pharmacy staff, following which questions were 
refined (Appendix B).  The questionnaire was made available electronically for all staff at 
SLaM to complete.  An advertisement was run in the weekly staff news bulletin, and emailed 
to all clinical team leaders and consultants in the Trust, requesting they pass this on to their 
team members.  All inpatient and outpatient team leaders were further contacted by phone 
to explain the study, and provided with paper copies of the questionnaire.  In this way all 
members of clinical staff in the Trust had an equal chance of response and therefore selection 
into the sample, keeping sampling error to a minimum.  The questionnaire was available 
electronically and in paper format over a 12 month period, allowing for rotation of junior doctor 
staff into and out of the Trust.  Team leaders were contacted twice after the initial call – once 
to confirm receipt of the electronic and paper questionnaires, and finally after allowing time 
for completion to encourage further responses.  Further, teaching sessions for junior doctors 
were directly provided with paper copies of the questionnaire.  Making the questionnaire 
available as widely as possible both electronically and in paper format increased 
convenience for responders, with an aim of increasing response rate.  It is however the case 
that this limited the scope for prompting or probing for further responses or clarification, 
although free text comment options were provided.   
The questionnaire was completed anonymously and demographic data collected: 
 Professional status 
 Main ward/community location 
 Gender 
 Age bracket 
Firstly, practitioners were asked to declare how familiar they were with the NICE 
schizophrenia guidelines (not at all/a little/fairly/very familiar): 
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‘How familiar are you with the NICE guidelines relating to treatment-resistant 
schizophrenia?’ 
Beliefs about the relative effectiveness of clozapine compared to other antipsychotics were 
explored using a 10 point Likert scale with a visual prompt, ranging from ‘much less effective’ 
to ‘much more effective’: 
‘How would you rate clozapine’s effectiveness in treating schizophrenia compared 
with other antipsychotics?’ 
Practitioners were asked directly about their clinical practice in clozapine initiation (without a 
direct prompt that their response may or may not adhere to guidelines): 
‘When would you typically consider authorising/supporting the initiation of clozapine 
treatment?’ 
Options for response to this question were: 
 As first line treatment 
 After one adequate antipsychotic trial 
 After two adequate antipsychotic trials  
 After three adequate antipsychotic trials  
 After four or more adequate antipsychotic trials  
Secondly, the familiarity of practitioners with the process of clozapine initiation was 
investigated.  Clozapine requires more pre-treatment testing and administration processes 
than any other available antipsychotic, necessitating full blood count testing, registration with 
a centralised data base for the patient, prescriber and pharmacy, as well as on-going 
monitoring and communication with the supplying company.  Questionnaire respondents 
were asked: 
‘How familiar are you with methods for the initiation of clozapine treatment?’ (not at 
all/a little/fairly/very familiar) 
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‘Approximately how many patients currently under your care are receiving 
clozapine?’ (free text answer) 
‘I have been responsible for authorising/supporting clozapine initiation and titration…’ 
 Within the last 6 months 
 Within the last year 
 More than a year ago 
 Never 
Thirdly, patients themselves are frequently cited by staff as being the main reason for non-
prescription of clozapine.  The beliefs of clinicians about patient experiences with clozapine 
were investigated: 
‘In terms of treatment satisfaction, how satisfied do you believe patients treated with 
clozapine are, compared with patients treated with other (atypical) antipsychotics?’ 
 much less satisfied 
 somewhat less satisfied 
 somewhat more satisfied 
 much more satisfied 
I asked respondents to rate the following ‘patient factors’ on their likelihood to lead to delays 
in the initiation of clozapine.  Response options were: infrequently/somewhat frequently/fairly 
frequently/very frequently/don’t know: 
 Refusal / reticence about obtaining baseline blood tests 
 Refusal / reticence about regular blood monitoring 
 Refusal / reticence due to need for hospital admission for titration 
 Patient unconvinced about clozapine’s efficacy 
 Patient concerned about tolerability 
 Significant medical factors / complications 
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Practitioners were asked to rate the following factors on their likelihood to delay prescribing, 
again with response options of: infrequently/somewhat frequently/fairly frequently/very 
frequently/don’t know.   Included in this question set were barriers that come from the clinician 
themselves regarding concerns around potential tolerability or medical complications. 
 Administrative (e.g. Time taken to register the patient with a clozapine monitoring 
service) 
 Obtaining baseline blood tests 
 Staff resources (e.g. Lack of staff to monitor clozapine) 
 Need for hospital admission (e.g. Delays in obtaining an admission) 
 Cost of clozapine medication 
 Concerns about tolerability 
 Significant medical factors / complications 
In order to evaluate opinion on the usefulness of additional administrative or clinical help in 
initiating clozapine, respondents were asked directly: 
‘In your team, would additional clinical and/or administrative resources facilitate the 
initiation of clozapine?’ (Yes/No) 
Respondents were also asked to rate the following factors in terms of helpfulness (not 
helpful/somewhat helpful/fairly helpful/very helpful/don’t know): 
 Additional administrative support (e.g. patient registration) 
 Additional staff dedicated to obtaining baseline blood tests 
 Dedicated hospital beds to enable initiation of clozapine as an inpatient 
 Dedicated staff to arrange and monitor the initiation of clozapine as an out-patient 
 Dedicated day-hospital placements to initiate clozapine as an outpatient 
Finally, I was interested in the relationship between staff perception of the scale of under-
prescribing of clozapine as compared to the reality demonstrated in my previous study.  
Participants were asked: 
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‘Approximately what percentage of patients under your care who are eligible for 
clozapine are not currently receiving clozapine?’ 
 0 – 20% 
 21 – 40% 
 41 – 60% 
 61 – 80% 
 81 – 100% 
 Statistical analysis 
Data were analysed using Microsoft Excel 2010 and IBM SPSS Statistics 21.  Responses 
from doctors (trainee psychiatrists and consultant psychiatrists combined) and pharmacy 
staff (pharmacists, pharmacy technicians and pre-registration pharmacists combined) were 
compared using the Wilcoxon-Mann-Whitney two-sample rank-sum test.  This test describes 
the shape of the distribution of scores in each group by ranking the data; the lowest score is 
given a rank of 1, the next highest a rank of 2, and so on.  In this way, the effect of outlying 
results is eliminated as all the analysis is carried out on the ranked position of the data, rather 
than the actual scores.  Higher mean ranks are equivalent to higher mean scores in the 
original data, and so the professional group with the highest mean rank will be the group that 
contains the greatest number of high scores from the questionnaire responses.  The Mann-
Whitney test statistic, U, is calculated using the sample sizes of the two groups, and the sum 
of the ranks for the first group.  It is directly related to Wilcoxon test statistic, W, and the two 
can be used interchangeably.  The z-score is calculated from the test statistic, the mean of 
the test statistic, and the standard error.  Finally, the asymptotic significance is given which 
is the probability of the test statistic of the magnitude calculated or above occurring if there 
were no difference between the two groups (the null hypothesis).   
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 Results 
In total, 144 responses were received, the majority of which were from females (58%, n = 
83).   The most commonly represented age group was between 26 and 35 years (47%, n = 
68).  At the time of sampling the majority of practitioners worked predominantly in inpatient 
areas (63%, n = 91).  Doctors were the most frequent responders (trainee psychiatrists, 42%, 
n = 60; consultant psychiatrists, 14%, n = 20), followed by members of pharmacy staff (16%, 
n = 23).   The distribution of respondents is shown in Table 3-1.  There was no forced function 
to answer all questions, and so the results reflect some degree of attrition of respondents 
throughout the questionnaire.  Responses to free-text questions are given in Appendix D. 
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  n % 
Gender 
Female 83 58 
Male 60 42 
Not answered 1 1 
Age 
18-25 years 6 4 
26-35 years 68 47 
36-45 years 40 28 
46-55 years 24 17 
56+ years 4 3 
Not answered 2 1 
Professional title 
Care coordinator 2 1 
Consultant psychiatrist 20 14 
Nurse 26 18 
Occupational therapist 1 1 
Pharmacy staff 23 16 
Psychologist 4 3 
Social worker 7 5 
Trainee psychiatrist 60 42 
Other 1 1 
Main working location 
Inpatient 91 63 
Outpatient 36 25 
Unknown 17 12 
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Table 3-2 Answers to questionnaire: factors likely to delay clozapine initiation 












 % (n) % (n) % (n) % (n) % (n)  
       
In your opinion, how frequently do the following patient factors lead to delays in the initiation of clozapine once clozapine treatment is 
indicated? 
Refusal/reticence about obtaining baseline blood tests 14 (18) 29 (37) 33 (42) 23 (30) 1 (1) 128 
Refusal/reticence about regular blood monitoring 9 (11) 27 (34) 31 (40) 34 (43) 0 (0) 128 
Refusal/reticence due to need for hospital admission for titration 26 (33) 22 (28) 18 (23) 14 (17) 19 (24) 125 
Patient unconvinced about clozapine's efficacy 29 (37) 32 (41) 23 (30) 7 (9) 9 (11) 128 
Patient concerned about tolerability 24 (31) 25 (32) 34 (44) 12 (15) 5 (6) 128 
Significant medical factors/complications 23 (29) 36 (46) 23 (30) 14 (18) 4 (5) 128 
       
How frequently do the following factors delay you from initiating/supporting clozapine titration in patients eligible for treatment? 
Administrative (e.g. time taken to register with monitoring 
scheme) 57 (69) 19 (23) 11 (13) 2 (3) 11 (13) 121 
Obtaining baseline blood tests 36 (43) 34 (40) 15 (18) 7 (8) 8 (10) 119 
Staff resources (e.g. lack of staff to monitor clozapine) 59 (71) 11 (13) 12 (14) 10 (12) 8 (10) 120 
Need for hospital admission (e.g. delays in obtaining an 
admission) 40 (48) 13 (15) 13 (15) 7 (8) 28 (33) 119 
Cost of clozapine medication 82 (99) 1 (1) 1 (1) 0 (0) 17 (20) 121 
Concerns about tolerability 35 (42) 33 (40) 20 (24) 7 (8) 6 (7) 121 
Significant medical factors/compliance 21 (25) 36 (44) 24 (29) 13 (16) 6 (7) 121 
       
Data are shown as percentage of respondents who answered each question
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Table 3-2 shows that patient factors were most often nominated as ‘very’ or ‘fairly’ frequently 
leading to delays in the initiation of clozapine – either refusal/reticence about obtaining 
baseline or regular blood tests.  Factors most often chosen as ‘not’ frequently leading to 
delays in clozapine initiation were the need for hospital admission for titration of clozapine, 
or patients being unconvinced of the efficacy of clozapine.  A lack of resources for monitoring 
clozapine was the factor most often chosen as likely to delay clozapine initiation, with staff 
concerns about tolerability, comorbid medical factors, or compliance ‘fairly’ frequently being 
an issue.  The cost of clozapine was clearly not an issue, with the majority of respondents 
feeling this way.
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Table 3-3 Answers to questionnaire: factors likely to aid access to clozapine 













 % (n) % (n) % (n) % (n) % (n)  
 
In your opinion, how helpful would the following factors be in terms of facilitating the initiation of clozapine, were they available? 
Additional administrative support (e.g. patient registration) 22 (26) 32 (38) 24 (28) 15 (18) 7 (8) 118 
Additional staff dedicated to obtaining baseline blood tests 15 (18) 28 (33) 27 (32) 27 (32) 3 (3) 118 
Dedicated hospital beds to enable initiation of clozapine as an inpatient 17 (20) 25 (29) 18 (21) 26 (30) 
15 
(17) 117 
Dedicated staff to arrange and monitor the initiation of clozapine as an outpatient 11 (13) 18 (21) 24 (28) 40 (47) 8 (9) 118 
Dedicated day-hospital placements to initiate clozapine as an outpatient 12 (14) 21 (25) 21 (24) 38 (45) 8 (9) 117 
       
Data are shown as percentage of respondents who answered each question
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Table 3-3 shows that factors nominated as ‘very helpful’ by responders to the survey were 
dedicated staff to initiation clozapine as an outpatient, and day-hospital placements for the 
same.  Dedicated inpatient beds were also thought likely to be helpful, as were staff focussed 
on obtaining baseline blood tests.  Extra administrative support for patient registration 
appeared likely to be less helpful. 
 Perceived familiarity with guidelines 
Self-perceived familiarity with the UK NICE schizophrenia guidelines was high, with 81% (n 
= 113 of 140 respondents) stating that they were ‘fairly’ (45%, n = 63) or ‘very’ (36%, n = 50) 
familiar with the guidance (Figure 3-1).   
 
Figure 3-1 Responses to ‘how familiar are you with the NICE guidelines relating to treatment-resistant 
schizophrenia?’ 
Nearly half (48%, n = 69 of 143 respondents) were also ‘very familiar’ with the methods of 
initiation of clozapine (Figure 3-2), with 56% (n = 79 of 141 respondents) stating that they 
had been responsible for authorising or supporting the initiation of clozapine therapy in the 
preceding six months.    A significant minority however (14%, n = 20) had ‘never’ done so 
(Figure 3-3).  Psychiatrists stated they had a median of 1 patient (range = 0 – 40, IQR = 6) 
































Figure 3-2 Responses to ‘How familiar are you with methods for the initiation of clozapine treatment?’ 
 
 
Figure 3-3 Responses to ‘I have been responsible for authorising/supporting clozapine initiation and 
titration…’ 
 Opinions of clozapine effectiveness 
When asked to rate the relative effectiveness of clozapine in treating schizophrenia on a 1 to 
10 Likert scale (1 indicating ‘much less effective’, 5 being ‘about the same’, and 10 ‘much 
more effective’ than other antipsychotics), the mode of the scores given was 8 (range 1 to 























































Figure 3-4 Responses to ‘how would you rate clozapine’s effectiveness in treating schizophrenia compared 
with other antipsychotics?’ 
Most (71%, n = 96 of 135 respondents) felt that patients were ‘somewhat more satisfied’ with 
clozapine treatment, compared with patients treated with other atypical antipsychotics.  
However, 19% (n = 25) thought that clozapine-treated patients are ‘somewhat less satisfied’ 
than their counterparts on atypical drugs (Figure 3-5). 
 
Figure 3-5 Responses to ‘In terms of treatment satisfaction, how satisfied do you believe patients treated 

































































The majority (78%, n = 105 of 134 respondents) of responders stated that they would 
consider authorising or supporting the initiation of clozapine after two adequate antipsychotic 
trials had failed.  A minority (14%, n = 19) would wait until three antipsychotics had been 
tried, 3% (n = 4) would postpone until the fourth antipsychotic had failed, and 4% (n = 4) 
would give clozapine after one adequate trial of another antipsychotic (Figure 3-6). 
 
Figure 3-6 Responses to ‘When would you typically consider authorising/supporting the initiation of clozapine 
treatment?’ 
Overall 35% (n = 50 of 143 respondents) of responders thought that between zero and 20% 
of their patients who were not receiving clozapine would be eligible to do so, and the same 
proportion stated that they didn’t know how many of their patients were not prescribed 















































Figure 3-7 Responses to ‘Approximately what percentage of patients under your care who are eligible for 
clozapine are not currently receiving clozapine?’ 
 Factors influencing clozapine delay 
Practitioners were asked how frequently they thought a range of factors were responsible for 
delays in the initiation of clozapine, once treatment was indicated.  Figure 3-8 presents the 
results, shown as the percentage of respondents who indicated that the factor restricts the 
use of clozapine ‘fairly’ or ‘very’ frequently.  The factors most frequently chosen as ‘very’ or 
‘fairly’ restrictive to clozapine use were patient refusal or reticence regarding baseline or 
ongoing blood tests, with more than 50% of respondents for each of these factors feeling this 
way.  The cost and administrative burden of clozapine were least likely to be nominated as 




































































































 Factors that reduce delays to clozapine initiation 
Practitioners were asked how frequently they thought a range of factors would help facilitate 
the initiation of clozapine, were they available.  The results are presented in Figure 3-9.  
Dedicated staff for outpatient clozapine initiation, obtaining baseline blood tests, and day 
hospital placements specifically for this purpose, were felt by more than half of respondents 
to be ‘very’ or ‘fairly’ helpful for increasing clozapine initiation. 
 
Figure 3-9 Responses to ‘How helpful would the following factors be in terms of facilitating the initiation of 
clozapine, were they available?’ 
 Comparison by profession 
Members of pharmacy staff declared better familiarity with the use of clozapine than other 
professionals; 68% (n = 15 of 22 respondents) were ‘very’ familiar with the NICE 
schizophrenia guidelines, compared with 27% (n = 21 of 79 respondents) of medical staff, 































































































Figure 3-10 Responses to ‘How familiar are you with the NICE guidelines relating to treatment resistant 
schizophrenia?’ 
A similar response pattern was evident when asked how familiar respondents were with the 
methods for the initiation of clozapine, with 74% (n = 17 of 23 respondents) of pharmacy staff 
feeling ‘very familiar’ with the process, representing the majority of responses for this 
professional group (Figure 3-11).  The most frequently selected response from medical staff 
was ‘fairly familiar’ (44%, n = 40 of 80 respondents). 
 










































































When asked to rate clozapine’s effectiveness compared with other atypical antipsychotics, 
pharmacy staff gave the highest scores (mean 8.2, SD = 1.1), doctors slightly lower (mean 



















































This is also reflected in professionals’ opinions of patient satisfaction with treatment; whilst 
the majority of all professionals thought patients were ‘somewhat more satisfied’ with 
clozapine treatment than other antipsychotics, both doctors and other health professionals 
gave a wider spread of results – 20% (n = 15 of 74 respondents) and 21% (n  = 8 of 38 
respondents) respectively thought patients were ‘somewhat less satisfied’, compared with 
just 9% (n = 2 of 23 respondents) of pharmacy staff (Figure 3-13). 
Figure 3-13 Responses to ‘In terms of treatment satisfaction, how satisfied do you believe patients treated 
with clozapine are, compared with patients treated with other (atypical) antipsychotics?’ 








How familiar are you with the NICE 
guidelines relating to treatment 
resistant schizophrenia? 
Doctor 79 46.80 0.003 
Pharmacy staff 22 66.07 
Total 101  
How familiar are you with methods for 
the initiation of clozapine treatment? 
Doctor 80 48.38 0.012 
Pharmacy staff 23 64.59 
Total 103  
How would you rate clozapine's 
effectiveness in treating schizophrenia 
compared with other antipsychotics? 
Doctor 78 49.08 0.201 
Pharmacy staff 23 57.52 
Total 101  
In terms of treatment satisfaction, how 
satisfied do you believe patients 
treated with clozapine are, compared 
with patients treated with other 
(atypical) antipsychotics? 
Doctor 74 48.69 0.806 
Pharmacy staff 23 50.00 
Total 97  
Table 3-4 demonstrates that pharmacy staff allocated higher scores to all questions than 
medical staff, shown by higher mean ranks in the first results column.  The data show (see 













































for familiarity with the NICE schizophrenia guidelines (U = 537.5, p = 0.003) and familiarity 
with methods for initiation of clozapine (U = 630.5, p = 0.012).  As the mean ranks for both 
questions were higher for the pharmacy group, I can conclude that pharmacy staff were more 
familiar than medical staff with the NICE schizophrenia guidelines and the methods for 
initiation clozapine, and that this difference was statistically significant.  There was no 
statistically significant difference between the two groups in rating of clozapine’s 
effectiveness (U= 747.0, p = 0.201) or opinions of patient treatment satisfaction (U = 828.0, 
p = 0.806).  Ranking of these later two questions was higher in the pharmacy group however, 
as shown in Table 3-4.  Pharmacy staff were therefore, on average, more familiar with NICE 
guidance, more familiar with clozapine initiation, felt clozapine was more effective, and felt 
patients were more satisfied with clozapine than their medical counterparts did. 
Table 3-5 Mann-Whitney test ranking for patient factor questions 







Refusal/reticence about obtaining 
baseline blood tests 
Doctor 74 48.10 0.944 
Pharmacy staff 21 47.64 
Total 95  
Refusal/reticence about regular blood 
monitoring 
Doctor 75 48.99 0.731 
Pharmacy staff 21 46.74 
Total 96  
Refusal/reticence due to need for 
hospital admission for titration 
Doctor 62 40.66 0.166 
Pharmacy staff 15 32.13 
Total 77  
Patient unconvinced about clozapine's 
efficacy 
Doctor 71 46.59 0.225 
Pharmacy staff 18 38.72 
Total 89  
Patient concerned about tolerability Doctor 74 47.26 0.862 
Pharmacy staff 20 48.40 
Total 94  
Significant medical 
factors/complications 
Doctor 74 45.57 0.738 
Pharmacy staff 17 47.85 
Total 91  
Doctors gave higher mean ranks for all questions relating to patient factors delaying 
clozapine initiation, as shown in Table 3-5, apart from patient concerns about tolerability, and 
significant medical complications, where pharmacy staff ranked higher.  As explained 
previously, the group with higher mean ranks contained the highest scores in response to 
the question.  Doctors therefore appeared to feel more strongly than the pharmacy staff that 
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patient factors (refusal of blood tests, hospital admission, concern about efficacy, tolerability 
or medical complications) were likely to impact on prescribing of clozapine.  Despite higher 
mean ranks, none of these differences between the groups reached statistical significance, 
as shown by the Mann-Whitney test statistics presented in Table 3-5 (all non-significant at p 
> 0.05) and Table 7-37 (Appendix B). 
The majority of all professionals responded that they would consider starting clozapine after 
two adequate antipsychotic trials (medical staff 88%, n = 66 of 75 respondents; pharmacy 
staff 74%, n = 17 of 23 respondents; others 61%, n = 22 of 36 respondents).  Staff members 
in the ‘other’ professions category had a larger proportional spread towards the three and 
four antipsychotic trial categories than the medical and pharmacist groups, with 28% (n = 10 
of 36 respondents) supporting starting after 3 antipsychotic trials, and 8% (n = 3 of 36 
respondents) after 4 trials (Figure 3-14). 
Figure 3-14 Responses to ‘When would you typically consider authorising/supporting the initiation of 
clozapine treatment?’ 
When asked to estimate what proportion of patients under their care were eligible to receive 
clozapine but were not currently doing so, the majority of pharmacy staff (58%, n = 7 of 12 
respondents) thought that more than a fifth of patients were in this position.  A lower 
percentage of medical staff (47%, n = 25 of 53 respondents) and other professionals (38%, 

























































Figure 3-15 Responses to ‘Approximately what percentage of patients under your care who are eligible for 
clozapine are not currently receiving clozapine?’ 
Pharmacy staff also gave differing opinions on the value of extra administrative or clinical 
staff in encouraging the use of clozapine – 74% (n = 17 of 23 respondents) thought this would 
be helpful, compared with 57% (n = 43 of 76 respondents) of doctors, and 51% (n = 21 of 41 
respondents) of other staff members.  When results from all professions were combined a 
narrow majority of responders (58%, n = 81 of 140 respondents) thought that additional 
clinical and/or administrative resources would facilitate the initiation of clozapine in their 
workplace (Figure 3-16). 
Figure 3-16 Responses to ‘In your team/workplace, would additional clinical and/or administrative resources 
facilitate the initiation of clozapine?’ 
When considering staff factors in clozapine delay, mean ranking was higher for all factors in 





































































suggests doctors placing higher emphasis on the importance of these issues than pharmacy 
staff.  However, none of these differences reach statistical significance, as shown by the test 
statistics in Table 3-6 (p > 0.05) and Table 7-38 (Appendix B). 
Table 3-6 Mann-Whitney test ranking for staff factor questions 






Administrative Doctor 69 45.10 0.751 
Pharmacy staff 21 46.81 
Total 90  
Obtaining baseline blood tests Doctor 69 45.42 0.762 
Pharmacy staff 20 43.55 
Total 89  
Staff resources Doctor 68 44.33 0.483 
Pharmacy staff 18 40.36 
Total 86  
Need for hospital admission Doctor 53 34.15 0.516 
Pharmacy staff 13 30.85 
Total 66  
Cost of clozapine medication Doctor 64 42.81 0.426 
Pharmacy staff 20 41.50 
Total 84  
Concerns about tolerability Doctor 69 46.86 0.080 
Pharmacy staff 19 35.95 
Total 88  
Significant medical 
factors/compliance 
Doctor 69 45.10 0.942 
Pharmacy staff 20 44.65 
Total 89  
Table 3-7 shows that mean ranking of enabling factors for clozapine initiation was higher for 
all suggestions in the doctor group, apart from the availability of dedicated hospital beds, 
where pharmacy staff ranked this higher.  The differences between the groups did not reach 
statistical significance for any of the enabling factors (see also Table 7-39, Appendix B). 
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Table 3-7 Mann-Whitney test ranking enabling factor questions 






Additional administrative support Doctor 68 46.15 0.117 
Pharmacy staff 19 36.32 
Total 87  
Additional staff dedicated to obtaining 
baseline blood tests 
Doctor 69 46.55 0.275 
Pharmacy staff 20 39.65 
Total 89  
Dedicated hospital beds to enable initiation 
of clozapine as an inpatient 
Doctor 62 37.04 0.388 
Pharmacy staff 13 42.58 
Total 75  
Dedicated staff to arrange and monitor the 
initiation of clozapine as an outpatient 
Doctor 66 42.11 0.934 
Pharmacy staff 17 41.59 
Total 83  
Dedicated day-hospital placements to 
initiate clozapine as an outpatient 
Doctor 63 41.06 0.967 
Pharmacy staff 18 40.81 
Total 81  
In summary, pharmacy staff reported themselves more familiar with NICE guidelines (median 
= ‘very familiar’) than doctors (median = ‘fairly familiar’, p = 0.003).  Pharmacy staff also felt 
more familiar with methods of initiation of clozapine (median = ‘very familiar’) than doctors 
(median = ‘fairly familiar, p = 0.012).  Differences in responses to other questions did not 
reach statistical significance. 
 Summary 
In total, 144 clinical staff completed the questionnaire.  The majority (81%) of respondents 
were ‘fairly’ or ‘very’ familiar with clozapine prescribing guidelines.  Members of pharmacy 
staff rated themselves more familiar with the guidelines and also procedures for initiation of 
clozapine than medical staff.  Barriers to prescribing most commonly stated as being ‘very 
frequently’ a problem were patient concerns about tolerability of clozapine or patient refusal 
to adhere to blood test monitoring.  Staff members also felt medical complications frequently 
prevented clozapine prescription.  Dedicated staff or day hospital placements devoted to 
clozapine initiation were identified as factors most likely to increase prescribing of clozapine.  
Professionals identified the dominant barriers to prescribing as being patient focussed – 
refusal of blood test monitoring or concerns about tolerability.  Clinician fears about 
compliance or medical complications were also important.  The development of outpatient 
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services specifically tasked with initiating clozapine may help to increase the frequency of 
prescribing of clozapine earlier in treatment than is currently seen. 
 Publications arising from this study 
See Appendix I: Siobhan Gee, Francis Vergunst, Oliver Howes, David Taylor (2014) 
Practitioner attitudes to clozapine initiation.  Acta Psychiatrica Scandinavica, 130(1):16
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4 Patient attitudes to clozapine initiation 
 Introduction 
Despite the established unique efficacy of clozapine in treatment-resistant schizophrenia, as 
shown in chapter 2 it remains under-prescribed (148).  The reasons for this are not clear but 
perhaps are most likely to lie at the interface between the patient and prescriber. I have 
shown in chapter 3 that the barriers psychiatry practitioners cited as most frequently 
preventing clozapine prescription are: patient refusal of regular blood testing; patient refusal 
of baseline blood testing; patient concerns about tolerability; medical complications; patient 
refusal of hospital admission; and the patient being unsure of efficacy (149). If one excludes 
co-morbid medical complications, the top five reasons that practitioners report for not 
prescribing clozapine are patient-related. This is at odds with research examining patient 
opinions of clozapine which are overwhelming positive, with tolerability and the need for 
blood tests considered to be problems far less frequently by patients than by clinicians (150). 
However, there is a significant bias in that the rather limited available literature is confined to 
the opinions of patients who are already taking clozapine.  By definition this cohort of patients 
will have consented to treatment and remained compliant with it. Surveys of existing patients 
could be said to confirm only what might otherwise be assumed.  Therefore, in this study I 
surveyed the perhaps more relevant views of those patients who are eligible for, but are not 
currently prescribed, clozapine, aiming to better understand the patient-related barriers to 
clozapine initiation.  
 Objectives 
 To establish the familiarity and acceptability of clozapine to patients who have never 
received clozapine, but would be eligible to do so. 
 To elucidate factors that put patients off trying clozapine. 
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 Method 
In order to inform the questions to be asked in the survey, conducting a focus group of 
patients was considered.  This would however be difficult to run with a group of patients all 
suffering acute psychosis, and additionally the key purpose of this study was to examine 
whether the opinions of clinicians expressed in the previous survey were borne out when 
presented to patients, rather than to develop new themes of enquiry.  Instead, the 
questionnaire for use in the study was designed to provide complementary answers to the 
questionnaire previously administered to psychiatric clinicians.  It was drafted, commented 
on and adjusted by the research team.  Alterations were made to the clarity of questions 
asked and simplicity of possible answers.  It was then piloted to 5 patients, and no further 
changes were required.  The questionnaire is available in Appendix E. 
Over a 593 day period, patients admitted to the acute wards at the Bethlem Royal Hospital 
were assessed for eligibility for the study.  Eligibility for inclusion in the study was determined 
by review of clinical case notes against the following criteria: 
 Admission to an acute psychiatric ward at the Bethlem Royal Hospital 
 Prescription of two or more antipsychotics over the course of the illness (up to and 
including the current prescription), each for at least 6 weeks and at a minimal effective 
dose (defined as outlined in chapter 2) 
 Diagnosis of schizophrenia or schizoaffective disorder 
 No previous trials of clozapine 
It was assumed that the principal reason for admission was psychiatric relapse, and that this 
could be due to medication failure.  Assessment of compliance with medication prior to 
admission was not made.  Detailed assessment of physical health pertinent to the safety of 
clozapine initiation was not made, but where it was immediately obvious from the clinical 
notes that patients would be excluded for these reasons from clozapine challenge, these 
patients were marked as ‘non-participants’. 
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Likert scales were used where possible, rather than the multiple choice style used in the 
practitioner survey.  Oral multiple choice questions would have been lengthy to explain to 
participants, and also would have increased the risk of interviewer bias as they attempt to fit 
any answer given into the predetermined response options.  I offered ‘don’t know’ where 
possible to reduce the chance of yea saying (151), and used follow-up open-ended questions 
to try to fully elicit participants’ understanding.  Open-ended questions can produce low 
response rates, and are also open to the potential for the researcher imposing their own 
interpretation on the answers, especially where participants are less articulate (151), and so 
open-ended questions were linked as much as possible to Likert or yes/no questions. 
Patients were approached for inclusion in the survey by the lead investigator (SG), and if 
consent was given then a face-to-face questionnaire administered (also by SG).  Patients 
were first asked whether or not they had heard of clozapine.  If they answered “no” then a 
brief paragraph (see 0) detailing the indication for clozapine (an antipsychotic, used to treat 
the symptoms of schizophrenia described as a reduction in hallucinations, improvement in 
concentration and thinking), common side effects (constipation, drowsiness, hypersalivation, 
dizziness on standing, tachycardia) and rare side effects (a reduction in white blood cells) 
was read to them.  They were fully informed of the need for blood testing and its frequency, 
and also that some people found clozapine to be the only medication effective for them.  This 
paragraph was also read to patients who replied that they had already heard of clozapine, if 
it became clear later in the interview that there were aspects of the treatment that they were 
either not aware of, or did not understand fully.  It was not initially read to all patients as I felt 
that this was likely to reduce participation in the study given the effect of active psychosis on 
the ability of patients to concentrate for long periods. 
Participants were then asked whether they had ever been asked to take clozapine, and if so 
what the outcome was.  They were asked whether they would consider taking clozapine now, 
were it to be offered to them.  A follow-up opened-ended question was asked to explore why 
they would/wouldn’t consider taking clozapine now. 
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Likert scales were used to assess patients’ opinions on the need for baseline blood tests, 
regular blood tests, the side effects, and the potential need for hospital admission to initiate 
clozapine.  Written descriptions were used to present the possible options, which ranged 
from ‘0’ (that doesn’t bother/worry me at all), ‘1’ (I’d be slightly bothered/worried but I’d still 
be willing to try it), ‘2’ (I’d be fairly bothered/worried but I’d still be willing to try it), ‘3’ (I’d be 
very bothered/worried but I’d still be willing to try it) to ‘4’ (I wouldn’t try clozapine because of 
this/the side effects).  Participants were also asked whether starting clozapine at home would 
be preferable to being admitted to hospital in order to titrate the dose. 
Finally, participants were asked to compare, as far as they were able, clozapine with 
medicines they had taken in the past, or were taking currently, and to rate how much they 
thought clozapine would help them.  A Likert scale was again used to gather responses, 
ranging from ‘0’ (clozapine would be a lot less helpful than other medicines I’ve had), ‘1’ 
(clozapine would be slightly less helpful than other medicines I’ve had), ‘2’ (clozapine would 
be about the same as other medicines I’ve had), ‘3’ (clozapine would be a bit better than 
other medicines I’ve had), to ‘4’ (clozapine would be a lot better than other medicines I’ve 
had’).  Where possible, their reasons for their answers were also noted. 
Patients who fully or partially completed the questionnaire were designated ‘participants’, 
and patients who refused to take part, or could not be interviewed for other reasons were 
designated ‘non-participants’.   
 Statistical analysis 
Independent t-tests for continuous variables and Pearson’s chi-squared test for categorical 
variables were used to compare the demographics of patients in the participating and non-
participating groups.  All data were analysed using SPSS version 22.   
 Results 
In total, 468 patients admitted to the wards were assessed for entry into the study.  Of these, 
116 fulfilled the eligibility criteria for the study and of these 25% (29 of 116 patients) refused 
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to take part, 5% (6 of 116 patients) were considered too unwell to provide informed consent, 
10% (12 of 116 patients) were discharged before an interview could take place, and 7% (8 
of 116 patients) were excluded for other reasons (predominantly a lack of sufficient English 
or transfer to another hospital before interview) (Table 4-1).  The remaining 61 patients were 
considered ‘participants’ in the survey, and of these 82% (50 of 61 patients) answered all the 
questions asked, with a further 18% (11 of 61 patients) answering at least 1 question. 
Table 4-1 Demographics and participation details shows the demographics of the total 
cohort, participants, and non-participants.  The majority of the total group (72%), participants 
(79%) and non-participants (66%) were male.  The majority in each group were also black 
(total group = 53%, participants = 51%, non-participants = 56%) and were diagnosed with 
schizophrenia (total group = 76%, participants = 74%, non-participants = 78%).  There were 
no statistically significant differences between the demographics of the participant and non-
participant groups. 
Table 4-1 Demographics and participation details 
 Total 
cohort, 
N = 116 
Participants, 
n = 61 
Non-
participants, 
n = 55 
p 
Mean age, years (range) 43  
(19 - 76) 
42  
(20 – 71) 
44  
(19 – 76) 
0.31 
Gender, male (%) 84 (72) 48 (79) 36 (66) 0.05 
Ethnicity, n (%) White 31 (27) 18 (30) 13 (24) 0.08 
Black 62 (53) 31 (51) 31 (56) 
Asian 12 (10) 4 (7) 8 (15) 
Mixed or other 11 (9) 8 (13) 3 (5) 
Mean days between admission and 
interview (range) 
13  
(0 – 68) 
11 (0 – 61) 15 (1 – 68) 0.21 
Diagnosis, n (%) Schizophrenia 88 (76) 45 (74) 43 (78) 0.15 
Schizoaffective 
disorder 
28 (24) 16 (26) 12 (22) 
Just over half of the patients surveyed had heard of clozapine (54%, 33 of 61 patients), and 
a fifth (19%, 11 of 57 patients) recalled being asked to consider taking it as a treatment for 
their illness (Table 4-2). 
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Table 4-2 Responses to ‘Have you heard of a medication called clozapine?’ 
When asked for their probable response if asked to take clozapine now, 35% of patients said 
they would refuse it (20 of 57 patients) although this was a narrow majority, with 30% (17 of 
57 patients) saying that they would be willing to try it (Table 4-3). 
Table 4-3 Responses to ‘If you were asked to take clozapine now, how would you respond?’ 
 N (%) 
If you were asked to take 
clozapine now, how would you 
respond? 
I’d take it 17 (30) 
I wouldn’t take it 20 (35) 
I might take it 2 (4) 
Don’t know 7 (12) 
Other 1 (2) 
 
Of those seventeen subjects that said they would take clozapine if it were offered to them 
now, fourteen provided further explanation (see Appendix F).  The most frequent theme (5 
patients) that emerged was that the patient wanted their mental health to improve, and felt 
that clozapine would be helpful in this way: 
“I want my mental health to recover” 
“I need something in addition to my current medicines” 
The next most common statements (4 patients) were related to trust in the opinion of the 
professionals caring for them: 
“If it would help I’d take it.  I trust the doctor’s opinion – if they say I need it then I’ll take it” 
“I know it would do me good.  I trust you.” 
For patients who stated that they would not take clozapine, might take it or were not sure if 
they would take it if it were offered to them, 38 provided a more detailed response.  The most 
commonly cited reason (15 patients) for either refusing clozapine or being unsure about 
treatment was related to the side effects or blood monitoring, and of these most responses 




Don’t know,  
n (%) 
Have you heard of clozapine? 61 33 (54) 26 (43) 2 (3) 
Have you ever been asked to take 
clozapine? 
57 11 (19) 40 (70) 6 (11) 
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focussed on the effects on the white blood cells or the blood monitoring in some way (8 
patients):  
“There are more negatives than positives… the side effects” 
“The constant monitoring.  The side effects – salivation, drowsiness.  I don’t like needles.” 
 “It kills white blood cells” 
“The white cell thing sounds risky” 
Other common themes included not believing that any medication was necessary at the 
moment (5 patients), being happy with the current medication (4 patients) and being unsure 
what the effects of clozapine might be (3 patients). 
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Table 4-4 Responses to Likert scale-measured questions 
  That doesn’t 
bother/worry 
me at all 
I’d be slightly 
bothered/worried but 
would still try 
clozapine 
I’d be fairly 
bothered/worried 
but would still try 
clozapine 
I’d be very 
bothered/worried 










N  n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
How would you 




54 19 (35) 6 (11) 5 (9) 5 (9) 17 (32) 1 (2) 1 (2) 
How would you 





54 15 (28) 5 (9) 4 (7) 7 (13) 22 (41) 0 (0) 1 (2) 
How much do 
the side effects 
of clozapine 
worry you? 
53 9 (17) 8 (15) 1 (2) 10 (19) 23 (43) 2 (4) 0 (0) 
How would you 
feel about being 
admitted to 
hospital in order 
to start 
clozapine? 




When asked how they felt about having blood taken before starting clozapine, a narrow 
majority of participants (35%, 19 of 54 patients) reported that this wouldn’t bother them at all 
(Table 4-4).  The opposite answer, ‘I wouldn’t try clozapine because of this’ was the next 
most common response (32%, 17 of 54 patients).  Proportionally more patients reported that 
regular blood tests would put them off trying clozapine (41%, 22 of 54 patients), with 28% 
(15 of 54 patients) stating that this wouldn’t bother them at all.  The side effects of clozapine 
were a barrier to clozapine for a substantial proportion of patients, with 43% (23 of 53 
patients) saying that this would put them off clozapine entirely and 19% (10 of 53 patients) 
reporting that the side effects would worry them very much.  In contrast, 17% (9 of 53 
patients) said the side effects didn’t worry them at all, and 15% (8 of 53 patients) said they 
would be slightly worried.  When asked how they would feel about coming into hospital in 
order to initiate clozapine, the largest proportion of patients (49%, 25 of 51 patients) said this 
would put them off trying clozapine.  However, a significant proportion (29%, 15 of 51 
patients) reported that being admitted in order to start clozapine wouldn’t bother them at all. 
When asked which side effects particularly worried them, 34 patients gave more detailed 
answers.  Of these, the most common side effect cited was dizziness or any cardiac 
complication (8 patients), followed by the effects on white blood cells (6 patients).  Some 
patients expressed beliefs they held about the medicine both in general and in relation to 
side effects: 
“I see other patients that drool, it means you are disabled.” 
“The strength of the pill makes me worried about collapsing.  You can’t miss a day of taking 
clozapine, so you are basically dependent on it.” 
Others weighed the balance of side effects against the potential benefits: 
“Medicines are there to improve and stay positive so I’m not worried about side effects.” 
“I know other people who take clozapine.  For them the psychosis is so bad the side effects are 
worth taking.  It’s a balance for each individual.  Therefore if I needed clozapine I wouldn’t care 
about the side effects because I would need it.” 
“I've had drooling on amisulpride before, so I wouldn't want this to happen again.  I don't need 
clozapine.  But I recognise that if psychosis is really bad then people need clozapine and then 
for them any negative problems (having to have bloods done, the side effects, being admitted) 
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are outweighed by the benefits.  So the problem is people not having any insight into the severity 
of their psychosis.” 
A clear majority of participants (67%, 34 of 51 patients) felt that starting clozapine at home 
would be better than being admitted to hospital, although a significant proportion (26%, 13 of 
51 patients) disagreed (4 (8%) did not give an opinion). 
Comments made by patients who stated that they would rather come into hospital to start a 
medicine than be at home included: 
“I would be worried about starting clozapine at home because side effects wouldn’t be 
monitored.” 
“A professional should be starting medicines so it is better to be in hospital for this, not at home.” 
“If you feel ill it’s better to come into hospital for medicines to be started because that’s where 
the doctors are – it’s better to be with them.” 
When asked to compare the likely effect of clozapine to other medicines they had taken, the 
majority of patients (32%, 16 of 50 patients) felt that it would be “a lot less helpful” for them, 
3 (6%) felt it would be slightly less helpful, and 6 (12%) felt it would be “about the same”.  
Twelve participants (24%) thought clozapine would be more helpful to them than their 
previous medication; “a bit better” (7 of 50 patients, 14%) or “a lot better” (5 of 50 patients, 
10%).  The second most common answer was “I don’t know” (20%, 10 of 50 patients).  Three 
participants’ answers could not be classified.   
 Summary 
I interviewed 61 of 116 eligible patients and 50 (82%) answered all questions.  At interview, 
33 of 61 participants (54%) had heard of clozapine and 17 of 57 (30%) said they would take 
it if asked.  Overall, 31 of 54 (57%) respondents said blood testing would not preclude them 
taking clozapine.  The necessity for hospital admission was seen as the greatest barrier to 
receiving clozapine – 25 of 51 respondents (49%) stated this would be a reason for refusing 
clozapine.  Concerns about adverse effects of clozapine were considered sufficient to refuse 
clozapine in 23 of 53 (43%) respondents.  Overall, 12 of 50 (24%) respondents felt clozapine 
would be helpful to them.  Patients’ acceptance of clozapine is likely to be improved by 
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offering the opportunity to start clozapine at home and by improved education about the 
therapeutic benefits of clozapine and the management of its adverse effects.  Blood testing 
does not appear to be an important barrier to initiation of clozapine. 
 Publications arising from this study 
See Appendix I: Siobhan Gee, Sukhwinder Shergill, David Taylor (2017) Patient attitudes 
to clozapine initiation.  International Clinical Psychopharmacology, 32(6):337-3
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5  Factors associated with changes in hospitalisation in 
patients prescribed clozapine 
 Introduction 
There is now a large body of evidence demonstrating that long periods of untreated 
psychosis are associated with increased symptom severity, and that the longer this delay is, 
the worse the symptoms are (152).  Clarke et al. (153) showed that the long term 
consequences of a prolonged untreated psychosis include a reduced likelihood of remission 
and reduced functional outcome, as well as increased psychopathology.  Cognitive function 
(154-157), occupational functioning (158, 159), forensic risk (160), subsequent psychiatric 
admissions (161), and even smoking habits (162) have all been shown to be adversely 
affected by a long untreated psychosis.  The initiation of antipsychotic medication in the first 
episode of psychosis results in better outcomes (163-166), and the latency of that treatment 
is a significant predictor of time to treatment response (167).  Further than this, a long 
untreated psychosis is also associated with poorer response to antipsychotic treatment once 
it is initiated (168).   
It is clear that the duration of untreated psychosis in first episode schizophrenia affects 
eventual response (both in latency and magnitude) to antipsychotics.  It is not clear if delays 
in starting clozapine treatment with consequent periods of poorly or incompletely treated 
psychosis also result in an adverse effect on response to clozapine and on clinical and 
functional outcomes. This study aims to examine the relationship between the delay in 
receiving clozapine and treatment outcomes after clozapine is started using inpatient 
admissions as a proxy marker for relapse, and investigate the consequence of stopping 
clozapine. 
 Objectives 
 To investigate the effect of clozapine on inpatient bed use. 
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 To examine whether the theoretical delay to starting clozapine affects inpatient bed use, 
once clozapine has been started. 
 To establish whether a patient’s age, ethnicity, diagnosis, gender, number of previous 
non-clozapine antipsychotics or whether they continued or discontinued clozapine affects 
inpatient bed use, once clozapine has been started. 
 Method 
I used the same patient data set described in chapter 2 for this study, with admissions data 
gathered from the time of diagnosis up to the study end date (01.11.14). 
 Exclusion criteria 
Of the original data set of 149 patients, 47 were excluded from this study (Table 5-1).  Of 
these 47, 31 patients had had contact at some point during their treatment history with 
forensic services.  Forensic psychiatric services are those that specialise in the assessment 
and treatment of people with mental health disorders undergoing legal or court proceedings, 
or who have offended (169).  For these patients, factors other than their mental state are 
likely to influence their length of stay in psychiatric services, as the Ministry of Justice may 
control their discharge date. 
Between the end of the previous study period and the end of the current study period 5 
patients died, and these were also excluded from the study.  Patients who were discharged 
out of SLaM were lost to follow up as their subsequent clinical notes were inaccessible.  This 
accounted for 9 patients.  Of the remaining 2 excluded patients, 1 was found to be a duplicate, 
and 1 had received clozapine before the start date of the previous study. 
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Table 5-1 Demographic details for patients excluded from analysis 
 Forensic 
patients (n = 
31) 
Deaths (n = 
5) 
Lost to 




Male, n (%) 29 (94) 4 (80) 6 (67) 0 (0) 
Age at first clozapine 
prescription, mean years 
30.32 38 24.67 38.5 
Ethnicity, 
n (%) 
White 10 (32) 3 (60) 5 (56) 2 (100) 
Black 18 (58) 2 (40) 4 (44) 0 (0) 
Asian 0 (0) 0 (0) 0 (0) 0 (0) 
Mixed 3 (10) 0 (0) 0 (0) 0 (0) 
Other 0 (0) 0 (0) 0 (0) 0 (0) 
Diagnosis, 
n (%) 
Schizophrenia 23 (74) 4 (80) 7 (78) 1 (50) 
Schizoaffective 3 (10) 0 (0) 1 (11) 0 (0) 
Other 5 (16) 1 (20) 1 (11) 1 (50) 
 Inclusion criteria 
Demographics and pre-clozapine prescribing histories were available as described 
previously from the data set (see chapter 2).  Data on inpatient admissions were also 
gathered from the clinical notes.  These data were collected from the date of first presentation 
of the patient to mental health services to the end date of the study (01.11.14).  The data 
collected were: 
 Number of admissions 
 Length of admission 
 Reason for admission (where clearly stated) 
All inpatient admissions to psychiatric services were considered an ‘admission’, regardless 
of the country in which the admission took place, or of the type of psychiatric institution to 
which the patient was admitted.  Inpatient admissions to institutions other than those 
specifically designated as ‘psychiatric’ were excluded (e.g. Admissions to general medical 
hospitals), even if the patient was reviewed by a psychiatrist during this admission, as the 
primary reason for admission was assumed to something other than a psychiatric relapse.  If 
the patient was subsequently transferred from a medical (or other) facility to a psychiatric 
inpatient institution, then the latter period was considered an ‘admission’ in the context of this 
study, and the start date of admission taken as the date of transfer to psychiatric services. 
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 Designation of index admission 
The ‘index admission’ was defined as the admission during which clozapine was 
commenced, if clozapine was commenced whilst the patient was an inpatient.  
Acknowledging the different methods for data analysis used by other authors (see 
discussion, chapter 7), I performed sensitivity analyses for 5 different methods (Figure 5-1): 
1. Simple mirror image division (30, 170-178) – days of admission before clozapine are 
attributed to the pre-clozapine period, days of admission after clozapine are attributed 
to the post-clozapine period. 
2. Excluding the entire index admission (84, 90, 177, 179, 180) 
3. Attributing the index admission up to the point of clozapine initiation to the pre-
clozapine period, excluding the first 14 days of the post-clozapine period from 
analysis, and then attributing any remaining days in the index admission to the post-
clozapine period (177, 181) 
4. Attributing the index admission pre-clozapine and the first 14 days of clozapine 
treatment to the pre-clozapine period, then attributing any remaining days of the 
index admission to the post-clozapine period (177) 
5. Attributing the index admission up to the point of clozapine initiation to the pre-




Figure 5-1 Sensitivity analysis methods 
I analysed the data using an intent to treat method, and separately for clozapine continuers 
and discontinuers. 
 Clozapine discontinuation data 
Clinical notes were used to gather data for: 
 Date clozapine was stopped 
 Date clozapine was restarted 
 Medication switched to once clozapine was stopped 
 Reason for clozapine being stopped 
Clozapine was considered to be ‘stopped’ where the stop was followed by a deliberate switch 
to a different antipsychotic medication.  Periods of non-compliance with clozapine, followed 
by retitration directly onto clozapine were not considered as a ‘stop’ episode, even if the 
retitration included a period of prescribing of a second antipsychotic to ‘cover’ the clozapine 
dose escalation.  Short term uses of other medication pending retitration were also excluded, 
where it was clear that the intention of the prescriber was to retitrate, and the delay was 














Clozapine start Start of 
study 14 days after clozapine start 
Index admission 
 131 
monitoring company, obtaining medication, or organising phlebotomy), and not by a clinical 
decision not to restart.  Further discussion and analysis of these data are presented in 
chapter 6. 
 Ethnicity categories 
Ethnicity codes were gathered directly from clinical notes.  Where required for statistical 
analysis, ethnicity categories were created using the standardised categories defined by the 




Table 5-2 Ethnicity code categories 



























Mixed White and Black African 
White and Black Caribbean 
White and Asian 
Caribbean and Asian 






 Statistical analysis 
For the intent to treat population (all patients, regardless of stopping or continuing clozapine), 
bias was tested using scatter plots, z-scores, skew and kurtosis, and tests of normality 
(Kolmogorov-Smirnov and Shapiro-Wilk).  z-scores and normality tests have been described 
in detail in Chapter 2.  There are two ways in which a population can deviate from normal – 
skew, which is a lack of symmetry around the mean, and kurtosis, which is how much the 
scores within the data cluster around the ends of the distribution curve.  Positively skewed 
patterns have the most frequent scores clustered at the lower end of the scale, and negatively 
skewed patterns have the most frequent scores clustered at the opposite, higher end of the 
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scale.  Data sets with positive kurtosis have many scores in the tails of the distribution (also 
termed ‘heavy-tailed’ or leptokurtic).  Data sets with negative kurtosis have fewer scores in 
the tails (also termed ‘light-tailed’ or platykurtic).  In a perfectly normal distribution, the values 
of skew and kurtosis are 0.  Any values above or below this indicate a deviation of the data 
from normal.   
Splitting the data into clozapine continuers and discontinuers, bias was examined using Q-Q 
plots, and paired samples t-tests and Wilcoxon signed rank tests used to compare days of 
admission and numbers of admissions before and after clozapine initiation.   
Paired samples t-tests were used to compare data before and after clozapine initiation.  The 
t-test is carried out by comparing the sample means for each set of data (in this case, data 
for before and after clozapine).  If the samples come from the same population, the means 
are expected to be roughly equal.  As the t-test uses numerical sample means, it can only be 
applied to continuous variables (in this data set, both variables are continuous).  The paired 
samples test is appropriate here (rather than the independent samples t-test) as each patient 
is a member of both groups (before and after clozapine).   
Wilcoxon signed rank test examines differences between results in two groups, where the 
results from each group come from the same participants (in this case, patients were in the 
‘pre-clozapine’ and ‘post-clozapine’ groups).  It is the non-parametric equivalent of the paired 
samples t-test presented above.  Wilcoxon signed rank test is particularly appropriate for this 
set of data as it compares the results in each group by ranking the scores, but also assigns 
the sign (positive or negative) of the difference in the scores to the rank.  In this way it 
examines the change in scores between the two groups.  For this analysis, the difference in 
days of admission was calculated by taking the days post-clozapine away from the days pre-
clozapine, and so a negative score means a higher number of days spent in hospital after 
clozapine was started.  A difference of 0 means that there was no difference in hospital bed 
days before or after clozapine.   
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Linear regression (ANOVA) was used to investigate whether the length of clozapine delay 
affected admission data before and after clozapine was started.  Multivariate analysis of 
variance (MANOVA) was used to look at the effect of the number of pre-clozapine 
antipsychotics, age, gender, ethnicity, diagnosis and continuing or discontinuing clozapine 
on admission data.  Assumptions were tested using Box’s test of equality of variance 
matrices, and multivariate and univariate tests carried out.  The MANOVA was followed up 
with discriminant function analysis where appropriate, and also conducted separately for 
clozapine continuers and discontinuers.  Data were analysed using IBM SPSS Statistics 22. 
 Results 
 Intent to treat group 
The majority of patients were male (62.7%), with a mean age of 38 years (Table 5-3). The 
most commonly represented ethnic group was British (38.2%), followed by Black African 
(11.8%) and Black British (8.8%).  Most patients had a diagnosis of schizophrenia (66.7%). 
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Table 5-3 Group demographics 
 Intent to treat group, n (%) Continuers, n (%) 
Discontinuers, 
n (%) 
N 102 67 35 
Male 64 (62.7) 37 (55.2) 27 (77.1) 
Mean age, years 38.64 39.43 37.11 
Ethnicity 
White 4 (3.9) 3 (4.5) 1 (2.9) 
Black British 9 (8.8) 4 (6.0) 5 (14.3) 
Black African 12 (11.8) 10 (14.9) 2 (5.7) 
Caribbean 8 (7.8) 4 (6.0) 4 (11.4) 
British 39 (38.2) 27 (40.3) 12 (34.3) 
Chinese 2 (2.0) 0 (0) 2 (5.7) 
Iranian 1 (1.0) 1 (1.5) 0 (0) 
Other African 7 (6.9) 5 (7.5) 2 (5.7) 
Eritrean 2 (2.0) 1 (1.0) 1 (2.9) 




7 (6.9) 6 (9.0) 1 (2.9) 
Cypriot 1 (1.0) 0 (0) 1 (2.9) 
Indian 3 (2.9) 2 (3.0) 1 (2.9) 
Pakistani 2 (2.0) 2 (3.0) 0 (0) 
Turkish 1 (1.0) 0 (0) 1 (2.9) 
Sri Lankan 1 (1.0) 0 (0) 1 (2.9) 
Bangladeshi 1 (1.0) 1 (1.5) 0 (0) 
Other 1 (1.0) 1 (1.5) 0 (0) 
Diagnosis 
F20 68 (66.7) 43 (64.2) 25 (71.4) 
F25 17 (16.7) 12 (17.9) 5 (14.3) 
F31 6 (5.9) 6 (9.0) 0 (0) 
Other 11 (10.8) 6 (9.0) 5 (14.3) 
 Method 1 
This is a simple mirror image division method – days of admission before clozapine initiation 
are attributed to the pre-clozapine period, days of admission after clozapine initiation are 
attributed to the post-clozapine period.   
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Figure 5-2 Method 1 analysis 
Outcome data are presented in Table 5-4. Overall, an increase in the number of days of 
admission after clozapine was started was found, but the number of admissions per year 
decreased. 





D(102) p W(102) p 
Mean number of days of admission per 
year pre-clozapine 
66.70     
Mean number of days of admission per 
year post-clozapine 
69.69 
Mean number of admissions per year 
pre-clozapine 
0.95 
Mean number of admissions per year 
post-clozapine 
0.21 
Net change in days of admission pre-post 
clozapine per yeara 
-2.98 0.213 < 0.0005 0.871 < 0.0005 
Net change in number of admissions 
pre/post clozapine per yeara 
0.73 0.200 < 0.0005 0.720 < 0.0005 
Mean theoretical clozapine delay (years) 3.93 0.213 < 0.0005 0.791 < 0.0005 
anegative number denotes higher number of days/admissions post-clozapine 
5.3.1.1.1 Bias 
As discussed previously in chapter 2, possible sources of bias in the data are outlying data 
scores, and violations of assumptions (normality and homoscedasticity or homogeneity of 
variance).  The scatterplot for these data is presented in Appendix G (Figure 7-3), and shows 
some outlying data points at both extremes of the primary outcome.  On examination, these 
outliers occur due to the entire mirror image study period being entirely within one single 
admission, meaning that these patients are always inpatients (100% of the time spent both 
pre- and post-clozapine is as an inpatient).  This introduces bias to the data set, as the reality 
for these patients is that much less than 100% of their total history is spent as an inpatient.  










periods are entirely within one single admission.  This bias will affect the estimate of the 
mean, the sum of the squared error and the standard deviation.  These data cannot be 
trimmed from the data set as they are from the inclusion population. 
Also as described in chapter 2, z-scores can be used to find outliers.  The frequencies of 
these scores in this data set are shown in Appendix G (Table 7-48).  For this data set, 1% of 
the cases were above 3.29 (extreme cases), 3.9% were greater than 2.58 (more than the 
expected 1% for probable outliers), and 2.9% had values greater than 1.96 (potential 
outliers).  The remaining cases constitute 92.2% of the values, and these lie within the normal 
range.  Therefore the data are not consistent with what would be expected from a normal 
distribution, where 95% of the data would be expected to fall with the normal range. 
The values for the skewness and kurtosis of these data are presented in Appendix G (Table 
7-49).  For the net change in the number of admissions per year, the clozapine theoretical 
delay, and the total number of antipsychotics prescriptions used before clozapine, the skew 
is positive, indicating a concentration of data points on the left side of the distribution curve.  
For net change in days of admissions per year, the skew is negative but very close to zero.  
All the measures show positive kurtosis, with the net change in number of admissions per 
year being the most affected.  This indicates a heavy and pointy tailed distribution.  All the 
values for z-skewness and z-kurtosis are above 3.29, meaning that they are significant at p 
< 0.001, indicating a problem with both skew and kurtosis in the data. 
As the z-scores showed a problem with outlying data scores in this sample, I performed tests 
for normality.  The results from these tests are presented in detail in Appendix G (Table 7-50), 
and above in Table 5-4.  From the Kolmogorov-Smirnov and Shapiro-Wilk tests, scores for 
the net change in days of admission per year, the net change in the number of admissions 
per year, the total number of antipsychotic prescriptions before clozapine, and the theoretical 
delay to starting clozapine, are significantly non-normal (p < 0.0005). 
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5.3.1.1.2 Wilcoxon signed rank test 
As the data are not normally distributed, as shown by the tests above, I used the non-
parametric Wilcoxon signed-rank test to establish differences in the change in days of 
admission per year pre- and post-clozapine.  The result for this test is shown in Appendix G 
(Figure 7-4). 
The histogram shows positively ranked results (those where there were a higher number of 
days spent in hospital before clozapine was started) in brown, and negatively ranked results 
in blue.  For these data there were 55 positive ranks, 40 negative ranks and 7 ties (where 
the number of days of admission was the same before and after clozapine).  The test score, 
T, is the sum of the positive ranks and is 2574.500.  The standard error for this result is 
269.407, and the z-score, which is calculated from the T score, is 1.093 (denoted as the 
‘standardized test statistic’ in the output table).  This z-score is non-significant at p = 0.274.  
This therefore finds no significant difference in the number of days spent in hospital after 
clozapine was initiated. 
I then repeated the test for the number of admissions per year before and after clozapine 
was started – again, the difference in admissions was calculated by taking the number of 
admissions per year post-clozapine away from the number of admissions per year pre-
clozapine, and so a negative number denotes a larger number of admissions after clozapine 
had started.  The results for this test are shown in Appendix G (Figure 7-5). 
For these data there were 81 positive ranks, 10 negative ranks and 11 ties.  The test score, 
T, is 3841.  The standard error for this result is 252.652, and the z-score is 6.919.  This z-
score is significant at p < 0.0005.  This therefore finds a significant difference in the number 
of admissions after clozapine was initiated.  From the histogram, it is clear that this test 
statistic is based on there being more positive differences than negative differences, 
therefore there was a significant decrease in the number of admissions after starting 
clozapine. 
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The effect size (r) for this result can be calculated by dividing the z-score by the square root 
of the number of observations in the data set (this is double the number of patients in the 
data, since each patient was associated with two result scores) = 0.48.  Using Cohen’s 
criteria, this is a medium effect size (between 0.3 and 0.5). 
 Method 2 
This method excludes the entire index admission:  
Figure 5-3 Method 2 analysis 
Outcome data are presented in Table 5-5. Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 
was started. 
Table 5-5 Outcome data, intent to treat group, analysis method 2 
Mean number of days of admission per year pre-clozapine 36.13 
Mean number of days of admission per year post-clozapine 19.39 
Mean number of admissions per year pre-clozapine 0.56 
Mean number of admission per year post-clozapine 0.21 
Net change in days of admission pre-post clozapine per yeara 16.74 
Net change in number of admissions pre/post clozapine per yeara 0.34 
Mean theoretical clozapine delay (years) 3.93 
anegative number denotes higher number of days/admissions post-clozapine 
5.3.1.2.1 Bias 
As for method one, the scatter plot is presented in Appendix G (Figure 7-6 Scatterplot, intent 
to treat group, analysis method 2)and shows some outlying data points at both extremes of 
the primary outcome.  On examination, these outliers occur due to the entire mirror image 
study period being entirely within one single admission, meaning that these patients are 
always inpatients (100% of the time spent both pre- and post-clozapine is as an inpatient).  









100% of their total history is spent as an inpatient.  This situation affects two cases.  For two 
further cases either the pre- or the post-clozapine periods are entirely within one single 
admission.  This bias will affect the estimate of the mean, the sum of the squared error and 
the standard deviation.  These data cannot be trimmed from the data set as they are from 
the inclusion population. 
The z-score results are also presented in Appendix G (Table 7-51), and indicate that 96.1% 
of the data points are within normal range.  This is above the commonly accepted limits of 
95%.  I did not therefore go on to calculate skew and kurtosis for this data set. 
5.3.1.2.2 Paired samples t-test 
The paired samples t-test results for these data are presented in Appendix G (Table 7-51), 
and show a significant difference between the days of admission per year pre-clozapine and 
days of admission per year post-clozapine (p = 0.004).  There is also a significant difference 
between the total number of admissions per year pre-clozapine and admissions per year 
post-clozapine (p < 0.0005). 
 Method 3 
This method attributes the index admission up to the point of clozapine initiation to the pre-
clozapine period, excluding the first 14 days of the post-clozapine period from analysis, and 
then attributing any remaining days in the index admission to the post-clozapine period.  
Figure 5-4 Method 3 analysis 
Outcome data are presented in Table 5-6. Overall both the number of days spent as an 
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D(102) p W(102) p 
Mean number of days of admission per 
year pre-clozapine 
66.70     
Mean number of days of admission per 
year post-clozapine 
64.28 
Mean number of admissions per year pre-
clozapine 
0.95 
Mean number of admission per year post-
clozapine 
0.21 
Net change in days of admission pre-post 
clozapine per yeara 
2.42 0.194 < 0.0005 0.886 < 0.0005 
Net change in number of admissions 
pre/post clozapine per yeara 
0.73 0.200 < 0.0005 0.720 < 0.0005 
Mean theoretical clozapine delay (years) 3.93 0.213 < 0.0005 0.791 < 0.0005 
anegative number denotes higher number of days/admissions post-clozapine 
5.3.1.3.1 Bias 
As for methods 1 and 2, the scatter plot (shown for this data set in Appendix G, Figure 7-7) 
shows some outlying data points at both extremes of the primary outcome.  On examination, 
these outliers occur due to the entire mirror image study period being entirely within one 
single admission, meaning that these patients are always inpatients (100% of the time spent 
both pre- and post-clozapine is as an inpatient).  This introduces bias to the data set, as the 
reality for these patients is that much less than 100% of their total history is spent as an 
inpatient.  This situation affects two cases.  For two further cases either the pre- or the post-
clozapine periods are entirely within one single admission.  This bias will affect the estimate 
of the mean, the sum of the squared error and the standard deviation.  These data cannot 
be trimmed from the data set as they are from the inclusion population. 
The z-score results are presented in Appendix G (Table 7-53).  For this data set, 1% of the 
cases were above 3.29 (extreme cases), 3.9% were greater than 2.58 (more than the 
expected 1% for probable outliers), and 2.9% had values greater than 1.96 (potential 
outliers).  The remaining cases constitute 92.2% of the values, and these lie within the normal 
range.  Therefore the data are not consistent with what would be expected from a normal 
distribution, where 95% of the data would be expected to fall with the normal range. 
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The investigations for skew and kurtosis are presented in Appendix G (Table 7-54).  For the 
net change in the clozapine theoretical delay, the net change in the number of admissions 
per year and the total number of antipsychotics prescriptions used before clozapine, the skew 
is positive, indicating a concentration of data points on the left side of the distribution curve.  
For net change in days of admissions per year, the skew is negative but close to zero.  All 
the measures show positive kurtosis, with the net change in number of admissions per year 
being the most affected.  This indicates a heavy and pointy tailed distribution.  All the values 
for z-skewness and z-kurtosis are above 3.29, meaning that they are significant at p < 0.001, 
indicating a problem with both skew and kurtosis in the data.  I therefore went on to perform 
the Kolmogorov-Smirnov and Shapiro-Wilk tests, the results of which are presented in detail 
in Appendix G (Table 7-55), and above in Table 5-6. 
From the Kolmogorov-Smirnov and Shapiro-Wilk tests, the scores for the net change in days 
of admission per year, net change in the number of admissions per year, total number of 
antipsychotic prescriptions before clozapine and the theoretical delay to starting clozapine 
are significantly non-normal (p <0.0005). 
5.3.1.3.2 Wilcoxon signed rank test 
As the data are not normally distributed, as shown by the tests above, I used the non-
parametric Wilcoxon signed-rank test to establish differences in the change in days of 
admission per year pre- and post-clozapine.  The result for this test is shown in Appendix G 
(Figure 7-8). 
For the data on days of admission per year, there were 64 positive ranks, 32 negative ranks 
and 6 ties.  The test score, T, is 2574.500.  The standard error for this result is 2879.500, 
and the z-score is 2.015.  This z-score is significant at p = 0.044.  This therefore finds a 
significant difference in the number of days spent in hospital after clozapine was initiated.  
From the histogram, it is clear that this test statistic is based on there being more positive 
differences than negative differences, therefore there was a significant decrease in the 
number of admissions after starting clozapine. 
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The effect size (r) for this result can be calculated by dividing the z-score by the square root 
of the number of observations in the data set = 0.14.  Using Cohen’s criteria, this is a small 
effect size (< 0.3). 
I then repeated the test for the number of admissions per year before and after clozapine 
was started – again, the difference in admissions was calculated by taking the number of 
admissions per year post-clozapine away from the number of admissions per year pre-
clozapine, and so a negative number denotes a larger number of admissions after clozapine 
had started.  The results for this test are shown in Appendix G (Figure 7-9). 
For these data there were 81 positive ranks, 10 negative ranks and 11 ties.  The test score, 
T, is 3841.  The standard error for this result is 252.652, and the z-score is 6.919.  This z-
score is significant at p < 0.0005.  This therefore echoes the t-test result, finding a significant 
difference in the number of admissions after clozapine was initiated.  From the histogram, it 
is clear that this test statistic is based on there being more positive differences than negative 
differences, therefore there was a significant decrease in the number admissions after 
starting clozapine. 
The effect size (r) for this result can be calculated by dividing the z-score by the square root 
of the number of observations in the data set (this is double the number of patients in the 
data, since each patient was associated with two result scores) = 0.48.  Using Cohen’s 
criteria, this is a medium effect size (between 0.3 and 0.5). 
 Method 4 
This method attributes the index admission pre-clozapine and the first 14 days of clozapine 
treatment to the pre-clozapine period, then attributing any remaining days of the index 
admission to the post-clozapine period. 
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Figure 5-5 Method 4 analysis 
Outcome data are presented in Table 5-7. Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 
was started. 
Table 5-7 Outcome data, intent to treat group, analysis method 4 
Mean number of days of admission per year pre-clozapine 72.26 
Mean number of days of admission per year post-clozapine 64.28 
Mean number of admissions per year pre-clozapine 0.95 
Mean number of admission per year post-clozapine 0.21 
Net change in days of admission pre-post clozapine per yeara 7.98 
Net change in number of admissions pre/post clozapine per yeara 0.73 
Mean theoretical clozapine delay (years) 3.93 
anegative number denotes higher number of days/admissions post-clozapine 
5.3.1.4.1 Bias 
The scatterplot for this data analysis is presented in Appendix G (Figure 7-10).  As for 
methods 1, 2 and 3, the scatter plot shows some outlying data points at both extremes of the 
primary outcome.  On examination, these outliers occur due to the entire mirror image study 
period being entirely within one single admission, meaning that these patients are always 
inpatients (100% of the time spent both pre- and post-clozapine is as an inpatient).  This 
introduces bias to the data set, as the reality for these patients is that much less than 100% 
of their total history is spent as an inpatient.  This situation affects two cases.  For two further 
cases either the pre- or the post-clozapine periods are entirely within one single admission.  
This bias will affect the estimate of the mean, the sum of the squared error and the standard 
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The z-score test data are shown in Appendix G (Table 7-56), and indicate that 97.1% of the 
data points are within normal range.  This is above the commonly accepted limits of 95%, 
and so no further investigation of bias was required.  
5.3.1.4.2 Paired samples t-test 
The paired samples t-test results are given in Appendix G (Table 7-57), and show no 
significant difference between the days of admission per year pre-clozapine and days of 
admission per year post-clozapine (p = 0.313).  There is a significant difference between the 
total number of admissions per year pre-clozapine and admissions per year post-clozapine 
(p < 0.0005). 
 Method 5 
This method attributes the index admission up to the point of clozapine initiation to the pre-
clozapine period, then excludes any remaining days of the index admission from analysis. 
Figure 5-6 Method 5 analysis 
Outcome data are presented in Table 5-8. Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 















D(102) p W(102) p 
Mean number of days of admission per 
year pre-clozapine 
66.70     
Mean number of days of admission per 
year post-clozapine 
19.39 
Mean number of admissions per year 
pre-clozapine 
0.95 
Mean number of admission per year 
post-clozapine 
0.21 
Net change in days of admission pre-
post clozapine per yeara 
47.31 0.186 < 0.0005 0.829 < 0.0005 
Net change in number of admissions 
pre/post clozapine per yeara 
0.73 0.200 < 0.0005 0.720 < 0.0005 
Mean theoretical clozapine delay 
(years) 
3.93 0.213 < 0.0005 0.791 < 0.0005 
anegative number denotes higher number of days/admissions post-clozapine 
5.3.1.5.1 Bias 
The scatterplot for these data are presented in Appendix G (Figure 7-11), and as for methods 
1, 2, 3 and 4, the scatterplot shows some outlying data points at both extremes of the primary 
outcome.  On examination, these outliers occur due to the entire mirror image study period 
being entirely within one single admission, meaning that these patients are always inpatients 
(100% of the time spent both pre- and post-clozapine is as an inpatient).  This introduces 
bias to the data set, as the reality for these patients is that much less than 100% of their total 
history is spent as an inpatient.  This situation affects two cases.  For two further cases either 
the pre- or the post-clozapine periods are entirely within one single admission.  This bias will 
affect the estimate of the mean, the sum of the squared error and the standard deviation.  
These data cannot be trimmed from the data set as they are from the inclusion population. 
The z-score results are presented in Appendix G (Table 7-58).  For this data set, 2% of the 
cases were above 3.29 (extreme cases), 1% were greater than 2.58 (equal to the expected 
1% for probable outliers), and 2.9% had values greater than 1.96 (potential outliers).  The 
remaining cases constitute 92.2% of the values, and these lie within the normal range.  
Therefore overall the data are not consistent with what would be expected from a normal 
distribution, where 95% of the data would be expected to fall with the normal range. 
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The tests for skew and kurtosis are presented in Appendix G (Table 7-59).  For the net 
change in the number of admissions and days of admission per year, the clozapine 
theoretical delay, and the total number of antipsychotics prescriptions used before clozapine, 
the skew is positive, indicating a concentration of data points on the left side of the distribution 
curve.  All the measures show also show positive kurtosis, with the net change in number of 
admissions per year being the most affected.  This indicates a heavy and pointy tailed 
distribution.  All the values for z-skewness and z-kurtosis are above 3.29, meaning that they 
are significant at p < 0.001, indicating a problem with both skew and kurtosis in the data. 
The tests for normality are presented in detail in Appendix G (Table 7-60) and above in Table 
5-8.  From the Kolmogorov-Smirnov and Shapiro-Wilk tests, scores for the net change in 
days of admission per year, net change in the number of admissions per year, total number 
of antipsychotic prescriptions before clozapine, and the theoretical delay to starting clozapine 
are significantly non-normal (p < 0.0005). 
5.3.1.5.2 Wilcoxon signed rank test 
As the data are not normally distributed, as shown by the tests above, I used the non-
parametric Wilcoxon signed-rank test to establish differences in the change in days of 
admission per year pre- and post-clozapine.  The result for this test is shown in Appendix G 
(Figure 7-12). 
For the data on days of admission per year, there were 77 positive ranks, 19 negative ranks 
and 6 ties.  The test score, T, is 3908.000.  The standard error for this result is 273.649, and 
the z-score is 5.774.  This z-score is significant at p < 0.0005.  This therefore finds a 
significant difference in the number of days spent in hospital after clozapine was initiated.  
From the histogram, it is clear that this test statistic is based on there being more positive 
differences than negative differences, therefore there was a significant decrease in the 
number of days of admission after starting clozapine. 
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The effect size (r) for this result can be calculated by dividing the z-score by the square root 
of the number of observations in the data set = 0.40.  Using Cohen’s criteria, this is a medium 
effect size (between 0.3 and 0.5). 
I then repeated the test for the number of admissions per year before and after clozapine 
was started – again, the difference in admissions was calculated by taking the number of 
admissions per year post-clozapine away from the number of admissions per year pre-
clozapine, and so a negative number denotes a larger number of admissions after clozapine 
had started.  The results for this test are shown in Appendix G (Figure 7-13). 
For these data there were 81 positive ranks, 10 negative ranks and 11 ties.  The test score, 
T, is 3841.  The standard error for this result is 252.652, and the z-score is 6.919.  This z-
score is significant at p < 0.0005.  This therefore echoes the t-test result, finding a significant 
difference in the number of admissions after clozapine was initiated.  From the histogram, it 
is clear that this test statistic is based on there being more positive differences than negative 
differences, therefore there was a significant decrease in the number admissions after 
starting clozapine. 
The effect size (r) for this result can be calculated by dividing the z-score by the square root 
of the number of observations in the data set (this is double the number of patients in the 
data, since each patient was associated with two result scores) = 0.48.  Using Cohen’s 
criteria, this is a medium effect size (between 0.3 and 0.5). 
 Summary 
Table 5-9 Intent to treat data, summary of normality of distributions and associated test results 
 Data within normal 
range (%) 
Days of admission per 
year (p) 
Admissions per year 
(p) 
Method 1 92.2 0.274a < 0.0005a 
Method 2 96.1 0.004b < 0.0005b 
Method 3 92.2 0.044a < 0.0005a 
Method 4 97.1 0.313b < 0.0005b 
Method 5 92.2 < 0.0005a < 0.0005a 
aWilcoxon signed rank test 
bPaired samples t-test 
As shown in Table 5-9, when testing for normality of the data distributions, methods 2 and 4 
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contain data that lies >95% within the normal range (and would therefore be considered 
normal distributions).  The statistical tests show that there is a statistically significant 
difference between days of admission per year pre- versus post-clozapine for methods 2, 3 
and 5 only, but that all methods of analysis show a statistically significant difference in the 
number of admissions per year. 
Calculation of z-scores for the intent to treat population for the different analysis methods 
shows that for methods 2 and 4, more than 95% of the data fall within the normal range.  For 
the other methods, 92.2% of the data fall within the normal range, below the usually accepted 
standard of 95%.  The data cannot be trimmed of outliers as they do represent part of the 
true sample population.  They will bias the estimates of the mean and affect the sum of the 
squared errors, and therefore the confidence intervals around the mean. 
Other reasons for the bias may be a violation of the assumption of normality.  If in fact the 
clozapine continuers and discontinuers should be considered as two different populations, 
then by combining them a bimodal distribution may occur.  However, the central limit theorem 
generally allows for sample sizes above 30 to produce a sampling distribution that 
approximates normal.  With a sample size of 102, as in this data set, the central limit theorem 
may apply provided the sample is not too severely skewed or subject to kurtosis.  The 
Kolmogorov-Smirnov and Shapiro-Wilk tests of normality of the distribution have been 
explained previously, and the results of these tests show that the data distribution is 
significantly non-normal.  This result is supported by positive skew scores for net change in 
days of admission pre- and post-clozapine use for all methods of data analysis, and positive 
kurtosis scores for the same.  Skew is negative for net change in numbers of days of 
admission pre- and post-clozapine use, but positive for numbers of admissions per year.  
However – tests for skew, kurtosis and normality are less useful when considering large data 
sets.  They are more likely to produce a significant result even for small and unimportant 
effects.  As mentioned above, the central limit theorem means that the assumption of 
normality matters less for larger sample sizes, because the sampling distribution will be 
normal regardless of the sample data.   
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Table 5-10 gives a summary of the data analysis for the intent to treat population.  For all 
methods of data analysis, there was a significant reduction in the total number of admissions 
per year after clozapine was started.  The majority of data analysis methods (2, 3 and 5) also 
showed a significant reduction in the number of days per year spent as an inpatient. 
Table 5-10 Intent to treat data summary 
 
Mean number of 
days of admission 
per year 
Mean number of 





























66.7 69.69 0.95 0.21 
-2.98 0.73 3.93 
p = 0.274 p < 0.0005 
Method 
2 
36.13 19.39 0.56 0.21 
16.74 0.34 3.93 
p = 0.004 p < 0.0005 
Method 
3 
66.7 64.28 0.95 0.21 
2.42 0.73 3.93 
p = 0.044 p < 0.0005 
Method 
4 
72.26 64.28 0.95 0.21 
7.98 0.73 3.93 
p = 0.313 p < 0.0005 
Method 
5 
66.7 19.39 0.95 0.21 
47.31 0.73 3.93 
p < 0.0005 p < 0.0005 
anegative number denotes higher number of days post-clozapine 
bnegative number denotes higher number of admissions post-clozapine 
 Clozapine continuers 
Having presented the data analysis for the intent to treat population above, I have repeated 
this analysis separately for patients who continued clozapine (clozapine continuers) and 
patients who discontinued clozapine (clozapine discontinuers).  The demographic data for 
clozapine continuers are presented in Table 5-3 above. 
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 Method 1 
This method is a simple mirror image division, where days of admission before clozapine are 
attributed to the pre-clozapine period, and days of admission after clozapine are attributed to 
the post-clozapine period (see Figure 5-2). 
Outcome data are presented in Table 5-11. Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 
was started. 
Table 5-11 Outcome data, clozapine continuers group, analysis method 1 
Mean number of days of admission per year pre-clozapine 64.29 
Mean number of days of admission per year post-clozapine 51.89 
Mean number of admissions per year pre-clozapine 0.88 
Mean number of admission per year post-clozapine 0.11 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
12.40 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
0.77 
Mean theoretical clozapine delay (years) 4.13 
 
5.3.2.1.1 Bias 
For this data analysis I first examined normal quantile-quantile (Q-Q plots) to assess 
normality within the distribution.  The Q-Q plot for this data analysis is presented in Appendix 
G (Figure 7-14).  The Q-Q plot plots the cumulative probability of a variable against the 
cumulative probability of a particular distribution (in the case of these data, a normal 
distribution).  Z-scores are calculated from the data (as described previously), and this score 
plotted against the z-score that would be expected if the distribution was normal.  If the data 
are distributed normally, then the plot will be a straight line (shown for reference on the 
graph).  The actual data z-scores are plotted against this line (shown as round circles), and 
any deviation of the z-scores from the line of normality therefore demonstrates problems in 
this regard.  Where data points sag above or below the normal line, kurtosis differs from the 
normal distribution.  Where the data points form an S-shaped curve, the data are skewed.  
The Q-Q plot presented here suggests a problem with kurtosis and skew.  The sample size 
for this analysis is smaller than that for the intent to treat analysis, although still larger than 
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that which is generally considered to adhere to normality under the central limit theorem.  
Nonetheless, due to the smaller sample size I have followed up paired sample t-tests with 
further non-parametric equivalent tests to account for the smaller sample size and to ensure 
a significant result is not missed by the parametric test. 
5.3.2.1.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-61), and this shows no significant difference between the 
days of admission per year pre-clozapine and days of admission per year post-clozapine (p 
= 0.107).  There is a significant difference between the total number of admissions per year 
pre-clozapine and admissions per year post-clozapine (p < 0.0005). 
5.3.2.1.3 Wilcoxon signed rank test 
For the data on days of admission per year, there were 44 positive ranks, 19 negative ranks 
and 4 ties (where the number of days of admission was the same before and after clozapine).  
The test score, T, is 1443.000 (see Appendix G, Figure 7-15).  The standard error for this 
result is 146.068, and the z-score is 2.978.  This z-score is significant at p = 0.03.  From the 
histogram, it is clear that this test statistic is based on there being more positive differences 
than negative differences, therefore there was a significant decrease in the number of days 
of admission after starting clozapine. 
The effect size (r) for this result can be calculated by dividing the z-score by the square root 
of the number of observations in the data set (this is double the number of patients in the 
data, since each patient was associated with two result scores) = 0.257.  Using Cohen’s 
criteria, this is a small effect size (< 0.3). 
For the difference in admissions, the histogram (presented in Appendix G, Figure 7-16) 
shows that there were 59 positive ranks, 4 negative ranks and 4 ties.  The test score, T, is 
1944.000.  The standard error for this result is 146.062, and the z-score is 6.408.  This z-
score is significant at p < 0.0005.  From the histogram, it is clear that this test statistic is 
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based on there being more positive differences than negative differences; therefore there 
was a significant decrease in the number of admissions after starting clozapine. 
The effect size (r) for this result can be calculated by dividing the z-score by the square root 
of the number of observations in the data set = 0.277.  Using Cohen’s criteria, this is a small 
effect size (< 0.3). 
 Method 2 
This method excludes the entire index admission from analysis (see Figure 5-3). 
Outcome data are presented in Table 5-12. Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 
was started. 
Table 5-12 Outcome data, clozapine continuers group, analysis method 2 
Mean number of days of admission per year pre-clozapine 34.70 
Mean number of days of admission per year post-clozapine 9.97 
Mean number of admissions per year pre-clozapine 0.50 
Mean number of admission per year post-clozapine 0.12 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
24.73 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
1.42 
Mean theoretical clozapine delay (years) 4.13 
 
5.3.2.2.1 Bias 
As for method 1, I first examined normal quantile-quantile (Q-Q plots) to assess normality 
within the distribution.  The Q-Q plot for this data analysis is presented in Appendix G (Figure 
7-17).  The Q-Q plot presented here suggests a problem with kurtosis and skew.  
5.3.2.2.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-62Table 7-62), and this shows a significant difference 
between admission days per year pre-clozapine and admission days per year post-clozapine 
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(p < 0.0005).  There is also a significant difference between admissions per year pre-
clozapine and admissions per year post-clozapine (p < 0.0005). 
5.3.2.2.3 Wilcoxon signed-rank test 
The histogram and associated data table are shown in Appendix G (Figure 7-18).  For the 
difference in days of admission per year, there were 42 positive ranks, 8 negative ranks and 
17 ties.  The test score, T, is 1109.000.  The standard error for this result is 103.592, and the 
z-score is 4.552.  This z-score is significant at p < 0.0005.  From the histogram, it is clear that 
this test statistic is based on there being more positive differences than negative differences, 
therefore there was a significant decrease in the number of days of admission after starting 
clozapine. 
The effect size (r) is 0.39.  Using Cohen’s criteria, this is a medium effect size (between 0.3 
and 0.5). 
For the difference in admissions per year (see Appendix G, Figure 7-19), there were 44 
positive ranks, 5 negative ranks and 18 ties.  The test score, T, is 1129.000.  The standard 
error for this result is 100.525, and the z-score is 5.138.  This z-score is significant at p < 
0.0005.  From the histogram, it is clear that this test statistic is based on there being more 
positive differences than negative differences, therefore there was a significant decrease in 
the number of admissions after starting clozapine. 
The effect size (r) is 0.22.  Using Cohen’s criteria, this is a small effect size (< 0.3). 
 Method 3 
This method attributes the index admission up to the point of clozapine initiation to the pre-
clozapine period, excluding the first 14 days of the post-clozapine period from analysis, and 
then attributes any remaining days in the index admission to the post-clozapine period (see 
Figure 5-4). 
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Outcome data are presented in Table 5-13. Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 
was started. 
Table 5-13 Outcome data, clozapine continuers group, analysis method 3 
Mean number of days of admission per year pre-clozapine 64.29 
Mean number of days of admission per year post-clozapine 46.59 
Mean number of admissions per year pre-clozapine 0.88 
Mean number of admission per year post-clozapine 0.12 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
17.70 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
0.77 
Mean theoretical clozapine delay (years) 4.13 
 
5.3.2.3.1 Bias 
As for method 1, I first examined normal quantile-quantile (Q-Q plots) to assess normality 
within the distribution.  The Q-Q plot for this data analysis is presented in Appendix G (Figure 
7-20).  The Q-Q plot presented here suggests a problem with kurtosis and skew.  
5.3.2.3.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-63), and this shows a significant difference between days 
of admission per year pre-clozapine and days of admission per year post-clozapine (p = 
0.025).  There is a significant difference between admissions per year pre-clozapine and 
admissions per year post-clozapine (p < 0.0005). 
 
5.3.2.3.3 Wilcoxon signed-rank test 
The histogram and associated data table are shown in Appendix G (Figure 7-21).  For the 
data on days of admission per year, there were 13 negative ranks, 51 positive ranks and 3 
ties.  The test score, T, is 1577.000.  The standard error for this result is 149.533, and the z-
score is 3.591.  This z-score is significant at p < 0.0005.  From the histogram, it is clear that 
this test statistic is based on there being more positive differences than negative differences, 
therefore there was a significant decrease in the number of days of admission after starting 
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clozapine.  The effect size (r) is 0.16.  Using Cohen’s criteria, this is a small effect size (< 
0.3). 
The histogram and associated data table are shown in Appendix G (Figure 7-22) for the 
change in admissions per year after starting clozapine.  For these data there were 4 negative 
ranks, 59 positive ranks and 4 ties.  The test score, T, is 1944.000.  The standard error for 
this result is 146.062, and the z-score is 6.408.  This z-score is significant at p < 0.0005.  
From the histogram, it is clear that this test statistic is based on there being more positive 
differences than negative differences, therefore there was a significant decrease in the 
number of admissions after starting clozapine.  The effect size (r) is 0.23.  Using Cohen’s 
criteria, this is a small effect size (< 0.3) 
 Method 4 
This method attributes the index admission pre-clozapine and the first 14 days of clozapine 
treatment to the pre-clozapine period, then attributes any remaining days of the index 
admission to the post-clozapine period. 
Outcome data are presented in Table 5-14.  Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 
was started. 
Table 5-14 Outcome data, clozapine continuers group, analysis method 4 
Mean number of days of admission per year pre-clozapine 69.78 
Mean number of days of admission per year post-clozapine 46.59 
Mean number of admissions per year pre-clozapine 0.88 
Mean number of admissions per year post-clozapine 0.12 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
23.19 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
0.77 




As for method 1, I first examined normal quantile-quantile (Q-Q plots) to assess normality 
within the distribution.  The Q-Q plot for this data analysis is presented in Appendix G (Figure 
7-23).  The Q-Q plot presented here suggests a problem with kurtosis and skew.  
5.3.2.4.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-64), and this shows a significant difference between days 
of admission per year pre-clozapine and days of admission per year post-clozapine (p = 
0.007).  There is a significant difference between admissions per year pre-clozapine and 
admissions per year post-clozapine (p < 0.0005). 
5.3.2.4.3 Wilcoxon signed-rank test 
The histogram and associated data table are shown in Appendix G (Figure 7-24).  For the 
data on days of admission per year, there were 53 positive ranks, 12 negative ranks and 2 
ties.  The test score, T, is 1664.000.  The standard error for this result is 153.024, and the z-
score is 3.865.  This z-score is significant at p < 0.0005.  From the histogram, it is clear that 
this test statistic is based on there being more positive differences than negative differences, 
therefore there was a significant decrease in the number of days of admission after starting 
clozapine.  The effect size (r) is 0.33.  Using Cohen’s criteria, this is a medium effect size 
(between 0.3 and 0.5). 
The histogram and associated data table are shown in Appendix G (Figure 7-25)  for the 
change in admissions per year after starting clozapine.  For these data there were 4 negative 
ranks, 59 positive ranks and 4 ties.  The test score, T, is 1944.000.  The standard error for 
this result is 146.062, and the z-score is 6.408.  This z-score is significant at p < 0.0005.  
From the histogram, it is clear that this test statistic is based on there being more positive 
differences than negative differences, therefore there was a significant decrease in the 
number of admissions after starting clozapine.  The effect size (r) is 0.23.  Using Cohen’s 
criteria, this is a small effect size (< 0.3). 
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 Method 5 
This method attributes the index admission up to the point of clozapine initiation to the pre-
clozapine period, then excludes any remaining days of the index admission from analysis 
(Figure 5-6).  
Outcome data are presented in Table 5-15. Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 
was started. 
Table 5-15 Outcome data, clozapine continuers group, analysis method 5 
Mean number of days of admission per year pre-clozapine 64.29 
Mean number of days of admission per year post-clozapine 9.97 
Mean number of admissions per year pre-clozapine 0.88 
Mean number of admission per year post-clozapine 0.11 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
54.32 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
0.77 
Mean theoretical clozapine delay (years) 4.13 
 
5.3.2.5.1 Bias 
As for method 1, I first examined normal quantile-quantile (Q-Q plots) to assess normality 
within the distribution.  The Q-Q plot for this data analysis is presented in Appendix G (Figure 
7-26).  The Q-Q plot presented here suggests a problem with kurtosis and skew.  
5.3.2.5.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-65), and this shows a significant difference between days of 
admission per year pre-clozapine and days of admission per year post-clozapine (p < 
0.0005).  There is also a significant difference between admissions per year pre-clozapine 
and admissions per year post-clozapine (p < 0.0005). 
5.3.2.5.3 Wilcoxon signed-rank test 
The histogram and associated data table are shown in Appendix G (Figure 7-27).  For the 
data on days of admission per year, there were 59 positive ranks, 5 negative ranks and 3 
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ties.  The test score, T, is 1957.000.  The standard error for this result is 149.593, and the z-
score is 6.132.  This z-score is significant at p < 0.0005.  From the histogram, it is clear that 
this test statistic is based on there being more positive differences than negative differences, 
therefore there was a significant decrease in the number of days of admission after starting 
clozapine.  The effect size (r) is 0.26.  Using Cohen’s criteria, this is a small effect size (< 
0.3). 
The histogram and associated data table are shown in Appendix G (Figure 7-28)  for the 
change in admissions per year after starting clozapine.  For these data there were 4 negative 
ranks, 59 positive ranks and 4 ties.  The test score, T, is 1944.000.  The standard error for 
this result is 146.062, and the z-score is 6.408.  This z-score is significant at p < 0.0005.  
From the histogram, it is clear that this test statistic is based on there being more positive 
differences than negative differences, therefore there was a significant decrease in the 
number of admissions after starting clozapine.  The effect size (r) is 0.23.  Using Cohen’s 
criteria, this is a small effect size (< 0.3).  
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Table 5-16 Clozapine continuers data summary 
 
Mean number of days of 
admission per year 
Mean number of 









Net change in days of 
admission pre-post 
clozapine per yeara 
Net change in number of 
admissions pre/post 





64.29 51.89 0.88 0.11 
12.4 0.77 4.13 
p =0.03 p < 0.0005 
Method 2 
34.7 9.97 0.5 0.12 
24.73 1.42 4.13 
p < 0.0005 p < 0.0005 
Method 3 
64.29 46.59 0.88 0.12 
17.7 0.77 4.13 
p < 0.0005 p < 0.0005 
Method 4 
69.78 46.59 0.88 0.12 
23.19 0.77 4.13 
p < 0.0005 p < 0.0005 
Method 5 
64.29 9.97 0.88 0.11 
54.32 0.77 4.13 
p < 0.0005 p < 0.0005 
anegative number denotes higher number of days post-clozapine 




Table 5-16 shows that there is a statistically significant difference between the number of 
days of admission pre- and post-clozapine for all methods of data analysis.  There is also a 
statistically significant difference between the number of admissions pre- and post-clozapine 
for all methods.  Note that the mean clozapine delay is numerically longer for clozapine 
continuers than for clozapine discontinuers, but this difference is not statistically significant 
(t-test = 0.626, p = 0.533). 
If patients keep taking clozapine, then no matter how you look at the data, they have fewer 
admissions per year and days per year as an inpatient when they are taking the clozapine 
compared to before they were taking the clozapine.  However, the magnitude of this 
difference differs depending on the analysis method. 
 Clozapine discontinuers 
 Method 1 
This is a simple mirror image division, whereby days of admission before clozapine are 
attributed to the pre-clozapine period, and days of admission after clozapine are attributed to 
the post-clozapine period (see Figure 5-2).  Demographic data for this group are presented 
in Table 5-3.  
Outcome data are presented in Table 5-17. Overall there was an increase in the number of 
days spent as an inpatient after clozapine had started, but a reduction in the total number of 
admissions per year. 
Table 5-17 Outcome data, clozapine discontinuers group, analysis method 1 
Mean number of days of admission per year pre-clozapine 71.33 
Mean number of days of admission per year post-clozapine 103.76 
Mean number of admissions per year pre-clozapine 1.08 
Mean number of admission per year post-clozapine 0.41 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
-32.43 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
0.66 




As described for clozapine continuers, I first examined normal quantile-quantile (Q-Q plots) 
to assess normality within the distribution.  The Q-Q plot for this data analysis is presented 
in Appendix G (Figure 7-29).  The Q-Q plot presented here suggests a problem with kurtosis 
and skew.  
5.3.3.1.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-66), and this shows a significant difference between the days 
of admission per year pre-clozapine and days of admission per year post-clozapine (p = 
0.040).  There is also a significant difference between the total number of admissions per 
year pre-clozapine and admissions per year post-clozapine (p = 0.002). 
5.3.3.1.3 Wilcoxon signed-rank test 
The histogram and associated data table are shown in Appendix G (Figure 7-30).  For the 
data for days of admission per year there were 11 positive ranks, 21 negative ranks and 3 
ties.  The test score, T, is 150.000.  The standard error for this result is 53.479, and the z-
score is 2.132.  This z-score is significant at p = 0.033.  From the histogram, it is clear that 
this test statistic is based on there being more negative differences than positive differences, 
therefore there was a significant increase in the number of days of admission after starting 
clozapine.  The effect size (r) is 0.255.  Using Cohen’s criteria, this is a small effect size 
(below 0.3). 
The histogram and associated data table are shown in Appendix G (Figure 7-31) for the 
change in admissions per year after starting clozapine.  For these data there were 6 negative 
ranks, 22 positive ranks and 7 ties.  The test score, T, is 337.500.  The standard error for this 
result is 43.912, and the z-score is 3.063.  This z-score is significant at p = 0.002.  From the 
histogram, it is clear that this test statistic is based on there being more positive differences 
than negative differences, therefore there was a significant decrease in the number of 
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admissions after starting clozapine.  The effect size (r) is 0.37.  Using Cohen’s criteria, this 
is a medium effect size (between 0.3 and 0.5). 
 Method 2 
This method excludes the entire index admission (see Figure 5-3).  
Outcome data are presented in Table 5-18. Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 
was started. 
Table 5-18 Outcome data, clozapine discontinuers group, analysis method 2 
Mean number of days of admission per year pre-clozapine 38.85 
Mean number of days of admission per year post-clozapine 37.43 
Mean number of admissions per year pre-clozapine 0.67 
Mean number of admission per year post-clozapine 0.41 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
1.42 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
0.25 
Mean theoretical clozapine delay (years) 3.53 
 
5.3.3.2.1 Bias 
As described for clozapine continuers, I first examined normal quantile-quantile (Q-Q plots) 
to assess normality within the distribution.  The Q-Q plot for this data analysis is presented 
in Appendix G (Figure 7-32).  The Q-Q plot presented here suggests a problem with kurtosis 
and skew.  
5.3.3.2.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-67), and this shows no significant difference between 
admission days per year pre-clozapine and admission days per year post-clozapine (p = 
0.906).  There is also no significant difference between admissions per year pre-clozapine 
and admissions per year post-clozapine (p = 0.78). 
 
 164 
5.3.3.2.3 Wilcoxon signed-rank test  
The histogram and associated data table are shown in Appendix G (Figure 7-33).  For these 
data there were 16 positive ranks, 15 negative ranks and 4 ties.  The test score, T, is 255.000.  
The standard error for this result is 51.029, and the z-score is 0.137.  This z-score is non-
significant at p = 0.891. 
The histogram and associated data table are shown in Appendix G (Figure 7-34) for the 
change in admissions per year after starting clozapine.  For these data there were 10 
negative ranks, 16 positive ranks and 9 ties.  The test score, T, is 237.000.  The standard 
error for this result is 39.372, and the z-score is 1.562.  This z-score is non-significant at p = 
0.118. 
 Method 3 
This method attributes the index admission up to the point of clozapine initiation to the pre-
clozapine period, excludes the first 14 days of the post-clozapine period from analysis, and 
then attributes any remaining days in the index admission to the post-clozapine period.  
Outcome data are presented in Table 5-19. Overall there was an increase in the number of 
days spent as an inpatient after clozapine had started, but a reduction in the total number of 
admissions per year. 
Table 5-19 Outcome data, clozapine discontinuers group, analysis method 3 
Mean number of days of admission per year pre-clozapine 71.33 
Mean number of days of admission per year post-clozapine 98.15 
Mean number of admissions per year pre-clozapine 1.08 
Mean number of admission per year post-clozapine 0.41 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
-26.81 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
0.66 
Mean theoretical clozapine delay (years) 3.53 
 
5.3.3.3.1 Bias 
As described for clozapine continuers, I first examined normal quantile-quantile (Q-Q plots) 
to assess normality within the distribution.  The Q-Q plot for this data analysis is presented 
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in Appendix G (Figure 7-35).  The Q-Q plot presented here suggests a problem with kurtosis 
and skew.  
5.3.3.3.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-68), and this shows no significant difference between days 
of admission per year pre-clozapine and days of admission per year post-clozapine (p = 
0.088).  There is a significant difference between admissions per year pre-clozapine and 
admissions per year post-clozapine (p = 0.002). 
5.3.3.3.3 Wilcoxon signed-rank test 
The histogram and associated data table are shown in Appendix G (Figure 7-36).  For the 
data for days of admission per year there were 13 positive ranks, 19 negative ranks and 3 
ties.  The test score, T, is 190.000.  The standard error for this result is 53.479, and the z-
score is -1.384.  This z-score is non-significant at p = 0.166.  
The histogram and associated data table are shown in Appendix G (Figure 7-37) for the 
change in admissions per year after starting clozapine.  For these data there were 6 negative 
ranks, 22 positive ranks and 7 ties.  The test score, T, is 337.500.  The standard error for this 
result is 43.912, and the z-score is 3.063.  This z-score is significant at p = 0.002.  From the 
histogram, it is clear that this test statistic is based on there being more positive differences 
than negative differences, therefore there was a significant decrease in the number of 
admissions after starting clozapine.  The effect size (r) is 0.37.  Using Cohen’s criteria, this 
is a medium effect size (between 0.3 and 0.5). 
 Method 4 
This method attributes the index admission pre-clozapine and the first 14 days of clozapine 
treatment to the pre-clozapine period, then attributes any remaining days of the index 
admission to the post-clozapine period.  
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Outcome data are present in Table 5-20.  Overall there was an increase in the number of 
days spent as an inpatient after clozapine had started, but a reduction in the total number of 
admissions per year. 
Table 5-20 Outcome data, clozapine discontinuers group, analysis method 4 
Mean number of days of admission per year pre-clozapine 77.01 
Mean number of days of admission per year post-clozapine 98.15 
Mean number of admissions per year pre-clozapine 1.08 
Mean number of admissions per year post-clozapine 0.41 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
-21.14 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
0.66 
Mean theoretical clozapine delay (years) 3.53 
 
5.3.3.4.1 Bias 
As described for clozapine continuers, I first examined normal quantile-quantile (Q-Q plots) 
to assess normality within the distribution.  The Q-Q plot for this data analysis is presented 
in Appendix G (Figure 7-38).  The Q-Q plot presented here suggests a problem with kurtosis 
and skew.  
5.3.3.4.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-69), and this shows no significant difference between days 
of admission per year pre-clozapine and days of admission per year post-clozapine (p = 
0.181).  There is a significant difference between admissions per year pre-clozapine and 
admissions per year post-clozapine (p = 0.002). 
5.3.3.4.3 Wilcoxon signed-rank test 
The histogram and associated data table are shown in Appendix G (Figure 7-39).  For these 
data there were 13 positive ranks, 19 negative ranks and 3 ties.  The test score, T, is 204.000.  
The standard error for this result is 53.479, and the z-score is -1.122.  This z-score is non-
significant at p = 0.262.  
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The histogram and associated data table are shown in Appendix G (Figure 7-40) for the 
change in admissions per year after starting clozapine.  For these data there were 6 negative 
ranks, 22 positive ranks and 7 ties.  The test score, T, is 337.500.  The standard error for this 
result is 43.912, and the z-score is 3.063.  This z-score is significant at p = 0.002.  From the 
histogram, it is clear that this test statistic is based on there being more positive differences 
than negative differences, therefore there was a significant decrease in the number of 
admissions after starting clozapine.  The effect size (r) is 0.37.  Using Cohen’s criteria, this 
is a medium effect size (between 0.3 and 0.5). 
 Method 5 
This method attributes the index admission up to the point of clozapine initiation to the pre-
clozapine period, then excludes any remaining days of the index admission from analysis 
(see Figure 5-6).  
Outcome data are presented in Table 5-21. Overall both the number of days spent as an 
inpatient per year and the number of total admissions per year were reduced after clozapine 
was started. 
Table 5-21 Outcome data, clozapine discontinuers group, analysis method 5 
Mean number of days of admission per year pre-clozapine 71.33 
Mean number of days of admission per year post-clozapine 37.43 
Mean number of admissions per year pre-clozapine 1.08 
Mean number of admission per year post-clozapine 0.41 
Net change in days of admission pre-post clozapine per year (negative number 
denotes higher number of days post-clozapine) 
33.90 
Net change in number of admissions pre/post clozapine per year (negative number 
denotes higher number of admissions post-clozapine) 
0.66 
Mean theoretical clozapine delay (years) 3.53 
 
5.3.3.5.1 Bias 
As described for clozapine continuers, I first examined normal quantile-quantile (Q-Q plots) 
to assess normality within the distribution.  The Q-Q plot for this data analysis is presented 
in Appendix G (Figure 7-41).  The Q-Q plot presented here suggests a problem with kurtosis 
and skew.  
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5.3.3.5.2 Paired samples t-test 
A paired samples t-test was conducted as described previously (the results of which are 
presented in Appendix G, Table 7-70), and this shows no significant difference between days 
of admission per year pre-clozapine and days of admission per year post-clozapine (p = 
0.083).  There is a significant difference between admissions per year pre-clozapine and 
admissions per year post-clozapine (p = 0.002). 
5.3.3.5.3 Wilcoxon signed-rank test 
The histogram and associated data table are shown in Appendix G (Figure 7-42).  For these 
data there were 18 positive ranks, 14 negative ranks and 3 ties.  The test score, T, is 339.000.  
The standard error for this result is 53.479, and the z-score is 1.402.  This z-score is non-
significant at p = 0.161.   
The histogram and associated data table are shown in Appendix G (Figure 7-43) for the 
change in admissions per year after starting clozapine.  For these data there were 6 negative 
ranks, 22 positive ranks and 7 ties.  The test score, T, is 337.500.  The standard error for this 
result is 43.912, and the z-score is 3.063.  This z-score is significant at p = 0.002.  From the 
histogram, it is clear that this test statistic is based on there being more positive differences 
than negative differences, therefore there was a significant decrease in the number of 
admissions after starting clozapine.  The effect size (r) is 0.37.  Using Cohen’s criteria, this 
is a medium effect size (between 0.3 and 0.5). 
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Table 5-22 Clozapine discontinuers data summary 
 
Mean number of days of 
admission per year 
Mean number of admissions 
per year  
Pre-clozapine Post-clozapine Pre-clozapine 
Post-
clozapine 
Net change in 
days of admission 
pre-post clozapine 
per yeara 
Net change in 
number of 
admissions pre/post 






71.33 103.76 1.08 0.41 
-32.43 0.66 3.53 
p =0.033 p = 0.002 
Method 2 
38.85 37.43 0.67 0.41 
1.42 0.25 3.53 
p = 0.891 p = 0.118 
Method 3 
71.33 98.15 1.08 0.41 
-26.82 0.66 3.53 
p = 0.116 p = 0.002 
Method 4 
77.01 98.15 1.08 0.41 
-21.14 0.66 3.53 
p = 0.262 p = 0.002 
Method 5 
71.33 37.43 1.08 0.41 
33.90 0.66 3.53 
p = 0.161 p = 0.002 
a negative number denotes higher number of days post-clozapine 
b negative number denotes higher number of admissions post-clozapine 
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Table 5-22 shows that there is a statistically significant difference between the mean number 
of days of admission per year pre- and post-clozapine for method 1 only.  This is the only 
method to attribute the entire post-clozapine index admission period to the post-clozapine 
data count.  The data show an increase in days spent in hospital after clozapine has been 
started; the opposite result to that found for clozapine continuers.   
Table 5-22 also shows that for clozapine discontinuers, there is a statistically significant 
difference between the mean number of admissions per year pre- and post-clozapine for all 
methods except method 2 – this method is the only one to entirely exclude the index 
admission.  For all the statistically significant results, a reduction in numbers of admissions 
per year after clozapine was started is shown. 
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 Summary of clozapine continuers versus discontinuers 
Table 5-23 Wilcoxon signed rank test summary for clozapine continuers versus discontinuers 
 Effect on days of admission per year after clozapine started Effect on numbers of admissions per year after clozapine 
started 
Clozapine continuers Clozapine discontinuers Clozapine continuers Clozapine discontinuers 
p Effect 
size 
Effect p Effect 
size 
Effect p Effect 
size 
Effect p Effect 
size 
Effect 
Method 1 0.003 0.257 Decrease 0.033 0.255 Increase < 0.0005 0.277 Decrease 0.002 0.37 Decrease 
Method 2 < 0.0005 0.39 Decrease 0.891 N/A No effect < 0.0005 0.22 Decrease 0.118 N/A No effect 
Method 3 < 0.0005 0.16 Decrease 0.166 N/A No effect < 0.0005 0.23 Decrease 0.002 0.37 Decrease 
Method 4 < 0.0005 0.33 Decrease 0.262 N/A No effect < 0.0005 0.23 Decrease 0.002 0.37 Decrease 
Method 5 < 0.0005 0.26 Decrease 0.161 N/A No effect < 0.0005 0.23 Decrease 0.002 0.37 Decrease 
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Table 5-23 summarises the data set out above.  For all methods of analysis for clozapine 
continuers, there is a change in the number of days spent as an inpatient once clozapine has 
been started. This change in the number of days of admission per year is only seen in the 
first analysis method for clozapine discontinuers; for all other methods of data analysis for 
discontinuers there was no change in the number of days of admission after the clozapine 
start date.  For both clozapine continuers and discontinuers, there was an effect on the total 
number of admissions per year.  This was regardless of the method of data analysis used, 
except for method 2 for discontinuers (no significant change). 
For method 1 clozapine continuers, days of admission were significantly higher before 
starting clozapine (Mdn = 41.24) than after starting clozapine (Mdn = 11.65), T = 1443, p = 
0.003, r = 0.257 (Table 5-23).  However, for clozapine discontinuers, days of admission were 
significantly lower before starting clozapine (Mdn = 31.44) than after starting clozapine (Mdn 
= 62.69), T = 150, p = 0.033, r = 0.255.  For clozapine continuers, the number of admissions 
was also significantly higher before starting clozapine (Mdn = 0.58) than after starting 
clozapine (Mdn =0.00), T = 1944, p < 0.0005, r = 0.277.  This was also true for those that 
discontinued clozapine, with the number of admissions being significantly higher before 
starting clozapine (Mdn = 0.82) than after starting clozapine (Mdn = 0.28), T = 337.5, p = 
0.002, r = 0.37. 
For method 2 clozapine continuers, days of admission were significantly higher before 
starting clozapine (Mdn = 18.64) than after starting clozapine (Mdn = 0.00), T = 1109, p = 
<0.0005, r = 0.39.  However, for clozapine discontinuers, days of admission were not 
statistically significantly different before starting clozapine (Mdn = 20.34) than after starting 
clozapine (Mdn = 17.87), T = 255, p = 0.891.  For clozapine continuers, the number of 
admissions was also significantly higher before starting clozapine (Mdn = 0.40) than after 
starting clozapine (Mdn =0.00), T = 1129, p < 0.0005, r = 0.22.  For those that discontinued 
clozapine, the number of admissions was not significantly different before starting clozapine 
(Mdn = 0.50) compared with after starting clozapine (Mdn = 0.28), T = 237, p = 0.118. 
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For method 3 clozapine continuers, days of admission were significantly higher before 
starting clozapine (Mdn = 41.24) than after starting clozapine (Mdn = 8.65), T = 1577, p < 
0.0005, r = 0.16.  However, for clozapine discontinuers, days of admission were not 
statistically significantly different before starting clozapine (Mdn = 31.44) than after starting 
clozapine (Mdn = 57.03), T = 190, p = 0.166.  For clozapine continuers, the number of 
admissions was also significantly higher before starting clozapine (Mdn = 0.58) than after 
starting clozapine (Mdn =0.00), T = 1944, p < 0.0005, r = 0.23.  This was also true for those 
that discontinued clozapine, with the number of admissions being significantly higher before 
starting clozapine (Mdn = 0.82) than after starting clozapine (Mdn = 0.28), T = 337.5, p = 
0.002, r = 0.37. 
For method 4 clozapine continuers, days of admission were significantly higher before 
starting clozapine (Mdn = 46.61) than after starting clozapine (Mdn = 8.65), T = 1664, p < 
0.0005, r = 0.33.  However, for clozapine discontinuers, days of admission were not 
statistically significantly different before starting clozapine (Mdn = 35.98) than after starting 
clozapine (Mdn = 57.03), T = 204, p = 0.262.  For clozapine continuers, the number of 
admissions was also significantly higher before starting clozapine (Mdn = 0.58) than after 
starting clozapine (Mdn =0.00), T = 1944, p < 0.0005, r = 0.23.  This was also true for those 
that discontinued clozapine, with the number of admissions being significantly higher before 
starting clozapine (Mdn = 0.82) than after starting clozapine (Mdn = 0.28), T = 337.5, p = 
0.002, r = 0.37. 
For method 5 clozapine continuers, days of admission were significantly higher before 
starting clozapine (Mdn = 41.24) than after starting clozapine (Mdn = 11.65), T = 1957, p < 
0.0005, r = 0.26.  However, for clozapine discontinuers, days of admission were not 
statistically significantly different before starting clozapine (Mdn = 31.44) compared with after 
starting clozapine (Mdn = 17.87), T = 339, p = 0.161.  For clozapine continuers, the number 
of admissions was also significantly higher before starting clozapine (Mdn = 0.58) than after 
starting clozapine (Mdn =0.00), T = 1944, p < 0.0005, r = 0.23.  This was also true for those 
that discontinued clozapine, with the number of admissions being significantly higher before 
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starting clozapine (Mdn = 0.82) than after starting clozapine (Mdn = 0.28), T = 337.5, p = 
0.002, r = 0.37. 
Overall, for patients that continued clozapine, days of admission per year after starting 
clozapine were fewer than before starting clozapine, with small to moderate effect sizes 
depending on the method of data analysis.  The number of admissions per year was also 
decreased after starting clozapine by staying on therapy, with a small effect size.  For patients 
that discontinued clozapine, there was either a small increase or no effect on the number of 
days spent as an inpatient per year after the start date of the clozapine, depending on how 
the data was analysed.  In common with those that continued clozapine however, those that 
discontinued also largely experienced fewer admissions per year after the clozapine was 
started, with a moderate effect size and some dependence on the method of data analysis. 
 Linear regression 
As discussed in chapter 2, linear regression allows for a single outcome to be predicted from 
a single predictor variable.  In this context, I have used it to investigate the relationship 
between the delay to clozapine use and the change in time spent as an inpatient once 
clozapine has been started.  The null hypothesis is that the length of time it takes for 
clozapine to be prescribed has no effect on the long term efficacy outcomes, as measured 
by the change in inpatient admissions.  I have completed this analysis for the intent to treat 
group, and separately for clozapine continuers and discontinuers. 
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 Intent to treat group 
5.3.5.1.1 Method 1 
 
Figure 5-7 Scatter plot for change in days of admission, intent to treat group, method 1 
The scatterplot for the data is shown above (Figure 5-7).  A positive relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more positive the net 
change in days of admission per year becomes.  Again, a positive net change denotes a 
lower number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-71).  The table shows 
that the value of R is 0.054, and since there is only one predictor variable (clozapine delay), 
this value represents the simple correlation between the net change in days of admission per 
year (the outcome variable) and clozapine delay.  The R2 is 0.003, meaning that the clozapine 
delay accounts for 0.3% of the variation in the change in days of admission.  Other variables 
must therefore account for the remaining 99.7% of the variation in the outcome variable. 
(years) 
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Next, I conducted an ANOVA.  The ANOVA investigates whether this model (with clozapine 
delay as a predictor variable) predicts the net change in days of admissions significantly 
better than simply using the mean net change in admissions would alone.  The results are 
presented in Appendix G (Table 7-72).  The sum of squares, associated degrees of freedom 
(df) and mean square are given in the table.  From these data, the F-ratio is calculated, and 
shown as 0.297.  This is non-significant at a p value of 0.587, and so the regression model 
does not predict net change in days of admission before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-73).  These show the individual 
contribution of particular variables to the model (in this case, just the theoretical delay to 
clozapine prescribing).  The value of b0 (the constant) is -6.487, and so when the clozapine 
delay is zero (the x-axis intercept on the scatterplot), the model predicts that the net change 
in admission days per year is -6.487.  This means that 6.487 more days are spent as an 
inpatient in the year following clozapine initiation, compared to the year before clozapine was 
started, when there is no delay to clozapine use.  The gradient of the regression line (b1) is 
given in the table as 0.892, and this shows the change in the outcome associated with a unit 
change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), the model 
predicts that the net change in days of admission will increase by 0.892 days.  This means 
that 0.892 fewer days of admission will be spent per year after clozapine initiation.  However, 
this model shows that clozapine delay only accounts for 0.3% of the effect on the net change 
in admission days.  The value of the regression co-efficient is also shown (b), and if this is 
significantly different to zero then this would confirm that the clozapine delay has a significant 
impact on the ability of the model to predict the net change in days of admission per year.  
The significance of this is tested in the ANOVA using a t-test, the results of which are shown 
in the final column of the table.  Both t-tests are non-significant at p > 0.05, meaning that the 
regression coefficients (b) are not significantly different to zero, and the theoretical delay to 
clozapine use does not make a significant contribution to the outcome of the net change in 
days of admission per year. 
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As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-74).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -1.566 and 3.583.  Since this interval 
includes zero, there is no relationship between clozapine theoretical delay and net change in 
number of days of admission in this population.   Additionally, the significance associated 
with this confidence interval is > 0.05 (p = 0.466), demonstrating no statistical significance. 
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-8).   
 
Figure 5-8 Scatterplot for change in number of admissions, intent to treat group, method 1 
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  
(years) 
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Again, a negative net change denotes a higher number of admissions after clozapine has 
started. 
The summary of the regression model is shown in Appendix G (Table 7-75).  The table shows 
that the value of R is 0.235, and since there is only one predictor variable (clozapine delay), 
this value represents the simple correlation between the net change in number of admissions 
per year (the outcome variable) and clozapine delay.  The R2 is 0.055, meaning that the 
clozapine delay accounts for 5.5% of the variation in the change numbers of admissions.  
Other variables must therefore account for the remaining 94.5% of the variation in the 
outcome variable. 
Next, I conducted an ANOVA.  The ANOVA investigates whether this model (with clozapine 
delay as a predictor variable) predicts the net change in admissions significantly better than 
simply using the mean net change in admissions would alone.  The results are presented in 
Appendix G (Table 7-76).  The sum of squares, associated degrees of freedom (df) and mean 
square are given in the table.  From these data, the F-ratio is calculated, and shown as 5.855.  
This is significant at a p value of 0.017, and so the regression model predicts net change in 
numbers of admissions before and after starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-77).  These show the individual 
contribution of particular variables to the model (in this case, just the theoretical delay to 
clozapine prescribing).  The value of b0 (the constant) is 0.973, and so when the clozapine 
delay is zero (the x-axis intercept on the scatterplot), the model predicts that the net change 
in number of admissions per year is 0.973.  This means that a patient has 0.973 fewer 
admissions in the year following clozapine initiation, compared to the year before clozapine 
was started when the delay to starting clozapine is zero.  The gradient of the regression line 
(b1) is given in the table as -0.061, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in admissions per year becomes more negative by 
0.061 admissions.  Therefore 0.061 more admissions will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay only accounts for 5.5% of the 
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effect on the net change in admission days.  The value of the regression co-efficient is also 
shown (b), and if this is significantly different to zero then this would confirm that the clozapine 
delay has a significant impact on the ability of the model to predict the net change in 
admissions per year.  The significance of this is tested in the ANOVA using a t-test, the 
results of which are shown in the final column of the table.  Both t-tests are significant at p < 
0.0005 and p = 0.017, meaning that the regression coefficients (b) are significantly different 
to zero, and the theoretical delay to clozapine use does make a significant contribution to the 
outcome of the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-78).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.110 and -0.025.  Since this interval does 
not include zero, there is a negative relationship between clozapine theoretical delay and net 
change in number of admissions in this population.   Additionally, the significance associated 
with this confidence interval is < 0.05 (p = 0.02), demonstrating statistical significance. 
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5.3.5.1.2 Method 2 
 
Figure 5-9 Scatterplot for change in days of admission, intent to treat group, method 2 
The scatterplot for the data is shown above (Figure 5-9).  A negative relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-79).  The table shows 
that the value of R is 0.95, and since there is only one predictor variable (clozapine delay), 
this value represents the simple correlation between the net change in days of admission per 
year (the outcome variable) and clozapine delay.  The R2 is 0.009, meaning that the clozapine 
delay accounts for 0.9% of the variation in the change in days of admission.  Other variables 
must therefore account for the remaining 99.1% of the variation in the outcome variable. 
(years) 
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The results of the ANOVA are presented in Appendix G (Table 7-80).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.901.  This is non-significant at a p value of 0.345, and so the regression 
model does not predict net change in days of admission before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-81).  The value of b0 (the 
constant) is 21.355, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 21.355.  
This means that 21.355 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started when the delay to starting 
clozapine is zero.  The gradient of the regression line (b1) is given in the table as -1.176, and 
this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in days of admission per year will become more negative by 1.176 days.  Therefore 
1.176 more days of admission will be spent per year post-clozapine initiation.  However, this 
model shows that clozapine delay only accounts for 0.9% of the effect on the net change in 
admission days.  The value of the regression co-efficient is also shown (b), and if this is 
significantly different to zero then this would confirm that the clozapine delay has a significant 
impact on the ability of the model to predict the net change in days of admission per year.  
The significance of this is tested in the ANOVA using a t-test, the results of which are shown 
in the final column of the table.  The t-test for the predictor variable of clozapine delay is non-
significant at p > 0.05, meaning that the regression coefficient (b) is not significantly different 
to zero, and the theoretical delay to clozapine use does not make a significant contribution 
to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-82) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -3.115 and 
0.679.  Since this interval includes zero, there is no relationship between clozapine 
theoretical delay and net change in number of days of admission in this population.   
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Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.191), 
demonstrating no statistical significance.   
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-10).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  
Again, a negative net change denotes a higher number of admissions after clozapine has 
started. 
 
Figure 5-10 Scatterplot for change in number of admissions, intent to treat group, method 2 
The summary of the regression model is shown in Appendix G (Table 7-83).  The table shows 
that the value of R is 0.112, and since there is only one predictor variable (clozapine delay), 
this value represents the simple correlation between the net change in number of admissions 
per year (the outcome variable) and clozapine delay.  The R2 is 0.013, meaning that the 
(years) 
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clozapine delay accounts for 1.3% of the variation in the change the numbers of admissions.  
Other variables must therefore account for the remaining 98.7% of the variation in the 
outcome variable. 
Next, I conducted an ANOVA.  The ANOVA investigates whether this model (with clozapine 
delay as a predictor variable) predicts the net change in admissions significantly better than 
simply using the mean net change in admissions would alone.  The results are presented in 
Appendix G (Table 7-84).  The sum of squares, associated degrees of freedom (df) and mean 
square are given in the table.  From these data, the F-ratio is calculated, and shown as 1.275.  
This is non-significant at a p value of 0.261, and so the regression model does not predict 
net change in numbers of admissions before and after starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-85).  These show the individual 
contribution of particular variables to the model (in this case, just the theoretical delay to 
clozapine prescribing).  The value of b0 (the constant) is 0.405, and so when the clozapine 
delay is zero (the x-axis intercept on the scatterplot), the model predicts that the net change 
in number of admissions per year is 0.405.  This means that a patient has 0.405 fewer 
admissions in the year following clozapine initiation, compared to the year before clozapine 
was started when the delay to starting clozapine is zero.  The gradient of the regression line 
(b1) is given in the table as -0.016, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in admissions per year will become more negative by 
0.016.  Therefore 0.016 more admissions will be spent per year post-clozapine initiation.  
However, this model shows that clozapine delay only accounts for 1.3% of the effect on the 
net change in admission days.  The value of the regression co-efficient is also shown (b), 
and if this is significantly different to zero then this would confirm that the clozapine delay has 
a significant impact on the ability of the model to predict the net change in admissions per 
year.  The significance of this is tested in the ANOVA using a t-test, the results of which are 
shown in the final column of the table.  The t-test for clozapine delay is non-significant at p = 
0.261, meaning that the regression coefficient (b) is not significantly different to zero, and the 
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theoretical delay to clozapine use does not make a significant contribution to the outcome of 
the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-86).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.040 and 0.007.  Since this interval does 
include zero, there is no relationship between clozapine theoretical delay and net change in 
number of admissions in this population.   Additionally, the significance associated with this 
confidence interval is p = 0.203, demonstrating no statistical significance. 
5.3.5.1.3 Method 3 
 
Figure 5-11 Scatterplot for change in days of admission, intent to treat group, method 3 
The scatterplot for the data is shown above (Figure 5-11).  A positive relationship is seen in 
(years) 
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the data, whereby the longer the delay in clozapine prescribing, the more positive the net 
change in days of admission per year becomes.  Again, a positive net change denotes a 
lower number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-87).  The table shows 
that the value of R is 0.16, and since there is only one predictor variable (clozapine delay), 
this value represents the simple correlation between the net change in days of admission per 
year (the outcome variable) and clozapine delay.  The R2 is < 0.0005, meaning that the 
clozapine delay accounts for less than 0.05% of the variation in the change in days of 
admission.  Other variables must therefore account for the remaining 99.95% of the variation 
in the outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-88).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.026.  This is non-significant at a p value of 0.871, and so the regression 
model does not predict net change in days of admission before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-89).  The value of b0 (the 
constant) is 1.370, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in days of admission per year is 1.370.  
This means that 1.370 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as 0.268, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that 0.268 fewer days of admission will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay accounts for less than 0.05% of 
the effect on the net change in admission days.  The value of the regression co-efficient is 
also shown (b), and if this is significantly different to zero then this would confirm that the 
clozapine delay has a significant impact on the ability of the model to predict the net change 
in admissions per year.  The significance of this is tested in the ANOVA using a t-test, the 
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results of which are shown in the final column of the table.  The t-test for the predictor variable 
of clozapine delay is non-significant at p > 0.05, meaning that the regression coefficient (b) 
is not significantly different to zero, and the theoretical delay to clozapine use does not make 
a significant contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-90) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between –2.291 and 
2.835.  Since this interval includes zero, there is no relationship between clozapine 
theoretical delay and net change in number of days of admission in this population.   
Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.17), 
demonstrating no statistical significance.   
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-12).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  




Figure 5-12 Scatterplot for change in number of admissions, intent to treat group, method 3 
The summary of the regression model is shown in Appendix G (Table 7-91).  The table shows 
that the value of R is 0.235, and since there is only one predictor variable (clozapine delay), 
this value represents the simple correlation between the net change in number of admissions 
per year (the outcome variable) and clozapine delay.  The R2 is 0.055, meaning that the 
clozapine delay accounts for 5.5% of the variation in the change numbers of admissions.  
Other variables must therefore account for the remaining 94.5% of the variation in the 
outcome variable. 
Next, I conducted an ANOVA.  The ANOVA investigates whether this model (with clozapine 
delay as a predictor variable) predicts the net change in admissions significantly better than 
simply using the mean net change in admissions would alone.  The results are presented in 
Appendix G (Table 7-92).  The sum of squares, associated degrees of freedom (df) and mean 
square are given in the table.  From these data, the F-ratio is calculated, and shown as 5.855.  
(years) 
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This is significant at a p value of 0.017, and so the regression model does predict net change 
in numbers of admissions before and after starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-93).  These show the individual 
contribution of particular variables to the model (in this case, just the theoretical delay to 
clozapine prescribing).  The value of b0 (the constant) is 0.973, and so when the clozapine 
delay is zero (the x-axis intercept on the scatterplot), the model predicts that the net change 
in number of admissions per year is 0.973.  This means that a patient has 0.973 fewer 
admissions in the year following clozapine initiation, compared to the year before clozapine 
was started.  The gradient of the regression line (b1) is given in the table as -0.061, and this 
shows the change in the outcome associated with a unit change in the predictor; therefore if 
clozapine delay is increased by 1 unit (1 year), the model predicts that the net change in 
admissions will become more negative by 0.061 admissions per year.  Therefore, 0.061 more 
admissions will be spent per year post-clozapine initiation.  However, this model shows that 
clozapine delay only accounts for 5.5% of the effect on the net change in admission days.  
The value of the regression co-efficient is also shown (b), and if this is significantly different 
to zero then this would confirm that the clozapine delay has a significant impact on the ability 
of the model to predict the net change in admissions per year.  The significance of this is 
tested in the ANOVA using a t-test, the results of which are shown in the final column of the 
table.  The t-test for clozapine delay is significant at p = 0.017, meaning that the regression 
coefficient (b) is significantly different to zero, and the theoretical delay to clozapine use does 
make a significant contribution to the outcome of the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-94).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.116 and -0.021.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
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in number of admissions in this population.   Additionally, the significance associated with 
this confidence interval is p = 0.027, demonstrating statistical significance. 
5.3.5.1.4 Method 4 
 
Figure 5-13 Scatterplot for change in days of admission, intent to treat group, method 4 
The scatterplot for the data is shown above (Figure 5-13).  A negative relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-95).  The table shows 
that the value of R is 0.19, and since there is only one predictor variable (clozapine delay), 
this value represents the simple correlation between the net change in days of admission per 
year (the outcome variable) and clozapine delay.  The R2 is < 0.0005, meaning that the 
clozapine delay accounts for less than 0.05% of the variation in the change in days of 
(years) 
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admission.  Other variables must therefore account for the remaining 99.95% of the variation 
in the outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-96).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.037.  This is non-significant at a p value of 0.847, and so the regression 
model does not predict net change in days of admission before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-97).  The value of b0 (the 
constant) is 9.284, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 9.284.  This 
means that 9.284 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as - 0.333, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission becomes more negative by 0.333 
days per year.  Therefore 0.333 extra days of admission will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay accounts for less than 0.05% of 
the effect on the net change in admission days.  The value of the regression co-efficient is 
also shown (b), and if this is significantly different to zero then this would confirm that the 
clozapine delay has a significant impact on the ability of the model to predict the net change 
in days of admission per year.  The significance of this is tested in the ANOVA using a t-test, 
the results of which are shown in the final column of the table.  The t-test for the predictor 
variable of clozapine delay is non-significant at p > 0.05, meaning that the regression 
coefficient (b) is not significantly different to zero, and the theoretical delay to clozapine use 
does not make a significant contribution to the outcome of the net change in days of 
admission per year. 
The bootstrapped confidence intervals (Table 7-98)  indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between –3.028 and 
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2.254.  Since this interval includes zero, there is no relationship between clozapine 
theoretical delay and net change in number of days of admission in this population.   
Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.820), 
demonstrating no statistical significance.   
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-14).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  
Again, a negative net change denotes a higher number of admissions after clozapine has 
started. 
 
Figure 5-14 Scatterplot for change in number of admissions, intent to treat group, method 4 
The summary of the regression model is shown in Appendix G (Table 7-99).  The table shows 
that the value of R is 0.235, and since there is only one predictor variable (clozapine delay), 
(years) 
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this value represents the simple correlation between the net change in number of admissions 
per year (the outcome variable) and clozapine delay.  The R2 is 0.055, meaning that the 
clozapine delay accounts for 5.5% of the variation in the change numbers of admissions.  
Other variables must therefore account for the remaining 94.5% of the variation in the 
outcome variable. 
Next, I conducted an analysis of variance (ANOVA).  The ANOVA investigates whether this 
model (with clozapine delay as a predictor variable) predicts the net change in admissions 
significantly better than simply using the mean net change in admissions would alone.  The 
results are presented in Appendix G (Table 7-100).  The sum of squares, associated degrees 
of freedom (df) and mean square are given in the table.  From these data, the F-ratio is 
calculated, and shown as 5.855.  This is significant at a p value of 0.017, and so the 
regression model does predict net change in numbers of admissions before and after starting 
clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-101).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.973, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.973.  This means that a patient has 0.973 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.061, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions will become more negative by 0.061 per year.  Therefore 0.061 more 
admissions will be spent per year post-clozapine initiation.  However, this model shows that 
clozapine delay only accounts for 5.5% of the effect on the net change in admission days.  
The value of the regression co-efficient is also shown (b), and if this is significantly different 
to zero then this would confirm that the clozapine delay has a significant impact on the ability 
of the model to predict the net change in admissions per year.  The significance of this is 
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tested in the ANOVA using a t-test, the results of which are shown in the final column of the 
table.  The t-test for clozapine delay is significant at p = 0.017, meaning that the regression 
coefficient (b) is significantly different to zero, and the theoretical delay to clozapine use does 
make a significant contribution to the outcome of the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-102).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.117 and -0.018.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
in number of admissions in this population.   Additionally, the significance associated with 
this confidence interval is p = 0.025, demonstrating statistical significance. 
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5.3.5.1.5 Method 5 
Figure 5-15 Scatterplot for change in days of admission, intent to treat group, method 5 
The scatterplot for the data is shown above (Figure 5-15).  A negative relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-103).  The table 
shows that the value of R is 0.208, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is 0.043, meaning 
that the clozapine delay accounts for 4.3% of the variation in the change in days of admission.  




The results of the ANOVA are presented in Appendix G (Table 7-104).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 4.502.  This is significant at a p value of 0.036, and so the regression 
model does predict net change in days of admission before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-105).  The value of b0 (the 
constant) is 63.723, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 63.723.  
This means that 63.723 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as – 4.178, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission will become more negative by 
4.178 days per year.  Therefore 4.178 more days of admission will be spent per year post-
clozapine initiation.  However, this model shows that clozapine delay accounts for less than 
4.3% of the effect on the net change in admission days.  The value of the regression co-
efficient is also shown (b), and if this is significantly different to zero then this would confirm 
that the clozapine delay has a significant impact on the ability of the model to predict the net 
change in admissions per year.  The significance of this is tested in the ANOVA using a t-
test, the results of which are shown in the final column of the table.  The t-test for the predictor 
variable of clozapine delay is significant at p = 0.036, meaning that the regression coefficient 
(b) is significantly different to zero, and the theoretical delay to clozapine use does make a 
significant contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-106) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -7.459 and 
-1.210.  Since this interval does not include zero, there is a genuine negative relationship 
between clozapine theoretical delay and net change in number of days of admission in this 
population.  This result is significant at p = 0.017.   
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The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-16).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  
Again, a negative net change denotes a higher number of admissions after clozapine has 
started. 
 
Figure 5-16 Scatterplot for change in number of admissions, intent to treat group, method 5 
The summary of the regression model is shown in Appendix G (Table 7-107).  The table 
shows that the value of R is 0.235, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.055, meaning 
that the clozapine delay accounts for 5.5% of the variation in the change numbers of 
admissions.  Other variables must therefore account for the remaining 94.5% of the variation 
(years) 
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in the outcome variable. 
Next, I conducted an ANOVA.  The ANOVA investigates whether this model (with clozapine 
delay as a predictor variable) predicts the net change in admissions significantly better than 
simply using the mean net change in admissions would alone.  The results are presented in 
Appendix G (Table 7-108).  The sum of squares, associated degrees of freedom (df) and 
mean square are given in the table.  From these data, the F-ratio is calculated, and shown 
as 5.855.  This is significant at a p value of 0.017, and so the regression model does predict 
net change in numbers of admissions before and after starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-109).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.973, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.973.  This means that a patient has 0.973 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.061, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions will become more negative by 0.061 admissions per year.  Therefore 
0.061 more admissions will be spent per year post-clozapine initiation.  However, this model 
shows that clozapine delay only accounts for 5.5% of the effect on the net change in 
admission days.  The value of the regression co-efficient is also shown (b), and if this is 
significantly different to zero then this would confirm that the clozapine delay has a significant 
impact on the ability of the model to predict the net change in admissions per year.  The 
significance of this is tested in the ANOVA using a t-test, the results of which are shown in 
the final column of the table.  The t-test for clozapine delay is significant at p = 0.017, meaning 
that the regression coefficient (b) is significantly different to zero, and the theoretical delay to 
clozapine use does make a significant contribution to the outcome of the net change in 
admissions per year. 
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As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-110).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.113 and -0.023.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
in number of admissions in this population.   Additionally, the significance associated with 
this confidence interval is p = 0.028, demonstrating statistical significance. 
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Table 5-24 Intent to treat group linear regression data summary 
  Linear 
regression 
ANOVA Co-efficients Bootstrapping Effect of increasing clozapine 
delay by 1 year 
R2 F B0 B1 
Method 
1 
Change in days of 
admission 
0.003 0.297 (p = 
0.587) 
-6.487 0.892 (p = 
0.587) 
-1.566 to 3.583 (p = 
0.466) 
0.892 fewer days of admission per 
year after clozapine has started 
 Change in number 
of admissions 
0.055 5.855 (p = 
0.017)* 
0.973 -0.061 (p = 
0.017)* 
-0.110 to -0.025 (p = 
0.02)* 
0.061 more admissions per year 
after clozapine has started 
Method 
2 
Change in days of 
admission 
0.009 0.901 (p = 
0.345) 
21.355 -1.176 (p = 
0.345) 
-3.115 to 0.679 (p = 
0.191) 
1.176 more days of admission per 
year after clozapine has started 
 Change in number 
of admissions 
0.013 1.275 (p = 
0.261) 
0.405 -0.016 (p = 
0.261) 
-0.040 to 0.007 (p = 
0.203) 
0.016 more admissions per year 
after clozapine has started 
Method 
3 
Change in days of 
admission 
<0.0005 0.026 (p = 
0.871) 
1.370 0.268 (p = 
0.871) 
–2.291 to 2.835 (p = 
0.17) 
0.268 fewer days of admission per 
year after clozapine has started 
 Change in number 
of admissions 
0.055 5.855 (p = 
0.017)* 
0.973 -0.061 (p = 
0.017)* 
-0.116 to -0.021 (p = 
0.027)* 
0.061 more admissions per year 
after clozapine has started 
Method 
4 
Change in days of 
admission 
<0.0005 0.037 (p = 
0.847) 
9.284 -0.333 (p = 
0.847) 
–3.028 to 2.254 (p = 
0.820) 
0.333 more days of admission per 
year after clozapine has started 
 Change in number 
of admissions 
0.055 5.855 (p = 
0.017)* 
0.973 -0.061 (p = 
0.017)* 
-0.116 to -0.018 (p = 
0.025)* 
0.061 more admissions per year 
after clozapine has started 
Method 
5 
Change in days of 
admission 
0.043 4.502 (p = 
0.036)* 
63.723 -4.178 (p = 
0.036)* 
-7.459 to -1.210 (p = 
0.017)* 
4.178 more days of admission 
after clozapine has started 
 Change in number 
of admissions 
0.055 5.855 (p = 
0.017)* 
0.973 -0.061 (p = 
0.017)* 
-0.116 to -0.023 (p = 
0.028)* 
0.061 more admissions per year 
after clozapine has started 
* reaches statistical significance at p <0.05 
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The data presented above are summarised in  Table 5-24.  For all 5 methods of data analysis, 
clozapine delay predicts less than 6% of the net change in days of admission or number of 
admissions per year before and after clozapine initiation.  The regression models for methods 
1, 3, 4 and 5, reached statistical significance for the relationship between clozapine delay 
and net change in the number of admission pre- and post-clozapine initiation.   Only the 
regression model for method 5 reached statistical significance for the relationship between 
clozapine delay and the net change in the number of days of admission pre- and post-
clozapine.  Of the models that reach statistical significance, all predict that an increase in the 
delay to clozapine use results in more days of admission or total admissions per year once 
clozapine has been started.  An increase in delay to clozapine initiation of one year results 
in an increase of 4.178 days of admission per year, and 0.061 admissions per year.  As the 
mean theoretical delay to clozapine use for this ITT group was 3.93 years, this results in an 
average increase of 16.42 days of admission, or 0.24 extra inpatient admissions.  All methods 
of data analysis, with the exception of the change in days of admission for method 1, predict 
that if clozapine delay is zero, there is a reduction in the number of days spent as an inpatient 
and the total number of inpatient admissions in the year following clozapine initiation. 
 Clozapine continuers 
Next, I repeated the linear regression for the clozapine continuers group. 
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5.3.5.2.1 Method 1 
 
Figure 5-17 Scatterplot for change in days of admission, clozapine continuers, method 1 
The scatterplot for the data is shown above (Figure 5-17).  A positive relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more positive the net 
change in days of admission per year becomes.  Again, a positive net change denotes a 
lower number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-111).  The table 
shows that the value of R is 0.065, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is 0.004, meaning 
that the clozapine delay accounts for 0.4% of the variation in the change in days of admission.  




The results of the ANOVA are presented in Appendix G (Table 7-112).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.274.  This is non-significant at a p value of 0.603, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-113).  The value of b0 (the 
constant) is 8.776, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 8.776.  This 
means that 8.776 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as 0.876, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission becomes more positive by 0.876 
days per year.  Therefore 0.876 fewer days of admission will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay accounts for less than 0.05% of 
the effect on the net change in admission days.  The value of the regression co-efficient is 
also shown (b), and if this is significantly different to zero then this would confirm that the 
clozapine delay has a significant impact on the ability of the model to predict the net change 
in admissions per year.  The significance of this is tested in the ANOVA using a t-test, the 
results of which are shown in the final column of the table.  The t-test for the predictor variable 
of clozapine delay is non-significant at p > 0.05, meaning that the regression coefficient (b) 
is not significantly different to zero, and the theoretical delay to clozapine use does not make 
a significant contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-114) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -1.382 and 
3.127.  Since this interval includes zero, there is no relationship between clozapine 
theoretical delay and net change in number of days of admission in this population.   
 203 
Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.443), 
demonstrating no statistical significance. 
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-18).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  
Again, a negative net change denotes a higher number of admissions after clozapine has 
started. 
 
Figure 5-18 Scatterplot for change in number of admissions, clozapine continuers, method 1 
The summary of the regression model is shown in Appendix G (Table 7-115).  The table 
shows that the value of R is 0.198, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.039, meaning 
that the clozapine delay accounts for 3.9% of the variation in the change numbers of 
(years) 
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admissions.  Other variables must therefore account for the remaining 96.1% of the variation 
in the outcome variable. 
Next, I conducted an ANOVA.  The ANOVA investigates whether this model (with clozapine 
delay as a predictor variable) predicts the net change in admissions significantly better than 
simply using the mean net change in admissions would alone.  The results are presented in 
Appendix G (Table 7-116).  The sum of squares, associated degrees of freedom (df) and 
mean square are given in the table.  From these data, the F-ratio is calculated, and shown 
as 2.645.  This is non-significant at a p value of 0.109, and so the regression model does not 
predict net change in numbers of admissions before and after starting clozapine significantly 
well. 
The model parameters are presented in Appendix G (Table 7-117).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.988, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.988.  This means that a patient has 0.988 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.052, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions becomes more negative by 0.052 admissions per year.  Therefore 
0.052 more admissions will be spent per year post-clozapine initiation.  However, this model 
shows that clozapine delay only accounts for 3.9% of the effect on the net change in 
admission days.  The value of the regression co-efficient is also shown (b), and if this is 
significantly different to zero then this would confirm that the clozapine delay has a significant 
impact on the ability of the model to predict the net change in admissions per year.  The 
significance of this is tested in the ANOVA using a t-test, the results of which are shown in 
the final column of the table.  The t-test for clozapine delay is non-significant at p = 0.109, 
meaning that the regression coefficient (b) is not significantly different to zero, and the 
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theoretical delay to clozapine use does not make a significant contribution to the outcome of 
the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-118).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.126 and -0.004.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
in number of admissions in this population.   However, the significance associated with this 
confidence interval is p = 0.140, demonstrating no statistical significance. 
5.3.5.2.2 Method 2 
 
Figure 5-19 Scatterplot for change in days of admission, clozapine continuers, method 2 
The scatterplot for the data is shown above (Figure 5-19).  A negative relationship is seen in 
(years) 
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the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-119).  The table 
shows that the value of R is 0.046, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is 0.002, meaning 
that the clozapine delay accounts for 0.2% of the variation in the change in days of admission.  
Other variables must therefore account for the remaining 99.8% of the variation in the 
outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-120).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.140.  This is non-significant at a p value of 0.709, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-121).  The value of b0 (the 
constant) is 26.727, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 26.727.  
This means that 26.727 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as - 0.481, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission becomes more negative by 0.481 
days per year.  Therefore 0.481 more days of admission will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay accounts for 0.2% of the effect on 
the net change in admission days.  The value of the regression co-efficient is also shown (b), 
and if this is significantly different to zero then this would confirm that the clozapine delay has 
a significant impact on the ability of the model to predict the net change in admissions per 
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year.  The significance of this is tested in the ANOVA using a t-test, the results of which are 
shown in the final column of the table.  The t-test for the predictor variable of clozapine delay 
is non-significant at p > 0.05, meaning that the regression coefficient (b) is not significantly 
different to zero, and the theoretical delay to clozapine use does not make a significant 
contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-122) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -2.347 and 
1.067.  Since this interval includes zero, there is no relationship between clozapine 
theoretical delay and net change in number of days of admission in this population.   
Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.590), 
demonstrating no statistical significance. 
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-20).  
A positive relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more positive the net change in number of admissions per year becomes.  
Again, a positive net change denotes a lower number of admissions after clozapine has 
started. 
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Figure 5-20 Scatterplot for change in number of admissions, clozapine continuers, method 2 
The summary of the regression model is shown in Appendix G (Table 7-123).  The table 
shows that the value of R is 0.127, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.016, meaning 
that the clozapine delay accounts for 1.6% of the variation in the change numbers of 
admissions.  Other variables must therefore account for the remaining 98.4% of the variation 
in the outcome variable. 
Next, I conducted an analysis of variance (ANOVA).  The ANOVA investigates whether this 
model (with clozapine delay as a predictor variable) predicts the net change in admissions 
significantly better than simply using the mean net change in admissions would alone.  The 
results are presented in Appendix G (Table 7-124).  The sum of squares, associated degrees 
of freedom (df) and mean square are given in the table.  From these data, the F-ratio is 
calculated, and shown as 1.059.  This is non-significant at a p value of 0.307, and so the 
(years) 
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regression model does not predict net change in numbers of admissions before and after 
starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-125).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.081, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.081.  This means that a patient has 0.081 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as 0.007, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in the number of admissions becomes more positive by 0.007 per year.  Therefore 
0.007 fewer admissions will be spent per year post-clozapine initiation.  However, this model 
shows that clozapine delay only accounts for 1.6% of the effect on the net change in 
admission days.  The value of the regression co-efficient is also shown (b), and if this is 
significantly different to zero then this would confirm that the clozapine delay has a significant 
impact on the ability of the model to predict the net change in admissions per year.  The 
significance of this is tested in the ANOVA using a t-test, the results of which are shown in 
the final column of the table.  The t-test for clozapine delay is non-significant at p = 0.307, 
meaning that the regression coefficient (b) is not significantly different to zero, and the 
theoretical delay to clozapine use does not make a significant contribution to the outcome of 
the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-126).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.004 and 0.021.  Since this interval does 
include zero, there is no relationship between clozapine theoretical delay and net change in 
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number of admissions in this population.   Additionally, the significance associated with this 
confidence interval is p = 0.317, demonstrating no statistical significance. 
5.3.5.2.3 Method 3 
 
Figure 5-21 Scatterplot for change in days of admission, clozapine continuers, method 3 
The scatterplot for the data is shown above (Figure 5-21).  A positive relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the less negative the net 
change in days of admission per year becomes.  Again, more positive net change denotes a 
lower number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-127).  The table 
shows that the value of R is 0.015, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is less than 0.0005, 
meaning that the clozapine delay accounts for less than 0.05% of the variation in the change 
(years) 
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in days of admission.  Other variables must therefore account for the remaining 99.95% of 
the variation in the outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-128).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.014.  This is non-significant at a p value of 0.906, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-129).  The value of b0 (the 
constant) is 16.861, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 16.861.  
This means that 16.861 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as 0.203, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission becomes more positive by 0.203 
days per year.  Therefore 0.203 fewer days of admission will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay accounts for less than 0.05% of 
the effect on the net change in admission days.  The value of the regression co-efficient is 
also shown (b), and if this is significantly different to zero then this would confirm that the 
clozapine delay has a significant impact on the ability of the model to predict the net change 
in admissions per year.  The significance of this is tested in the ANOVA using a t-test, the 
results of which are shown in the final column of the table.  The t-test for the predictor variable 
of clozapine delay is non-significant at p > 0.05, meaning that the regression coefficient (b) 
is not significantly different to zero, and the theoretical delay to clozapine use does not make 
a significant contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-130) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -2.349 and 
2.469.  Since this interval includes zero, there is no relationship between clozapine 
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theoretical delay and net change in number of days of admission in this population.   
Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.858), 
demonstrating no statistical significance. 
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-22).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  
Again, a negative net change denotes a higher number of admissions after clozapine has 
started. 
 
Figure 5-22 Scatterplot for change in number of admissions, clozapine continuers, method 3 
The summary of the regression model is shown in Appendix G (Table 7-131).  The table 
shows that the value of R is 0.198, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.039, meaning 
(years) 
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that the clozapine delay accounts for 3.9% of the variation in the change numbers of 
admissions.  Other variables must therefore account for the remaining 96.1% of the variation 
in the outcome variable. 
Next, I conducted an ANOVA.  The ANOVA investigates whether this model (with clozapine 
delay as a predictor variable) predicts the net change in admissions significantly better than 
simply using the mean net change in admissions would alone.  The results are presented in 
Appendix G (Table 7-132).  The sum of squares, associated degrees of freedom (df) and 
mean square are given in the table.  From these data, the F-ratio is calculated, and shown 
as 2.645.  This is non-significant at a p value of 0.109, and so the regression model does not 
predict net change in numbers of admissions before and after starting clozapine significantly 
well. 
The model parameters are presented in Appendix G (Table 7-133).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.998, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.998.  This means that a patient has 0.998 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.052, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions will become more negative by 0.052 per year.  Therefore 0.052 more 
admissions will be spent per year post-clozapine initiation.  However, this model shows that 
clozapine delay only accounts for 3.9% of the effect on the net change in admission days.  
The value of the regression co-efficient is also shown (b), and if this is significantly different 
to zero then this would confirm that the clozapine delay has a significant impact on the ability 
of the model to predict the net change in admissions per year.  The significance of this is 
tested in the ANOVA using a t-test, the results of which are shown in the final column of the 
table.  The t-test for clozapine delay is non-significant at p = 0.109, meaning that the 
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regression coefficient (b) is not significantly different to zero, and the theoretical delay to 
clozapine use does not make a significant contribution to the outcome of the net change in 
admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-134).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.129 and -0.005.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
in number of admissions in this population.   However, the significance associated with this 
confidence interval is p = 0.142, demonstrating no statistical significance. 
 215 
5.3.5.2.4 Method 4 
 
Figure 5-23 Scatterplot for change in days of admission, clozapine continuers, method 4 
The scatterplot for the data is shown above (Figure 5-23).  A negative relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-135).  The table 
shows that the value of R is 0.030, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is 0.001, meaning 
that the clozapine delay accounts for 0.1% of the variation in the change in days of admission.  




The results of the ANOVA are presented in Appendix G (Table 7-136).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.059.  This is non-significant at a p value of 0.809, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-137).  The value of b0 (the 
constant) is 25.030, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 25.030.  
This means that 25.030 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as - 0.445, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission becomes more negative by 0.445 
days per year.  Therefore 0.445 more days of admission will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay accounts for 0.1% of the effect on 
the net change in admission days.  The value of the regression co-efficient is also shown (b), 
and if this is significantly different to zero then this would confirm that the clozapine delay has 
a significant impact on the ability of the model to predict the net change in admissions per 
year.  The significance of this is tested in the ANOVA using a t-test, the results of which are 
shown in the final column of the table.  The t-test for the predictor variable of clozapine delay 
is non-significant at p > 0.05, meaning that the regression coefficient (b) is not significantly 
different to zero, and the theoretical delay to clozapine use does not make a significant 
contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-138) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -3.181 and 
2.220.  Since this interval includes zero, there is no relationship between clozapine 
theoretical delay and net change in number of days of admission in this population.   
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Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.760), 
demonstrating no statistical significance. 
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-24).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  
Again, a negative net change denotes a higher number of admissions after clozapine has 
started. 
 
Figure 5-24 Scatterplot for change in number of admissions, clozapine continuers, method 4 
The summary of the regression model is shown in Appendix G (Table 7-139).  The table 
shows that the value of R is 0.198, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.039, meaning 
that the clozapine delay accounts for 3.9% of the variation in the change numbers of 
(years) 
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admissions.  Other variables must therefore account for the remaining 96.1% of the variation 
in the outcome variable. 
Next, I conducted an ANOVA.  The ANOVA investigates whether this model (with clozapine 
delay as a predictor variable) predicts the net change in admissions significantly better than 
simply using the mean net change in admissions would alone.  The results are presented in 
Appendix G (Table 7-140).  The sum of squares, associated degrees of freedom (df) and 
mean square are given in the table.  From these data, the F-ratio is calculated, and shown 
as 2.645.  This is non-significant at a p value of 0.109, and so the regression model does not 
predict net change in numbers of admissions before and after starting clozapine significantly 
well. 
The model parameters are presented in Appendix G (Table 7-141).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.998, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.998.  This means that a patient has 0.998 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.052, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions will become more negative by 0.052 per year.  Therefore 0.052 more 
admissions will be spent per year post-clozapine initiation.  However, this model shows that 
clozapine delay only accounts for 3.9% of the effect on the net change in admission days.  
The value of the regression co-efficient is also shown (b), and if this is significantly different 
to zero then this would confirm that the clozapine delay has a significant impact on the ability 
of the model to predict the net change in admissions per year.  The significance of this is 
tested in the ANOVA using a t-test, the results of which are shown in the final column of the 
table.  The t-test for clozapine delay is non-significant at p = 0.109, meaning that the 
regression coefficient (b) is not significantly different to zero, and the theoretical delay to 
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clozapine use does not make a significant contribution to the outcome of the net change in 
admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-142).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.127 and -0.005.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
in number of admissions in this population.   However, the significance associated with this 
confidence interval is p = 0.153, demonstrating no statistical significance. 
5.3.5.2.5 Method 5 
 
Figure 5-25 Scatterplot for change in days of admission, clozapine continuers, method 5 
The scatterplot for the data is shown above (Figure 5-25).  A negative relationship is seen in 
(years) 
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the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-143).  The table 
shows that the value of R is 0.196, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is 0.038, meaning 
that the clozapine delay accounts for 3.8% of the variation in the change in days of admission.  
Other variables must therefore account for the remaining 96.2% of the variation in the 
outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-144).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 2.596.  This is non-significant at a p value of 0.112, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-145).  The value of b0 (the 
constant) is 68.574, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 68.574.  
This means that 68.574 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as – 3.447, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission becomes more negative by 3.447 
days per year.  Therefore 3.447 more days of admission will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay accounts for 3.8% of the effect on 
the net change in admission days.  The value of the regression co-efficient is also shown (b), 
and if this is significantly different to zero then this would confirm that the clozapine delay has 
a significant impact on the ability of the model to predict the net change in admissions per 
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year.  The significance of this is tested in the ANOVA using a t-test, the results of which are 
shown in the final column of the table.  The t-test for the predictor variable of clozapine delay 
is non-significant at p > 0.05, meaning that the regression coefficient (b) is not significantly 
different to zero, and the theoretical delay to clozapine use does not make a significant 
contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-146) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -7.647 and 
-0.431.  Since this interval does not include zero, there is a genuine negative relationship 
between clozapine theoretical delay and net change in number of days of admission in this 
population.  However, this result is non-significant at p = 0.079.   
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-26).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  




Figure 5-26 Scatterplot for change in number of admissions, clozapine continuers, method 5 
The summary of the regression model is shown in Appendix G (Table 7-147).  The table 
shows that the value of R is 0.198, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.039, meaning 
that the clozapine delay accounts for 3.9% of the variation in the change numbers of 
admissions.  Other variables must therefore account for the remaining 96.1% of the variation 
in the outcome variable. 
Next, I conducted an ANOVA.  The ANOVA investigates whether this model (with clozapine 
delay as a predictor variable) predicts the net change in admissions significantly better than 
simply using the mean net change in admissions would alone.  The results are presented in 
Appendix G (Table 7-148).  The sum of squares, associated degrees of freedom (df) and 
mean square are given in the table.  From these data, the F-ratio is calculated, and shown 
as 2.645.  This is non-significant at a p value of 0.109, and so the regression model does not 
(years) 
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predict net change in numbers of admissions before and after starting clozapine significantly 
well. 
The model parameters are presented in Appendix G (Table 7-149).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.998, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.998.  This means that a patient has 0.998 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.052, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions becomes more negative by 0.052 admissions per year.  Therefore 
0.052 more admissions will be spent per year post-clozapine initiation.  However, this model 
shows that clozapine delay only accounts for 3.9% of the effect on the net change in 
admission days.  The value of the regression co-efficient is also shown (b), and if this is 
significantly different to zero then this would confirm that the clozapine delay has a significant 
impact on the ability of the model to predict the net change in admissions per year.  The 
significance of this is tested in the ANOVA using a t-test, the results of which are shown in 
the final column of the table.  The t-test for clozapine delay is non-significant at p = 0.109, 
meaning that the regression coefficient (b) is not significantly different to zero, and the 
theoretical delay to clozapine use does not make a significant contribution to the outcome of 
the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-150).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.127 and -0.002.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
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in number of admissions in this population.   However, the significance associated with this 
confidence interval is p = 0.153, demonstrating no statistical significance. 
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Table 5-25 Clozapine continuers group linear regression data summary 
  Linear 
regression 
ANOVA Co-efficients Bootstrapping Effect of increasing delay to 
clozapine use by 1 year 
R2 F B0 B1 
Method 
1 
Change in days of 
admission 
0.004 0.274 (p = 
0.603) 
8.776 0.876 (p = 
0.603) 
-1.382 to 3.127 (p = 
0.443) 
0.876 fewer days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.039 2.645 (p = 
0.109) 
0.988 -0.052 (p = 
0.109) 
-0.126 to -0.004 (p = 
0.140) 
0.052 more admissions per year 
after clozapine has started 
Method 
2 
Change in days of 
admission 
0.002 0.140 (p = 
0.709) 
26.727 -0.481 (p = 
0.709) 
-2.347 to 1.067 (p = 
0.590) 
0.481 more days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.016 1.059 (p = 
0.307) 
0.081 0.007 (p = 
0.307) 
-0.004 to 0.021 (p = 
0.317) 
0.007 fewer admissions per year 
after clozapine has started 
Method 
3 
Change in days of 
admission 
< 0.0005 0.014 (p = 
0.906) 
16.861 0.203 (p = 
0.906) 
-2.349 to 2.469 (p = 
0.858) 
0.203 fewer days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.039 2.645 (p = 
0.109) 
0.988 -0.052 (p = 
0.109) 
-0.129 to -0.005 (p = 
0.142) 
0.052 more admissions per year 
after clozapine has started 
Method 
4 
Change in days of 
admission 
0.001 0.059 (p = 
0.809) 
25.030              -0.445 (p = 
0.809) 
-3.181 to 2.220 (p = 
0.760) 
0.445 more days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.039 2.645 (p = 
0.109) 
0.988 -0.052 (p = 
0.109) 
-0.127 to -0.005 (p = 
0.153) 
0.052 more admissions per year 
after clozapine has started 
Method 
5 
Change in days of 
admission 
0.038 2.596 (p = 
0.112) 
68.574 -3.447 (p = 
0.112) 
-7.647 to -0.431 (p = 
0.079) 
3.447 more days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.039 2.645 (p = 
0.109) 
0.988 -0.052 (p = 
0.109) 
-0.127 to -0.002 (p = 
0.153) 
0.052 more admissions per year 
after clozapine has started 
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Table 7-25 summarises the data presented above.  For all 5 methods of data analysis, 
clozapine delay predicts less than 4% of the net change in days of admission and number of 
admissions per year before and after clozapine initiation.  None of the models reached 
statistical significance for the relationship between clozapine delay and net change in days 
of admission pre- and post-clozapine initiation.  All methods of data analysis predict that if 
clozapine delay is zero, there is a lower number of days of admission and a lower total 
number of admissions per year once clozapine has been started. 
 Clozapine discontinuers 
The linear regression was then repeated for the clozapine discontinuers group. 
5.3.5.3.1 Method 1 
 
Figure 5-27 Scatterplot for change in days of admission, clozapine discontinuers, method 1 
The scatterplot for the data is shown above (Figure 5-27).  A positive relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the less negative the net 
(years) 
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change in days of admission per year becomes.  Again, more positive net change denotes a 
lower number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-151).  The table 
shows that the value of R is 0.005, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is less than 0.0005, 
meaning that the clozapine delay accounts for less than 0.05% of the variation in the change 
in days of admission.  Other variables must therefore account for the remaining 99.95% of 
the variation in the outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-152).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.001.  This is non-significant at a p value of 0.977, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-153).  The value of b0 (the 
constant) is -32.775, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is -32.775.  
This means that 32.775 more days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as 0.097, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission will become more positive by 
0.097 days per year.  Therefore 0.097 fewer days of admission will be spent per year post-
clozapine initiation.  However, this model shows that clozapine delay accounts for less than 
0.05% of the effect on the net change in admission days.  The value of the regression co-
efficient is also shown (b), and if this is significantly different to zero then this would confirm 
that the clozapine delay has a significant impact on the ability of the model to predict the net 
change in admissions per year.  The significance of this is tested in the ANOVA using a t-
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test, the results of which are shown in the final column of the table.  The t-test for the predictor 
variable of clozapine delay is non-significant at p > 0.05, meaning that the regression 
coefficient (b) is not significantly different to zero, and the theoretical delay to clozapine use 
does not make a significant contribution to the outcome of the net change in days of 
admission per year. 
The bootstrapped confidence intervals (Table 7-154) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -4.642 and 
5.594.  Since this interval includes zero, there is no relationship between clozapine 
theoretical delay and net change in number of days of admission in this population.   
Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.970), 
demonstrating no statistical significance. 
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-28).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  




Figure 5-28 Scatterplot for change in number of admissions, clozapine discontinuers, method 1 
The summary of the regression model is shown in Appendix G (Table 7-155).  The table 
shows that the value of R is 0.320, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.102, meaning 
that the clozapine delay accounts for 10.2% of the variation in the change numbers of 
admissions.  Other variables must therefore account for the remaining 89.8% of the variation 
in the outcome variable. 
Next, I conducted an analysis of variance (ANOVA).  The ANOVA investigates whether this 
model (with clozapine delay as a predictor variable) predicts the net change in admissions 
significantly better than simply using the mean net change in admissions would alone.  The 
results are presented in Appendix G (Table 7-156).  The sum of squares, associated degrees 
of freedom (df) and mean square are given in the table.  From these data, the F-ratio is 
calculated, and shown as 3.765.  This is non-significant at a p value of 0.061, and so the 
(years) 
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regression model does not predict net change in numbers of admissions before and after 
starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-157).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.943, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.943.  This means that a patient has 0.943 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.079, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions will become more negative by 0.079 admissions per year.  Therefore 
0.079 more admissions will be spent per year post-clozapine initiation.  However, this model 
shows that clozapine delay only accounts for 10.2% of the effect on the net change in 
admission days.  The value of the regression co-efficient is also shown (b), and if this is 
significantly different to zero then this would confirm that the clozapine delay has a significant 
impact on the ability of the model to predict the net change in admissions per year.  The 
significance of this is tested in the ANOVA using a t-test, the results of which are shown in 
the final column of the table.  The t-test for clozapine delay is non-significant at p = 0.061, 
meaning that the regression coefficient (b) is not significantly different to zero, and the 
theoretical delay to clozapine use does not make a significant contribution to the outcome of 
the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-158).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.170 and -0.031.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
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in number of admissions in this population.   Additionally, the significance associated with 
this confidence interval is p = 0.027, demonstrating statistical significance. 
5.3.5.3.2 Method 2 
 
Figure 5-29 Scatterplot for change in days of admission, clozapine discontinuers, method 2 
The scatterplot for the data is shown above (Figure 5-29).  A negative relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-159).  The table 
shows that the value of R is 0.193, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is 0.037, meaning 
that the clozapine delay accounts for 3.7% of the variation in the change in days of admission.  
(years) 
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Other variables must therefore account for the remaining 96.3% of the variation in the 
outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-160).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 1.279.  This is non-significant at a p value of 0.266, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-161).  The value of b0 (the 
constant) is 11.724, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 11.724.  
This means that 11.724 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as – 2.918, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission will become more negative by 
2.918 days per year.  Therefore 2.918 more days of admission will be spent per year post-
clozapine initiation.  However, this model shows that clozapine delay accounts for 3.7% of 
the effect on the net change in admission days.  The value of the regression co-efficient is 
also shown (b), and if this is significantly different to zero then this would confirm that the 
clozapine delay has a significant impact on the ability of the model to predict the net change 
in admissions per year.  The significance of this is tested in the ANOVA using a t-test, the 
results of which are shown in the final column of the table.  The t-test for the predictor variable 
of clozapine delay is non-significant at p > 0.05, meaning that the regression coefficient (b) 
is not significantly different to zero, and the theoretical delay to clozapine use does not make 
a significant contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-162) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -6.469 and 
-0.127.  Since this interval does not include zero, there is a genuine negative relationship 
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between clozapine theoretical delay and net change in number of days of admission in this 
population.  However, this result is non-significant at p = 0.093.   
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-30).  
A positive relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more positive the net change in number of admissions per year becomes.  
Again, a positive net change denotes a lower number of admissions after clozapine has 
started. 
 
Figure 5-30 Scatterplot for change in number of admissions, clozapine discontinuers, method 2 
The summary of the regression model is shown in Appendix G (Table 7-163).  The table 
shows that the value of R is 0.136, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.019, meaning 
that the clozapine delay accounts for 1.9% of the variation in the change numbers of 
(years) 
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admissions.  Other variables must therefore account for the remaining 98.1% of the variation 
in the outcome variable. 
Next, I conducted an analysis of variance (ANOVA).  The ANOVA investigates whether this 
model (with clozapine delay as a predictor variable) predicts the net change in admissions 
significantly better than simply using the mean net change in admissions would alone.  The 
results are presented in Appendix G (Table 7-164).  The sum of squares, associated degrees 
of freedom (df) and mean square are given in the table.  From these data, the F-ratio is 
calculated, and shown as 0.623.  This is non-significant at a p value of 0.436, and so the 
regression model does not predict net change in numbers of admissions before and after 
starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-165).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.359, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.359.  This means that a patient has 0.359 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as 0.015, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions will become more positive by 0.015 admissions per year of extra delay. 
Therefore 0.015 fewer admissions will be spent per year post-clozapine initiation.  However, 
this model shows that clozapine delay only accounts for 1.9% of the effect on the net change 
in admission days.  The value of the regression co-efficient is also shown (b), and if this is 
significantly different to zero then this would confirm that the clozapine delay has a significant 
impact on the ability of the model to predict the net change in admissions per year.  The 
significance of this is tested in the ANOVA using a t-test, the results of which are shown in 
the final column of the table.  The t-test for clozapine delay is non-significant at p = 0.436, 
meaning that the regression coefficient (b) is not significantly different to zero, and the 
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theoretical delay to clozapine use does not make a significant contribution to the outcome of 
the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-166).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.014 and 0.051.  Since this interval does 
include zero, there is no relationship between clozapine theoretical delay and net change in 
number of admissions in this population.   Additionally, the significance associated with this 
confidence interval is p = 0.051, demonstrating no statistical significance. 
5.3.5.3.3 Method 3 
Figure 5-31 Scatterplot for change in days of admission, clozapine discontinuers, method 3 
The scatterplot for the data is shown above (Figure 5-31).  A negative relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
(years) 
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change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-167).  The table 
shows that the value of R is 0.023, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is 0.001, meaning 
that the clozapine delay accounts for 0.1% of the variation in the change in days of admission.  
Other variables must therefore account for the remaining 99.9% of the variation in the 
outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-168).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.017.  This is non-significant at a p value of 0.898, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-169).  The value of b0 (the 
constant) is -25.284, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is -25.284.  
This means that 25.284 more days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as -0.435, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission will become more negative by 
0.435 per year of extra delay.  Therefore 0.435 more days of admission will be spent per year 
post-clozapine initiation.  However, this model shows that clozapine delay accounts for only 
0.01% of the effect on the net change in admission days.  The value of the regression co-
efficient is also shown (b), and if this is significantly different to zero then this would confirm 
that the clozapine delay has a significant impact on the ability of the model to predict the net 
change in admissions per year.  The significance of this is tested in the ANOVA using a t-
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test, the results of which are shown in the final column of the table.  The t-test for the predictor 
variable of clozapine delay is non-significant at p > 0.05, meaning that the regression 
coefficient (b) is not significantly different to zero, and the theoretical delay to clozapine use 
does not make a significant contribution to the outcome of the net change in days of 
admission per year. 
The bootstrapped confidence intervals (Table 7-170) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -5.171 and 
4.694.  Since this interval includes zero, there is no relationship between clozapine 
theoretical delay and net change in number of days of admission in this population.   
Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.842), 
demonstrating no statistical significance. 
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-32).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  




Figure 5-32 Scatterplot for change in number of admissions, clozapine discontinuers, method 3 
The summary of the regression model is shown in Appendix G (Table 7-171).  The table 
shows that the value of R is 0.320, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.102, meaning 
that the clozapine delay accounts for 10.2% of the variation in the change numbers of 
admissions.  Other variables must therefore account for the remaining 89.8% of the variation 
in the outcome variable. 
Next, I conducted an analysis of variance (ANOVA).  The ANOVA investigates whether this 
model (with clozapine delay as a predictor variable) predicts the net change in admissions 
significantly better than simply using the mean net change in admissions would alone.  The 
results are presented in Appendix G (Table 7-172).  The sum of squares, associated degrees 
of freedom (df) and mean square are given in the table.  From these data, the F-ratio is 
calculated, and shown as 3.765.  This is non-significant at a p value of 0.061, and so the 
(years) 
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regression model does not predict net change in numbers of admissions before and after 
starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-173).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.943, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.943.  This means that a patient has 0.943 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.079, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions will become more negative by 0.079 admissions for each extra year of 
clozapine delay.  Therefore 0.079 more admissions will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay only accounts for 10.2% of the 
effect on the net change in admission days.  The value of the regression co-efficient is also 
shown (b), and if this is significantly different to zero then this would confirm that the clozapine 
delay has a significant impact on the ability of the model to predict the net change in 
admissions per year.  The significance of this is tested in the ANOVA using a t-test, the 
results of which are shown in the final column of the table.  The t-test for clozapine delay is 
non-significant at p = 0.061, meaning that the regression coefficient (b) is not significantly 
different to zero, and the theoretical delay to clozapine use does not make a significant 
contribution to the outcome of the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-174).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.171 and -0.028.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
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in number of admissions in this population.   However, the significance associated with this 
confidence interval is p = 0.026, demonstrating statistical significance. 
5.3.5.3.4 Method 4 
 
Figure 5-33 Scatterplot for change in days of admission, clozapine discontinuers, method 4 
The scatterplot for the data is shown above (Figure 5-33).  A negative relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-175).  The table 
shows that the value of R is 0.049, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is 0.002, meaning 
that the clozapine delay accounts for 0.2% of the variation in the change in days of admission.  
(years) 
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Other variables must therefore account for the remaining 99.8% of the variation in the 
outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-176).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 0.078.  This is non-significant at a p value of 0.781, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-177).  The value of b0 (the 
constant) is -17.783, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is -17.783.  
This means that 17.783 more days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as – 0.951, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission becomes more negative by 0.951 
days.  Therefore 0.951 more days of admission will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay accounts for 0.2% of the effect on 
the net change in admission days.  The value of the regression co-efficient is also shown (b), 
and if this is significantly different to zero then this would confirm that the clozapine delay has 
a significant impact on the ability of the model to predict the net change in admissions per 
year.  The significance of this is tested in the ANOVA using a t-test, the results of which are 
shown in the final column of the table.  The t-test for the predictor variable of clozapine delay 
is non-significant at p > 0.05, meaning that the regression coefficient (b) is not significantly 
different to zero, and the theoretical delay to clozapine use does not make a significant 
contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-178) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -6.453 and 
4.577.  Since this interval includes zero, there is no relationship between clozapine 
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theoretical delay and net change in number of days of admission in this population.   
Additionally, the significance associated with this confidence interval is > 0.05 (p = 0.662), 
demonstrating no statistical significance. 
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-34).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  
Again, a negative net change denotes a higher number of admissions after clozapine has 
started. 
Figure 5-34 Scatterplot for change in number of admissions, clozapine discontinuers, method 4 
The summary of the regression model is shown in Appendix G (Table 7-179).  The table 
shows that the value of R is 0.320, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.102, meaning 
that the clozapine delay accounts for 10.2% of the variation in the change numbers of 
(years) 
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admissions.  Other variables must therefore account for the remaining 89.8% of the variation 
in the outcome variable. 
Next, I conducted an analysis of variance (ANOVA).  The ANOVA investigates whether this 
model (with clozapine delay as a predictor variable) predicts the net change in admissions 
significantly better than simply using the mean net change in admissions would alone.  The 
results are presented in Appendix G (Table 7-180).  The sum of squares, associated degrees 
of freedom (df) and mean square are given in the table.  From these data, the F-ratio is 
calculated, and shown as 3.765.  This is non-significant at a p value of 0.061, and so the 
regression model does not predict net change in numbers of admissions before and after 
starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-181).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.943, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.943.  This means that a patient has 0.943 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.079, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions will become more negative by 0.079 admissions per year of clozapine 
delay.  Therefore 0.079 more admissions will be spent per year post-clozapine initiation.  
However, this model shows that clozapine delay only accounts for 10.2% of the effect on the 
net change in admission days.  The value of the regression co-efficient is also shown (b), 
and if this is significantly different to zero then this would confirm that the clozapine delay has 
a significant impact on the ability of the model to predict the net change in admissions per 
year.  The significance of this is tested in the ANOVA using a t-test, the results of which are 
shown in the final column of the table.  The t-test for clozapine delay is non-significant at p = 
0.061, meaning that the regression coefficient (b) is not significantly different to zero, and the 
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theoretical delay to clozapine use does not make a significant contribution to the outcome of 
the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-182).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.159 and -0.033.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
in number of admissions in this population.   However, the significance associated with this 
confidence interval is p = 0.031, demonstrating statistical significance. 
5.3.5.3.5 Method 5 
Figure 5-35 Scatterplot for change in days of admission, clozapine discontinuers, method 5 
The scatterplot for the data is shown above (Figure 5-35).  A negative relationship is seen in 
the data, whereby the longer the delay in clozapine prescribing, the more negative the net 
(years) 
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change in days of admission per year becomes.  Again, a negative net change denotes a 
higher number of days of admission after clozapine has started. 
The summary of the regression model is shown in Appendix G (Table 7-183).  The table 
shows that the value of R is 0.249, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in days of 
admission per year (the outcome variable) and clozapine delay.  The R2 is 0.062, meaning 
that the clozapine delay accounts for 6.2% of the variation in the change in days of admission.  
Other variables must therefore account for the remaining 93.8% of the variation in the 
outcome variable. 
The results of the ANOVA are presented in Appendix G (Table 7-184).  The sum of squares, 
associated degrees of freedom (df) and mean square are given in the table.  From these 
data, the F-ratio is 2.176.  This is non-significant at a p value of 0.150, and so the regression 
model does not predict net change in admissions before and after starting clozapine 
significantly well. 
The model parameters are presented in Appendix G (Table 7-185).  The value of b0 (the 
constant) is 54.970, and so when the clozapine delay is zero (the x-axis intercept on the 
scatterplot), the model predicts that the net change in admission days per year is 54.970.  
This means that 54.970 fewer days are spent as an inpatient in the year following clozapine 
initiation, compared to the year before clozapine was started.  The gradient of the regression 
line (b1) is given in the table as – 5.968, and this shows the change in the outcome associated 
with a unit change in the predictor; therefore if clozapine delay is increased by 1 unit (1 year), 
the model predicts that the net change in days of admission becomes more negative by 5.968 
days.  Therefore 5.968 more days of admission will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay accounts for 6.2% of the effect on 
the net change in admission days.  The value of the regression co-efficient is also shown (b), 
and if this is significantly different to zero then this would confirm that the clozapine delay has 
a significant impact on the ability of the model to predict the net change in admissions per 
year.  The significance of this is tested in the ANOVA using a t-test, the results of which are 
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shown in the final column of the table.  The t-test for the predictor variable of clozapine delay 
is non-significant at p > 0.05, meaning that the regression coefficient (b) is not significantly 
different to zero, and the theoretical delay to clozapine use does not make a significant 
contribution to the outcome of the net change in days of admission per year. 
The bootstrapped confidence intervals (Table 7-186) indicate that the population value for b 
(the regression coefficient) for clozapine theoretical delay is likely to lie between -11.913 and 
-2.213.  Since this interval does not include zero, there is a genuine negative relationship 
between clozapine theoretical delay and net change in number of days of admission in this 
population.   This result is significant at p = 0.034.  
The linear regression is then repeated using the net change in the number of admissions per 
year as the dependent variable.  The scatterplot for the data is shown below (Figure 5-36).  
A negative relationship is seen in the data, whereby the longer the delay in clozapine 
prescribing, the more negative the net change in number of admissions per year becomes.  
Again, a negative net change denotes a higher number of admissions after clozapine has 
started. 
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Figure 5-36 Scatterplot for change in number of admissions, clozapine discontinuers, method 5 
The summary of the regression model is shown in Appendix G (Table 7-187).  The table 
shows that the value of R is 0.320, and since there is only one predictor variable (clozapine 
delay), this value represents the simple correlation between the net change in number of 
admissions per year (the outcome variable) and clozapine delay.  The R2 is 0.102, meaning 
that the clozapine delay accounts for 10.2% of the variation in the change numbers of 
admissions.  Other variables must therefore account for the remaining 89.8% of the variation 
in the outcome variable. 
Next, I conducted an analysis of variance (ANOVA).  The ANOVA investigates whether this 
model (with clozapine delay as a predictor variable) predicts the net change in admissions 
significantly better than simply using the mean net change in admissions would alone.  The 
results are presented in Appendix G (Table 7-188).  The sum of squares, associated degrees 
of freedom (df) and mean square are given in the table.  From these data, the F-ratio is 
calculated, and shown as 3.765.  This is non-significant at a p value of 0.061, and so the 
(years) 
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regression model does not predict net change in numbers of admissions before and after 
starting clozapine significantly well. 
The model parameters are presented in Appendix G (Table 7-189).  These show the 
individual contribution of particular variables to the model (in this case, just the theoretical 
delay to clozapine prescribing).  The value of b0 (the constant) is 0.943, and so when the 
clozapine delay is zero (the x-axis intercept on the scatterplot), the model predicts that the 
net change in number of admissions per year is 0.943.  This means that a patient has 0.943 
fewer admissions in the year following clozapine initiation, compared to the year before 
clozapine was started.  The gradient of the regression line (b1) is given in the table as -0.079, 
and this shows the change in the outcome associated with a unit change in the predictor; 
therefore if clozapine delay is increased by 1 unit (1 year), the model predicts that the net 
change in admissions becomes more negative by 0.079 admissions per year, per extra year 
of clozapine delay.  Therefore 0.079 more admissions will be spent per year post-clozapine 
initiation.  However, this model shows that clozapine delay only accounts for 10.2% of the 
effect on the net change in admission days.  The value of the regression co-efficient is also 
shown (b), and if this is significantly different to zero then this would confirm that the clozapine 
delay has a significant impact on the ability of the model to predict the net change in 
admissions per year.  The significance of this is tested in the ANOVA using a t-test, the 
results of which are shown in the final column of the table.  The t-test for clozapine delay is 
non-significant at p = 0.061, meaning that the regression coefficient (b) is not significantly 
different to zero, and the theoretical delay to clozapine use does not make a significant 
contribution to the outcome of the net change in admissions per year. 
As discussed previously in this chapter and in chapter 2, the data may not conform to the 
parameters of a normal distribution, and so I also performed bootstrapping procedures to 
account for this.  The results are shown in Appendix G (Table 7-190).  The bootstrapped 
confidence intervals indicate that the population value for b (the regression coefficient) for 
clozapine theoretical delay is likely to lie between -0.160 and -0.038.  Since this interval does 
not include zero, there is a relationship between clozapine theoretical delay and net change 
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in number of admissions in this population.   However, the significance associated with this 
confidence interval is p = 0.028, demonstrating statistical significance. 
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Table 5-26 Clozapine discontinuers group, linear regression data summary 
  Linear 
regression 
ANOVA Co-efficients Bootstrapping Effect of increasing delay to 
clozapine use by 1 year 
R2 F B0 B1 
Method 
1 
Change in days of 
admission 




0.097 (p = 
0.977) 
-4.642 to 5.594 (p = 
0.970) 
0.097 fewer days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.102 3.765 (p = 
0.061) 
0.943 -0.079 (p = 
0.061) 
-0.170 to -0.031 (p = 
0.027)* 
0.079 more admissions per year 
after clozapine has started 
Method 
2 
Change in days of 
admission 
0.037 1.279 (p = 
0.266) 
11.724 -2.918 (p = 
0.266) 
-6.469 to -0.127 (p = 
0.093) 
2.918 more days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.019 0.623 (p = 
0.436) 
0.359 0.015 (p = 
0.436) 
- 0.014 to 0.051 (p = 
0.051) 
0.015 fewer admissions per year 
after clozapine has started 
Method 
3 
Change in days of 
admission 




-0.435 (p = 
0.898) 
-5.171 and 4.694 (p = 
0.842) 
0.435 more days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.102 3.765 (p = 
0.061) 
0.943 -0.079 (p = 
0.061) 
-0.170 to -0.028 (p = 
0.026)* 
0.079 more admissions per year 
after clozapine has started 
Method 
4 
Change in days of 
admission 
0.002 0.078 (p = 
0.781) 
-0.951 -0.951 (p = 
0.781) 
-6.453 to 4.577 (p = 
0.662) 
0.951 more days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.102 3.765 (p = 
0.061) 
0.943 -0.079 (p = 
0.061) 
-0.159 to -0.033 (p = 
0.031)* 
0.079 more admissions per year 
after clozapine has started 
Method 
5 
Change in days of 
admission 
0.062 2.176 (p = 
0.150) 
54.970 -5.968 (p = 
0.150) 
-11.913 and -2.213 (p 
= 0.034)* 
5.968 more days of admission per 
year after clozapine has started 
Change in number 
of admissions 
0.102 3.765 (p = 
0.061) 
0.943 -0.079 (p = 
0.061) 
-0.160 to -0.038 (p = 
0.028)* 
0.079 more admissions per year 
after clozapine has started 
*statistically significant at p >0.05
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Table 5-26 summarises the data set out above.  For all the methods of data analysis, 
clozapine delay predicts less than 11% of the net change in days of admission and number 
of admissions per year before and after clozapine initiation.  None of the models reached 
statistical significance for the relationship between clozapine delay and net change in days 
of admission or net change in the number of admissions pre-and post-clozapine.  
Bootstrapped confidence intervals for methods 1, 3, 4 and 5 suggest a statistically significant 
relationship between clozapine delay and net change in number of admissions, and for 
method 5 also for the change in days of admission, but the models overall still lack statistical 
significance.  If the delay to clozapine use is zero, there is a variation in the effect on the 
inpatient days and total admissions after clozapine has started depending on the data 
analysis method used.  All methods predict a lower number of total admissions per year after 
clozapine has started, but some show an increase in the number of days of admission. 
 Multivariate analysis of variance 
Mutivariate analysis of variance (MANOVA) allows testing of the difference between two 
groups (in this case, before and after clozapine), but with more than one outcome variable.  
This is therefore an extension of the above described linear regression, where only one 
outcome variable (the change in days or admission or number of admissions) was 
investigated.  Further, the MANOVA can be used to investigate data with several 
independent variables.  This is useful for this data set as investigations set out in chapter 2 
suggested that some variables associated with the data (age, gender, diagnosis), in 
additional to the variable of theoretical clozapine delay already examined through ANOVA, 
may have an effect on the outcome variables. 
Although I could conduct ANOVAs for each outcome variable (that is, for the net change in 
numbers of admissions as well as the change in days of admission presented above), this is 
not advisable as it risks type I errors occurring.  Carrying out multiple statistical tests on the 
same data is not only bad practice, it also means that the effect of any relationship between 
the outcome variables is lost. 
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The dependent variables used for the MANOVA analysis (the outcome variables) were the 
net change in total admissions per year, and the net change in days of admission per year.  
It is sensible to include both these outcome variables in the same model, as they might be 
expected to affect each other, and the difference between them is clinically interesting.  A 
large number of days of admission per year may reflect a few lengthy admission periods, or 
many short ones.  Using only days of admission alone as an outcome variable cannot provide 
this level of information.  The fixed factors for the MANOVA are grouping categories for the 
data that can be examined for effects on the outcome.  These were chosen based on 
interesting results from the previous analyses (age, gender, ethnicity, diagnosis), or because 
they might logically be expected to affect the outcome variables (being a clozapine continuer 
or discontinuer; the number of previous antipsychotics taken).  The fixed variable categories 
were grouped as follows in Table 5-27: 
Table 5-27 MANOVA fixed variable categories 
Fixed factor Categories 
Number of previous antipsychotics 1 to 2 
3 to 5 
6 to 10 
> 10 
Age (years) 20 - 29 
30 - 39 
40 – 49 
50 – 59 
60 – 69 










I conducted the MANOVA first for the intent to treat group as a whole, then separately for 
clozapine continuers and discontinuers.  
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 MANOVA – intent to treat group 
5.3.6.1.1 Variables and factors 
The number of patients in each category for the fixed factors is given in table in Appendix G 
(Table 7-191). 
5.3.6.1.2 Testing assumptions 
The MANOVA depends on four assumptions.  Firstly, that the data are independent; that is, 
all residuals are statistically independent (residuals are the differences between the value a 
model predicts and the value actually seen in the data – in other words, the error associated 
with the model).  Secondly, that the data were randomly sampled (in this case, the data set 
consists of the entire population.  Characterisation of the excluded patients from the sample 
was completed in chapter 2).  Thirdly, that the residuals have multivariate normality.  Finally, 
that the variances in each group are roughly equal (homogeneity of covariance matrices), 
and that the correlation between the two outcome variables is the same in all groups. 
The assumption of equality of covariance matrices can be tested using Box’s test, which 
should be non-significant if the matrices are similar.  The results from Box’s test are less 
robust where the sample sizes within the population are different, and the table in Appendix 
G (Table 7-192) shows that this is the case.  Unfortunately the only remedy for this is to 
delete random patients in the larger groups in order to achieve more similarly sized 
categories, but this causes a loss of power to the results.  The results table shows Box’s test 
to be non-significant at p = 0.370, therefore the covariance matrices can be assumed to be 
roughly equal. 
5.3.6.1.3 MANOVA test statistics 
The main MANOVA test statistics are presented in Appendix G (Table 7-193).  The test 
results are given for the intercept of the model (where the MANOVA is characterised as a 
linear model) in the first row of the table, and then for each grouping variable in the 
subsequent rows.  The statistics for the grouping variables give an indication of the influence 
of these variables on the outcome measures.  There are four test statistics shown in the first 
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output column; Pillai’s Trace, Wilk’s Lambda, Hotelling’s Trace, and Roy’s Largest Root.  
Each differ in the robustness of their results.  Roy’s Largest Root is less reliable for platykurtic 
distributions (those with negative kurtosis) – previous analysis in this chapter showed the 
data to display positive kurtosis.  Roy’s Root is also not robust where the homogeneity of 
covariance matrices is untenable, in this case the Pillai’s Trace statistic is more reliable.  
However, this statistic is affected by unequal sample sizes, as in this data set.  This is why 
Box’s test is important for this data analysis, and since this suggests that the covariance 
matrices can be assumed to be equal it is reasonable to assume that Pilliai’s Trace is 
accurate. 
In the second output column, the test statistics are converted into F-ratios (an indication of 
the overall difference between group means) with the corresponding degrees of freedom.  
The final column shows the significance values associated with the F-ratios for each test 
statistic.  For gender, ethnicity, diagnosis, being a clozapine continuer or discontinuer and 
the number of antipsychotics used before clozapine, all the multivariate test statistics are 
non-significant at p > 0.05, suggesting that there are no between-group differences for the 
net change in admission days or admissions pre/post clozapine on these measures.  For the 
variable of age, all the multivariate test statistics are significant, suggesting that there is a 
between-group difference for the net change in admission days or admissions pre/post 
clozapine for this variable.  This result gives no information on the nature of this interaction, 
whether it affects both outcome variables or just one, and how the categories within the age 
group differ from each other.  To investigate this further, univariate tests and discriminant 
function analyses are required. 
5.3.6.1.4 Univariate test statistics 
Levene’s test of equality of variances has been described earlier in this thesis; briefly, it tests 
the assumption of homogeneity of variables for each of the outcome variables.  The results 
are presented in Appendix G (Table 7-194), and are non-significant for the net change in the 
number of admissions pre/post clozapine per year (p = 0.134), but significant for the net 
change in days of admission pre/post clozapine per year (p = 0.014).  This suggests that the 
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assumption of homogeneity of variance has not been met for this latter variable, and the 
multivariate test statistics may be less robust. 
Next, an ANOVA summary table is shown in Appendix G (Table 7-195) for each of the 
dependent variables.  An ANOVA is conducted for every fixed variable, and the 
corresponding residual sum of squares and total sums of squares.  The F-ratio for each 
univariate ANOVA is given in the sixth column, and the significance value for this in the final 
column.  The data show that age (p = 0.029) and being a clozapine continuer or discontinuer 
(p = 0.029) have a significant effect on the net change in days of admission pre-post 
clozapine per year.  All other factors have no significant impact on either dependent variable. 
5.3.6.1.5 MANOVA summary – intent to treat group 
Using Pillai’s trace, there was a significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, V = 0.73, F(10, 40) = 2.28, p = 0.032.  
Using Wilk’s lambda, there was a significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, Λ = 0.40, F(10, 38) = 2.22, p = 0.038.  
Using Hotelling’s trace statistic, there was a significant effect of age on the net change in 
days and numbers of admissions pre/post clozapine per year, T = 1.20, F(10, 36) = 2.15, p 
= 0.045.  Using Roy’s largest root, there was a significant effect of age on the net change in 
days and numbers of admissions pre/post clozapine per year, Θ = 0.81, F(5, 20) = 3.22, p = 
0.027. 
However, separate univariate ANOVAs on the outcome variables revealed significant age 
effects on the net change in days of admission pre-post clozapine per year, F(5, 20) = 3.17, 
p = 0.029 but a non-significant effect of age on the net change in number of admissions pre-
post clozapine per year, F(5,20) = 2.01, p = 0.120. 
Using Pillai’s trace, there was no significant effect of clozapine continuation/discontinuation 
on the net change in days and numbers of admissions pre/post clozapine per year, V = 0.22, 
F(2, 19) = 2.76, p = 0.089.  Using Wilk’s lambda, there was no significant effect of clozapine 
continuation/discontinuation on the net change in days and numbers of admissions pre/post 
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clozapine per year, Λ = 0.78, F(2, 19) = 2.75, p = 0.089.  Using Hotelling’s trace statistic, 
there was no significant effect of clozapine continuation/discontinuation on the net change in 
days and numbers of admissions pre/post clozapine per year, T = 0.29, F(2, 19) = 2.75, p = 
0.089.  Using Roy’s largest root, there was no significant effect of clozapine 
continuation/discontinuation on the net change in days and numbers of admissions pre/post 
clozapine per year, Θ = 0.29, F(2, 19) = 2.75, p = 0.089. 
However, separate univariate ANOVAs on the outcome variables revealed significant 
clozapine continuation/discontinuation effects on the net change in days of admission pre-
post clozapine per year, F(1, 20) = 5.51, p = 0.029 but a non-significant effect of clozapine 
continuation/discontinuation on the net change in number of admissions pre-post clozapine 
per year, F(1,20) = 3.80, p = 0.066. 
A significant effect for clozapine continuation/discontinuation is seen for the univariate test 
but not the multivariate statistics.  Previous analysis has shown that being a clozapine 
continuer results in a net decrease in the number of days of admission post-clozapine, but 
for clozapine discontinuers there is no difference after the drug is started.  As the multivariate 
analysis does not distinguish between the variables within the clozapine 
continuer/discontinuer group, but the univariate analysis does, this may explain the difference 
in test statistics.  However, the univariate test cannot take account of any correlation between 
the outcome variables; in order to evaluate this discriminant function analysis is required. 
5.3.6.1.6 Discriminant function analysis - age 
The MANOVA examines a linear combination of variables, and so where the MANOVA test 
statistics suggest a significant relationship is present, discriminant function analysis allows 
the linear combination to be examined in more detail.  The MANOVA found statistically 
significant differences within the age and clozapine continuer/discontinuer groups, and so I 
followed both these variables up with discriminant analyses, dealing first with the age 
variable. 
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The first output table is shown in Appendix G (Table 7-196), and provides the eigenvalues 
for each variate.  The variates are the linear combinations of the outcome variables.  They 
are used to discriminate groups of patients; in this case, which age group they belong to, and 
so are called the discriminant function variates.  The eigenvalues are equivalent to the F-
ratios calculated in ANOVA analysis.  The eigenvalues are then converted into the 
percentage of the variance they account for (third column in the table).  The final column 
shows the canonical correlation, which, when squared, gives an effect size (synonymous to 
the R2 value, explained earlier in the context of linear regression).  The eigenvalues table 
shows that the first variate explains 91.4% of the variance, with a canonical R2 of 0.095, 
whereas the second explains only 8.6%, with a canonical R2 of 0.98.    
The second output table (Table 7-197) shows the significance tests for both variates (‘1 
through 2’) and the significance for the second variate, once the first has been removed 
(second row).  Wilk’s Lambda is the product of the unexplained variance of each of the 
variates.  Large eigenvalues (which correspond to large experimental effects) produce small 
values for Wilks’ Lambda, and so statistical significance is achieved when Wilks’ Lambda is 
small.  This table shows that neither the combination of variates or the second variate alone 
significantly discriminate the groups, as the significance values for both are > 0.05. 
The next output table (Table 7-198) shows the canonical variate correlation coefficients, 
which indicate the relative contribution of each outcome variable to the discriminant function 
variates.  For both variates, there is a positive relationship with the change in days of 
admission and number of admissions (all outcome values are positive).  This means that 
both variates affect the changes in days and numbers of admissions in the same way.  The 
output values can vary between -1 and 1, and so the results suggest that the change in days 
of admission has a slightly higher influence on the first variate, and the number of admissions 
has a larger influence on the second variate.   
Finally, a combined-groups plot is presented in Appendix G (Figure 7-44).  This plots the 
variate scores for each patient, grouped according to the age group to which the patient 
belonged. The group centroids are shown as blue squares; these are the mean variate 
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scores for each group.  The discriminant function plot shows that the first function (across 
the horizontal axis) discriminates the extremes of age groups (20 – 29 and 60 – 79) from the 
30 – 59 year old groups, and the second function (across the vertical axis) differentiates the 
older age groups (60 – 79) from the younger groups (20 – 59). 
5.3.6.1.7 Summary – MANOVA for age 
The MANOVA was followed up with discriminant analysis, which revealed two discriminant 
functions.  The first explained 91.4% of the variance, canonical R2 = 0.095, whereas the 
second explained only 8.6%, canonical R2 = 0.98.  In combination these discriminant 
functions did not significantly differentiate the groups, Λ = 0.90, χ2(10) = 10.67, p = 0.384, 
and removing the first function did not alter this result, Λ = 0.99, χ2(4) = 0.954, p = 0.917.  
The correlations between outcomes and the discriminant functions revealed that the net 
change in days of admission pre/post clozapine per year was not loaded evenly onto the two 
functions (r = 0.996 for the first function, and 0.090 for the second), but that the net change 
in days was loaded more highly onto the first function.  The net change in number of 
admissions pre/post clozapine per year loaded more highly onto the second function (r = 
0.853) than the first function (r = 0.552).  The discriminant function plot shows that the first 
function discriminates the extremes of age groups (20 – 29 and 60 – 79) from the 30 – 59 
year old groups, and the second function differentiates the older age groups (60 – 79) from 
the younger groups (20 – 59). 
The MANOVA indicates that age can have a significant effect on the length of time spent in 
hospital after clozapine has been started.  The ANOVA suggests that this effect is on the 
number of days of admission per year, but not on the total number of admissions per year.  
The discriminant analysis suggests that the separation within the age groups can best be 
explained in terms of one underlying dimension, and in this context the dimension is likely to 
be age itself, but finds this effect to be non-significant. 
A histogram plotting the age categories against the mean net change in days of admission 
and number of admissions presented in Appendix G (Figure 7-45) shows that as age 
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increases from 20 – 49, the net change in the number of days of admission per year 
decreases.  This means that the older patients are, the less benefit they obtain from clozapine 
initiation (the lower the net change in admission days after clozapine is initiated, the higher 
the number of days of admission).  Of note, the bars for age groups 60 – 69 and 70 – 79 
describe only one patient each, and therefore could be considered outliers.  The net change 
in the number of admissions per year is minimal, and as found in the MANOVA not 
statistically significant. 
This analysis found two apparently outlying results in the age categories 60 – 69 and 70 – 
79, each of which contain only one patient each.  There are two ways of dealing with these 
outlying results; firstly, to repeat the analysis removing these upper age categories and 
creating one >50 years category in replacement; and secondly to remove the outliers entirely 
from the analysis. 
 MANOVA, upper age categories combined 
Here I have repeated the MANOVA analysis presented above but with one larger upper age 
category (> 50 years) to incorporate the outlying results found previously.  The fixed variable 
categories for age are now: 
 20 – 29 years 
 30 -39 years 
 40 – 49 years 
 > 50 years 
The number of patients in each category for the fixed factors is given in table in Appendix G 
(Table 7-199). 
5.3.6.2.1 Testing assumptions 
The results from Box’s test are shown in Appendix G (Table 7-200).  The table shows Box’s 
test to be non-significant at p = 0.370, therefore the covariance matrices can be assumed to 
be roughly equal. 
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5.3.6.2.2 MANOVA test statistics 
The main MANOVA test statistics are presented in Appendix G (Table 7-201).  For gender, 
ethnicity, diagnosis, being a clozapine continuer or discontinuer and the number of 
antipsychotics used before clozapine, all the multivariate test statistics are non-significant at 
p > 0.05, suggesting that there are no between-group differences for the net change in 
admission days or admissions pre/post clozapine on these measures.  For the variable of 
age, all the multivariate test statistics are significant, suggesting that there is a between-
group difference for the net change in admission days or admissions pre/post clozapine for 
this variable.  This result gives no information on the nature of this interaction, whether it 
affects both outcome variables or just one, and how the categories within the age group differ 
from each other.  To investigate this further, univariate tests and discriminant function 
analyses are required. 
5.3.6.2.3 Univariate test statistics 
Levene’s test of equality of variances has been described earlier in this thesis; briefly, it tests 
the assumption of homogeneity of variables for each of the outcome variables.  The results 
are presented in Appendix G (Table 7-202), and are non-significant for the net change in the 
number of admissions pre/post clozapine per year (p = 0.139), but significant for the net 
change in days of admission pre/post clozapine per year (p = 0.014).  This suggests that the 
assumption of homogeneity of variance has not been met for this latter variable, and the 
multivariate test statistics may be less robust. 
Next, an ANOVA summary table is shown in Appendix G (Table 7-203) for each of the 
dependent variables.  The data show that age (p = 0.009) and being a clozapine continuer 
or discontinuer (p = 0.029) have a significant effect on the net change in days of admission 
pre-post clozapine per year.  All other factors have no significant impact on either dependent 
variable. 
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5.3.6.2.4 MANOVA summary, upper age categories combined 
Using Pillai’s trace, there was a significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, V = 0.55, F(6, 40) = 2.54, p = 0.035.  
Using Wilk’s lambda, there was a significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, Λ = 0.50, F(6, 38) = 2.62, p = 0.032.  
Using Hotelling’s trace statistic, there was a significant effect of age on the net change in 
days and numbers of admissions pre/post clozapine per year, T = 0.89, F(6, 36) = 2.68, p = 
0.030.  Using Roy’s largest root, there was a significant effect of age on the net change in 
days and numbers of admissions pre/post clozapine per year, Θ = 0.75, F(3, 20) = 5.01, p = 
0.009. 
However, separate univariate ANOVAs on the outcome variables revealed significant age 
effects on the net change in days of admission pre-post clozapine per year, F(3, 20) = 5.01, 
p = 0.009 but a non-significant effect of age on the net change in number of admissions pre-
post clozapine per year, F(3,20) = 2.64, p = 0.077. 
Using Pillai’s trace, there was no significant effect of clozapine continuation/discontinuation 
on the net change in days and numbers of admissions pre/post clozapine per year, V = 0.22, 
F(2, 19) = 2.76, p = 0.089.  Using Wilk’s lambda, there was no significant effect of clozapine 
continuation/discontinuation on the net change in days and numbers of admissions pre/post 
clozapine per year, Λ = 0.78, F(2, 19) = 2.75, p = 0.089.  Using Hotelling’s trace statistic, 
there was no significant effect of clozapine continuation/discontinuation on the net change in 
days and numbers of admissions pre/post clozapine per year, T = 0.29, F(2, 19) = 2.75, p = 
0.089.  Using Roy’s largest root, there was no significant effect of clozapine 
continuation/discontinuation on the net change in days and numbers of admissions pre/post 
clozapine per year, Θ = 0.29, F(2, 19) = 2.75, p = 0.089. 
However, separate univariate ANOVAs on the outcome variables revealed significant 
clozapine continuation/discontinuation effects on the net change in days of admission pre-
post clozapine per year, F(1, 20) = 5.51, p = 0.029 but a non-significant effect of clozapine 
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continuation/discontinuation on the net change in number of admissions pre-post clozapine 
per year, F(1,20) = 3.80, p = 0.066. 
A significant effect for clozapine continuation/discontinuation is seen for the univariate test 
but not the multivariate statistics.  Previous analysis has shown that being a clozapine 
continuer results in a net decrease in the number of days of admission post-clozapine, but 
for clozapine discontinuers there is no difference before or after the drug is started.  As the 
multivariate analysis does not distinguish between the variables within the clozapine 
continuer/discontinuer group, but the univariate analysis does, this may explain the difference 
in test statistics.  However, the univariate test cannot take account of any correlation between 
the outcome variables; in order to evaluate this discriminant function analysis is required. 
5.3.6.2.5 Discriminant function analysis (age), upper age categories combined 
The first output table is shown in Appendix G (Table 7-204), and provides the eigenvalues 
for each variate.  The eigenvalues table shows that the first variate explains 99.6% of the 
variance, with a canonical R2 of 0.044, whereas the second explains only 0.4%, with a 
canonical R2 of 0.0002.    
The second output table (Wilk’s Lambda, Table 7-205) shows the significance tests for both 
variates (‘1 through 2’) and the significance for the second variate, once the first has been 
removed (second row).  This table shows that neither the combination of variates or the 
second variate alone significantly discriminate the groups, as the significance values for both 
are > 0.05. 
The next output table shows the canonical variate correlation coefficients (Table 7-206).  For 
both variates, there is a positive relationship with the change in days of admission and 
number of admissions (all outcome values are positive).  The results suggest that the change 
in days of admission has a slightly higher influence on the first variate, and the number of 
admissions has a larger influence on the second variate.   
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Finally, a combined-groups plot is presented in Appendix G (Figure 7-46 MANOVA, 
combined group plot, age variable combined, intent to treat group).  The discriminant function 
plot shows little separation between the age groups across either outcome variable. 
5.3.6.2.6 MANOVA - summary for age, upper age categories combined 
The MANOVA was followed up with discriminant analysis, which revealed two discriminant 
functions.  The first explained 99.6% of the variance, canonical R2 = 0.044, whereas the 
second explained only 0.4%, canonical R2 = 0.0002.  In combination these discriminant 
functions did not significantly differentiate the groups, Λ = 0.956, χ2(6) = 4.45, p = 0.617, and 
removing the first function did not alter this result, Λ = 1.00, χ2(2) = 0.017, p = 0.992.  The 
correlations between outcomes and the discriminant functions revealed that the net change 
in days of admission pre/post clozapine per year was not loaded evenly onto the two 
functions (r = 0.969 for the first function, and 0.246 for the second), but that the net change 
in days was loaded more highly onto the first function.  The net change in number of 
admissions pre/post clozapine per year loaded more highly onto the second function (r = 
0.919) than the first function (r = 0.313).  The discriminant function plot shows little separation 
between the age groups.  
The MANOVA indicates that age can have a significant effect on the length of time spent in 
hospital after clozapine has been started.  The ANOVA suggests that this effect is on the 
number of days of admission per year, but not on the total number of admissions per year.  
The discriminant analysis suggests that the separation within the age groups can best be 
explained in terms of one underlying dimension, and in this context the dimension is likely to 
be age itself, but this result did not reach statistical significance. 
A histogram plotting the age categories against the mean net change in days of admission 
and number of admissions presented in Appendix G (Figure 7-47 MANOVA histogram, age 
variable combined, intent to treat group) shows that as age increases from 20 – 49, the net 
change in the number of days of admission per year decreases.  This means that the older 
patients are, the less benefit they obtain from clozapine initiation (the lower the net change 
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in admission days after clozapine is initiated).  The new > 50 years category shows an 
increase again in the net change in admissions that is not in keeping with the general trend 
for the rest of the data.  Observations from the scatterplot and inspection of the data suggest 
that this may be due to undue influence from the two outlying patients discussed previously 
in the upper age groups (60 – 69 and 70 – 79 years).  The net change in the number of 
admissions per year is minimal, and as found in the MANOVA not statistically significant. 
 MANOVA – age outliers removed 
This analysis removes the two outlying patients in the age category > 59 years in order to 
gauge the effect of these two patients on the overall result. 
5.3.6.3.1 Fixed factors 
The number of patients in each category for the fixed factors is given in table in Appendix G 
(Table 7-207). 
5.3.6.3.2 Testing assumptions 
The results from Box’s test are shown in Appendix G (Table 7-208).  The table shows Box’s 
test to be non-significant at p = 0.370, therefore the covariance matrices can be assumed to 
be roughly equal. 
5.3.6.3.3 MANOVA test statistics 
The main MANOVA test statistics are presented in Appendix G (Table 7-209).  For gender, 
ethnicity, diagnosis, being a clozapine continuer or discontinuer and the number of 
antipsychotics used before clozapine, all the multivariate test statistics are non-significant at 
p > 0.05, suggesting that there are no between-group differences for the net change in 
admission days or admissions pre/post clozapine on these measures.  For the variable of 
age, all the multivariate test statistics are significant, suggesting that there is a between-
group difference for the net change in admission days or admissions pre/post clozapine for 
this variable.  This result gives no information on the nature of this interaction, whether it 
affects both outcome variables or just one, and how the categories within the age group differ 
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from each other.  To investigate this further, univariate tests and discriminant function 
analyses are required. 
5.3.6.3.4 Univariate test statistics 
Levene’s test of equality of variances has been described earlier in this thesis; briefly, it tests 
the assumption of homogeneity of variables for each of the outcome variables.  The results 
are presented in Appendix G (Table 7-210), and are non-significant for the net change in the 
number of admissions pre/post clozapine per year (p = 0.128), but significant for the net 
change in days of admission pre/post clozapine per year (p = 0.012).  This suggests that the 
assumption of homogeneity of variance has not been met for this latter variable, and the 
multivariate test statistics may be less robust. 
Next, an ANOVA summary table is shown in Appendix G (Table 7-211) for each of the 
dependent variables.  The data show that age (p = 0.016) and being a clozapine continuer 
or discontinuer (p = 0.029) have a significant effect on the net change in days of admission 
pre-post clozapine per year.  For this analysis, age also has a significant effect on the net 
change in the number of admissions per year (p = 0.43).  All other factors have no significant 
impact on either dependent variable. 
5.3.6.3.5 MANOVA summary, age outliers removed 
Using Pillai’s trace, there was a significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, V = 0.60, F(6, 40) = 2.87, p = 0.020.  
Using Wilk’s lambda, there was a significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, Λ = 0.48, F(6, 38) = 2.81, p = 0.023.  
Using Hotelling’s trace statistic, there was a significant effect of age on the net change in 
days and numbers of admissions pre/post clozapine per year, T = 0.915, F(6, 36) = 2.75, p 
= 0.027.  Using Roy’s largest root, there was a significant effect of age on the net change in 
days and numbers of admissions pre/post clozapine per year, Θ = 0.66, F(3, 20) = 4.39, p = 
0.016. 
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Separate univariate ANOVAs on the outcome variables revealed significant age effects on 
both the net change in days of admission pre-post clozapine per year, F(3, 20) = 4.34, p = 
0.016, and the net change in number of admissions pre-post clozapine per year, F(3,20) = 
3.25, p = 0.043. 
Using Pillai’s trace, there was no significant effect of clozapine continuation/discontinuation 
on the net change in days and numbers of admissions pre/post clozapine per year, V = 0.22, 
F(2, 19) = 2.76, p = 0.089.  Using Wilk’s lambda, there was no significant effect of clozapine 
continuation/discontinuation on the net change in days and numbers of admissions pre/post 
clozapine per year, Λ = 0.78, F(2, 19) = 2.75, p = 0.089.  Using Hotelling’s trace statistic, 
there was no significant effect of clozapine continuation/discontinuation on the net change in 
days and numbers of admissions pre/post clozapine per year, T = 0.29, F(2, 19) = 2.75, p = 
0.089.  Using Roy’s largest root, there was no significant effect of clozapine 
continuation/discontinuation on the net change in days and numbers of admissions pre/post 
clozapine per year, Θ = 0.29, F(2, 19) = 2.75, p = 0.089. 
However, separate univariate ANOVAs on the outcome variables revealed significant 
clozapine continuation/discontinuation effects on the net change in days of admission pre-
post clozapine per year, F(1, 20) = 5.51, p = 0.029 but a non-significant effect of clozapine 
continuation/discontinuation on the net change in number of admissions pre-post clozapine 
per year, F(1,20) = 3.80, p = 0.066. 
A significant effect for clozapine continuation/discontinuation is seen for the univariate test 
but not the multivariate statistics.  Previous analysis has shown that being a clozapine 
continuer results in a net decrease in the number of days of admission post-clozapine, but 
for clozapine discontinuers there is no difference before or after the drug is started.  As the 
multivariate analysis does not distinguish between the variables within the clozapine 
continuer/discontinuer group, but the univariate analysis does, this may explain the difference 
in test statistics.  However, the univariate test cannot take account of any correlation between 
the outcome variables; in order to evaluate this discriminant function analysis is required.  
Removing the two outlying age categories (>59 years) from the analysis now means that the 
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net change in number of admissions per year is also significantly different for the age 
categories, as well as net change in days of admission per year. 
5.3.6.3.6 Discriminant function analysis (age), age outliers removed 
The first output table is shown in Appendix G (Table 7-212), and provides the eigenvalues 
for each variate.  The eigenvalues table shows that the first variate explains 99.2% of the 
variance, with a canonical R2 of 0.051, whereas the second explains only 0.8%, with a 
canonical R2 of 0.0004.    
The second output table (Wilk’s Lambda, Table 7-213) shows the significance tests for both 
variates (‘1 through 2’) and the significance for the second variate, once the first has been 
removed (second row).  This table shows that neither the combination of variates or the 
second variate alone significantly discriminate the groups, as the significance values for both 
are > 0.05. 
The next output table (Table 7-214) shows the canonical variate correlation coefficients.  For 
both variates, there is a positive relationship with the change in days of admission and 
number of admissions (all outcome values are positive).  The results suggest that the change 
in days of admission has a slightly higher influence on the first variate, and the number of 
admissions has a larger influence on the second variate.   
Finally, a combined-groups plot is presented in Appendix G (Figure 7-48).  The discriminant 
function plot shows little separation between the age groups across either outcome variable. 
5.3.6.3.7 MANOVA summary for age, age outliers removed 
The MANOVA was followed up with discriminant analysis, which revealed two discriminant 
functions.  The first explained 99.2% of the variance, canonical R2 = 0.051, whereas the 
second explained only 0.8%, canonical R2 = 0.0004.   In combination these discriminant 
functions did not significantly differentiate the groups, Λ = 0.947, χ2(6) = 5.23, p = 0.510, and 
removing the first function did not alter this result, Λ = 1.00, χ2(2) = 0.042, p = 0.979.  The 
correlations between outcomes and the discriminant functions revealed that the net change 
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in days of admission pre/post clozapine per year was not loaded evenly onto the two 
functions (r = 0.020 for the first function, and -0.009 for the second), but that the net change 
in days was loaded more highly onto the first function.  The net change in number of 
admissions pre/post clozapine per year loaded more highly onto the second function (r = 
1.868) than the first function (r = -0.386).  The discriminant function plot shows little 
separation between the age groups.  
The MANOVA indicates that age can have a significant effect on the length of time spent in 
hospital after clozapine has been started.  The ANOVA suggests that this effect is on both 
the number of days of admission per year and on the total number of admissions per year.  
The discriminant analysis suggests that the separation within the age groups can best be 
explained in terms of one underlying dimension, and in this context the dimension is likely to 
be age itself.  This result remains statistically non-significant. 
A histogram plotting the age categories against the mean net change in days of admission 
and number of admissions presented in Appendix G (Figure 7-49 MANOVA histogram, age 
outliers removed, intent to treat group) shows that as age increases from 20 – 49, the net 
change in the number of days of admission per year decreases.  This means that the older 
patients are, the less benefit they obtain from clozapine initiation (the lower the net change 
in admission days after clozapine is initiated).  The new > 50 years category shows a small 
decrease in the net change in admissions.   
 MANOVA - clozapine continuers 
Next, I repeated the MANOVA presented above for clozapine continuers only. 
5.3.6.4.1 Fixed factors 
The number of patients in each category for the fixed factors is given in table in Appendix G 
(Table 7-215). 
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5.3.6.4.2 Testing assumptions 
The results from Box’s test are shown in Appendix G (Table 7-216).  The table shows Box’s 
test to be non-significant at p = 0.692, therefore the covariance matrices can be assumed to 
be roughly equal. 
5.3.6.4.3 MANOVA test statistics 
The main MANOVA test statistics are presented in Appendix G (Table 7-217).  For gender, 
ethnicity, diagnosis, being a clozapine continuer or discontinuer and the number of 
antipsychotics used before clozapine, all the multivariate test statistics are non-significant at 
p > 0.05, suggesting that there are no between-group differences for the net change in 
admission days or admissions pre/post clozapine on these measures.  For the variable of 
age, test statistics for Pillai’s Trace, Wilk’s Lambda and Hotelling’s Trace for age are also 
non-significant, although Roy’s largest root does reach significance.  This result gives no 
information on the nature of this interaction, whether it affects both outcome variables or just 
one, and how the categories within the age group differ from each other.  To investigate this 
further, univariate tests and discriminant function analyses are required. 
5.3.6.4.4 Univariate test statistics 
Levene’s test of equality of variances has been described earlier in this thesis; briefly, it tests 
the assumption of homogeneity of variables for each of the outcome variables.  The results 
are presented in Appendix G (Table 7-218), and are non-significant for the net change in the 
number of admissions pre/post clozapine per year (p = 0.175), but significant for the net 
change in days of admission pre/post clozapine per year (p < 0.0005).  This suggests that 
the assumption of homogeneity of variance has not been met for this latter variable, and the 
multivariate test statistics may be less robust. 
Next, an ANOVA summary table is shown in Appendix G (Table 7-219) for each of the 
dependent variables.  The data show that none of the factors have a significant impact on 
either dependent variable. 
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5.3.6.4.5 MANOVA summary 
Using Pillai’s trace, there was no significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, V = 0.689, F(6, 26) = 2.276, p = 0.067.  
Using Wilk’s lambda, there was no significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, Λ = 0.414, F(6, 24) = 2.216, p = 0.077.  
Using Hotelling’s trace statistic, there was no significant effect of age on the net change in 
days and numbers of admissions pre/post clozapine per year, T = 1.166 F(6, 22) = 2.138, p 
= 0.089.  However, using Roy’s largest root, there was a significant effect of age on the net 
change in days and numbers of admissions pre/post clozapine per year, Θ = 0.886, F(3, 13) 
= 3.838, p = 0.036. 
Separate univariate ANOVAs on the outcome variables revealed no significant age effects 
on either the net change in days of admission pre-post clozapine per year, F(3, 13) = 3.289, 
p = 0.055, or the net change in number of admissions pre-post clozapine per year, F(3, 13) 
= 3.106, p = 0.064. 
5.3.6.4.6 Discriminant function analysis (age) 
The first output table is shown in Appendix G (Table 7-220), and provides the eigenvalues 
for each variate.  The eigenvalues table shows that the first variate explains 92.2% of the 
variance, with a canonical R2 of 0.056, whereas the second explains only 7.8%, with a 
canonical R2 of 0.0049.    
The second output table (Wilk’s Lambda, Table 7-221) shows the significance tests for both 
variates (‘1 through 2’) and the significance for the second variate, once the first has been 
removed (second row).  This table shows that neither the combination of variates or the 
second variate alone significantly discriminate the groups, as the significance values for both 
are > 0.05. 
The next output table (Table 7-222) shows the canonical variate correlation coefficients.  For 
both variates, there is a positive relationship with the change in days of admission and 
number of admissions (all outcome values are positive).  The results suggest that the change 
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in days of admission has a slightly higher influence on the first variate, and the number of 
admissions has a larger influence on the second variate.   
Finally, a combined-groups plot is presented in Appendix G (Figure 7-50).  The discriminant 
function plot shows little separation between the age groups across either outcome variable, 
with only a little separation for the youngest age group along the first function. 
5.3.6.4.7 MANOVA, summary for age 
The MANOVA was followed up with discriminant analysis, which revealed two discriminant 
functions.  The first explained 92.2% of the variance, canonical R2 = 0.056, whereas the 
second explained only 7.8%, canonical R2 = 0.0049.  In combination these discriminant 
functions did not significantly differentiate the groups, Λ = 0.939, χ2(6) = 3.817, p = 0.701, 
and removing the first function did not alter this result, Λ = 0.995, χ2(2) = 0.304, p = 0.859.  
The correlations between outcomes and the discriminant functions revealed that the net 
change in days of admission pre/post clozapine per year was not loaded evenly onto the two 
functions (r = 0.968 for the first function, and 0.249 for the second), but that the net change 
in days was loaded more highly onto the first function.  The net change in number of 
admissions pre/post clozapine per year loaded more highly onto the second function (r = 
0.928) than the first function (r = 0.372).  The discriminant function plot shows separation 
between the 20 – 29 age group and the other age groups.  
A histogram plotting the age categories against the mean net change in days of admission 
and number of admissions presented in Appendix G (Figure 7-51) shows that as age 
increases from 20 – 49, the net change in the number of days of admission per year 
decreases.  This means that the older patients are, the less benefit they obtain from clozapine 
initiation (the lower the net change in admission days after clozapine is initiated).  The 50 - 
59 years category shows an increase again in the net change in admissions that is not in 
keeping with the general trend for the rest of the data.   
The MANOVA indicates that for clozapine continuers, age can have a significant effect on 
the length of time spent in hospital after clozapine has been started.  However, this result is 
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not seen in univariate analysis.  The discriminant analysis suggests that the separation within 
the age groups can best be explained in terms of one underlying dimension, and in this 
context the dimension is likely to be age itself, although this did not reach statistical 
significance. 
 MANOVA – clozapine discontinuers 
Next, I repeated the MANOVA presented above for clozapine discontinuers only. 
5.3.6.5.1 Fixed factors 
The number of patients in each category for the fixed factors is given in table in Appendix G 
(Table 7-223). 
5.3.6.5.2 Testing assumptions 
The results from Box’s test are shown in Appendix G (Table 7-224).  The table shows Box’s 
test to be non-significant at p = 0.212, therefore the covariance matrices can be assumed to 
be roughly equal. 
5.3.6.5.3 MANOVA test statistics 
The main MANOVA test statistics are presented in Appendix G (Table 7-225).  For ethnicity, 
age, and the number of antipsychotics used before clozapine, all the multivariate test 
statistics are non-significant at p > 0.05, suggesting that there are no between-group 
differences for the net change in admission days or admissions pre/post clozapine on these 
measures.  For the variable of gender, all tests reach significance.  For diagnosis, Roy’s 
Largest Root gives a significant result.  This result gives no information on the nature of this 
interaction, whether it affects both outcome variables or just one, and how the categories 
within the age group differ from each other.  To investigate this further, univariate tests and 
discriminant function analyses are required. 
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5.3.6.5.4 Univariate test statistics 
Levene’s test of equality of variances has been described earlier in this thesis; briefly, it tests 
the assumption of homogeneity of variables for each of the outcome variables.  The results 
are presented in Appendix G (Table 7-226), and are non-significant for the net change in the 
number of admissions pre/post clozapine per year (p = 0.186), and also non-significant for 
the net change in days of admission pre/post clozapine per year (p = 0.220).  This suggests 
that the assumption of homogeneity of variance has been met for both variables. 
Next, an ANOVA summary table is shown in Appendix G (Table 7-227) for each of the 
dependent variables.  The data show that age, ethnicity, and the number of antipsychotics 
taken before clozapine have no significant impact on the net change in days of admission or 
number of admissions per year.  However, gender and diagnosis both are found to have a 
statistically significant impact on both variables for gender, and on days of admission for 
diagnosis. 
5.3.6.5.5 MANOVA summary 
Using Pillai’s trace, there was no significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, V = 0.203, F(4, 16) = 0.452, p = 0.770.  
Using Wilk’s lambda, there was no significant effect of age on the net change in days and 
numbers of admissions pre/post clozapine per year, Λ = 0.797, F(4, 14) = 0.421, p = 0.791.  
Using Hotelling’s trace statistic, there was no significant effect of age on the net change in 
days and numbers of admissions pre/post clozapine per year, T = 0.255, F(4, 12) = 0.382, p 
= 0.817.  Using Roy’s largest root, there was no significant effect of age on the net change 
in days and numbers of admissions pre/post clozapine per year, Θ = 0.255, F(2, 8) = 1.018, 
p = 0.404. 
Using Pillai’s trace, there was a significant effect of gender on the net change in days and 
numbers of admissions pre/post clozapine per year, V = 0.595, F(2, 7) = 5.145, p = 0.042.  
Using Wilk’s lambda, there was a significant effect of gender on the net change in days and 
numbers of admissions pre/post clozapine per year, Λ = 0.797, F(2, 7) = 5.145, p = 0.042.  
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Using Hotelling’s trace statistic, there was a significant effect of gender on the net change in 
days and numbers of admissions pre/post clozapine per year, T = 1.470, F(2, 7) = 5.145, p 
= 0.042.  Using Roy’s largest root, there was a significant effect of age on the net change in 
days and numbers of admissions pre/post clozapine per year, Θ = 0.1.470, F(2, 7) = 5.145, 
p = 0.042. 
Using Pillai’s trace, there was no significant effect of diagnosis on the net change in days 
and numbers of admissions pre/post clozapine per year, V = 0.617, F(4, 16) = 1.784, p = 
0.181.  Using Wilk’s lambda, there was no significant effect of diagnosis on the net change 
in days and numbers of admissions pre/post clozapine per year, Λ = 0.410, F(4, 14) = 1.965, 
p = 0.155.  Using Hotelling’s trace statistic, there was no significant effect of diagnosis on the 
net change in days and numbers of admissions pre/post clozapine per year, T = 1.372, F(4, 
12) = 2.058, p = 0.150.  Using Roy’s largest root, there was a significant effect of diagnosis 
on the net change in days and numbers of admissions pre/post clozapine per year, Θ = 1.322, 
F(2, 8) = 5.289, p = 0.034. 
Separate univariate ANOVAs on the outcome variables revealed significant gender effects 
on both the net change in days of admission pre-post clozapine per year, F(2, 8) = 5.986, p 
= 0.040, and the net change in number of admissions pre-post clozapine per year, F(2, 8) = 
11.760, p = 0.009.  There were also significant diagnosis effects on the net change in days 
of admission pre-post clozapine per year, F (2, 8) = 5.255, p = 0.035, but not on the net 
change in number of admissions pre-post clozapine per year, F(2, 8) = 2.368, p = 0.156. 
5.3.6.5.6 Discriminant analysis (age) 
I followed the significant MANOVA findings for age, gender and diagnosis with discriminant 
analysis.  The first, for age, is described below. 
The first output table is shown in Appendix G (Table 7-228), and provides the eigenvalues 
for each variate.  The eigenvalues table shows that the first variate explains 88% of the 
variance, with a canonical R2 of 0.095, whereas the second explains only 12%, with a 
canonical R2 of 0.014.    
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The second output table (Wilk’s Lambda, Table 7-229) shows the significance tests for both 
variates (‘1 through 2’) and the significance for the second variate, once the first has been 
removed (second row).  This table shows that neither the combination of variates or the 
second variate alone significantly discriminate the groups, as the significance values for both 
are > 0.05. 
The next output table shows the canonical variate correlation coefficients (Table 7-230).  For 
both variates, there is a positive relationship with the change in days of admission and 
number of admissions (all outcome values are positive).  The results suggest that the change 
in days of admission has a slightly higher influence on the first variate, and the number of 
admissions has a larger influence on the second variate.   
Finally, a combined-groups plot is presented in Appendix G (Figure 7-52).  The discriminant 
function plot shows some separate between the age groups on function 1, and also some 
separation for the higher age group (50 – 59 years) along function 2.  This is seen more 
clearly in the histogram presented in Appendix G (Figure 7-53), with the net change in days 
of admission becoming more negative with increasing age.  A more negative net change 
corresponds to more days being spent in hospital after clozapine has started. 
5.3.6.5.7 MANOVA summary for age 
The MANOVA was followed up with discriminant analysis, which revealed two discriminant 
functions.  The first explained 88.0% of the variance, canonical R2 = 0.095, whereas the 
second explained only 12.0%, canonical R2 = 0.014.  In combination these discriminant 
functions did not significantly differentiate the groups, Λ = 0.892, χ2(6) = 3.542, p = 0.738, 
and removing the first function did not alter this result, Λ = 0.986, χ2(2) = 0.442, p = 0.802.  
The correlations between outcomes and the discriminant functions revealed that the net 
change in days of admission pre/post clozapine per year was not loaded evenly onto the two 
functions (r = 0.998 for the first function, and 0.065 for the second), but that the net change 
in days was loaded more highly onto the first function.  The net change in number of 
admissions pre/post clozapine per year loaded more highly onto the second function (r = 
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0.847) than the first function (r = 0.531).  The discriminant function plot shows separation 
between all age groups.  
The MANOVA and univariate statistics indicate that for clozapine discontinuers, age has no 
significant effect on the length of time spent in hospital after clozapine has been started.  The 
discriminant analysis shows wide scatter across the variables, again indicating no significant 
relationship, although the histogram (Figure 7-53) shows that the trend is for increasing age 
to mean more days spent in hospital after starting clozapine. 
5.3.6.5.8 Discriminant analysis (gender) 
The first output table is shown in Appendix G (Table 7-231), and provides the eigenvalues 
for the variate.  The gender variable consists of only two categories, and so the eigenvalues 
table shows that the data were described by only one variate explaining 100% of the data, 
with a canonical R2 of 0.040.    
The second output table (Wilk’s Lambda, Table 7-232) shows the significance tests for the 
variate, and shows that this variate did not significantly discriminate the groups, as the 
significance value is > 0.05. 
The next output table shows the canonical variate correlation coefficients (Table 7-233).  For 
the variates, there is a positive relationship with the change in days of admission and number 
of admissions (all outcome values are positive).  The results suggest that the change in days 
of admission has a slightly higher influence.  
Finally, a histogram presented in Appendix G (Figure 7-54) shows a positive net change in 
days of admission for male clozapine discontinuers, and a negative net change in days of 
admission for female clozapine discontinuers.  However, this difference is not statistically 
significantly different as demonstrated in the previous tests. 
5.3.6.5.9 MANOVA, summary for gender 
The MANOVA was followed up with discriminant analysis, which revealed one discriminant 
function.  This function explained 100% of the variance, canonical R2 = 0.040.  This 
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discriminant function did not significantly differentiate the groups, Λ = 0.960, χ2(2) = 1.318, p 
= 0.517.  It is important to note that there were statistically significantly more men than women 
in the discontinuation group compared to continuers. 
The MANOVA indicates that for clozapine discontinuers, gender has no significant effect on 
the length of time spent in hospital after clozapine has been started (and that the significant 
result seen in the univariate ANOVA is therefore likely to be a false positive).  The histogram 
presented in Appendix G (Figure 7-54) suggests that female discontinuers are more likely to 
have a negative net change in days of admission after starting clozapine, but this result is 
not statistically significant. 
5.3.6.5.10 Discriminant function analysis (diagnosis) 
The first output table is shown in Appendix G (Table 7-234), and provides the eigenvalues 
for each variate.  The eigenvalues table shows that the first variate explains 72.2% of the 
variance, with a canonical R2 of 0.082, whereas the second explains only 27.8%, with a 
canonical R2 of 0.033.    
The second output table (Wilk’s Lambda, Table 7-235) shows the significance tests for both 
variates (‘1 through 2’) and the significance for the second variate, once the first has been 
removed (second row).  This table shows that neither the combination of variates nor the 
second variate alone significantly discriminate the groups, as the significance values for both 
are > 0.05. 
The next output table shows the canonical variate correlation coefficients (Table 7-236).  For 
both variates, there is a positive relationship with the change in days of admission and 
number of admissions (all outcome values are positive).  The results suggest that the change 
in days of admission has a slightly higher influence on the first variate, and the number of 
admissions has a larger influence on the second variate.   
Finally, a combined-groups plot is presented in Appendix G (Figure 7-55).  The discriminant 
function plot shows separation between the diagnostic groups principally on function 1.  This 
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is seen more clearly in the histogram presented in the Appendix G (Figure 7-56), with the net 
change in days of admission becoming more negative for those with a diagnosis of 
schizoaffective disorder.  A more negative net change corresponds to more days being spent 
in hospital after clozapine has started. 
5.3.6.5.11 MANOVA, summary for diagnosis 
The MANOVA was followed up with discriminant analysis, which revealed two discriminant 
functions.  The first explained 72.2% of the variance, canonical R2 = 0.082, whereas the 
second explained 27.8%, canonical R2 = 0.033.  In combination these discriminant functions 
did not significantly differentiate the groups, Λ = 0.887, χ2(4) = 3.783, p = 0.436, and removing 
the first function did not alter this result, Λ = 0.967, χ2(1) = 1.072, p = 0.301.  The correlations 
between outcomes and the discriminant functions revealed that the net change in days of 
admission pre/post clozapine per year was not loaded evenly onto the two functions (r = 
0.999 for the first function, and 0.554 for the second), but that the net change in days was 
loaded more highly onto the first function.  The net change in number of admissions pre/post 
clozapine per year loaded more highly onto the second function (r = 0.832) than the first 
function (r = 0.043).  The discriminant function plot shows separation between all diagnostic 
groups, but the points are widely scattered. 
The MANOVA indicates that for clozapine discontinuers, diagnosis has no significant effect 
on the length of time spent in hospital after clozapine has been started.  The discriminant 
analysis suggests that there is separation within the diagnostic groups and that this can best 
be explained in terms of one underlying dimension, and in this context the dimension is likely 
to be diagnosis itself, but this result is not statistically significant.  The univariate ANOVA 
analysis is therefore likely to be a false positive result. 
 Summary 
Analysis of the intent to treat population found a statistically significant difference between 
the number of admissions per year before and after clozapine had started.  All methods of 
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data analysis found a reduction in the mean number of admissions per year after clozapine 
initiation, with a range of a reduction of 0.34 to 0.73 admissions per year.  A statistically 
significant difference between the number of days of admission per year pre-clozapine 
initiation compared to the number of days of admission per year post-clozapine initiation was 
also found when the portion of the index admission that remained after clozapine was started 
was either entirely discounted, or at least the first 14 days of this post-clozapine index 
admission was removed from analysis.  This could be explained by a proportion of patients 
starting on clozapine, but then stopping before the end of the index admission, elongating 
this post-clozapine period and reducing the proportional difference between the pre- and 
post-clozapine admission days per year.  If this were the case however, this difference would 
be expected to remain evident in subgroup analysis of clozapine discontinuers, but be 
eliminated for clozapine continuers – this is not the case.  The net change in days of 
admission varied widely depending on the method of data analysis used, being most marked 
for methods 2 (a reduction of 16.74 days) and 5 (a reduction of 47.31 days), where the post-
clozapine portion of the index admission was excluded from analysis. 
There was a statistically significant difference between the number of admissions per year 
pre- and post-clozapine for clozapine continuers, regardless of how the data were analysed.  
In other words, if you keep taking the clozapine, you have fewer admissions per year than 
you did before you started the clozapine.  The median reduction in the number of admissions 
per year was 0.77, representing an 78% reduction from the median number of admissions 
per year pre-clozapine (0.88).  There was also a statistically significant difference in days of 
admission per year pre- and post-clozapine for clozapine continuers, with a median reduction 
of 23.19 days per year.  The smallest net change was seen in data analysis method 1, where 
the entire post-clozapine section of the index admission was included in data analysis.  This 
again suggests that this post-clozapine period is proportionally long – it may be that time to 
discharge is lengthy once clozapine is initiated, above the 2 week titration period (method 4, 
which attributed this fortnight to the pre-clozapine period, retained statistical difference 
between the pre- and post-data and found a larger net change in days of admission per year).  
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It is possible that there is a latency to clozapine response, which contributes to this time to 
discharge.  
For clozapine discontinuers, there was no statistically significant difference between days of 
admission pre- and post-clozapine unless the entire post-clozapine index admission time is 
attributed to the post-clozapine period (method 1), where the number of days of admission 
per year post-clozapine is higher than that pre-clozapine.  This is difficult to explain, but may 
be due to a heterogeneous sample of clozapine discontinuers; patients discontinued 
clozapine at different time points (some may have discontinued during the index admission) 
but were analysed as one group.  It is also possible that patients that go on to discontinue 
clozapine are more likely to have fewer days of admission per year pre-clozapine than post-
clozapine; this is reflected in the net change in days of admission being negative for 3 of the 
methods of analysis, but positive for all methods for clozapine continuers.  This means that 
discontinuing clozapine means you are likely to have more days of admission after starting 
it.  If you continue clozapine, this is reversed (you have more days of admission before the 
clozapine than after).  If you stop taking the clozapine, then you spend more days as an 
inpatient after the date you originally started the clozapine compared to before you took it, 
unless you ignore the time period spent during the index admission once clozapine had been 
started.  If you ignore this, then you spend more time as an inpatient per year before you 
started the clozapine compared to afterwards.  This effect is lessened if you ignore the entire 
index admission (method 2) compared to ignoring only the post-clozapine index admission 
period (method 5).  For all data analysis methods except method 2 (disregarding the entire 
index admission), a reduction of the number of admissions per year of 0.66 was shown after 
clozapine initiation.  This represents a 62% reduction, lower than that seen for clozapine 
continuers. 
Whether you stop or continue clozapine and regardless of the method used to analyse the 
data, the number of admissions per year is lower after clozapine has been started compared 
to before.  However, continuing clozapine leads to fewer inpatient admissions after the 
clozapine has been started compared to stopping the clozapine.  Continuing clozapine also 
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leads to a reduction in the number of days of admission per year, whereas if clozapine is 
discontinued, this effect is lost.  For clozapine continuers therefore, not only might they 
experience fewer admissions per year, but those admissions may also be shorter. 
From z-score calculation, less than 95% of the data fall within the normal distribution range 
for all analysis methods except 2 and 4.  The reason for this bias is partly the presence of 
outliers within the sample population.  These are cases where the entire study period falls 
within the index admission, resulting in the patient appearing to be an inpatient for the entirety 
of their history.  There are further cases where either the entire pre-clozapine period or the 
entire post-clozapine period are spent as an inpatient, again giving the appearance of much 
higher proportions of inpatient stay per year than is perhaps really the case.  This problem is 
usually encountered where the length of the study period is relatively short, caused by a 
relatively short time period between the start of the illness and clozapine initiation.  This is 
likely to mean that patients who experience a shorter clozapine delay (the sooner clozapine 
is started in an illness course the less likely a lengthy clozapine delay, although this is not 
necessarily always the case – patients could receive 3 antipsychotics in quick succession 
and then wait a long time for clozapine.  Generally though this tends not to be the prescribing 
pattern) may appear to have more inpatient stays per year than is truly representative.  If 
clozapine delay is associated with inpatient stay, then this will lessen the apparent strength 
of this result.  This type of outlier (where the entire study period lies entirely within the index 
admission) is removed from one end of the scale (100% admission) for method 2, as this 
method discounts the index admission from analysis.  These cases will instead appear to 
have 0% admissions during their entire illness.  It may be that the central limit theorem means 
that the population may be considered normally distributed, and Levene’s test (although of 
less importance for large groups) broadly supports this.  Nonetheless, I have reported non-
parametric tests where the data are assessed to be non-normal.   
In analysis of the effect of clozapine delay on the net change in days of admission pre- and 
post-clozapine initiation, regression models for the intent to treat population found the delay 
to account for less than 10% of the net change.  This was true for clozapine continuers when 
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analysed as a subgroup, and also for discontinuers.  Of the intent to treat group models that 
reached statistical significance, all predicted that an increase in the delay to clozapine use 
results in more days of admission or total admissions per year once clozapine had started.  
No models for the clozapine continuers subgroup reached statistical significance, although 
all methods of data analysis predicted a lower number of days of admission and total 
admissions per year after clozapine had started if the delay to starting was zero.  It was also 
the case that no models for the clozapine discontinuers group reached statistical significance, 
but some variation was seen in the effect on the number of days of admission after clozapine 
initiation when the delay to clozapine was zero; some predicted an increase, some a 
decrease.  All predicted a reduction in the total number of admissions per year. 
Multivariate analysis of variance of the intent to treat group found no effect of the number of 
pre-clozapine antipsychotics, gender, ethnicity or diagnosis on the net change in admission 
(days or total episodes) in the pre-clozapine compared to the post-clozapine period.  A 
significant effect of age was revealed, finding that increasing age conferred a reduction in 
the net change in number of days of admission per year.  Older patients therefore saw a 
reduced benefit from clozapine.  This observation held true for those who continued to take 
clozapine only – for those who discontinued clozapine there was no significant effect of age.   
It is possible that this is due to the smaller effect size in the population that discontinued, and 
the smaller patient numbers in this group – a larger study may find a significant effect as 
seen in the continuing group.  Of note, the significant result found in the multivariate analysis 
was not significant in the following discriminant function analysis, which suggested that the 
net change in days of admission or admissions after clozapine initiation were not 
discriminated by age.  
Those that discontinued clozapine were also significantly separated in diagnosis – patients 
with a diagnosis of schizoaffective disorder (F25) had a negative net change in days of 
admission, showing an increase in days of admission after clozapine initiation.  There was 
also a significant effect of gender, with women that discontinued clozapine having an overall 
net negative change in days of admission after clozapine initiation, showing that more days 
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were spent in hospital after clozapine was started compared with before.  The clozapine 
discontinuers group contained a significantly higher proportion of men, so this result is based 
on a small number of female clozapine discontinuers (n = 8).  Again, these results were not 
significant in discriminant function analysis. 
In conclusion, taking clozapine reduces both the number of days per year you spend as an 
inpatient, and also the number of admissions you have per year, compared to the time before 
you started clozapine.  If you stay on the clozapine, this reduction in inpatient stay is greater 
than if you start it, but then stop.  The amount of time it takes from the time a patient is eligible 
for clozapine, to the time it is actually prescribed, makes no difference to the reduction in 
admission days and total admissions a patient can expect once the clozapine has started.   
Younger patients derive more benefit from clozapine when measured in time spent as an 
inpatient. 
 Publications arising from this study 
See Appendix I: Siobhan Gee, Sukhwinder Shergill and David Taylor (2016) Factors 
associated with changes in hospitalisation in patients prescribed clozapine.  Journal of 
Psychopharmacology, 30(8):819-25  
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6 Factors influencing clozapine discontinuation 
 Introduction 
Clozapine remains the antipsychotic of choice in treatment-resistant schizophrenia (20).  
Despite its superior efficacy in refractory illness compared with other antipsychotics (183), as 
described in chapter 2 it is used less frequently and later in treatment than recommended 
(148).  There is no doubt that, in terms of managing the symptoms, the use of antipsychotic 
medication improves outcomes compared to placebo (184), and in the management of 
treatment-refractory schizophrenia, clozapine is superior to other antipsychotic medication 
(183).  Poor control of symptoms is significantly harmful, not only to patients with respect to 
their quality of life (185), but also has a considerable financial impact on healthcare resource 
(186).  One of the main difficulties is ensuring patient continuation with treatment.  As shown 
in chapter 5, those who persist with clozapine treatment show a large reduction in hospital 
bed days (187). 
The costs of clozapine therapy largely occur at the beginning of treatment.  Baseline blood 
tests, weekly blood count monitoring, possible inpatient admissions or intensive home input 
for titration are all largely within the first 18 weeks of treatment.  Should clozapine therapy be 
successful, over a period of time it is expected that this cost will be recouped as the length 
of time the patient remains in the community increases, with no inpatient admissions, a 
reduction in the intensity and frequency of healthcare professionals input, and increased 
contribution to society through improved social and occupational functioning.  I have shown 
that discontinuing clozapine is likely to lead to increased illness severity.  Clearly the savings 
to the NHS, as well as the clinical benefits to the patient, therefore only remain if the patient 
continues to comply with clozapine treatment.   
I examined the reasons for clozapine discontinuation in a cohort of patients in South East 
London, with the aim of identifying factors that may predict the likelihood of stopping 
treatment.  Previous studies have found that age (56, 102-104, 109) and ethnicity (77, 102, 
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103, 111, 118) may affect the likelihood of clozapine discontinuation.  I have previously 
shown that there is a wide variation in delay to accessing clozapine and the number of 
antipsychotics used prior to clozapine within this population (148).  I hypothesise that these 
factors, along with gender and diagnosis might also affect the risk of clozapine 
discontinuation. 
 Objectives 
 To establish what proportion of patients discontinue clozapine. 
 To describe clozapine discontinuation and restart patterns. 
 To investigate the effect of a patient’s age, ethnicity, diagnosis, length of theoretical delay 
to starting clozapine, and number of previous non-clozapine antipsychotics on the 
likelihood of discontinuing clozapine. 
 Method 
All patients who commenced clozapine for the first time between 1st January 2006 and 15th 
April 2010 at SLaM were included in the study.  Data extraction methods and definitions have 
been described in detail previously in chapter 2; in brief, ethnicity, duration of illness and 
treatment history were extracted from the clinical notes.  Patients under the care of forensic 
services were included in the cohort for this study.  Adequate antipsychotic treatment 
episodes were defined as the prescription of a regular daily dose of an antipsychotic at or 
above a minimum therapeutic dose for at least 6 weeks.  The maximum theoretical delay in 
clozapine initiation was defined as the time from the end of the second adequate 
antipsychotic treatment episode to first clozapine use.  Where clinical notes were missing, so 
precluding a complete prescribing history, patients were excluded from the analysis. 
Patients were classified as ‘discontinuers’ where clozapine was stopped at least once during 
the time of the study.  Clozapine discontinuation was established from the review of the 
clinical notes.  Clozapine was classified as ‘discontinued’ where its cessation was followed 
by a deliberate switch to a different medication.  Periods of non-compliance followed by re-
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titration directly onto clozapine were not considered as clozapine ‘discontinuation’, even if 
another antipsychotic was used to ‘cover’ the re-titration period.  Short term use of other 
antipsychotics pending re-titration to clozapine were also not considered as ‘discontinuation’, 
where it was clear from the clinical notes that the intention was to re-titrate, and the delay 
was caused only by practical or logistical reasons. 
Patients were included in the ‘discontinuation’ group if they discontinued clozapine (as 
defined above) at any point during the study period.  This included patients who discontinued 
clozapine and were never restarted, but also those with other patterns of discontinuation – 
those who stopped for a period of time but were later restarted, and those who repeated this 
discontinuation/restart pattern multiple times.  The reason for the discontinuation, the 
antipsychotic(s) switched to, and cause of death where applicable, was taken from the clinical 
notes.  Patients who did not stop clozapine at any time were classified as ‘continuers’.  
Patients were counted as ‘continuers’ until they were censored (lost to follow up, LTFU) or 
the study ended (01.11.14). 
 Statistical analysis 
Data were analysed using SPSS version 22.  Clozapine continuers and discontinuers were 
compared using t-tests and chi-squared tests.  Binary logistic regression was used to 
investigate variables that may predict clozapine discontinuation.  Categorical predictor 
variables were gender, ethnicity and diagnosis.  Continuous predictor variables were age, 
length of clozapine delay, and number of antipsychotics prescribed previous to clozapine 
initiation.  Multiway crosstabulations were performed for all categorical variables, and 
ethnicity and diagnosis categories collapsed where necessary to avoid violating 
assumptions.  Sequential models were analysed using each variable as a single predictor. 
 Results 
Of the total sample of 133 patients, 48 discontinued clozapine during the study period.  From 
the total sample, 31 patients were under the care of forensic services; of which 13 
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discontinued clozapine.  Five patients from the original data set had died at the time of the 
second study end point.  These patients were removed from the current analysis. 
I performed a t-test for continuous variables (age, gender, clozapine delay, number of 
prescriptions prior to clozapine) and a chi-squared test for variables with more than 2 
categories (ethnicity and diagnosis) to establish whether the two groups (clozapine 
continuers and discontinuers) differed in terms of these variables.  The results of these tests 
are presented in Appendix H (Table 7-237, Table 7-238, Table 7-239) and the resulting p 
values shown in the final column of the table below (Table 6-1).  As described previously in 
this thesis, where Levene’s test is not significant (also presented in Appendix H, Table 7-237), 
the variances of the two groups are roughly equal and the assumption of homogeneity of 
variances is tenable.  Levene’s test is significant for gender, and so equal variances for this 
variable should not be assumed. 
Table 6-1 Demographics 
 Continuers (n = 
85) 
Discontinuers (n = 
48) 
p 
Male, n (%) 53 (62.4) 40 (83.3) 0.007 
Mean age, years 37.87 (range 20 – 
78) 
34.63 (range 17 – 
59) 
0.072 
Diagnosis, n (%) F20 58 (68.2) 33 (68.8) 0.335 
F25 13 (15.3) 7 (14.6) 
F31 6 (7.1) 3 (6.3) 
Other 8 (9.4) 5 (10.4) 
Clozapine theoretical delay, 
years 
4.00 (range 0 – 
18) 
3.73 (range 0 – 19) 0.741 
Total number of antipsychotic 
prescriptions before clozapine 
5.60 (range 1 – 
24) 
5.44 (range 1 – 18) 0.813 
The details of the clozapine discontinuation events are shown in Table 6-2 and Figure 6-1 
below. 
Table 6-2 Medication stop and switch details 
 N (%) 
Total number of clozapine stops 1 34 (70.8) 
2 10 (20.8) 
3 4 (8.3) 
4 2 (4.2) 
First drug switched to Olanzapine 13 (27.1) 
Amisulpride 10 (20.8) 
Risperidone 10 (20.8) 
Aripiprazole 4 (8.3) 
Flupenthixol 3 (6.3) 
Haloperidol 2 (4.2) 
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 N (%) 
Quetiapine 2 (4.2) 
Aripiprazole + olanzapine 1 (2.1) 
Zuclopenthixol 1 (2.1) 
Pipothiazine 1 (2.1) 
Nothing 1 (2.1) 
First formulation switched to Oral 39 (81.3) 
Depot 8 (16.7) 
Nothing 1 (2.1) 
First drug class switched to Typical 7 (14.6) 
Atypical 40 (83.3) 
Nothing 1 (2.1) 
Reason for first stop Patient refusing 29 (60.4) 
Red blood result 9 (18.8) 
Patient refusing due to side 
effects 
4 (8.3) 
Patient refusing blood tests 3 (6.3) 
Medical requirement 2 (4.2) 
Diagnosis changed 1 (2.1) 
Clozapine restarted after first stop Yes 34 (70.8) 
No 14 (29.2) 
Second drug switched to Pipothiazine 2 (14.3) 
Olanzapine 2 (14.3) 
Risperidone 2 (14.3) 
Flupenthixol 2 (14.3) 
Haloperidol 2 (14.3) 
Zuclopenthixol 2 (14.3) 
Amisulpride 1 (7.1) 
Paliperidone 1 (7.1) 
Second formulation switched to Oral 6 (42.9) 
Depot 8 (57.1) 
Second drug class switched to Typical 8 (57.1) 
Atypical 6 (42.9) 
Reason for second stop Patient refusing 11 (78.6) 
Patient refusing due to side 
effects 
2 (14.3) 
Red blood result 1 (7.1) 
Clozapine restarted after second stop Yes 10 (71.4) 
No 4 (28.6) 
Third drug switched to Risperidone 2 (50.0) 
Flupenthixol 1 (25.0) 
Quetiapine 1 (25.0) 
Third formulation switched to Oral 3 (75.0) 
Depot 1 (25.0) 
Third drug class switched to Typical 1 (25.0) 
Atypical 3 (75.0) 
Reason for third stop Patient refusing 3 (75.0) 
Red blood result 1 (25.0) 
Clozapine restarted after third stop Yes 2 (50.0) 
No 2 (50.0) 
Fourth drug switched to Olanzapine 1 (50.0) 
Risperidone 1 (50.0) 
Fourth formulation switched to Oral 2 (100.0) 
Fourth drug class switched to Atypical 2 (100.0) 
Reason for fourth stop Patient refusing 1 (50.0) 
Red blood result 1 (50.0) 
Clozapine restarted after fourth stop No 2 (100.0) 
Total number of clozapine restarts 0 14 (29.2) 
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 N (%) 
1 24 (50.0) 
2 8 (16.7) 
3 2 (4.2) 
 
 
Figure 6-1 Medication stop and switch details 
 Binary logistic regression 
Binary logistic regression is logistic regression where the outcome variable has two 
categories (in this case, being a clozapine continuer or discontinuer).  In this context, logistic 
regression can be used to predict the outcome (discontinuing or continuing clozapine) from 
a combination of categorical and continuous predictor variables.  The categorical predictor 
variables for this analysis are gender, ethnicity, and diagnosis.  The continuous predictor 
variables are age, the length of the delay to starting clozapine, and the number of previous 
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antipsychotics given.  The aim is to establish whether any of these variables in combination 
can predict the likelihood of a patient stopping clozapine. 
It is first important to produce contingency tables for the categorical variables.  This process 
has been described previously in this thesis.  Briefly, the goodness-of-fit tests when 
performing logistic regression assume that each possible combination of categories contains 
an expected result of at least 1, and no more than 20% of the combinations contain expected 
frequencies of results of less than 5.  This is checked by performing multiway 
crosstabulations of the data, and the results tables for these are presented in Appendix H. 
The first crosstabulations table is for gender and ethnicity (Table 7-240), and it is evident that 
several expected counts are below 1, and many are below 5.  The power of the test is 
therefore reduced.  Remedies to this include; collecting more data (this is not possible), 
accepting this loss of power (this is not desirable), or merging some of the categories within 
the variables to create larger categories that would avoid having too few expected 
frequencies.  The same situation can be seen in the second crosstabulations table (which 
examines gender and diagnosis, Table 7-241), where 27% of the expected count frequencies 
are below 5.  In order to solve this problem and improve the strength of the subsequent 






The next crosstabulation table shown in Appendix H (Table 7-242) outlines the results from 
the new ethnicity categories.  Unfortunately, some expected counts within the cells remain 






The results from this second category merge are shown in the next crosstabulation table in 
Appendix H (Table 7-243), and produces 3 expected counts below 5 (8% of the total), and 
no counts below 1.  This is an acceptable result and so these new categories for the ethnicity 
variable should be used for the subsequent analyses. 




The results of the crosstabulations for this can be seen in Appendix H (Table 7-244).  This 
table shows 4 expected counts to be below 5, which is an acceptable 11% of the total.  None 
are below 1. 
As I had no clear, evidence-based or theoretical reason to logically expect any one variable 
to predict the likelihood of discontinuing clozapine over any of the other variables, I chose 
first to enter the predictor variables individually and sequentially into the logistic regression, 
in order to gauge the magnitude of effect each had on the outcome alone.  The variables 
used in each model are shown below in Table 6-3: 
Table 6-3 Sequential binary logistic regression model variables 
Model Covariate (independent variable) Dependent variable 
1 Gender  
 




5 Length of clozapine delay 
6 Number of antipsychotics prior to 
clozapine 
I chose to enter gender as the first variable, as the t-test performed above showed a 
statistically significant difference between the number of male patients in the discontinuer 
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and continuer groups.  The overall model summary statistics for each of the six models are 
shown below.  The chi-square statistic is given for the overall model (in the row labelled 
‘model’), and for the change since the previous model (in the row labelled ‘block’).  The 
associated degrees of freedom are given in the next column, and the significance value for 
the test in the final column.   
Table 6-4 Sequential binary logistic regression model summary statistics 
  Chi-square df p 
Model 1 Block 6.812 1 0.009 
 Model 6.812 1 0.009 
Model 2 Block 1.222 1 0.269 
 Model 8.035 2 0.018 
Model 3 Block 2.375 2 0.305 
 Model 10.409 4 0.034 
Model 4 Block 0.416 2 0.812 
 Model 10.826 6 0.094 
Model 5 Block 0.232 1 0.630 
 Model 11.057 7 0.136 
Model 6 Block 0.022 1 0.883 
 Model 11.079 8 0.197 
 
Table 6-4 shows that model 1 is a significant fit of the data, χ2 (1) = 6.812, p = 0.009.  Model 
2 is a significant fit of the data, χ2 (2) = 8.035, p = 0.018.  Model 3 is a significant fit of the 
data, χ2 (4) = 10.409, p = 0.034.  Model 4 is a not a significant fit of the data, χ2 (6) = 10.826, 
p = 0.094.  Model 5 is not a significant fit of the data, χ2 (7) = 11.057, p = 0.136.  Model 6 is 
not a significant fit of the data, χ2 (8) = 11.079, p = 0.197.  However, no model is a significant 
improvement over model 1 (all block significances > 0.05), so adding each interaction term 
to the first has virtually no effect on the fit. 
The binary logistic regression therefore shows that gender is the sole predictor variable that 
significantly contributes to the prediction of the outcome (continuing or discontinuing 
clozapine).  Consequently, I went on to run the logistic regression with gender as the sole 
predictor variable.  The iteration history for this model is shown in Appendix H (Table 7-245), 
and gives the -2LL (-2 log likelihood) as 173.954.  The -2LL is the logistic regression 
equivalent of the residual sum of squares described earlier in this thesis in relation to multiple 
regression.  It gives an indication of the amount of error in the categorical model by adding 
the probabilities associated with the predicted and actual outcomes.  Large values for this 
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statistic therefore suggest a poorly fitting model, because the larger the 2 log likelihood, the 
more errors, or unexplained observation in the data, there are.  The -2LL given in this output 
relates to the model before the gender variable was added (it is the baseline -2LL). 
The summary statistics for the model are shown in the next table in Appendix H (Table 
7-246).  This shows the -2LL for the model after gender has been added as a predictor 
variable to be 167.134.  The chi-square statistic for this model, calculated in the first model 
in the above regressions is 6.182, with a highly significant p of 0.009.  This chi-square statistic 
is the difference between the baseline -2LL (173.954) and the current -2LL (167.134). 
The classification table shown in Appendix H (Table 7-247) demonstrates that the model 
correctly classifies 85 patients as continuers (100%), but misclassifies zero patients as 
discontinuing when in fact, 48 did (0% accuracy).  Overall, this gives the model accuracy for 
prediction of the outcome of 63.9%. 
The Wald statistic is given in the next table in Appendix H (Table 7-248) as 6.100, with a 
significance of 0.014, indicating that gender is making a significant contribution to the 
prediction of continuing or discontinuing clozapine. 
Earlier, I described Levene’s test for the gender variable as being significant, meaning that 
equal variances should not be assumed.  I have described the bootstrapping process that 
deals with this problem extensively in previous chapters.  The bootstrapping results for the 
variables are given in Table 7-249 in Appendix H, and show the bootstrap re-estimates of 
the standard error.  This changes the significance value for the b to p = 0.010 (from 0.021, 
and remaining significant).  The bootstrap confidence interval indicates that the population 
value for b lies between 0.235 and 2.138, and since this interval does not include zero I can 
conclude that there is a genuine positive relationship between gender and continuing or 
discontinuing clozapine.    
As described previously in relation to linear regression, the R value (the multiple correlation 
coefficient) gives a measure for how well the model fits the observed data.  The R value is 
the correlation between the outcome variable and the predictor variable, and can vary 
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between -1 and 1.  The R is calculated by taking the square root of the Wald statistic (6.100) 
minus twice the degrees of freedom for this statistic (2 x 1), divided by the baseline -2LL 
(173.947). The value of R is therefore 0.15. 
This value cannot simply be squared to give the R2 value described in this thesis when 
discussing linear regression, because as described above the R for logistic regression 
depends on the Wald statistic, which may be inaccurate when the regression coefficient b 
value is large (the standard error is increased in this circumstance, which results in an 
underestimation of the Wald statistic and a risk of a Type II error).  Instead, I have calculated 
Hosmer and Lemeshow’s measure (R2L) by taking away the -2LL of the model (167.134) 
from the baseline -2LL (173.947), then dividing by the -2LL of the baseline (173.947).  This 
gives a value for R2L of 0.039.  The model summary table presented earlier also gives two 
other measures of R2; Cox and Snell’s R2 (0.05) and Nagelkerke’s R2 (0.068).  These give 
slightly different values of R2 but can all be used to provide a measure of the effect size of 
the model. 
Table 7-248 in the Appendix also provides a value for the odds ratio (Exp(B)).  This is 
calculated as the exponential of the b for the predictor variable (e1.105), and is 3.019.  This 
indicates that the odds of a patient who is male discontinuing clozapine is 3.019 times higher 
than those of a female patient discontinuing.  The confidence intervals for this odds ratio are 
provided in the table as 1.256 – 7.255.  As this interval does not contain 1, there is confidence 
that the direction of the relationship observed in the sample is true in the population; i.e. that 
as the predictor increases (more likely to be male), the odds of the outcome (clozapine 
discontinuation) also increases. 
The table of residuals (the residuals are the differences between the values of the outcome 
predicted by the model and those observed in the sample) in Appendix H (Table 7-250)  lists 
the expected probability of discontinuing clozapine based on the model.  The only predictor 
of discontinuing clozapine that was included in the model was gender, and this was given a 
value of either 1 (male) or 0 (female).  The probability values in the table are derived from 
using these values in the logistic regression equation, along with their respective regression 
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coefficients (b).  The table shows that when a patient is male, there is a probability (shown 
as predicted probability of discontinuing) of 0.430 that they will discontinue clozapine (43% 
chance of discontinuing clozapine if the patient is male).  For female patients, the probability 
of discontinuing is 0.2 (20% chance of discontinuing clozapine if the patient is female).  This 
table also provides the residual statistics, which look for points where the model fits the data 
poorly, and points that exert undue influence on the model.  In this way, the residuals provide 
an assessment of how well the model fits the data.  Cook’s distance looks for individual cases 
that influence the model, and any values for this statistic that are more than 1 indicate that 
that particular case is impacting on the model’s ability to predict all the other cases.  For this 
data set, all of the values for Cook’s distance are less than 1.  The leverage values, also 
shown in the table, are a gauge of the influence of the actual value of the outcome variable 
over the predicted values for the variable.  The average leverage value is defined as the 
number of predictors in the model plus 1 (1 + 1) divided by the sample size (133), and is 
therefore 0.015.  If no individual patients are exerting undue influence on the model, then all 
the leverage values should be close to this average, with a boundary of twice the average 
(0.03) requiring investigation, and three times the average (0.045) being a cut-off point.  For 
this data set, the leverage values for all the cases are within the boundary of twice the 
average leverage.    The normalised residual values are given in the next column.  As the 
residuals represent the error associated with the model, when they are small the model is a 
good fit of the sample data.  For standardised residuals, as presented here, the residuals are 
converted into z-scores (discussed previously in this thesis).  In a normally distributed 
sample, only 5% of the residuals (or z-scores) should lie outside +/- 1.96, 1% should lie 
outside +/- 2.58, and none should be above 3.  For these data, the standardised residuals 
for 8 cases lie outside +/- 1.96, which is equivalent to 6% of the total.  None are outside the 
larger values.  Finally, the DFBeta is the difference between a parameter that has been 
estimated using all the cases in the data set and that estimated when one case is excluded.  
It is therefore useful to identify cases that have a large influence on the parameters of the 
model.  The DFBeta is calculated for each patient and the constant in the regression equation 
in the penultimate column, and each patient and the predictor variable (being male) in the 
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final column.  Absolute values for either DFBeta that are above 1 indicate cases that 
substantially influence the model parameters; no values for these data are above 1.  Overall, 
the model diagnostics suggest that the model is reliable and has not been influenced unduly 
by any subset of cases. 
 Binary logistic regression summary 
The coefficients of the model predicting whether a patient discontinued clozapine [95% BCa 
bootstrap confidence intervals based on 1000 samples] are shown below in Table 6-5. 
Table 6-5 Binary logistic regression model coefficients 
  95% CI for odds ratio 
b Lower Odds Upper 
Constant -1.386 
[-2.398, -0.694] 
   
Gender (male) 1.105* 
[0.235, 2.138] 
1.256 3.019 7.255 
Model χ2 (1) = 6.812, p = 0.009.   
* p =0.014 
 Survival analysis 
The total sample included 133 patients; of these, 48 (36%) discontinued.  The patients in this 
study can therefore be described as either ‘surviving’ to the end of the study (remaining on 
clozapine), or not surviving (discontinuing clozapine before the end of the study).  However, 
the total study time was different for each patient.  The follow up time for each patient in the 
study was the time from first clozapine use to the date of the end of the study (01.11.14), and 
therefore each patient had a different follow up time as start times differed.  Each patient also 
had a different survival time (meaning the time from starting clozapine to the outcome event 
occurring – i.e. either discontinuation, or the end of the study if the patient did not discontinue 
clozapine). 
 Actuarial survival analysis 
One option for reporting survival times for these data is to report the proportion of patients 
surviving at a fixed time point, e.g. At 1 year, 2 years, 3 years.  This has the disadvantage of 
restricting the analysis to patients for whom complete information is available at the time 
point – i.e. some will be lost to follow up before completing the time period and will be 
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excluded from the analysis.  If the time period studied is short, then any effect of time on the 
rate of occurrence of the event may not be seen – i.e. the rate of occurrence of 
discontinuation may not remain constant over time.  It might be logical to expect the probably 
of discontinuing to be higher in the first year due to blood test frequency, and then to decrease 
over time as the blood monitoring burden reduces.  Alternatively the probability of 
discontinuing may increase over time as the regular input from health care services forced 
by frequent blood testing decreases. 
For this method of survival analysis, the starting point for each patient is the start date of the 
clozapine prescription, and the end point (a binary variable) is continuing or discontinuing 
clozapine.  The calculated time between these two points is the survival time for the patient.  
All patients in the study had a survival time of at least 4 years, and so up to this point the 
probability of discontinuing is simply the number of patients that discontinued clozapine 
divided by the number of patients that continued clozapine.  Naturally, the probability of 
continuing clozapine is therefore 1 minus the probability of discontinuing clozapine.  The 
following probabilities can be calculated for the first 4 years using this method (see Table 6-6 
below). 
Table 6-6 Actuarial survival analysis, years 1 - 4 
Within… Probability of 
discontinuing 
Probability of continuing 
Year 1 12 / 133 = 0.09 1 – 0.09 = 0.91 
Year 2 6 / 121 = 0.05 1 – 0.05 = 0.95 
Year 3 7 / 115 = 0.06 1 – 0.06 = 0.94 
Year 4 11 / 108 = 0.1 1 – 0.1 = 0.9 
 
After year 4, some patients are lost to follow up for the later time periods because they 
entered the study too late to allow longer follow up times – i.e. they started clozapine in 2010.  
In order to calculate the probability of discontinuing in these time periods these patients who 
were effectively unable to complete the defined follow-up period must be accounted for 
(these patients are known as ‘censored’).  This is done by estimating that on average, each 
censored patient was observed for half the follow up period without experiencing any 
discontinuation event.  Therefore the probability of discontinuing during this interval is the 
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number of observed discontinuations divided by the size of the cohort minus half the losses 
due to censoring.  In other words, censoring reduces the effective size of the cohort by half 
the size of the group lost to follow up.  This is important as rather than removing them from 
the group entirely, the censored patients still contribute information to the overall probability 
of discontinuing. 
For the years following year 4, the following probabilities can now be calculated, taking 
censored patients into account (Table 6-7). 
Table 6-7 Actuarial survival analysis, years 5 - 8 
Within… Effective size of cohort, 





Year 5 97 – (0.5 x 3) = 95.5 4 / 95.5 = 0.04 1 – 0.04 = 0.96 
Year 6 90 – (0.5 x 22) = 79 5 / 79 = 0.06 1 – 0.06 = 0.94 
Year 7 63 – (0.5 x 19) = 53.5 3 / 53.5 = 0.06 1 – 0.06 = 0.94 
Year 8 41 – (0.5 x 24) = 29 0 / 29 = 0 1 – 0 = 1.0 
Year 9 17 0 1 
 
The cumulative probabilities for discontinuing clozapine can be estimated by multiplying the 
probability of continuing clozapine in the previous year(s) by the probability of discontinuing 
in the current year.  These are presented in Table 6-8 below. 
Table 6-8 Actuarial survival analysis cumulative clozapine discontinuation probabilities 
Year Calculation Cumulative probability of discontinuing 
during this year 
1 N/A 0.09 
2 0.91 x 0.05 0.05 
3 0.91 x 0.95 x 0.06 0.05 
4 0.91 x 0.95 x 0.94 x 0.10 0.08 
5 0.91 x 0.95 x 0.94 x 0.90 x 0.04 0.03 
6 0.91 x 0.95 x 0.94 x 0.90 x 0.96 x 
0.06 
0.04 
7 .91 x 0.95 x 0.94 x 0.90 x 0.96 x 0.94 
x 0.06 
0.04 
8 0.91 x 0.95 x 0.94 x 0.90 x 0.96 x 
0.94 x 0.94 x 0 
0.00 
Probability of discontinuing clozapine at any point during the 9 year follow-up period = 0.38 
Cumulative survival probability for the cohort = 0.62 
Using the data calculated above, the actuarial life table can be constructed, with the 
corresponding life curve below in Table 6-9 and Figure 6-2 Actuarial life curve 
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Table 6-9 Actuarial life table 








follow up (L) 
Effective size 




the year (D/(N-0.5L)) 
Probability of 
continuing through 




1 133 12 0 133 0.09 0.91 0.91 
2 121 6 0 121 0.05 0.95 0.86 
3 115 7 0 155 0.06 0.94 0.81 
4 108 11 0 108 0.10 0.90 0.73 
5 97 4 3 95.5 0.04 0.96 0.70 
6 90 5 22 79 0.06 0.94 0.66 
7 63 3 19 53.5 0.06 0.94 0.62 
8 41 0 24 29 0.00 1.00 0.62 
9 17 0 0 17 0.00 1.00 0.62 
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Figure 6-2 Actuarial life curve 
 Kaplan-Meier survival analysis 
The actuarial method does not require information on the exact time at which 
discontinuations or censoring occurred.  Only knowledge of the status of the patient at each 
of the limits of each time interval is required.  Since these data include the exact times of 
discontinuation and censoring, survival probabilities can be estimated immediately after each 
patient’s discontinuation event without the need to aggregate data into intervals of time.  This 
method of survival analysis is the Kaplan-Meier method.  The survival table for this method 
is given in Appendix H (Table 7-251), and shows each individual patient on a separate row 
of the table, in the order in which they discontinued clozapine or were censored from the 
study, along with the time point at which this occurred.  From this table, the survival curve 
presented below can be constructed (Figure 6-3). 
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Figure 6-3 Kaplan-Meier survival curve, total patient cohort 
The previous data analysis presented in this chapter suggested that male patients may be 
more likely to discontinue clozapine than females.  I therefore completed the Kaplan-Meier 
survival analysis separately for males and females.  A summary table of the cases is provided 
in Appendix H (Table 7-252), showing that of the 93 male patients, 40 discontinued clozapine 
at some point during the study, and 53 (57%) were censored.  For the 40 female patients, 8 
discontinued clozapine and 32 (80%) were censored.  Overall, of the 133 cases, 48 
discontinued and the remaining 85 were censored (63.9%).  The corresponding survival 
table, differentiated for male and female patients is given in Appendix H (Table 7-253), and 
the Kaplan-Meier survival curve is below (Figure 6-4). 
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Figure 6-4 Kaplan-Meier survival curve, separated for gender 
 Relative risk 
The risk estimate of discontinuing depending on being male or female can be calculated, and 
the table presented in Appendix H (Table 7-254) shows the risk estimate for male patients 
discontinuing to be 2.151, meaning that the risk of discontinuing clozapine if a patient is male 
is more than twice that if they are female.  This is the same as calculating the relative risk of 
discontinuing from the numbers of patients in each group; the risk of a male patient 
discontinuing (the number of males that discontinued, 40, divided by the total male patients 
in the sample, 93) divided by the risk of a female patient discontinuing (the number of females 
that discontinued, 8, divided by the total number of females in the sample, 40).  This 
calculates the relative risk of discontinuing for males versus females to be 2.15.  The chi-
square test associated with this risk estimate is also given in Appendix H (Table 7-255), and 
shows the significance value to be 0.011.  Therefore there is a significant association 
between gender and whether a patient discontinued clozapine or not, χ2 (1) = 6.421, p = 
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0.011.  Based on the odds ratio, the risk of discontinuing clozapine was 2.15 times higher if 
a patient was male. 
 Summary 
For the current analysis, 16 patients from the original cohort of 149 patients were excluded.  
Of the excluded patients, 5 had died between the end of the previous study and the end of 
the current analysis, 9 were lost to follow up (discharged out of the Trust), and 2 were 
excluded for other reasons (1 duplicate patient, 1 had received clozapine before the start 
date of the analysis).  After exclusions, the study population consisted of 133 patients. 
Of the study population of 133 patients, 48 discontinued clozapine at least once during the 
study period.  Of these 48 discontinuers, 14 (29%) stopped permanently.  The remaining 
71% (34 patients) were eventually restarted on clozapine after failure of other treatments.  Of 
these 34 patients, 24 remained on the clozapine, and 14 discontinued a second time.  Of this 
cohort, 10 patients were restarted on clozapine for a third time following a break using non-
clozapine antipsychotics, 4 patients stopped permanently.  Of the 10 patients who restarted 
clozapine a third time, 4 discontinued again.  Of these 4 patients, 2 were not restarted on 
clozapine, and 2 were rechallenged a fourth time.  Both patients who started clozapine again 
after the fourth discontinuation stopped the clozapine again, both permanently this time.  
Patients who died during the study are reported separately.  The mean time to clozapine 
discontinuation was 1032 days, with a range of 1 – 2524 days.  The majority of discontinuing 
patients (75%) stopped clozapine within the first 4 years of treatment.  
Clozapine discontinuers were more likely to be male (t = 2.77, p = 0.007).  Based on the odds 
ratio, the odds of discontinuing clozapine were 2.15 (95% CI 1.1 – 4.2) times higher if a 
patient was male.  There were no statistically significant differences between clozapine 
continuers and discontinuers in terms of their age when clozapine was first started (t = 1.81, 
p = 0.072), ethnicity (χ2 = 4.62, p = 0.34) or diagnosis (χ2 = 0.012, p = 1.00).  Binary logistic 
regression found sequential models using individual variables as predictors to be non-
significant for age (χ2 = 1.22, p = 0.27), ethnicity (χ2 = 2.38, p = 0.31), diagnosis (χ2 = 0.42, 
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p = 0.81), length of clozapine delay (χ2 = 0.23, p = 0.63) and the number of antipsychotics 
used prior to clozapine (χ2 = 0.02, p = 0.88), but significant for gender (χ2 = 6.81, p = 0.009).  
Most patients who discontinued clozapine (n = 34 of the total cohort of 48 discontinuers, 
71%) stopped clozapine just once, with a further 10 patients (21%) stopping twice, 4 patients 
(8%) stopping three times and a further 2 patients (4%) stopping four times.  After the first 
clozapine stop, most were switched to an oral (n = 39, 81%), atypical (n = 40, 83%) 
antipsychotic.  Of these patients, the majority (n = 34, 71%) restarted clozapine.  Over a 
quarter of discontinuing patients (n = 14, 29%) stopped clozapine at least twice during the 
study period, and following this second stop 71% (n = 10) restarted clozapine for a second 
time.  After the second clozapine discontinuation, most patients were given depot 
antipsychotic treatment (n = 8, 57%).  In total, 8% of patients (n = 4) stopped clozapine three 
times, and two of these patients were restarted after the third stop.  Of these two patients, 
both stopped clozapine a fourth time, and neither were restarted after this fourth stop. 
The most frequent drug switched to in the first instance was olanzapine (n = 13, 27%), 
followed by amisulpride (n = 10, 21%) and risperidone (n = 10, 21%).  Other drugs chosen 
included aripiprazole, flupenthixol, haloperidol, quetiapine, zuclopenthixol, pipothazine, and 
a combination of aripiprazole and olanzapine.  One patient was given no antipsychotic after 
clozapine was discontinued, as the diagnosis of schizophrenia was by that time uncertain.  
After a second discontinuation of clozapine, the medication chosen to switch to varied widely, 
with no clear majority for any particular drug (pipothiazine, flupenthixol, haloperidol, 
amisulpride, olanzapine, risperidone, paliperidone, zuclopenthixol were all presented). 
The most common reason for discontinuing clozapine for the first time was patient refusal (n 
= 36, 75%).  Where documented in the clinical notes, this was further specified as refusal of 
blood tests (n = 3, 6%) and refusal due to adverse effects (n = 4, 8%).  No specific reason 
for treatment refusal was given for 29 patients (60%).  Clozapine was stopped due to blood 
dyscrasia for 9 patients (19%), another medical reason for 2 patients (4%), and due to a 
change in diagnosis for one patient (2%).   
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At the end point of the study, 5 patients had died.  Of these, 3 (60%) were taking clozapine 
at the time of death.  For those taking clozapine, causes of death were suicide (n = 1), ‘blood 
clots’ (n = 1) and pneumonia (n = 1).  The remaining two patients died following pulmonary 
embolism (n = 1) and ‘collapse’ (n = 1). 
 Publications arising from this study 
See Appendix I: Siobhan Gee, Sukhwinder Shergill, David Taylor (2018) Long-term follow-
up of clozapine prescribing.  Journal of Psychopharmacology, online first  
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7 Discussion 
This thesis examines prescribing of clozapine in an NHS Trust in South East London.  I 
investigated the point at which clozapine was prescribed in a patient’s treatment course, the 
reasons for prescribing (or non-prescribing) from the perspective of clinicians, the opinions 
of patients on starting clozapine, the consequences of prescribing later in a patient’s illness, 
and the effects of discontinuing clozapine.  An extensive retrospective case note review, a 
healthcare professional survey and a patient interview series were conducted, leading to 
publication of 5 original peer-reviewed journal articles. 
Every patient’s schizophrenia is different.  The symptoms and their relative severity are 
different, the onset and illness course are different, and the effect of medications on these 
elements is different.  Although the majority of patients will respond to one antipsychotic or 
another, it is clear that for about a third, the only antipsychotic that is effective is clozapine.  
This response to clozapine, or lack of response to other antipsychotics, is used to define the 
diagnostic subtype ‘treatment-resistant’ schizophrenia.  Evidence from trials that show a lack 
of response to non-clozapine antipsychotics even in the first episode of illness (70) suggest 
that at least for some patients, treatment-resistance may be an inherent part of the condition 
from the start.  The defining characteristic of this group of patients may be considered to be 
a response of symptoms to clozapine.  As discussed earlier in this thesis, the common mode 
of action for all antipsychotics is blockade of dopamine receptors, specifically D2.  For non-
treatment-resistant patients, the degree of D2 blockade provided by antipsychotic medication 
broadly correlates with clinical response for non-clozapine antipsychotics (188).  This does 
not appear to be the case for patients with treatment-resistant illnesses, where even 
maximum dopamine blockade does not alleviate symptoms (189).  Correspondingly, 
dopamine blockade does not explain why clozapine is effective; where treatment-resistant 
patients are switched from a depot antipsychotic to clozapine, there is no delay in response 
to clozapine despite the depot still completely occupying dopamine receptors well after it has 
been stopped, and treatment switched to clozapine (190).  Treatment-resistant patients 
appear therefore to have normal dopamine functioning (191), and clozapine is effective in 
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treating their symptoms through some other mechanism, possibly related to other 
neurotransmitters such as glutamate (192).  Further support to the glutamate theory of 
clozapine action comes from the observation that treatment-responsive patients, healthy 
volunteers, and, crucially, clozapine-resistant patients, all appear to have normal levels of 
glutamate and glutamine in the putamen, whereas clozapine-responsive patients have 
elevated levels of these chemicals (193).  This different mechanism of action for clozapine is 
important in relation to the questions raised and answered in this thesis, since the effect of 
delayed use may be different to that seen for other antipsychotics (such as in delayed 
treatment in the first episode of schizophrenia). 
My first study characterised the point at which clozapine was introduced to patient’s treatment 
plan, and found a mean of 3.93 years from the point of a theoretical ‘treatment-resistant’ 
schizophrenia diagnosis to receiving clozapine.  This is an improvement on the previous 
finding in the same Trust of 5 years (71), but still illustrates prescribing practices falling far 
outside those recommended by evidence-based guidelines.  Further to this, not only are 
patients receiving trials of multiple non-clozapine antipsychotics prior to clozapine (a mean 
of 5.6 antipsychotics, with a range of 1 – 20), but these antipsychotics are also often (in 34% 
of patients) being prescribed in supramaximal doses (both as monotherapy and 
polypharmacy).   
My finding of an almost 4 year delay to clozapine with a wide range in time delays across the 
population sample is in common with a similar study conducted in 2013, also in England.  
Najim and colleagues found a 5 year delay to clozapine initiation in their retrospective chart 
review of outpatients on clozapine, with a range of 0.2 – 16.1 years (72).  In Turkey, Ucok et 
al. found a shorter delay of 2.4 years (100).  Both papers used the same criteria for calculation 
of theoretical delay to clozapine as in my research, and so it may be that the differences 
reflect different practices in other countries, or, as suggested by Ucok et al. on closer 
inspection of their data, a difference in speed of access to clozapine depending on the type 
of unit in which the patient was being treated.  Other authors report total time to clozapine 
prescription – i.e. time from first presentation to psychiatric services until clozapine is started.  
 308 
I found this to be a mean of 8.6 years in my patient group, a figure in keeping with those 
reported elsewhere.  In a 2008 study patients in New Zealand experienced a mean of 9.7 
years to clozapine initiation (66), although this had markedly reduced by 2014 to 5.3 years 
(73).  A longer time delay of 11.8 years was calculated by Laker et al. in an English cohort in 
1998 (109), and a shorter time again by reported by Harrison et al. in New Zealand in 2010 
of just 2.8 years, albeit after an injection of government funding targeted at decreasing the 
time delay (99). 
All these studies, including mine, calculated the ‘theoretical’ delay to clozapine as the time 
from the end of a six week period of being on a second antipsychotic, to starting clozapine.  
This strict definition of the point at which treatment-resistance occurs is taken from Kane’s 
1988 paper (20), and although not arbitrary (most treatment response to antipsychotics 
occurs within the first 6 weeks, if any positive effect is to be seen) it is a definition that will 
not adequately describe all clinical journeys.  Time to response to antipsychotic treatment is 
variable, and it is possible that some patients may begin to respond after 6 weeks – and 
perhaps some clinicians choose longer medication trials for this reason before switching to 
clozapine.  A trial of many years however seems somewhat unreasonable.  Indeed, a meta-
analysis conducted by Agid and colleagues demonstrated that the overall clinical 
improvement seen with antipsychotics is greatest in the first week of treatment, compared to 
later weeks (194).  This result was repeated in a longer term 1 year study by Leucht et al. 
(195), where the reduction in overall psychotic symptoms was greatest in the first two weeks 
(accounting for 32% of the reduction), with an additional 12.5% in weeks 3 and 4, and the 
change in this first month being higher than that added in the subsequent 48 weeks of the 
first year of treatment.  Even more strikingly, a study of acutely ill patients given fluphenazine 
found that those who failed to respond (defined as less than a 20% reduction in psychotic 
symptoms) in the first week were also guaranteed to remain non-responders by week 4 (196).  
It is also possible that some patients respond initially to a second antipsychotic trial, but then 
latterly ‘become’ treatment-resistant.  If this were the case, a pattern of medication use of two 
antipsychotics prior to clozapine, with a long latency to clozapine starting would be expected.  
I did not find this; instead I found multiple antipsychotic trials being given, frequently in 
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combination and at higher doses than those licensed.  This suggests non-response to these 
medication trials and a probable diagnosis of treatment-resistance much earlier in the illness 
than the introduction of clozapine would suggest, even if not at exactly 6 weeks after the 
second antipsychotic trial was started. 
A further interesting observation from the pre-clozapine prescribing data presented in this 
thesis is the high proportion of what could be described, at least on initial inspection, as poor 
prescribing.  In my study 34.2% of patients had supramaximal doses of antipsychotics 
prescribed – a practice that is unlicensed, in the case of monotherapy (representing 45.9% 
of the supramaximal doses), and lacking a clear evidence base in the case of both 
monotherapy and polypharmacy.  It has long been the case that mortality is believed to 
increase with antipsychotic polypharmacy (197, 198), although more recent studies have 
failed to find this association (199, 200).  A recent meta-analysis found polytherapy with 
antipsychotics more effective for prevention of rehospitalisation than monotherapy with all 
other oral antipsychotics, except for clozapine (201).  Nonetheless, it is the case that pill 
burdens may be increased, side effects are inevitably increased or compounded, and so the 
rationale for this prescribing strategy is unclear.  Presumably, prescribers see a lack of 
efficacy of the non-clozapine antipsychotics, prompting dose increases in the hope of also 
increasing efficacy, or combining non-clozapine antipsychotics with the same aim (and 
perhaps targeting different mechanisms of action).  An alternative reasoning for the use of 
polypharmacy is an attempt to reduce side effects; if higher doses of one drug are intolerable, 
using a second may allow dose reduction of the first.  Despite these arguments, trials have 
largely failed to find substantial benefits to either strategy, but the risks of high dose 
prescribing (polypharmacy increases the likelihood of this occurring), particularly to long term 
cardiovascular and metabolic health, are clear (202).  Efforts have been made, both locally 
and nationally, to reduce high dose prescribing (145), and the use of polypharmacy had 
reduced from 65% in the same hospital Trust in 2003 (71) to 54% in the current study.  
Nonetheless, my data show that these undesirable prescribing practices persist. 
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Surprisingly, the number of inadequate antipsychotic trials pre-clozapine was also high in my 
sample (70.5% of patients).  The definition of an ‘inadequate’ trial is of course somewhat 
artificial – each patient will respond differently in terms of doses that are either effective or 
tolerated – but despite this, the number of inadequate trials prescribed is considerable.  Of 
these, 41% were due to a prescribing duration of less than 6 weeks – this may be reasonable 
and unavoidable if the patient cannot or will not tolerate a 6 week trial due to side effects.  
Underdosing occurred in 33.6% of the inadequate trials, again possibly reasonable since the 
‘minimum effective dose’ will naturally be lower than the average for some.  It is also possible 
that prescribing was unintentionally inadequate – that is, clinicians were simply unaware of 
the commonly accepted minimally effective doses, or that 6 weeks is generally suggested as 
a minimum time course to assess effectiveness.  However, both recommendations are freely 
available in local prescribing guidelines.  It also seems illogical that for patients not 
responding to an antipsychotic (as was eventually the case for all the patients in the cohort, 
as they were all finally given clozapine) doses were not increased.   It is conceivable that for 
patients who were highly symptomatic, six weeks was perhaps too long to wait for response 
– an understandable pressure to do something other than simply waiting in the face of 
continued symptomatology may be a factor.  Overall one can envisage many different clinical 
scenarios that would explain my finding of such a high frequency of inadequate antipsychotic 
trials.  To the best of my knowledge no other authors have studied the prevalence of 
inadequate prescribing in this way in naturalistic samples. 
Within the Trust, approximately 350 patients present with new onset schizophrenia each 
year.  Of these, one third (117 patients) can be expected to be treatment-resistant.  Yet less 
than half that number (just 50 patients) start clozapine each year.  Unfortunately, and as 
previously described, this is not unusual, either within the UK (80) or internationally (52, 63).  
The most recent comprehensive UK survey of prescribing in schizophrenia (the National 
Audit of Schizophrenia (203)) reported 23.7% of patients to be prescribed clozapine, with 
high variations between Trusts.  Of the sample studied, 40% of patients appeared to be 
treatment-resistant and eligible for clozapine, but were not prescribed it.  In the most part, 
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this thesis therefore describes a cohort of patients with treatment-resistant schizophrenia 
who are unusual in their peer group, in that they received clozapine to treat their illness. 
I found female patients experienced a longer delay to clozapine initiation.  Alessi-Severini 
and colleagues found women had a shorter length of therapy prior to clozapine (7.7 years, 
compared to 8.9 years in men)  (59), but most other authors found clozapine users more 
likely to be male (52-54, 75, 76) or for there to be no difference in prescribing prevalence 
between genders (67, 77, 204).  An increased proportion of men in clozapine-receiving 
populations does not necessarily mean a longer delay to clozapine for women, as the risk of 
developing schizophrenia is higher for men (205).  It has been suggested that men suffer a 
more severe illness course than women (54), which may explain the shorter time course to 
clozapine in my group, if prescribers are more likely to reserve clozapine for their most ill 
patients.  Nielsen and colleagues found that in their cohort of clozapine patients, women had 
been given more non-clozapine antipsychotics in the period before clozapine started than 
men, and had also had more hospital admissions and inpatient bed days in this period, 
suggesting a higher illness burden (63).  They did not however find any statistically significant 
difference in the prevalence of clozapine prescribing between the genders.  Although I did 
not gather illness severity data for my cohort, all patients experiencing a treatment delay to 
clozapine initiation were, by definition, eligible to receive clozapine, regardless of symptom 
burden.  It is possible that female patients were eligible to start clozapine, but their prescribers 
deemed their symptoms not severe enough to warrant clozapine.  There may be other 
reasons – perhaps female patients are considered more likely to be non-compliant with 
clozapine and/or concurrent blood testing.  Concerns around prescribing of clozapine to 
women of child-bearing age may also play a part.  It may be that female patients are offered 
clozapine but are more likely to refuse.  Other authors have found women to be less adherent 
to medication regimens than men (206, 207), although where this has been studied in 
patients with schizophrenia, no differences between the genders have been demonstrated in 
terms of antipsychotic compliance (208, 209).  If females have a higher burden of co-morbid 
medical conditions this may also limit clozapine prescribing.   
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I did not find an interaction effect of age on the delay to clozapine use, once illness duration 
was controlled for.  Older age has been associated with a longer delay by several other 
groups (71, 72), as has duration of illness (72).  Illness duration is of particular relevance as 
clozapine was only made available in the UK in 1990, and so for some patients clozapine 
may not have been available in the earlier stages of their illnesses.  The finding by other 
groups of a longer delay to clozapine use in older patients may be partly explained by 
prescribers being less likely to readily consider clozapine for patients who have more 
comorbid physical illnesses, which is more likely in those who are older.  It has also been 
suggested that younger patients are more likely to be treated robustly more quickly, as the 
drive to reduce a long term symptom burden with associated social deficits may be felt more 
urgently in younger patients.  In my clinical experience, some prescribers also express a view 
that patients who have been unwell for long periods of time are less likely to respond to 
medication, reducing confidence in clozapine being effective in older patients.  This 
assumption is investigated in this thesis.  It is encouraging that at this Trust, older patients 
do not appear to be treated differently from their younger counterparts.  
I also found no effect of diagnosis or ethnicity on clozapine delay.  Many other groups have 
demonstrated a higher representation of Caucasian patients in clozapine cohorts (53, 54, 
77).  Patients of African-American heritage may find access to clozapine more challenging 
as the presence of Benign Ethnic Neutropaenia (BEN) is more likely, and other authors have 
suggested that cultural factors also have an effect on prescribing in this group (54).  It is 
reassuring that I found neither race nor diagnosis affected delays in prescribing.  This may 
partly reflect the ethnic mix at this Trust; the population it serves in South East London has 
one of the highest proportion of Black patients in the UK (182). 
An obvious reason for delay in prescribing clozapine is a lack of knowledge of the relevant 
guidelines (71).  This seems unlikely to be the case for my cohort, since the NICE guidelines 
for schizophrenia (which specify the prescribing of clozapine in treatment-resistant 
schizophrenia) have been widely available, and unchanged in this regard, for more than a 
decade.  A lack of familiarity with clozapine itself may be more likely – it is a drug with unique 
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monitoring requirements, both at baseline and in the long term.  This theory is supported by 
evidence of wide variation in prescribing rates of clozapine within (75) and between Trusts 
(57, 58, 62, 78, 80, 81, 203).  Prescribing seems to beget prescribing, with high volume 
prescribers (of any psychotropic) more likely to prescribe clozapine in a large study in the 
USA (81).  Better support structures for prescribers, in the form of better access to general 
practice and more community care options were linked with higher clozapine prescribing 
rates in France (62).  A lack of knowledge and confidence, especially in younger prescribers 
in outpatient settings appear likely to reduce prescribing of a complex drug (204), suggesting 
a need for not only staff education (62, 75, 81, 204) but also administrative support (54, 81, 
210).  Finally, patients themselves are frequently considered a barrier to prescribing, usually 
due to clinician fears of non-compliance either with the medication itself or the attendant 
blood tests (53, 71, 82). 
I surveyed staff members to establish their opinions of clozapine, its efficacy, initiation, and 
factors that might help to reduce barriers to prescribing.  Two methods were considered for 
doing this; face-to-face interviews, and self-administered questionnaires.  The Trust employs 
4600 staff across four London boroughs and so researcher-administered interviews or 
questionnaires were considered impractical.  Additionally, the target population consists of 
any member of clinical staff who may be involved in clozapine treatment in any way – 
including influencing of patient opinions as well as directly prescribing.  This therefore 
presents a widely heterogeneous population, including health care assistants, nurses, 
doctors, pharmacists, psychologists, social workers, occupational therapists and so on.  This 
heterogeneity necessitated a large sample size in order to increase precision and reduce 
sampling error.  Self-administered questionnaires allowed me to target the largest possible 
population, and had the additional benefit of being free from interviewer effects or variability.  
It is possible that being asked questions about medication by a Trust pharmacist would have 
elicited different responses than those given anonymously, especially from prescribers who 
may have felt obliged to give the ‘approved’ guideline-driven answers.   
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The questionnaire used in this study aimed to investigate four main themes that may 
contribute to a delay and/or under prescription of clozapine in treatment-resistant 
schizophrenia.  These themes were identified from the clinical experience of the research 
team, feedback from the pilot questionnaire, and review of the relevant literature.  These 
were: (i) a lack of knowledge of the guidelines and associated evidence supporting the use 
of clozapine as a third-line antipsychotic, and/or a personal lack of confidence in the 
effectiveness of clozapine when compared to other antipsychotics; (ii) patient reluctance to 
take tablets or agree to blood testing; (iii) psychiatrist concerns about future compliance or 
the development of side effects; and (iv) administrative hurdles to prescribing. 
Doubts about the efficacy of clozapine were suggested as a barrier to prescribing by Taylor 
et al. in 2003 (71), and Downs and colleagues (80) felt that the publication of prescribing 
guidelines for clozapine contributed to increased prescribing rates in their review of English 
NHS Trusts.  In Swinton et al.’s 1999 case note review and interview of forensic patients 
eligible for, but not prescribed clozapine (82), three quarters of the patients interviewed stated 
an unwillingness to comply with blood testing.  Doctors asked in the same study also cited 
the likelihood of refusal of blood tests or the drug itself, either immediately or on discharge, 
as a reason for not prescribing.   Patient reluctance to take tablets or agree to blood testing, 
and psychiatrist concerns about future compliance with therapy were also suggested by 
Taylor and colleagues (71) as reasons for the delay they found in clozapine prescribing in a 
cohort of treatment-resistant patients with schizophrenia in South East London.  A further 
theme was that of administrative hurdles presenting barriers to prescribing in a variety of 
ways.  A lack of staff to take blood samples was suggested by Swinton (82) as a reason for 
non-prescription of clozapine.  Taylor (71) proposed that prescriber as well as patient fears 
about haemotoxicity or other side effects may affect prescription rates.  The cost of clozapine 
prescribing was also put forward as a barrier.  An increase in available funding to support 
clozapine initiation was given by Wheeler and colleagues as a way to increase prescribing 
rates in their 2008 retrospective chart review of patients with psychosis in New Zealand (66). 
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My study found that most practitioners who are directly involved in patient care considered 
themselves familiar with guidelines relating to the prescribing of clozapine, and felt that 
clozapine was an effective drug choice for patients with treatment-resistant schizophrenia.  It 
is surprising that this claimed familiarity is not reflected in actual prescribing patterns within 
this Trust (148).  Various explanations have been suggested (82, 127, 128, 211-213), but to 
my knowledge this is the first study to ask practitioners who are involved in prescribing 
decisions directly about their reasons for non-prescribing of clozapine.  Unfamiliarity with the 
guidelines had been suggested as an obvious reason for non-adherence (63, 211), but here 
I have found that the majority of practitioners report familiarity with the guidelines, indicating 
this does not appear to explain non-adherence among practitioners in my study. 
Historically, clozapine could only be initiated during a hospital admission.  This is no longer 
the case, and starting clozapine in the community setting has been shown to be safe and 
effective (212, 213).  In the past, concerns have been raised about the high resource burden 
this places on community teams (twice daily monitoring of vital signs is usually recommended 
for the first 7 – 14 days) (213).  My survey suggests practitioners perceive this to be an on-
going problem, with a majority indicating that dedicating community staff members, or 
creating day hospital beds specifically to support clozapine initiation would be a positive step.  
This would involve an up-front cost but, but balanced against the potential for clozapine to 
reduce relapse (85) might result in long term savings.  The idea of dedicating staff members 
in the community to clozapine initiation has been trialled locally.  A psychiatrist-led clinic 
assessed patients with treatment-resistant schizophrenia for clozapine initiation (or other 
interventions as appropriate), and demonstrated a five-fold increase in community-based 
clozapine initiation (214), although the cost-effectiveness of the service has not yet been 
evaluated. 
A common theme in my survey was that of patients themselves being the reason for non-
prescription of clozapine – either refusing to comply with the necessary blood tests, or else 
being unwilling to try a medication associated with so many side effects.  When patients 
taking clozapine are asked directly for their views on it however, the vast majority are positive, 
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despite the obvious inconveniences (97, 135, 150).  However, these surveys have been 
limited to the opinions of patients already taking clozapine.  Perhaps the results of these, 
coupled with the results of my survey, suggest that counselling of prospective clozapine 
patients by those already taking clozapine might be more focussed on patient needs than 
the current, professional-led model. 
Potential non-compliance with oral therapy was also a concern identified in my study.  Not 
taking medication in the way in which it was prescribed is certainly not exclusive to psychiatry.  
Concordance with prescribing regimens tends to be at its lowest when the condition being 
treated is chronic, the medication prescribed is prophylactic (or viewed as such by the 
patient), and the consequences of stopping the medicine are delayed (215).  Ensuring 
concordance for patients with psychosis does however have some specific challenges, 
perhaps most obviously a lack of insight into the illness which often accompanies psychotic 
symptoms, leading (naturally) to a refusal to take medication.  Insight can fluctuate 
throughout the illness course, and is not always associated with non-compliance; it is not 
unusual for patients who are adamant there is nothing wrong with them to nonetheless 
continue to take medication for their (to them, non-existent) illness.  Equally, a lack of what 
might be termed insight into the need for treatment is not exclusively the experience of 
patients with psychiatric illnesses – health beliefs around pharmaceutical medicines being 
harmful or unnatural, or that medicines should only be taken if you are sick (and not 
prophylactically) abound in those with physical health illnesses as well.  There are of course 
other consequences of psychotic illnesses that may make regular medication compliance 
difficult, not least the distractibility and disorganisation that often accompanies active 
psychotic symptoms.  Indeed, an increase in psychopathology has been shown to reduce 
medication compliance levels (215).  Patients with mental illnesses are also more likely to 
abuse substances, which in turn increases the likelihood of non-compliance (215).  A further 
factor which affects the chances of medication concordance is the acceptability of the 
medication itself; or conversely, the level of discomfort the patient experiences from the 
medication.  A treatment that is ineffective, leaving the patient with unpleasant symptoms, is 
unlikely to be something the patient will wish to take regularly.  The presence of side effects 
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is also more likely to lead to medicine refusal or non-compliance.  In their study of 84 patients, 
Van Putten et al. found 46% to be at least partially non-compliant, and the likelihood of non-
compliance was associated with the presence of EPSEs (216).  A further consideration is the 
trust that patients put in their prescribing psychiatrist – it is often the case that different 
psychiatrists recommend different treatments for similar cases, and this does not go 
unnoticed by patients.  An increasing level of mistrust in prescribing decisions is likely to lead 
to increasing levels of non-compliance (125). 
Measuring the extent of non-compliance is challenging.  In a study of 82 patients with 
glaucoma, doses of eye drops that were self-administered at home by patients were 
measured using an electronic device (217).  The patients themselves were asked how many 
doses they missed, and they consistently underestimated; the proportion of missed doses 
was actually up to three times higher than that reported by the patients themselves.  Even 
more strikingly, when their prescribing ophthalmologists were asked to estimate the degree 
of their patient’s non-compliance, the doctors were completely inaccurate, with their 
estimates being no better than random.  This inability of the prescriber to assess compliance 
is also the case in psychiatry.  McClellan and colleagues tested medication levels in the urine 
of 286 patients, finding that 8% were actually taking no medication at all, and almost a quarter 
were taking less than they were prescribed (218).  When the psychiatrists doing the 
prescribing were interviewed, their predictions of compliance in their patients were wrong in 
20% of cases, with 29% thinking their patient was taking the medication, when they weren’t, 
and perhaps even more surprisingly, 71% thinking their patient wasn’t taking the medication, 
when they were.  As well as using electronic devices and measuring drug levels in urine, 
compliance can also be assessed using pill counts and prescription refills.  The former does 
not guarantee where the pill went after it was removed from the packet, and of course the 
latter also does not prove that the patient isn’t simply stockpiling medication at home.  A 
review of published reports using all these strategies suggested that overall compliance with 
antipsychotics averages about 58%, with a range of 24 – 90% (219).  Patient interviews are 
generally a less accurate way of assessing compliance, and clinicians usually assess their 
patients as more likely to be taking the medication than they really are (the same study found 
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prescribers to think that on average patients are 72% compliant with antipsychotic 
medication). 
Focussing on clozapine, fear of non-compliance has been identified previously as a barrier 
to prescribing (82, 220), although compliance with clozapine is actually better compared with 
other antipsychotics (118, 221).  Recent data show that rehospitalisation rates for patients 
receiving depot medication are higher than those receiving clozapine (222), suggesting that 
the alternatives which guarantee compliance may still be worse for patient outcomes.  
Interestingly, in my study of pre-clozapine prescribing choices 57% of patients had been 
prescribed a depot medication.  Although it cannot be assumed that this is due to non-
compliance with oral medication in all cases, it might suggest that not taking tablets was not 
a significant concern for at least 43% of my cohort.  It may instead be the case that non-
compliance with blood tests is more of a concern than non-compliance with the medication 
itself.  Clozapine does have the advantage over some other antipsychotics of having a readily 
available plasma level assay, and of course the patient is already subject to regular blood 
tests during which, presumably, plasma concentrations could also be checked to assure 
compliance.  This doesn’t seem to provide any immunity from the inability of prescribers to 
tell whether their patients are taking the medication or not; in a large review of clozapine 
plasma concentrations sent to a London pathology laboratory, no clozapine was detected in 
1.5% of samples, despite these patients being prescribed doses up to 900mg (223). 
The introduction of strict blood count monitoring reduced the incidence of clozapine-induced 
agranulocytosis to 0.38% from 1 – 2% - a saving of an estimated 137 lives over a 5 year 
period in a review of the monitoring system in the USA (224).  The monitoring of full blood 
counts for patients receiving clozapine has therefore not only allowed this medication to be 
made available again to patients who otherwise had no other evidence-based treatment 
options, it has also probably prevented a considerable number of deaths worldwide.  Whilst 
this is undeniably positive, I have shown that the blood tests themselves may also prevent 
patients from accessing clozapine, either because the idea of regular testing is unacceptable, 
or more directly because the rigid parameters within which the levels of white cells must fall 
 319 
exclude otherwise treatment-adherent patients from therapy.  This may occur due to the 
presence of BEN, which the monitoring guidelines attempt to adjust for, or due to other 
factors.  Other medications may affect white cell counts, as may co-morbid medical 
conditions or external factors.  Patients returning plasma levels of white blood cells outside 
of the acceptable ranges for these reasons are not necessarily at any increased risk of 
clozapine-induced agranulocytosis, but due to the licensing restrictions may nonetheless be 
barred from clozapine treatment. 
Additionally, long term testing may be significantly off-putting for patients.  Monitoring of white 
cell counts is mandatory on a monthly basis after the first year of treatment (during which it 
is more frequent) for the entire time the patient is taking clozapine, despite the fact that the 
risk of clozapine-induced agranulocytosis is reduced by this point to being no higher than 
that with any other antipsychotic, or indeed death from other causes, such as road traffic 
accidents (225).  Consequently, there is a call from some practitioners to relax the blood 
monitoring rules since they are seen as an unnecessary, costly, and time-consuming activity.  
Evidence that doing so may increase clozapine acceptability is provided by countries that do 
not have such strict monitoring requirements; 71% of Icelandic patients (where the remote 
nature of parts of the country makes frequent blood testing sometimes impossible) taking 
clozapine remained compliant with therapy for 20 years, although overall use in the country 
remains below optimal levels (11% of all patients with schizophrenia) (226).  Prescribing rates 
in China, where blood testing is recommended but not mandatory, are much higher, although 
other factors may also influence the choice of clozapine as a first-line treatment (91).  
Extremely strict blood monitoring policies have been blamed in part for the very low levels of 
clozapine use in Japan (52), but prescribing rates in Columbia, where clozapine prescribing 
is not restricted to treatment-resistant cases and is not bound by blood monitoring rules, are 
comparable to countries where restrictions are in place (52).  Detailed economic analysis of 
strict monitoring protocols for clozapine has shown these also lack cost-effectiveness (227), 
with very small benefits in quality-adjusted survival (less than 1 day per patient) coming from 
not only high monetary costs, but also, as I have shown, costs to the likelihood of establishing 
patients on clozapine in the first place.  Also of importance is consideration of the risk of harm 
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to the patient of not starting clozapine – taking clozapine reduces mortality from suicide (228).  
It is worth noting a counter-argument here – that the increased patient-clinician contact that 
arises from the compulsory blood testing is actually beneficial in reducing psychotic relapse, 
as earlier detection and intervention may be possible (229).  
One way of improving the acceptability of blood sampling for clozapine may be to move from 
venous blood sampling to capillary sampling.  Point of care testing (POCT) devices allow 
capillary sampling of the Full Blood Count (FBC) in the clinic or in the patient’s home, 
returning a result whilst the patient is present, and allowing medication dispensing all within 
the same consultation.  The current system of venous sampling requires attendance at a 
blood testing appointment, which may be at a different location to the psychiatric clinic 
(commonly the local acute hospital), waiting for the blood test results to be made available 
to the dispensing pharmacist (usually a few days), then for the patient to attend the 
psychiatric clinic to pick up their clozapine.  Simplifying this process may make this easier to 
comply with.  POCT devices are used in other settings for rapid diagnosis of malaria and HIV 
(230), and although some concerns have been raised (poor finger prick technique, sampling 
site, and the nature of capillary blood itself have all be shown to reduce the reliability of 
results), it has been used successfully for clozapine monitoring.  Nielsen and colleagues 
describe a cross-over study comparing venous and capillary sampling for patients taking 
clozapine, with patients reporting POCT to be less painful and more convenient, and 63% of 
patients and 87% of clinicians finding it preferable to traditional venous testing (231). 
The difference in opinions between professional groups is an important finding of this survey 
of practitioner attitudes to clozapine initiation.  In my experience, prescribing is often a 
multidisciplinary decision.  My study suggests that pharmacists tend to be both more 
confident in the practice of prescribing clozapine, and also in its potential benefits.  As a 
result, the presence of pharmacists at the point of prescribing decisions may presumably 
increase the likelihood of clozapine being prescribed, and so a greater number and 
availability of pharmacists in organisations could improve clozapine prescribing patterns.  
There is increasing recognition of the importance of access to specialist pharmacists (10, 
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123).  Educational and practical support from colleagues more experienced in the use of 
clozapine has been shown in New York state to increase clozapine prescribing rates (232), 
suggesting a positive influence of readily accessible advice from more confident co-workers. 
It has been shown repeatedly that simply publishing guidelines intended to improve patient 
care does not, in fact, do so (131, 133, 233).  Local education, audit and feedback are 
effective (75, 126) but the long term impact of these has not been evaluated.  It seems that, 
at least locally, a lack of knowledge of the guidelines is not the barrier to prescribing, and so 
further education is presumably not the solution.  My survey suggests that further investment 
is needed in services designed to initiate clozapine treatment in the community.  Allowing 
organisational factors to delay or prevent initiation of the most effective medication for 
treatment resistant schizophrenia is clinically unacceptable.  It is also potentially 
economically wasteful (90).  Practitioners in my study showed concern over patient refusal 
of treatment, primarily due to tolerability or blood tests.  Patient surveys suggest that these 
concerns may be inflated (97, 135, 150), and practitioners should be mindful of avoiding 
allowing their own perceptions of future treatment acceptability to influence prescribing.   
Overall, this survey shows that practitioners know when and how to prescribe clozapine.  
Their barriers to prescribing are patient focussed – concerns about tolerability, co-morbid 
medical problems, compliance, or refusal to comply with blood test monitoring.  The presence 
of staff members motivated to help patients make informed decisions about drug therapy, 
appears to be a key factor in increasing access to clozapine.  Healthcare professionals know 
that clozapine is an effective medication, and they also know that a significant proportion of 
the patients under their care should be receiving it, where they are not.  What halts the 
movement of pen to prescription pad are patient-led issues – potential, perceived, or real.  
No other study has attempted to examine these issues by asking the opinions of patients 
themselves – specifically patients who are eligible to take clozapine, but are not doing so. 
I conducted a survey that aimed to evaluate and categorise the opinions of potential 
clozapine patients about clozapine initiation, its side effects and potential effectiveness.  The 
patients included were specifically selected as those who were not taking, and had not ever, 
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taken clozapine previously, and who were also acutely unwell.  This group of patients were 
considered to reflect most accurately those that clinicians might expect to treat in daily 
practice and for whom clozapine should be considered the treatment of choice. 
Three methods for questionnaire administration were considered.  Firstly, self-administration 
was deliberated.  This has the advantages of being quick and cheap in terms of research-
investigator time and input, and so may be able to attempt to reach a larger sample.  It would 
also avoid interviewer bias and be convenient for responders, allowing patients to complete 
the questionnaire at a time of their choosing.  However, this method is associated with a high 
chance of non-response or incomplete responses.  Importantly, the nature of the population 
being studied (actively psychotic patients) would limit the types of questions and number of 
questions that could be included in a survey where no explanation of questions would be 
possible.  It would also be likely to result in a biased return of responses, because presumably 
patients who are more unwell, less able to concentrate, have a poor understanding of written 
English or a learning disability are less likely to attempt or complete the survey.  It would also 
be impossible to quantify the reasons behind non-response in this method.  No prompting or 
probing with follow up questions would be possible, and it could not be guaranteed that the 
intended recipient actually provided the responses.  In terms of question design, only 
questions highly salient to the patient would be possible otherwise the risk of non-response 
would be increased, and for the same reason the opportunity for use of open questions would 
be limited.  Additionally no control over the order in which the questions would be answered 
would be possible. 
Interviewer-administered questionnaires avoid many of these pitfalls, ensuring robust 
answers and also allowing for a higher number and more complex questions to be asked.  A 
higher return rate is likely, and the reasons for non-response or exclusion from the study can 
be recorded.  In this way a better quantification of potential bias (exclusion of those with poor 
or no English, concentration problems, comprehension problems and so on) would be 
possible.  However, this type of data collection is not anonymous, even though analysis 
would be, and this may be off-putting to some participants.  It is open to interviewer bias and 
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is time consuming.  The most robust method for this type of survey is to use a structure laying 
technique, following up patients in the weeks after the initial interview in order to allow 
communicative validation of the content of the statements gathered, but this was felt to be 
impossible to complete given the nature of the clinical journey of patients through the hospital 
and into the community.  Additionally the focus of the study was to investigate patient 
opinions at the time of medication change, i.e. when a new medication (clozapine) is likely to 
be considered, which is assumed to be early in admission.  Patient opinions may change as 
the acute mental health crisis that necessitated admission resolves. 
Finally, data gathering from clinical notes was considered.  This has the clear advantage of 
being able to capture the complete sample, with no patients lost due to being transferred to 
different wards, or otherwise engaged in other activities making them impossible to interview.  
This is also likely to represent the least sample-biased option, as it avoids patients being 
unable or unwilling to fill in a questionnaire.  However, I have found previously that 
documentation of medication decision-making in clinical notes is usually poor, and the results 
from this type of study would rely on good note-making around offering clozapine and the 
reasons for refusal.  The results would also therefore be open to bias as any reason for 
refusal is documented by the doctor who offered the drug.  Additionally any decision by the 
prescriber to not offer clozapine based on assumptions of patient-related barriers to 
clozapine treatment provides data related to the prescriber decision rather than that of the 
patient.  In terms of patient opinions, it therefore would not capture data relating to patients 
who are eligible for but are not offered clozapine. 
After review of options, interviewer-administered questionnaires were felt to be the most 
appropriate method.  Question design was carefully considered.  As much as possible, 
yes/no questions were used as these have a greater reliability than frequency scales in 
people with mental health difficulties (151).  Finlay et al. (151) also suggest that cognitive 
impairment predisposes to response bias and social desirability, with participants responding 
to the topic rather than the particular question, or ‘yea saying’ which introduces systemic 
acquiescence bias.  The latter can be improved by avoiding yes/no questions and instead 
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introducing either/or options, but Finlay warns this may increase the risk of last choice 
responding.  Ideally, the validity of responses should be demonstrated using nonsense 
questions or pairs of reverse worded questions in order to measure acquiescence, but this 
may lead to confusion in my patient cohort, and also create long questionnaires which are 
unlikely to be completed by patients for whom a lack of concentration is part of their psychotic 
illness.  The questionnaire used, along with the Likert scales used as visual aids for 
interviewees, is included in Appendix E. 
A significant proportion of patients interviewed in this survey (46%) reported that they had 
never heard of clozapine, and 70% said they had never been asked to take it.  I did not 
interrogate the clinical notes to establish whether this was the case, and arguably patients 
cannot be expected to recall all medicines that have been discussed with them in the past, 
but the lack of awareness by patients of the drug is striking and may be relevant to the low 
prescription rates of clozapine in this Trust (148).  Conversely, this lack of familiarity may be 
seen as encouraging, as patients do not necessarily enter into a conversation about 
clozapine with preconceived ideas about its benefits or disadvantages.  Further to this, 46% 
of patients stated that they would either take clozapine were it to be offered to them, or that 
they were unsure.  A minority (35%) rejected the idea outright. 
I found in my survey of health care professionals that clinicians consider patients’ refusal to 
undergo blood tests to be the main barrier to prescribing of clozapine (149).  In this study of 
patient opinions, a high degree of concern was expressed by some patients about this, with 
36% of participants stating that blood tests would put them off trying clozapine.  However, 
this proportion does not represent the majority – the remainder felt that the blood tests 
presented no worry at all (31%) or that they would be worried only to some extent, but still 
willing to try clozapine (30%).  Thus for 61% of patients eligible for clozapine, blood testing 
was not a barrier to its use. 
Also in my previous study, clinicians felt that the next most worrying aspect of clozapine 
therapy for patients was overall tolerability.  I found 43% of patients to be unwilling to try 
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clozapine because of adverse effects, although again the majority were either not worried at 
all, or worried but still open to considering treatment (53%). 
When considering hospital admission as a barrier to patients willingly accepting clozapine 
treatment, 49% of patients stated that this would mean they would not want to try the 
medication.  Of the remaining patients, almost a third (29%) did not feel this was a concern 
at all, and this was further reflected in a similar percentage actively wishing to be in hospital 
rather than at home to start clozapine (26%).  Therefore the main barrier to using clozapine 
in this cohort of patients is not blood testing but the apparent necessity to be admitted to start 
clozapine.  
Finally, patients did not appear to consider clozapine to be as effective as the available data 
suggest it is, with 38% thinking it would be less helpful than other medicines they have taken 
previously, or were taking at the time of the study, just 24% thinking it would be better, and 
12% considering it to be about the same.  It is possible that patients were taking into account 
the burden of side effects, hospital admission and blood monitoring when answering this 
question – and this perhaps makes it all the more relevant.  Nonetheless, educating patients 
about the potential benefits of clozapine is likely to prove beneficial in the attempt to get more 
people on to clozapine. 
To my knowledge, this is the first study to evaluate opinions about clozapine of patients who 
are not taking the drug, but who, in accordance with local and national guidelines (234, 235), 
should be doing so.  Further, this is the only study to ask patients about clozapine at a time 
of acute psychiatric relapse, the point at which treatment changes are most likely to be 
considered in ‘real life’.  Other authors have described the attitudes of patients who have 
already been established on clozapine, and these are overwhelmingly positive.  Patients 
were repeatedly found not to mind the blood monitoring (94, 150), to prefer clozapine to their 
previous medications (94, 96, 236), and to find it generally helpful for them when compared 
to other medicines – even when they were considered to lack insight into their condition (93).  
These studies cannot be said to represent the views of patients who are not taking clozapine, 
and therefore cannot help to address the issue of chronic under prescribing of the medication. 
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My results do not show that patients are universally against the idea of clozapine, but that 
concerns about hospital admission (49% of patients wouldn’t try clozapine because of this), 
adverse effects (43%) and, to a lesser extent, blood monitoring (41%) are important.  These 
concerns do not apply to every patient however, and patients vary in the degree to which 
they express concern about these facets of treatment.  A reluctance to be admitted to hospital 
in order to start a medication is understandable.  Of course, medication changes are often 
prompted by psychiatric relapse, and so hospital admission may be necessary for reasons 
beyond purely medication initiation, and this aspect is not reflected in my survey.  
Nonetheless, avoiding hospital admission where possible is desirable not only for patients 
(although it should be noted that a significant proportion of patients in this survey expressed 
a wish to be in the perceived safety of the hospital environment when starting new 
medication), but also for NHS Trusts under pressure from a lack of available inpatient beds.  
As discussed previously, resources specifically targeted at enabling community-based 
clozapine titration may be helpful (214), a process that has been shown to be both safe and 
effective (237). 
The adverse effects of clozapine are concerning to both clinicians and patients, as 
demonstrated by both surveys.  Whilst some side effects are rare (agranulocytosis, 
myocarditis), others are common and at least modifiable, if not treatable (constipation, 
sialorrhoea, drowsiness).  Ensuring that prescribers are confident in managing side effects 
is clearly essential, but it is also important that all staff members involved in patient care are 
also well-informed.  Distressing symptoms may not be recognised as side effects by patients, 
but care co-ordinators, nurses, occupational therapists, social workers and others may have 
more regular contact with patients than their psychiatrists do, and these allied healthcare 
professionals could play a key role in identifying mediation-related problems before they 
result in patients abandoning treatments.  My survey of practitioners found staff members 
other than doctors and pharmacists are less familiar with clozapine prescribing guidelines, 
less assured of the effectiveness of clozapine compared with other antipsychotics, and less 
likely to think that patients under their care required it.  Training should therefore target all 
health professionals, not just prescribers.      
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It is clear that there is also a need to increase patient awareness of the benefits of clozapine.  
I found that almost half of patients who would be considered eligible for clozapine treatment 
had never heard of it (46%), let alone knew anything about it.  Clinicians should therefore be 
mindful not to assume that patients have prior knowledge of clozapine (either in terms of 
benefits or drawbacks).  Rettenbacher et al. (238) found that patients with schizophrenia 
usually estimated other chronic diseases to be considerably worse than theirs, and so the 
authors suggested that patients might not take their illness seriously enough to consider 
taking medication to treat it.  Regular discussions between healthcare professionals and 
patients about schizophrenia and its treatment course may improve this attitude, potentially 
increasing familiarity with clozapine and decreasing what might be considered a detrimental 
‘fear of the unknown’.  It may also be beneficial to move away from the practice of introducing 
the idea of an entirely new medication with unique monitoring requirements and side effects 
at the point of acute psychotic relapse.  Instead, the treatment pathway for schizophrenia 
should be made transparent and clear to patients from the outset of illness.  This may make 
initiating clozapine at a time of severe illness somewhat easier. 
Increasing familiarity with clozapine may also help reduce the understandable fear of side 
effects shown in my survey of patients.  Knowing what to expect may improve tolerability, or 
at least reassure patients that some things are likely to improve with time (drowsiness, 
dizziness), which might reduce the risk of treatment refusal during the initial stages (when 
side effects are also likely to be most burdensome).  Clozapine support groups could be 
useful, allowing open discussions with knowledgeable staff members about individual 
benefits and problems (239).  Patient-to-patient support may be of particular value.  This idea 
is largely unexplored in this context, but more commonly employed in physical health 
conditions.  A frequent (and reasonable) complaint expressed by patients during medication 
counselling is the lack of ‘lived’ experience of the staff member – they have never taken the 
drug in question, or experienced the side effects – and this was also commented on by 
patients in my survey.  Patient advocates for clozapine might be perceived as more 
trustworthy in this regard.  Patients with psychotic disorders may be particularly isolated 
compared to others in terms of access to support groups, as they are less likely to use the 
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internet or social media.  One study showed 56% of patients with schizophrenia use text 
messaging, 48% have an email address, and just 27% access social media (mostly 
Facebook) daily (240).  In contrast, a survey of patients with asthma found 82% use text 
messaging, 77% use email, and 65% use Facebook at least weekly (241).  Efforts to engage 
patients early in their treatment pathways, and specifically with respect to clozapine, may 
help to reduce outright refusal of clozapine initiation, and later discontinuation.  Peer support 
groups should be considered for improvement in medication acceptability, and are of benefit 
in multiple domains – one Dutch RCT of peer support groups for psychosis demonstrated 
improvements in social support, self-esteem and quality of life (242).   
I have shown so far that a delay to clozapine initiation at this Trust in South East London 
remains, and have examined the opinions of both clinicians and patients to investigate the 
possible reasons for this.  Next, I considered the possible consequences of this treatment 
delay on clinical response, using inpatient admissions as the primary outcome.  I 
hypothesised that a longer delay to commencing clozapine may be associated with a less 
favourable clinical outcome, based on observations in first episode psychosis where longer 
durations of untreated psychosis are associated with poorer eventual response to treatment 
(167).  I also investigated the effect of continuing or stopping clozapine treatment on long 
term outcomes.  
This study may be considered a ‘mirror image’ study, with one side of the ‘mirror’ (pre-
clozapine) being compared with the other side (post-clozapine).  Several methodological 
issues in relation to this warrant discussion; the length of time included in the study on each 
side of the ‘mirror’, and the point at which the mirror is placed with respect to the inpatient 
admission during which clozapine was started.  Mirror image methods allow for comparisons 
within patients, which avoids the selection bias that is inherent to the non-randomised nature 
of observational data.  There are, however, drawbacks to this sort of analysis.  Symptoms 
(and therefore requirement for inpatient admission) may naturally subside over time, and the 
lack of a control group (patients are effectively used as their own ‘control’) means that this 
effect may be overlooked.  Also due to the non-random sample selection, regression to the 
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mean is also possible.  Finally, asymmetrical treatment durations on each side of the mirror 
point may also contribute to data bias – generally, the ‘post-mirror’ period needs to be as 
long as possible in order to capture a maximum amount of data where it is not known how 
long the effect of an intervention might last.  This is especially true of a disorder such as 
schizophrenia, where the chronic, relapsing and remitting nature of the illness means that 
the longer the time period studied, the more translatable the data becomes to a wider 
population. 
There are several options for the length of time included on each side of the mirror point.  
The first is a straight comparison mirror image, where the length of time included on each 
side of the mirror point is the total length of the patient journey, from the date of first contact 
with psychiatric services to the study end point.  This is likely to mean that the pre-clozapine 
period included in the study is a different length to the post-clozapine period and so no within-
patient direct comparisons can be made of the data.  This method has the advantage of 
including all available data for each patient, and avoiding any loss of data at the extreme 
ends of patient journeys.  A fixed period mirror image can be used, where the length of time 
studied is fixed for all participants on either side of the mirror point, e.g. 5 years either side 
of the mirror point are included.  This means that there is no asymmetry in the data as seen 
with the first method, and it also allows a direct comparison of data between patients as well 
as within patients, rather than further manipulating the data to provide admission days per 
time period.  However, In order for all patients to be included and be studied for the same 
time period, this time period has to be set at the shortest pre- or post-clozapine time period 
within the data set.  For this data set, this is just 45 days, and so this method would result in 
a total study period length of only 90 days, and a large amount of lost data.  An individualised 
mirror image method keeps the time periods on either side of the mirror point equal for each 
patient, but allows them to be different between patients.  The length of the mirrored time 
period for each patient is the time from first contact with psychiatric services to the clozapine 
start date (mirror point), or from the mirror point to the end of the study, whichever is longer.  
The advantage of this technique is the symmetrical studies within each patient, allowing 
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direct comparison within patients, but maintaining the maximum length of the study period.  
Nonetheless, some data may be lost at the extreme ends of patient journeys. 
The length of the ‘mirror’ period chosen by other authors varies considerably, but is generally 
in the range of 1 – 3 years pre- and post-medication initiation.  Some authors acknowledge 
that longer periods of follow up are preferable in order to observe differences in outcomes 
(84), and longer treatment episodes are likely to reduce regression to the mean, since if the 
new treatment (clozapine) is started as an inpatient (a time of admission ‘cost’), this ‘cost’ will 
subside over time (243).  This regression to the mean is further neutralised if individualised 
treatment episodes are considered, i.e. using an individual study period length for each 
patient (243).  The use of a control group can further reduce the risk of regression to the 
mean, and some studies do use this method (89, 181).  However, this introduces a risk of 
selection bias, which is avoided by including the entire population over a period of time who 
were ‘selected’ to start clozapine.  Many mirror image studies employ asymmetrical study 
periods.  Commonly, a longer post-mirror (89, 172, 178, 181) period is used, but longer pre-
mirror (179, 244) periods are also employed.  Asymmetry in the time period studied is a 
problem if the new treatment takes some time to take effect – shortening the post-mirror 
period may result in benefits to the new treatment being missed.  This may be the case for 
clozapine, where up to a year is required for response to be demonstrated (245). 
I chose to use an individualised mirror image approach, as this reduces regression to the 
mean by customising each study period to each patient.  I used individualised symmetrical 
mirror image periods.  Using a fixed post-study period would mean either using the shortest 
post-clozapine time period within the data set (1712 days) or removing patients from the 
analysis who did not have a sufficiently long period of follow up data available.  The average 
post-clozapine time period available for study was 2497 days (range = 1712 – 3551 days), 
and so restricting the data to the shortest time period would mean a loss of an average of 
785 days of data (range = 0 – 1839 days).  Additionally, the pre-clozapine study period would 
also need to be curtailed for the whole data set to the shortest time period available (45 days), 
resulting in a loss of an average of 2288 days of data (range = 0 – 8879 days).   For this 
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study, each individualised mirror image period was chosen by observing the pre-clozapine 
time period (time from diagnosis to clozapine initiation) and the post-clozapine time period 
(time from clozapine initiation to end of study).  Whichever time period was shorter was taken 
as the mirror image period for data collection on each side of the clozapine initiation date for 
that patient.  For example, if a patient had a time from diagnosis to clozapine initiation of 200 
days, and a time from clozapine initiation to the end of the study of 175 days, the total mirror 
image time period would be 350 days (175 x 2), with a pre- and post-clozapine study time of 
175 days, disregarding the first 25 days of the pre-clozapine period. 
Further to the length of the mirror image period, the way in which the index admission is 
treated (for patients who started clozapine as an inpatient, this is the admission during which 
clozapine was initiated) should also be considered.  In order to avoid ‘double counting’ of this 
admission, it is necessary to consider how this admission should be designated – whether in 
the ‘pre-clozapine’ period or the ‘post-clozapine’ period.  Several options were considered.  
The entire admission could be counted in the pre-clozapine period, as the original reason for 
admission is assumed to be a psychiatric relapse, which is assumed to be attributable to the 
failure of the previous antipsychotic medication.  However, should clozapine be insufficiently 
effective and so the patient be subject to inpatient admission for an extended period of time 
after it is started, these inpatient admission days, arguably due to the failure of clozapine, 
would be attributed to the previous antipsychotic medication which the patient was no longer 
taking.  Alternatively, the number of days during the index admission before clozapine was 
started could be attributed to the pre-clozapine period, and the number of days after 
clozapine was started could be attributed to the post-clozapine period.  This has the 
advantage of taking into account the fact that clozapine may not be considered for initiation 
immediately during the admission, and indeed other antipsychotics may be trialled first.  If 
this occurs then this time period should not be attributed to clozapine.  However, allocating 
all admission days after the date of clozapine commencement to clozapine also has some 
problems.  Clozapine usually takes 2 weeks to titrate to an ‘average’ dose, and indeed often 
longer than this to establish the patient on a stable, effective dose.  During this dose titration 
period, clozapine may not be at a therapeutic plasma concentration, and so this time period 
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may be considered unfairly attributed to the drug.  Additionally, extra physical health 
monitoring is required during this titration period, meaning that patients are unlikely to be 
discharged during this time, and so even if clozapine is effective during this period, the patient 
will remain in hospital and appear (for the purposes of this study), ‘unwell’.  A further 
complication is that the date taken as the ‘start date’ of clozapine in this study was the date 
at which the patient was registered with the relevant clozapine monitoring company.  Patients 
can start taking clozapine at any point up to 10 days after this date.  Excluding the first 14 
days of the post-clozapine period from the analysis would remove some of the confounding 
from the clozapine titration period, although as described above few patients reach stability 
exactly 2 weeks after starting the drug.  A further strategy would be to include the first 14 
days of clozapine treatment in the analysis, but to attribute them to the pre-clozapine, rather 
than the post-clozapine period.  Finally, excluding the index admission entirely from the 
analysis would remove all the problems with ‘carry over’ costs from the previous treatment, 
but may also exclude some vital information from the data. 
The index admission is treated in various ways by other authors conducting studies with 
similar methodology.  Many authors do not explicitly state how they designated the index 
admission, but categorise admissions after the index admission as ‘rehospitalisation post-
clozapine’, implying that the entire index admission was attributed to the pre-clozapine 
period.  Where days of admission rather than total numbers of admissions are considered, 
the simplest form of analysis is frequently employed, assigning all days pre-clozapine to the 
non-clozapine antipsychotics, and all days after the clozapine start date to clozapine.  
Aitchison et al. (244) looked at the cost-effectiveness of clozapine in a mirror image study, 
examining admission data for the 3 years preceding clozapine and comparing it to the year 
following.  They included the index admission in their analysis, and indeed found that 
excluding it resulted in very low rates of readmission for patients taking clozapine.  The 
majority of other studies choose to exclude the index admission entirely.  Meltzer et al. (84) 
compared admission data for the 2 years before and after starting clozapine, and argued that 
the index admission should be excluded from this analysis for several reasons.  Firstly, the 
study was not a ‘real-life’ project but rather patients were enrolled in the trial and then 
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underwent a drug-free period in the run up to starting clozapine.  Other studies that have 
introduced an artificial admission period for the purpose of the study, or have artificially 
prolonged the admission period for the purposes of the study, have chosen to include the 
index admission but shorten it for the purposes of analysis to account for this – Revicki et al. 
(89) shortened their index admission length to 14 days for this reason.  Similarly, Reid et al. 
(181) excluded 90 days of the post-clozapine admission period from analysis to account for 
titration of the drug.  
Meltzer also argues, in common with many other authors, that a relapse in mental state prior 
to clozapine initiation should be attributed to the failure of the non-clozapine antipsychotic.  
He extends this argument to include patients who relapsed and were non-compliant with their 
previous medication, again arguing that the non-compliance is a failure of the non-clozapine 
antipsychotic.  The fact that clozapine can be initiated as an outpatient is also cited as a 
reason to exclude the index admission from analysis, since this then means that clozapine 
cannot be responsible for the initial reason for admission.  Even though in clinical practice it 
is sometimes the case that initiation of clozapine is the sole reason for admission, often owing 
to resource restrictions for starting it as an outpatient, arguably this cost of admission should 
nonetheless not be attributed to the drug itself.  This was not the opinion held by Drew et al. 
(178), who attributed the entire index admission to clozapine if it was clear that this admission 
was prompted expressly for the purpose of initiating the drug.  Further, Meltzer points out 
that the longer the duration of follow up a study employs (in the case of his 1993 study, 2 
years), the less relevant the index admission period becomes in the final analysis as cost 
savings will still be made regardless of its inclusion in calculations.  This assertion is backed 
up by Hayhurst et al. (90) who performed a similar clozapine cost-effectiveness study to 
Meltzer et al., again studying costs for two years before and after initiation, and finding that 
by including the index admission, although cost savings for clozapine were smaller, savings 
were still made. 
Faires et al. (177) looked at costs associated with antipsychotic treatment over the period of 
a year, and performed a detailed sensitivity analysis of 4 different methods for data analysis.  
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The methods were: a simple pre/post medication analysis; exclusion of the index admission; 
exclusion of the first 14 days of the post-medication period; and attribution of the first 14 days 
of the post-medication period to the pre-medication period.  Of these methods, the simplest 
analysis found no difference between the pre- and post-medication periods, perhaps 
reinforcing the assumption by Meltzer that longer follow up periods are necessary to observe 
differences.  Small differences were seen with the two more complex analyses, where the 
first 14 days of the new medication were either excluded entirely or attributed to the first 
medication, but the biggest differences were observed when the index admission was 
removed entirely from the analysis.  The authors concluded that the costs that are attributable 
to the first medication do have a directional impact on economic costs, but most of these are 
acute care costs associated with the index admission. 
In their mirror image study of the depot medication paliperidone, Taylor et al. (179) also 
carried out sensitivity analysis, finding (in common with other authors (246)) that excluding 
the index admission from analysis revealed larger differences in admission data between the 
pre- and post-medication periods.  They also analysed cases by defining the pre-medication 
period as admissions before the medication was started, but including the days of the index 
admission up to the point at which the medicine was commenced, and the post-medication 
period as all admissions after the discharge date of the index admission, rejecting the post-
mirror point days of the index admission from analysis.  They argued that this method is the 
most clinically relevant.  I chose 5 different methods of data analysis concerning the treatment 
of the index admission for this study, outlined in detail in chapter 5. 
Finally, using an intent to treat method, where all admissions post-clozapine initiation are 
attributed to clozapine regardless of whether the patient continued to take the treatment or 
not, is the method most commonly employed by other authors (30, 84, 89, 90, 170, 172, 175, 
176, 180, 181, 244).  This method assumes that discontinuing the treatment is a sign of 
treatment failure, and therefore any subsequent admissions are the result of this failure, and 
the treatment itself.  However, the most common reason for clozapine discontinuation has 
been shown to be non-compliance with either blood tests or the medication itself (117), both 
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led by patients rather than clinicians, and it could be argued that this is not a failure per se of 
the medication.  Others are of the opinion that non-compliance with a medication constitutes 
failure (84), since the decision by the patient to stop medication is often driven by a lack of 
insight (which could be considered a failure of the drug to fully treat the illness) or a lack of 
tolerability.  I analysed the data using an intent to treat method, and then separately for those 
that continued clozapine for the length of the study, and those that discontinued treatment. 
Analysis of the intent to treat population found a reduction in the mean number of days of 
admission per year and in the mean number of admissions per year once clozapine had been 
started.  The reduction in the number of days of admission was statistically significant only 
where either the entire index admission was discounted, the 2 week period after clozapine 
initiation was discounted, or the remainder of the index admission after clozapine was started 
was discounted.  The biggest reduction was seen when the latter analysis method was 
employed.  The same pattern of reduction in both mean days of admission per year and 
mean total admissions per year was also seen for those who continued to take clozapine for 
the entire length of the study, although here the differences were larger and all analysis 
methods returned statistically significant results.  No significant difference was seen in days 
of admission per year for those that discontinued clozapine, although a reduction in the total 
number of admissions per year remained.  This sensitivity analysis suggests that the portion 
of the index admission after clozapine has commenced is highly relevant when considering 
the overall apparent effectiveness of the drug.  The effect of excluding it either entirely or in 
part is marked, suggesting that it is proportionally lengthy in comparison to any admissions 
that occur later, after clozapine has been started and after the initial index admission.  The 
finding that those who discontinue clozapine still have a reduction in the total number of 
admissions per year after the index admission, but no reduction in the mean number of days 
of admission per year (although not statistically significant, for some methods of data analysis 
patients who discontinued clozapine had a trend for more days of admission per year after 
the clozapine had been started) suggests that on average, these patients have longer 
inpatient admissions than their counterparts who continued to take the clozapine.  
Presumably this is because admissions are necessary for those that continue clozapine 
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largely due to temporary treatment breaks, which are quickly remedied with rapid positive 
results, but for those that discontinue clozapine symptoms remain poorly treated by non-
clozapine antipsychotics, necessitating longer inpatient stays.  Further research in this topic 
is required, with detailed examination of the reasons for admission for both patient groups, 
and for those that discontinued clozapine, in relation to the time at which they stopped the 
medication. 
Overall, I found (in common with previous authors) that clozapine reduced the number of bed 
days per year (a reduction of 16 – 47 bed days per year for the intent to treat population, 
depending on the data analysis method) and also the number of inpatient admissions per 
year (0.7 fewer admissions per patient, per year).  These reductions were largely due to the 
results for those who continued to take the clozapine, with no significant reduction in bed 
days for those that discontinued during the study.  Patients who continued to take clozapine 
experienced a larger reduction in the mean number of admissions per year (0.8 – 1.5 per 
patient, per year) compared to those who discontinued the clozapine (0.25 – 0.7 per patient, 
per year).  This finding has significant implications for the economic benefits of clozapine, as 
well as the obvious benefits for patients in improvement in clinical symptoms.  A similar 
reduction in hospitalisation rates was shown by Ucok and colleagues (100), who 
demonstrated a drop from 0.87 admissions in the year preceding clozapine initiation to 0.11 
in the year following clozapine starting (0.76 fewer admissions per year).  In their follow up 
study, Hayhurst et al. (90) found a comparable reduction in readmissions after clozapine 
initiation of two thirds, and a drop in bed days of 33 over the two year study.  Similarly, Ahn 
et al. (247) demonstrated a reduction of 22.39 bed days per year in their study of patients in 
South Korea, and a reduction of 1.45 admissions per year.  Larger benefits were reported by 
Nielsen and colleagues (204) in their two year mirror image study of patients starting 
clozapine.  They found a reduction of 206 bed days in the two year post-clozapine period 
(103 days per patient per year), and a drop in admissions of 1.5 in the same time period (0.75 
admissions per patient per year).  Smaller benefits were shown by Latimer et al. (57) of a 
reduction of 3.4 bed days per year after clozapine initiation.  A recent meta-analysis of trials 
looking at the effect of clozapine on hospital admissions found a median reduction of 34 days 
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after clozapine initiation (229).  Some of the differences in results between studies may be 
explained by differing patient populations (specifically in terms of illness severity at the time 
of clozapine initiation, but also demographics), but choice of data analysis method may also 
have a significant effect, as discussed above. The studies of Ucok, Hayhurst and Nielsen all 
used mirror image designs similar to that reported in this thesis, with Hayhurst and Nielsen 
also excluding the index admission from outcome calculations.  These latter authors also 
accounted for patients who discontinued clozapine, in contrast to Ucok, Latimer and Ahn – 
these authors treated the entire patient cohort as an intent to treat group, with no separate 
analysis for clozapine continuers or discontinuers.  The study conducted by Latimer et al. is 
somewhat different from the others, gathering data on clozapine use from prescription fills 
only, and being based only on patients taking clozapine for at least six months.  The lack of 
inclusion of discontinuation of clozapine as a confounding factor may have contributed to 
their finding of a lower overall benefit of clozapine. Further differences between studies may 
be explained by variation in inpatient admission criteria between countries and time points.   
My study found the length of clozapine delay had no effect on the number of inpatient 
admissions, or days spent as an inpatient per year, once clozapine had been commenced.   
This has important implications for prescribers, who can be reassured that clozapine is 
expected to bring a clinical benefit to their patients irrespective of the length of time they may 
have spent during their illness taking other antipsychotics.  Clozapine should not be withheld 
from patients even if they have been in contact with mental health services for extended 
periods of time.  Other studies using the same methodology for clinical outcome as that 
presented in this thesis have also found no statistically significant association between the 
delay to clozapine use and the number of inpatient admissions after clozapine was started.  
However, in Harrison et al.’s retrospective review of 402 patients receiving clozapine in New 
Zealand (99), a shorter delay to clozapine use was associated with fewer previous inpatient 
hospitalisations, but this correlation failed to reach statistical significance.  Of note, only 
patients who had been taking clozapine for 3 years or more were included in this aspect of 
their analysis, and the low patient numbers may have underpowered the study.  I did not 
undertake a power calculation for my group, and it is possible that larger patient numbers 
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would have revealed an association.  In contrast, a recent analysis by Ucok et al. (100) used 
clinician, patient and carer’s opinions to assign patients to those with ‘good’ response and 
‘minimal or no’ response to clozapine.  Using these criteria, they found that a ‘good’ response 
was associated with a shorter delay to clozapine initiation, when compared to with those in 
the ‘minimal or no’ response group.  This result may reflect some degree of selection bias, 
as they also found that ‘good’ responders were more likely to have had fewer admissions 
prior to clozapine commencement, suggesting perhaps that these patients suffered a less 
severe illness course than their counterparts in the ‘minimal or no’ response group.  In Japan, 
Yoshimura and colleagues reviewed 90 patients with treatment-resistant schizophrenia, all 
of whom had been taking clozapine for at least 3 months (101).  They showed delay to 
clozapine initiation was a predictor of response to treatment, measured by clinical rating 
scales.  In their study, a ‘critical treatment window’ of 2.8 years, from time of treatment-
resistant diagnosis to clozapine prescription, conferred an 82% response rate if the delay 
length fell below this cut off, and a 31% response rate and increased likelihood of receiving 
ECT (electro-convulsive therapy) if above it.  Comparing results across these studies is 
clearly hampered by differing patient populations and data collection and analysis methods. 
My study showed an attenuation of the benefits to days spent as an inpatient as the age at 
which clozapine was introduced increased.  This is not simply an effect of older patients 
having less follow up time in the study, as each patient acted as their own control in my 
individualised mirror image study.  It is also not confounded by the length of delay to 
clozapine initiation (older patients may have been ill at a time before clozapine was available 
in the UK) – this factor was found to have no effect on outcomes.  This result was found on 
some statistical measures and not others, so further research is required to establish the 
strength of this association.  Other authors have demonstrated a younger age at onset of 
schizophrenia and longer durations of illness is associated with poorer response to clozapine 
(248).  The implication of this finding is that those patients who present with symptoms at a 
younger age have a more severe illness, and that longer treatment durations are related to 
a progressive and worsening illness course that becomes less responsive to treatment over 
time.  I did not control for age of onset of schizophrenia.  It is possible that the patients in the 
 339 
older age categories also developed schizophrenia at a younger age than those in the 
younger age cohorts, although this would imply that they had also had longer illness 
durations and most likely longer clozapine delays, which I did not find to be associated with 
the outcome variable.  A higher illness severity, or increased treatment-resistance at older 
ages is a plausible explanation, aligning with observations of worsening outcomes with longer 
durations of untreated psychosis in first-episode schizophrenia (167).  Ucok et al. (100) also 
found that younger patients were more likely to have a ‘good’ response to clozapine.  It is 
possible that older patients are more likely to have experienced more relapses during their 
illness course, and more relapses have previously been shown to have an adverse effect on 
long term outcome (249).  Conversely, younger age has also been associated with an 
increased likelihood of relapse (249) (although other authors have also found no association 
between response to treatment and age (250)).  Whatever the underlying reasons, although 
my study shows that benefits are found from commencing clozapine at any stage in the 
treatment course, regardless of age, it also shows an increased benefit from earlier initiation.  
My finding of increased long term outcome benefits with initiation of clozapine at a younger 
age, and the findings of others that shorter delays to clozapine use may result in better 
treatment-response, prompts questioning of whether clozapine should be initiated even 
earlier in treatment pathways than currently recommended.  The most obvious barrier to use 
of clozapine as a first line treatment for schizophrenia is the burden of side effects (some, 
but not all unique to clozapine compared to other antipsychotics) and regular blood tests 
(unique to clozapine).  This might be expected to affect patient acceptability and long term 
concordance with treatment; indeed, in Woerner et al.’s 2003 trial treating 34 patients with 
clozapine as a first-line antipsychotic, only 32% remained on clozapine by the end of the 
year-long study (251), despite response rates of 66%.  This response rate demonstrates that 
clozapine is not only effective in treatment-resistant schizophrenia, but also in non-treatment-
resistant illness.  This potential was realised by Meltzer and colleagues in a 2 year 
randomised trial comparing clozapine to typical antipsychotics in non-treatment-resistant 
schizophrenia (252) – here, clozapine not only provided effective symptom relief, but also 
reduced relapse and rehospitalisation rates in comparison to the other treatments.  A larger, 
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year-long study conducted by Lieberman et al. (253) also found clozapine superior to a 
typical antipsychotic (chlorpromazine) in speed of treatment response and time spent in 
remission for treatment-naïve patients (although there was no difference in overall response, 
in terms of symptomatology, side effects and overall remission rates).  
Although clozapine is effective in both treatment-resistant and non-treatment-resistant 
schizophrenia, prescribing in treatment-naïve patients remains an unusual practice, and 
understandably so.  Assuming that approximately 30% of patients will either already have, 
or go on to develop a treatment-resistant illness, this would leave around two thirds of first-
episode patients being given clozapine where another antipsychotic would also be effective 
– arguably subjecting them to unnecessary blood tests and avoidable side effects.  Trialling 
a non-clozapine antipsychotic in the first instance therefore seems reasonable, but if this fails 
research has shown disappointing efficacy for any antipsychotic other than clozapine.  Agid 
and colleagues applied a treatment algorithm to 123 patients with schizophrenia in Toronto 
(141), allowing treatment with an atypical antipsychotic initially, followed by a second atypical 
if this was ineffective, followed by clozapine.  Importantly, they dictated a shorter than usual 
4 week period to assess treatment response at each stage, so access to clozapine was 
theoretically possible within the first 8 weeks of presenting to psychiatric services.  They 
found, in common with established evidence, that three quarters of patients responded to the 
first antipsychotic prescribed.  The remaining 25% were given a second atypical medication, 
and of these just 23% responded (representing only 6% of the entire cohort).  The non-
responders were offered clozapine, and this had a beneficial effect for 77% of these patients 
on positive and negative symptoms, as well as overall clinical impressions.  Other studies 
have also demonstrated longer term outcome benefits – Tiihonen et al. describe an 
observational study of 2230 patients in Finland presenting to inpatient services for the first 
time (254) and showed that those who received clozapine during this first contact had lower 
treatment discontinuation rates and rehospitalisation risks compared to those given a variety 
of other medications, including depots.  Overall, patients receiving clozapine (or 
perphenazine depot or olanzapine) in the first 30 days of hospitalisation had the lowest risk 
of stopping treatment for any reason, compared to those started on other antipsychotics (or 
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no antipsychotic).   The lowest risk of rehospitalisation in this study was associated with 
starting perphenazine depot (59% reduction in relative risk compared to haloperidol), 
followed by olanzapine (41% reduction in relative risk) and clozapine (39% reduction in 
relative risk).  More recently, and with longer follow-up times of up to 20 years, Taipale and 
colleagues showed that clozapine (and depot antipsychotics) was associated with the lowest 
risk of rehospitalisation in both chronic and first-episode patients with schizophrenia (255).  
These studies support an argument for early use of clozapine in the treatment journey.   
My study, whilst of a smaller population than those published previously, benefits from wider 
inclusion criteria and longer follow up times.  I did not exclude patients who were in the first 
few months of treatment, who were acutely unwell, were current inpatients, had received 
clozapine for less than a defined period of time, or were taking less than a defined number 
of milligrams of clozapine per day, as other studies have done (99, 100, 204).  I have shown 
that taking clozapine results in a reduction in the number of days spent as an inpatient per 
year.  Patients experience this reduction in bed days regardless of the chronicity of their 
illness.  Clinicians can be confident that prescribing clozapine will confer a positive outcome 
to their patients regardless of when in the illness course it is started, and they should continue 
to make every effort to help their patients comply with treatment to maintain this benefit.  
Further, although I have shown no effect of delay to clozapine initiation on long term 
outcomes, I have shown that the benefits to clozapine administration may be attenuated with 
advancing age, suggesting that early initiation of clozapine in the illness is to be 
recommended.  However, my research also shows that this positive effect is maintained only 
if the patient continues to take the clozapine – if the treatment is stopped, then the number 
of days spent as an inpatient returns to the level it was before the clozapine was started, in 
most analyses of the data (in one analysis method more days were spent as an inpatient 
once clozapine had been stopped, in one other the number of inpatient days was fewer).  
Other authors have also demonstrated worsening outcomes on stopping clozapine – in 
Atkinson’s case series review of 35 patients who had discontinued clozapine (106), global 
functioning scores were significantly lower after stopping the drug.  Studies using 
hospitalisation as an outcome measure have similarly reported more readmissions and 
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increased lengths of stay for patients who discontinue clozapine (90), or surprisingly, no 
effect on hospitalisation status whether clozapine was continued or not (109).  This 
heterogeneity of results may be due to analysis methods chosen, as I have shown in this 
thesis, but also local differences in optimisation of clozapine prescribing and side effect 
management, inpatient admission policies, community support, and other factors that might 
influence readmissions.  Significantly, my separate analysis of data for patients who 
continued or discontinued clozapine demonstrates the importance of this approach.  
Analysing patient cohorts on an intent-to-treat basis underrepresents the benefits of 
clozapine. 
Continuing to take clozapine conferred a larger long term benefit to time spent as an inpatient 
than starting but then stopping the drug.  In my final study, described in chapter 6, I found an 
encouraging two thirds of patients remaining compliant with clozapine during long term follow 
up.  In my cohort, 36% of patients discontinued clozapine at least once.  This is not dissimilar 
to reports by other authors, although reported rates of discontinuation range widely from 16 
– 66% (90, 102, 107, 115, 172, 178, 245, 256-258).  The same authors also found that the 
majority of patients who discontinued clozapine did so within the first year of treatment; I did 
not find this to be the case, with 25% of discontinuers in my study stopping clozapine within 
the first 229 days (7.5 months). 
I used a strict definition of discontinuation (complete and deliberate switch to a different 
antipsychotic, rather than including brief breaks that resulted in immediate retitration) partly 
because the non-clozapine antipsychotic prescriptions used to cover brief retitration breaks 
would not meet the criteria of being ‘adequate treatment episodes’, but also because 
inconsistent documentation of these episodes made data collection difficult.  Most other 
authors do not define their criteria for discontinuation (115-117, 172).  In their 15 year 
retrospective study of 320 patients taking clozapine, Davis et al. (102) defined any clozapine 
interruption of more than 4 days as a discontinuation event.  In their cohort 57% of patients 
stopped clozapine at least once, with the highest frequency in the first 3 – 6 months, and just 
16% of clozapine discontinuers restarted.  Half of the patients in their study had discontinued 
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clozapine by 6.9 years.  In contrast, Munro and colleagues (103) used a discontinuation 
definition essentially mirroring that described in this thesis – i.e., withdrawal from the central 
clozapine monitoring service – and found discontinuation rates of 34% in year one, dropping 
significantly after this.  Similarly, Legge et al. (105) defined discontinuation as an absence of 
a clozapine prescription for at least 3 months, and found a similar clozapine discontinuation 
rate of 38% in year one. 
In my study, of the patients who discontinued clozapine in the study described in this thesis, 
71% stopped just once.  Of these, 71% restarted treatment with clozapine.  To my knowledge, 
no other research has examined the prescribing patterns on stopping and restarting 
clozapine or other medications in this degree of detail.  The high proportion of patients 
restarting clozapine is encouraging, suggesting some acknowledged benefit to the treatment 
in the first instance (or recognition of the lack of benefit of other available options).  The 
majority of medicines chosen for patients who discontinued clozapine the first time were 
atypical antipsychotics, and this probably reflects local prescribing practices.  Interestingly, 
most patients were switched to oral antipsychotics rather than injectable options, suggesting 
that non-compliance with oral medication was not the overriding reason for clozapine 
discontinuation.  Few other authors have studied post-clozapine medication choices, and 
where they have, the local guidelines would be expected to influence choices.  A similar study 
in 2007 in the same Trust found that 44% of patients were switched to a polypharmacy 
regimen after clozapine was stopped (106).  I found just one patient was prescribed 
polypharmacy in my study, and this may suggest a shift in prescribing practices since the 
introduction of prescribing improvement programmes (259). 
My study demonstrates that it is not possible to predict future clozapine discontinuation from 
a presenting patient’s age, ethnic background, diagnosis or previous treatment history, and 
this reflects my experience in clinical practice.  Previous studies have found that older 
patients (56, 102-104, 109) and those of African-Caribbean origin (77, 102, 103, 105, 111, 
118) are more likely to discontinue clozapine.  This variability in reported risks for 
discontinuation (some authors, in addition to the present study have found no association 
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between age (111, 112, 118) or ethnicity (111, 112) and stopping clozapine) may be due to 
population heterogeneity between studies or differing selection criteria for initiating clozapine.  
Even within similar populations in the same country (subject to the same prescribing 
guidelines and restrictions), differences have been noted in discontinuation rates within NHS 
Trusts (104), suggesting that localised clinical practices may also have a significant influence.  
Growing familiarity with clozapine over the past 25 years will also have played a part. 
The data presented here suggest that men are more likely than women to stop clozapine.  
To my knowledge, male gender has not previously been linked with a higher risk of clozapine 
discontinuation.  This finding is in contrast to results from other authors, including Davis et 
al. (102) who found in their cohort of 320 patients that females were more likely to stop 
treatment, although 91% of their cohort were male, and this result lacked statistical 
significance.  In Nielsen et al.’s (204) study of 633 patients, females had a shorter time to 
readmission to an inpatient unit.  It has been suggested previously that male gender is 
associated with a better response to clozapine (260, 261) and non-response to medication 
is associated with treatment discontinuation (118).  It is possible that in my study, prescribing 
of clozapine was reserved for more severely ill women than men, resulting in a female cohort 
with a greater illness burden at baseline who may be less likely to benefit from clozapine – 
and this has been demonstrated previously (204, 262).  However, delay to clozapine initiation 
and the number of previous antipsychotics prescribed did not differ in my study between men 
and women, suggesting a similar baseline illness severity, and I did not find women more 
likely to discontinue clozapine.  Conversely, other authors have shown females to respond 
better to clozapine than males – in Kohler-Forsberg et al.’s Danish study of clozapine patients 
over two years, women had a greater functional response to clozapine (250), potentially 
implying a lower likelihood of discontinuation and supporting my findings.  The same group 
also found a shorter time from diagnosis of schizophrenia to clozapine use (although no 
‘theoretical delay’ to prescribing was calculated) conferred an improved response to 
clozapine, but only in female patients.  I did not find delay to clozapine use affected long term 
outcomes in my cohort. 
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I have demonstrated that the benefits of clozapine therapy, in terms of reduction in inpatient 
admissions, are sustained only if patients continue to comply with treatment (187).  On 
clozapine discontinuation, the beneficial reduction in inpatient bed days is lost.  Patient non-
compliance with therapy and the emergence of adverse effects are consistently noted in the 
literature as the main reasons for clozapine discontinuation (102, 107, 113, 115-117, 172, 
178).  In my study, the most common reason for discontinuation of clozapine (when 
documented) was that the patient refused to continue therapy, rather than it being a 
prescriber decision based on adverse effects; and this continued to be the case for 
subsequent clozapine treatment breaks.  Whilst it may be considered reassuring that medical 
crises or blood dyscrasias were not a dominant feature of clozapine discontinuation, the 
reasons behind patients refusing treatment were not well documented and forms a vital topic 
for future research.  Where possible in this study I elucidated the reason behind patient-
driven treatment discontinuation, but found this to be generally poorly recorded in the clinical 
notes.  Where documentation did exist, it was patient refusal of continuing blood tests that 
dominated reasons for stopping, and I have shown previously that this is a concern raised 
by clinicians when considering initiating clozapine (263).  The risk of clozapine-induced blood 
dyscrasia decreases exponentially over time (264), and other authors have argued that 
reducing or stopping the requirement for regular blood monitoring would be justifiable (264).  
I have suggested that antipathy to blood monitoring may be a recurring reason for treatment 
cessation by patients, so removing regular blood tests may increase compliance.  Alternative 
strategies aimed at making blood testing simpler or at least more accessible, such as 
introducing point-of-care testing may also be useful (265). 
In conclusion, this study suggests that clozapine discontinuation cannot be predicted from a 
patient’s age, ethnicity, diagnosis, or chronicity of illness.  Male patients may be more likely 
to stop clozapine, but this result requires further investigation.  The main reason for 
discontinuation is reported to be patient refusal to continue with treatment.  Despite this, 70% 
of patients who stopped clozapine were restarted, and of these about two thirds continued to 
take the medication.  Further research should focus on the reasons for patient-led 
discontinuation of clozapine, with a view to identifying modifiable factors.  During this part of 
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the study five patients died, three of whom were taking clozapine at the time of death.  It was 
beyond the scope of this investigation to pursue the role or otherwise of clozapine in the 
cause of death, although the frequency with which death was the cause of clozapine 
discontinuation was lower in my study (8%) than reported elsewhere (13%) (117). 
 Limitations 
Excepting the practitioner and patient survey aspects to this thesis, the research presented 
here was conducted using retrospective data collection.  The data retrieved by this method 
are inevitably limited by the quality of clinical data recording.  Where available I consulted 
multiple data sources to gather and verify information, but due to the long follow-up duration 
of my studies (which add to their strengths) at times this information was inaccessible. 
There are several factors which need to be considered with respect to the design of my study 
into the effects of clozapine on inpatient admissions described in chapter 2.  The use of 
inpatient admission data as a proxy marker for the mental state of a patient may be 
misleading.  Patients may be admitted to psychiatric units for a range of reasons that may 
not reflect a relapse in mental state, including social reasons.  In clinical practice however I 
feel this is rare, and in the study population in South East London the illness severity required 
for inpatient admission, given the continued pressure on inpatient bed resources, is generally 
considered to be high.  For these reasons I think it unlikely that patients in my cohort were 
admitted for reasons other than a relapse in mental illness.  I also believe that inpatient bed 
days are an important outcome in their own right, given the impact of inpatient admissions 
on scarce health system resources.   
Conversely, it is possible that patients were not admitted despite a psychiatric relapse.  I did 
not include input from community-based home treatment or crisis teams, and it is possible 
that as a result, inpatient admission data were underestimated.  However, it is expected that 
whilst to some degree access to inpatient services may have changed over the course of the 
study, in general the severity of illness that would prompt inpatient admission is likely to have 
remained broadly the same, and so this possible source of underestimation of illness should 
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have remained the same for every patient during the course of the study.  It is also true of 
course that being in (or out) of hospital is not necessarily directly related to increased (or 
decreased) morbidity.    
Further, it is possible that the length of inpatient admissions may have been affected by other 
factors outside mental state.  Wolff et al. (266) found an affective disorder diagnosis and 
higher disease severity to be associated with longer lengths of stay.  Conversely, risk to 
others, substance abuse, ongoing somatic care needs and male gender were associated 
with shorter lengths of stay.  I did not account for the possible confounders of comorbid 
affective or physical illness, disease severity, substance abuse or risk of violence.  The ‘mirror 
image’ nature of this study, using each patient as their own comparator, is expected to 
minimise the impact of some of this on the overall results since for each individual, social and 
other factors are likely to remain broadly the same over the study period.  However, the 
mirror-image design also introduces a degree of bias to the results, as it inherently involves 
non-random assignment of patients, and there is no blinding (including in results evaluation).  
There are also difficulties making assessments of data based on retrospective clinical note 
review – I have attempted to overcome these by interrogating multiple data sources where 
available, including clinic letters and pharmacy dispensing systems.  As noted above in 
relation to the study conducted by Ucok et al. (100), it is possible that patients who were 
started on clozapine earlier were selected to do so by clinicians because they were thought 
more likely to respond, or more likely to comply with treatment.  It is therefore possible that 
patients that started clozapine earlier are systematically different to those who started later. 
I did not include data on where clozapine was initiated.  It is possible that patients who have 
clozapine initiated in hospital rather than in a community setting are more likely to remain 
compliant with therapy, as they presumably receive more support and encouragement as the 
clinical response to clozapine develops.  By the same reasoning, patients with longer hospital 
admissions after stabilising on clozapine treatment may be more likely to continue to comply 
with treatment if clinical response and insight continues to develop over time.  If this is the 
case, patients under the care of forensic services might be expected to have better 
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compliance rates with clozapine than other patients, as admission lengths are frequently 
much longer.  I am not aware of data to support this theory but this should be the subject of 
further study. 
A further unfortunate limitation of my research is the lack of detail concerning the reasons for 
patient refusal to continue with clozapine therapy.  This reflects a lack of documentation by 
clinicians at the time, but may contribute to an underestimation of the influence of adverse 
effects on decisions to discontinue treatment.  My finding that only 7.5% of patients 
discontinued clozapine due to side effects, a lower proportion than that reported in other 
studies, either suggests effective management of these by local prescribers or that a 
proportion of the ‘patient refusal’ category is in fact, at least in part, because of side effect 
burden. 
The clinician questionnaire study described in chapter 3 was also subject to some 
methodological problems.  The questionnaire was made available to all practitioners at 
SLaM, but the majority of responses were from younger, trainee psychiatrists.  It is likely that 
this cohort have less influence on treatment plans than their consultant colleagues, and this 
might explain the apparent disconnect between the guidelines, with which the prescribers 
claimed to be familiar, and actual prescribing patterns.  Since my study, Tungaraza and 
Farooq (267) have undertaken a similar survey but canvassing the opinions specifically of 
consultant psychiatrists.  They also found that significant proportions of respondents had few 
clozapine patients currently under their care, and despite widely declaring good exposure to 
clozapine use, at least at trainee level, gaps in knowledge that implied a lack of familiarity 
with the drug were demonstrated.  Over 80% of consultants in this survey agreed that 
clozapine was delayed in use, and the main barriers identified largely mirrored my results – 
concerns around side effects (specifically metabolic) and refusal of blood tests. 
Completion of my questionnaire was voluntary, and it may be that some practitioners 
declined to participate because they do not use clozapine in their current practice.  This may 
have led to over-reporting of familiarity with the guidelines or the medication.  SLaM has 
many ‘national’ inpatient beds, some specifically for complex cases of treatment-resistant 
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psychosis.  Its practitioners may therefore see a high proportion of patients with significant 
medical problems that preclude clozapine use, potentially explaining the relatively high level 
of concern expressed about this in the survey.  Equally, the presence of these services may 
mean the practitioners sampled will have had more exposure to clozapine use, and so a 
greater awareness of guidelines than in other areas.  The survey asked practitioners for their 
personal views of clozapine prescribing and so individual bias due to previous experiences 
cannot be ruled out (and some of these experiences may be unique to SLaM, as mentioned).  
Whilst this may limit the potential for extrapolation of the results to other practitioners or 
geographical areas, it can be assumed that the influence of personal past experience on 
subsequent prescribing patterns is a universal phenomenon (128).  As the questionnaire was 
self-reported it is possible that responder biases have influenced the results.  This was 
minimised by conducting the survey anonymously but cannot be excluded. 
With regards to the face-to-face patient interviews described in chapter 4, some specific 
practical issues arose.  For many patients some time was needed before the questionnaire 
was started in order to build a relationship sufficient to allow questions to be answered.  This 
often required a discussion about current medication and side effects.  Patients were more 
likely to disengage from the interview if language was used that focussed on ‘you’, i.e. ‘if you 
take clozapine, you need to have regular blood tests’.  This often led to immediate 
discontinuation of the questionnaire as participants misinterpreted this as news that their 
medication regimen would be changing to clozapine.  This difficulty over patient’s ability to 
grasp a hypothetical concept (imagining they might be taking clozapine) was common.  Using 
language that referred instead to ‘other people’ rather than ‘you’ (i.e. ‘people that take 
clozapine have to have regular blood tests’) helped to depersonalise the idea and reduced 
the chance of interview termination.  It was apparent that to some extent stigma around 
clozapine contributed to this, as mentioned in the free-text comments provided by some 
patients.   
Not mentioning the word ‘research’, and instead calling the survey a ‘project’ also increased 
the number of patients willing to engage from the start – this may reflect the high number of 
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approaches patients receive to participate in research projects at SLaM.  Starting 
conversations with ‘I am conducting a research project’ was often met with comments about 
not wanting more scans or blood tests or rating scales to be done.  Instead, engaging patients 
with ‘I’m interested in this drug that other people sometimes take and I’d like your opinion’ 
was much more successful.  Women were more difficult to engage, often displaying more 
hostility towards the investigator than male patients did.  It was not possible to quantify but I 
suspected that increased sexual disinhibition in male patients meant they were more likely 
to be willing to participate in interviews with a female interviewer. 
Finally, the high levels of thought disorder or distractibility in many patients meant that a lot 
of time was required to complete questionnaires, with questions taking many minutes to 
answer.  The Likert scales were generally well understood, and the visual prompts very 
helpful.  
 Ways in which this research could have been performed 
differently 
I did not undertake power calculations for any part of this thesis, and it is possible that as a 
result, some results did not reach statistical significance owing to low patient numbers.  The 
number of patients included in the retrospective data analysis was as large as possible at 
the time – patients were excluded from analysis for reasons of missing data alone – but 
numbers could have been increased by lengthening the time window for inclusion in the 
study.   
I made the questionnaire available to as many staff members as possible, and so it was not 
possible to calculate sample return proportions in my clinician opinions survey.  In hindsight, 
it may have been more valuable to have limited the scope of survey inclusion, allowing 
calculation of response rate and strengthening the value and generalisability of my results.  I 
did not use any incentives to increase questionnaire return, but doing so may have helped 
raise response rates. 
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The age of patients used throughout this research was their age at the end point of the study.  
As part of the research question was the influence of age on outcomes, the age used should 
have been the age of the patient at the point of clozapine initiation.  However, patients 
included in the study were those starting clozapine within a 4 year period, and so the impact 
of this discrepancy is likely to be minimal since the largest margin by which patient age would 
change would be 4 years. 
I did not account for readmissions that occurred within a short time frame of discharge.  Other 
authors have considered readmissions within 2 weeks of hospital discharge as ‘immature 
discharges’ (266) that should be counted as part of the previous admission.  This is a 
reasonable argument and I could have considered this in my data analysis.  The current 
method of analysis, discounting the effect of ‘immature discharges’, would overestimate the 
numbers of admissions per year (but the numbers of days of admission would remain 
unchanged). 
 Conclusion 
I have shown clozapine is effective and underused.  It reduces the amount of time spent as 
an inpatient, yet prescribing is delayed by an average of 4 years.  Clinicians think they know 
when and how to prescribe clozapine, as dictated by overwhelming peer-reviewed evidence 
and multiple clinical guidelines, yet polypharmacy, supramaximal antipsychotic doses and 
numerous sequential non-clozapine antipsychotics are all strategies still used for symptom 
control instead of clozapine.  Staff members cite the main reasons for under prescribing being 
patient refusal to comply with bloods, or intolerability of side effects.  Patients themselves 
have often never heard of clozapine, and the majority would not rule out clozapine outright 
due to either compulsory blood tests or side effects, although both these issues are highly 
relevant to them.   
The lack of symptom control and increased time spent in hospital notwithstanding, delaying 
clozapine prescribing makes no difference to its long-term benefits.  It does however provide 
more benefit if patients keep taking it, with reductions in inpatient admissions lost if clozapine 
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is stopped.  Most patients do remain compliant with clozapine, with men being more likely to 
stop taking it than women. 
Improving prescribing rates of clozapine might be achieved by offering dedicated support in 
the community in order to initiate clozapine.  Reducing blood test requirements, or making 
testing easier would undoubtedly help, as would familiarising patients with the drug earlier 
on in their treatment pathways, focussing on reducing fear of side effects and the need to 
explain complex and perhaps unpleasant short-term processes that may provide longer term 
gains at a time of acute psychotic relapse.  Enabling patients to remain compliant with 
clozapine once it has been started is vital to reduce the likelihood of inpatient admissions.  
Men may require particular support.   
 Further research 
Each facet of the research described in this thesis has inevitably generated further questions.  
In my study of the delay to initiating clozapine, I showed a high proportion of apparently 
inadequate trials of antipsychotics.  Investigating further the reasons for prescribing of 
inadequate trials may suggest strategies to avoid this phenomenon and speed access to 
therapeutic treatment (whether clozapine or otherwise).  Detailed statistical analysis of this 
cohort showed that females had longer delays to clozapine initiation than their male 
counterparts.  This finding requires replication and further investigation.  A larger sample size 
is likely to be required, as well as assessment of illness severity between the genders, as 
this has been suggested as a possible reason for differing prescribing rates.  Other authors 
have also shown differences in delays in starting clozapine between outpatient and inpatient 
settings (100).  This could be examined post-hoc from my data.   
My study of the effect of clozapine on inpatient admission status found mixed results in 
detailed statistical analysis for the effects of age on this outcome.  This requires further 
investigation using larger patient cohorts. 
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Clearly, ensuring compliance with clozapine treatment as far as possible is beneficial.  The 
reasons for discontinuation are multiple, as reported by other authors, but importantly may 
change over time and differ between treatment settings.  Reasons for discontinuation of 
clozapine were poorly documented in my study, showing that further retrospective data 
collection for this outcome is unlikely to be helpful.  Prospective follow-up of patients taking 
clozapine may be more helpful, with the added possibility of gathering patient views on 
clozapine discontinuation in a timely manner.  Further, reasons for not restarting clozapine 
for those patients who discontinue were not studied in this thesis.  This is a further barrier 
point to continued clozapine therapy which is worthy of investigation, with a view to 
developing strategies to enable resuming treatment.  A small case series (268) in 1999 
suggested that clozapine is less effective on restarting – this is an important finding not 
replicated by a larger study.  Post-hoc analysis of my data, again using inpatient admissions 
as a proxy marker for efficacy of treatment could be used to investigate this.  An extension 
of this work is to investigate the reasons for readmission to hospital in patients still taking 
clozapine.  Some of this may be temporary non-compliance, not picked up in my study, or 
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Appendix A. Statistical data for chapter 2 
Table 7-1 Z-scores 




Extreme outliers (z-score > 3.29) 3 1.3 2.0 2.0 
Probable outliers (z-score > 2.58) 1 .4 .7 2.7 
Potential outliers (z-score > 1.96) 7 3.1 4.7 7.4 
Normal range 138 61.6 92.6 100.0 
Total 149 66.5 100.0  
Table 7-2 Kolomogorov-Smirnov and Shapiro-Wilk tests of normality 
 Kolmogorov-Smirnov Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Included 
patients 
Age 0.105 149 < 0.0005 0.933 149 < 0.0005 
Sex 0.435 149 < 0.0005 0.585 149 < 0.0005 
Ethnicity 0.287 149 < 0.0005 0.762 149 < 0.0005 
Primary diagnosis 0.464 149 < 0.0005 0.539 149 < 0.0005 
Duration of Illness 
(years) 
0.132 149 < 0.0005 0.888 149 < 0.0005 
Theoretical Delay 
(years) 
0.217 149 < 0.0005 0.776 149 < 0.0005 
Excluded 
patients 
Age 0.121 75 0.008 0.956 75 0.010 
Sex 0.357 75 < 0.0005 0.635 75 < 0.0005 
Ethnicity 0.378 75 < 0.0005 0.706 75 < 0.0005 
Primary diagnosis 0.391 75 < 0.0005 0.669 75 < 0.0005 
Duration of Illness 
(years) 
0.091 70 0.200 0.954 70 0.012 
Table 7-3 Levene's test for homogeneity of variance 
 Levene 
Statistic 
df1 df2 Sig. 
Age Based on Mean 4.173 1 217 0.042 
Based on Median 3.222 1 217 0.074 
Based on Median and with adjusted df 3.222 1 207.940 0.074 
Based on trimmed mean 3.760 1 217 0.054 
Sex Based on Mean 10.290 1 217 0.002 
Based on Median 5.068 1 217 0.025 
Based on Median and with adjusted df 5.068 1 215.878 0.025 
Based on trimmed mean 10.290 1 217 0.002 
Ethnicity Based on Mean 0.136 1 217 0.713 
Based on Median 2.653 1 217 0.105 
Based on Median and with adjusted df 2.653 1 114.832 0.106 
Based on trimmed mean 0.472 1 217 0.493 
Primary 
diagnosis 
Based on Mean 26.524 1 217 <0.0005 
Based on Median 8.177 1 217 0.005 
Based on Median and with adjusted df 8.177 1 180.131 0.005 




Based on Mean 21.992 1 217 <0.0005 
Based on Median 18.902 1 217 <0.0005 
Based on Median and with adjusted df 18.902 1 182.928 <0.0005 
Based on trimmed mean 21.071 1 217 <0.0005 
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Table 7-4 Independent samples t-test for continuous variables, comparing included and excluded patient 
group means 
 Levene's Test for 
Equality of 
Variances 
t-test for Equality of Means 



















 -5.017 111.874 <0.0005 -8.764 1.747 -12.225 -5.303 









 -6.612 92.487 <0.0005 -7.837 1.185 -10.191 -5.483 














-8.764 0.010 1.773 0.001 -12.217 -5.379 
Equal variances 
not assumed 
-8.764 0.010 1.773 0.001 -12.217 -5.379 
Duration of Illness in years 
Equal variances 
assumed 
-7.837 -0.005 1.101 0.001 -10.000 -5.752 
Equal variances 
not assumed 
-7.837 -0.005 1.101 0.001 -10.000 -5.752 
Table 7-6 Chi-square test for continuous variable of gender, comparing included and excluded patient groups 






Pearson Chi-Square 4.917 1 0.027  
Continuity Correction 4.287 1 0.038 
Likelihood Ratio 4.854 1 0.028 
Fisher's Exact Test  0.029 0.020 
Linear-by-Linear 
Association 
4.895 1 0.027  
N of Valid Cases 224  
0 cells (0.0%) have expected count less than 5. The minimum expected count is 27.46. 
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Table 7-7 Chi-square test for continuous variable of ethnicity, comparing included and excluded patient 
groups 
5 cells (41.7%) have expected count less than 5. The minimum expected count is 0.33. 










12.121 5 0.033 0.024  
Likelihood 
Ratio 
12.759 5 0.026 0.031 
Fisher's 
Exact Test 




5.199 1 0.023 0.023 0.012 0.003 




Table 7-8 Crosstabulation for ethnicity of included compared to excluded patient groups 
 Included patients Excluded patients Total 
White Count 61a 45b 106 
Expected Count 70.5 35.5 106.0 
% within Ethnicity 57.5% 42.5% 100.0% 
% within Included / 
Excluded 40.9% 60.0% 47.3% 
% of Total 27.2% 20.1% 47.3% 
Std. Residual -1.1 1.6  
Mixed race Count 12a 2a 14 
Expected Count 9.3 4.7 14.0 
% within Ethnicity 85.7% 14.3% 100.0% 
% within Included / 
Excluded 8.1% 2.7% 6.3% 
% of Total 5.4% 0.9% 6.3% 
Std. Residual 0.9 -1.2  
Asian and Asian 
British 
Count 7a 5a 12 
Expected Count 8.0 4.0 12.0 
% within Ethnicity 58.3% 41.7% 100.0% 
% within Included / 
Excluded 4.7% 6.7% 5.4% 
% of Total 3.1% 2.2% 5.4% 
Std. Residual -0.3 0.5  
Black or Black 
British 
Count 61a 20b 81 
Expected Count 53.9 27.1 81.0 
% within Ethnicity 75.3% 24.7% 100.0% 
% within Included / 
Excluded 40.9% 26.7% 36.2% 
% of Total 27.2% 8.9% 36.2% 
Std. Residual 1.0 -1.4  
Other Ethnic 
Category 
Count 8a 2a 10 
Expected Count 6.7 3.3 10.0 
% within Ethnicity 80.0% 20.0% 100.0% 
% within Included / 
Excluded 5.4% 2.7% 4.5% 
% of Total 3.6% 0.9% 4.5% 
Std. Residual 0.5 -0.7  
Not Stated Count 0a 1a 1 
Expected Count 0.7 0.3 1.0 
% within Ethnicity 0.0% 100.0% 100.0% 
% within Included / 
Excluded 0.0% 1.3% 0.4% 
% of Total 0.0% 0.4% 0.4% 
Std. Residual -0.8 1.1  
Total Count 149 75 224 
Expected Count 149.0 75.0 224.0 
% within Ethnicity 66.5% 33.5% 100.0% 
% within Included / 
Excluded 100.0% 100.0% 100.0% 
% of Total 66.5% 33.5% 100.0% 
Each subscript letter denotes a subset of Included / Excluded categories whose column proportions do not 
differ significantly from each other at the 0.05 level.  
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White Count 61a 45b 106 
Expected Count 70.5 35.5 106.0 
% within Ethnicity 57.5% 42.5% 100.0% 
% within Included / Excluded 40.9% 60.0% 47.3% 
% of Total 27.2% 20.1% 47.3% 
Std. Residual -1.1 1.6  
Black Count 61a 20b 81 
Expected Count 53.9 27.1 81.0 
% within Ethnicity 75.3% 24.7% 100.0% 
% within Included / Excluded 40.9% 26.7% 36.2% 
% of Total 27.2% 8.9% 36.2% 
Std. Residual 1.0 -1.4  
Other Count 27a 10a 37 
Expected Count 24.6 12.4 37.0 
% within Ethnicity 73.0% 27.0% 100.0% 
% within Included / Excluded 18.1% 13.3% 16.5% 
% of Total 12.1% 4.5% 16.5% 
Std. Residual 0.5 -0.7  
Total Count 149 75 224 
Expected Count 149.0 75.0 224.0 
% within Ethnicity 66.5% 33.5% 100.0% 
% within Included / Excluded 100.0% 100.0% 100.0% 
% of Total 66.5% 33.5% 100.0% 
Each subscript letter denotes a subset of Included / Excluded categories whose column proportions do not 
differ significantly from each other at the 0.05 level. 
Table 7-10 Chi-square test for continuous variable of ethnicity, comparing included and excluded patient 
groups, categories merged 










7.333 2 0.026 0.025  
Likelihood Ratio 7.369 2 0.025 0.027 
Fisher's Exact 
Test 
7.190   0.027 
Linear-by-Linear 
Association 
5.197 1 0.023 0.027 0.014 0.006 
N of Valid Cases 224  
0 cells (0.0%) have expected count less than 5. The minimum expected count is 12.39. 
Table 7-11 Chi-square test for continuous variable of diagnosis, comparing included and excluded patient 
groups 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 10.647 3 0.014 
Likelihood Ratio 10.144 3 0.017 
Linear-by-Linear Association 8.741 1 0.003 
N of Valid Cases 224  
2 cells (25.0%) have expected count less than 5. The minimum expected count is 2.01. 
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Table 7-12 Crosstabulation for diagnosis of included compared to excluded patient groups 
Each subscript letter denotes a subset of Included / Excluded categories whose column 






Schizophrenia Count 116a 49b 165 
Expected Count 109.8 55.2 165.0 
% within diagnosis 70.3% 29.7% 100.0% 
% within Included / 
Excluded 
77.9% 65.3% 73.7% 
% of Total 51.8% 21.9% 73.7% 
Std. Residual 0.6 -0.8  
Schizoaffective 
Disorder 
Count 24a 12a 36 
Expected Count 23.9 12.1 36.0 
% within diagnosis 66.7% 33.3% 100.0% 
% within Included / 
Excluded 
16.1% 16.0% 16.1% 
% of Total 10.7% 5.4% 16.1% 
Std. Residual 0 0  
Bipolar Disorder Count 8a 9a 17 
Expected Count 11.3 5.7 17.0 
% within diagnosis 47.1% 52.9% 100.0% 
% within Included / 
Excluded 
5.4% 12.0% 7.6% 
% of Total 3.6% 4.0% 7.6% 
Std. Residual -1.0 1.4  
Other Count 1a 5b 6 
Expected Count 4.0 2.0 6.0 
% within diagnosis 16.7% 83.3% 100.0% 
% within Included / 
Excluded 
0.7% 6.7% 2.7% 
% of Total 0.4% 2.2% 2.7% 
Std. Residual -1.5 2.1  
Total Count 149 75 224 
Expected Count 149.0 75.0 224.0 
% within Primary diagnosis 66.5% 33.5% 100.0% 
% within Included / 
Excluded 
100.0% 100.0% 100.0% 
% of Total 66.5% 33.5% 100.0% 
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Schizophrenia Count 116a 49b 165 
Expected Count 109.8 55.2 165.0 
% within Diagnosis 70.3% 29.7% 100.0% 
% within Included / Excluded 77.9% 65.3% 73.7% 
% of Total 51.8% 21.9% 73.7% 
Std. Residual 0.6 -0.8  
Schizoaffective 
disorder 
Count 24a 12a 36 
Expected Count 23.9 12.1 36.0 
% within Diagnosis 66.7% 33.3% 100.0% 
% within Included / Excluded 16.1% 16.0% 16.1% 
% of Total 10.7% 5.4% 16.1% 
Std. Residual 0 0  
Other Count 9a 14b 23 
Expected Count 15.3 7.7 23.0 
% within Diagnosis 39.1% 60.9% 100.0% 
% within Included / Excluded 6.0% 18.7% 10.3% 
% of Total 4.0% 6.3% 10.3% 
Std. Residual -1.6 2.3  
Total Count 149 75 224 
Expected Count 149.0 75.0 224.0 
% within Diagnosis 66.5% 33.5% 100.0% 
% within Included / Excluded 100.0% 100.0% 100.0% 
% of Total 66.5% 33.5% 100.0% 
Each subscript letter denotes a subset of Included / Excluded categories whose column proportions do not 
differ significantly from each other at the 0.05 level. 
Table 7-14 Chi-square test for continuous variable of diagnosis, comparing included and excluded patient 
groups, categories merged 









Pearson Chi-Square 8.808 2 0.012 0.012  
Likelihood Ratio 8.269 2 0.016 0.020 
Fisher's Exact Test 8.310  0.016 
Linear-by-Linear 
Association 
7.179 1 0.007 0.008 0.006 0.003 
N of Valid Cases 224  
0 cells (0.0%) have expected count less than 5. The minimum expected count is 7.70. 
 373 
Figure 7-1 Relationship between theoretical delay to clozapine initiation and duration of the illness 
Table 7-15 Regression model summary (duration of illness) 
R R Square Adjusted R Square Std. Error of the Estimate 
0.037 0.001 -0.005 51.109 
Table 7-16 ANOVA (duration of illness) 
 Sum of Squares df Mean Square F Sig. 
Regression 537.729 1 537.729 0.206 0.651 
Residual 383977.224 147 2612.090   
Total 384514.953 148    






B Std. Error Beta 
(Constant) 45.015 5.530  8.140 <0.0005 
Duration of illness 
(months) 
-0.048 0.106 -0.037 -0.454 0.651 
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Table 7-18 Bootstrap for model coefficients (duration of illness) 








Constant 45.015 -0.762 5.781 0.001 32.456 55.782 
Duration of illness 
(months) 
-0.048 0.020 0.116 0.635 -0.227 0.243 
Figure 7-2 Relationship between theoretical delay to clozapine initiation and age 
Table 7-19 Regression model summary (age) 
R R Square Adjusted R Square Std. Error of the Estimate 
0.147 0.022 0.015 50.590 
Table 7-20 ANOVA (age) 
 Sum of Squares df Mean Square F Sig. 
Regression 8288.314 1 8288.314 3.238 0.074 
Residual 376226.639 147 2559.365   
Total 384514.953 148    
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B Std. Error Beta 
Constant 66.055 13.267  4.979 <0.0005 
Age 
(months) 
-0.067 0.037 -0.147 -
1.800 
0.074 
Table 7-22 Bootstrap for model coefficients (age) 
 B Bootstrap 
Bias Std. Error Sig. (2-tailed) 95% Confidence Interval 
Lower Upper 
Constant 66.055 0.190 11.904 0.001 44.154 91.316 
Age (months) -0.067 -3.133E-5 0.028 0.016 -0.126 -0.011 
Table 7-23 Multiple regression analysis model summary 




Change Statistics DurbinWatson 
R2 F df1 df2 Sig. F 
Model 
1 
0.147 0.022 0.015 50.590 0.022 3.238 1 147 0.074  
Model 
2 
0.147 0.022 0.008 50.760 <0.0005 0.015 1 146 0.902 1.740 
Table 7-24 Levene's test for homogeneity of variance for ANCOVA 
F df1 df2 Sig. 
2.019 67 81 0.001 
Table 7-25 ANCOVA 
Source Type III Sum of Squares df Mean Square F Sig. 
Corrected Model 139923.799 68 2057.703 0.673 0.953 
Intercept 27246.679 1 27246.679 8.192 0.004 
Age 2089.929 1 2089.929 0.684 0.411 
Duration of illness 131635.485 67 1964.709 0.643 0.968 
Error 244591.154 80 3057.389  
Total 664853.000 149  
Corrected Total 384514.953 148 
Table 7-26 Levene's test for homogeneity of variance for ANCOVA 
F df1 df2 Sig. 
2.445 115 33 0.002 
Table 7-27 ANCOVA 
Source Type III Sum of Squares df Mean Square F Sig. 
Corrected Model 302452.699 116 2607.351 1.017 0.498 
Intercept 77365.460 1 77365.460 30.168 <0.0005 
Duration of illness 157.712 1 157.712 0.061 0.806 
Age 301914.969 115 2625.348 1.024 0.488 
Error 82062.254 32 2564.445  
Total 664853.000 149  
Corrected Total 384514.953 148 
  
 376 
Table 7-28 Independent samples t-test results (gender) 
 Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 



















  -2.435 66.408 0.018 -24.537 10.077 -44.653 -4.421 













-24.537 0.057 9.849 0.018 -44.502 -5.927 
Equal variances not 
assumed 
-24.537 0.057 9.849 0.021 -44.502 -5.927 
Table 7-30 Levene's test for homogeneity of variance (ethnicity) 
Levene Statistic df1 df2 Sig. 
0.725 2 146 0.486 
Table 7-31 ANOVA (ethnicity) 
 Sum of 
Squares 
df Mean Square F Sig. 
Between Groups 2553.194 2 1276.597 0.488 0.615 
Within Groups 382023.692 146 2616.601  
Total 384576.886 148  
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Table 7-32 ANOVA post-hoc tests (ethnicity) 










Tukey HSD White Black -3.443 9.262 0.927 -25.37 18.49 
Other 8.236 11.824 0.766 -19.76 36.23 
Black White 3.443 9.262 0.927 -18.49 25.37 
Other 11.678 11.824 0.586 -16.32 39.68 
Other White -8.236 11.824 0.766 -36.23 19.76 
Black -11.678 11.824 0.586 -39.68 16.32 
Gabriel White Black -3.443 9.262 0.976 -25.81 18.92 
Other 8.236 11.824 0.857 -19.75 36.22 
Black White 3.443 9.262 0.976 -18.92 25.81 
Other 11.678 11.824 0.677 -16.31 39.67 
Other White -8.236 11.824 0.857 -36.22 19.75 
Black -11.678 11.824 0.677 -39.67 16.31 
Games-
Howell 
White Black -3.443 9.656 0.932 -26.36 19.47 
Other 8.236 10.448 0.711 -16.79 33.26 
Black White 3.443 9.656 0.932 -19.47 26.36 
Other 11.678 10.016 0.478 -12.36 35.72 
Other White -8.236 10.448 0.711 -33.26 16.79 
Black -11.678 10.016 0.478 -35.72 12.36 
Table 7-33 Levene's test for homogeneity of variance (diagnosis) 
Levene Statistic df1 df2 Sig. 
0.798 2 146 0.452 
Table 7-34 ANOVA (diagnosis) 
 Sum of 
Squares 
df Mean Square F Sig. 
Between Groups 8002.128 2 4001.064 1.551 0.215 
Within Groups 376574.758 146 2579.279  
Total 384576.886 148  
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Table 7-35 ANOVA post-hoc tests (diagnosis) 















0.731 11.389 0.998 -26.24 27.70 
Other -30.616 17.573 0.193 -72.23 11.00 
Schizoaffective 
disorder 
Schizophrenia -0.731 11.389 0.998 -27.70 26.24 
Other -31.347 19.851 0.258 -78.35 15.66 
Other Schizophrenia 30.616 17.573 0.193 -11.00 72.23 
Schizoaffective 
disorder 
31.347 19.851 0.258 -15.66 78.35 
Gabriel Schizophrenia Schizoaffective 
disorder 
0.731 11.389 1.000 -25.02 26.48 
Other -30.616 17.573 0.135 -67.57 6.34 
Schizoaffective 
disorder 
Schizophrenia -0.731 11.389 1.000 -26.48 25.02 
Other -31.347 19.851 0.286 -77.95 15.25 
Other Schizophrenia 30.616 17.573 0.135 -6.34 67.57 
Schizoaffective 
disorder 





0.731 9.475 0.997 -22.29 23.76 
Other -30.616 17.104 0.224 -77.92 16.68 
Schizoaffective 
disorder 
Schizophrenia -0.731 9.475 0.997 -23.76 22.29 
Other -31.347 18.281 0.239 -80.04 17.35 
Other Schizophrenia 30.616 17.104 0.224 -16.68 77.92 
Schizoaffective 
disorder 
31.347 18.281 0.239 -17.35 80.04 
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Appendix C. Statistical data for chapter 3 













How familiar are you 
with the NICE 
guidelines relating to 
treatment resistant 
schizophrenia? 







How familiar are you 
with methods for the 
initiation of clozapine 
treatment? 











compared with other 
antipsychotics? 







In terms of treatment 
satisfaction, how 
satisfied do you 
believe patients treated 
with clozapine are, 
compared with patients 
treated with other 
(atypical) 
antipsychotics? 









Table 7-37 Mann-Whitney test statistics for patient factor questions 














baseline blood tests 






about regular blood 
monitoring 






to need for hospital 
admission for titration 





























Table 7-38 Mann-Whitney test statistics for staff factor questions 





























Need for hospital 
admission 





Cost of clozapine 
medication 





















Table 7-39 Mann-Whitney test statistics for enabling factor questions 




















dedicated to obtaining 
baseline blood tests 






beds to enable 
initiation of clozapine 
as an inpatient 





Dedicated staff to 
arrange and monitor 
the initiation of 
clozapine as an 
outpatient 






placements to initiate 
clozapine as an 
outpatient 







Appendix D. Practitioner attitudes to clozapine initiation: free 
text comments 
Table 7-40 Free-text responses to 'In your opinion, how frequently do the following patient factors lead to 
delays in the initiation of clozapine once clozapine treatment is indicated?' 
Comment 
Tolerability and side effects are a huge worry for patients who, from my experience, do not 
feel that this is seen as an important point when compared to reasons for starting clozapine 
Even though patients refuse obtaining blood monitoring faily [sic] frequent [sic], the staff 
continue to work really hard in negotating [sic] with the patient, exploring reasons for refusal 
and offering support and reassurance 
TB medication is less effective on clozapine - i [sic] remember that being an issue for one of 
my clients 
Patients often lack insight into illness so do not want any treatment at all don't mind a 
treatment requiring blood tests 
Weight gain seems to be a regular concern for patients and in addition some concerns such 
as hypersalivation and constipation 
Relatives not keen on clozapine 
No beds available to admit to start titration 
Prescribers' lack of confidence in prescribing clozapine 
Patient fears about side effects of medication - Fairly frequently 
Influence of concerns about above factors from parents/carers 
Low baseline neutorphil [sic] count - somewhat frequently 
Expedient discharge - very frequently 
Side effect profile 
Unpleasant scary side effects involving heart racing etc.  Need for monitoring makes it look 
'scary' 
Pharmacy's hilariously inflexible approach to dispensing clozapine when patients do not turn 
up as expected or out of hours etc. causes many cases requiring retitration [sic], bearing in 
mind most patients are admitted out of hours 
Alcohol intake, likely to disengage: somewhat frequently 
Table 7-41 Free-text responses to 'How frequently do the following factors delay you from 
initiating/supporting clozapine titration in patients eligible for treatment?' 
Comment 
Not really involved in Clozapine [sic] initiation 
Obtaining bloods on a regular basis (rather than only baseline bloods) may be sometimes an 
issue 
We are a specialist unit for clozapine re-titration so our experience will be atypical 
Inability to impose a clozapine trial on certain patients, where all else have failed and patient 
remains floridly symptomatic and poses risks to self and others. 
Young age 
Management in community - somewhat frequently 




Table 7-42 Free-text responses to 'In your opinion, how helpful would the following factors be in terms of 
facilitating the initiation of clozapine, were they available?' 
 Comment 
1 More support for patients around decision making, including preparing for potential side 
effects in advance 
2 Please note- these questions are not applicable to Spring Ward 
3 Waiting list may affect initaiting [sic] clozaping [sic] once the need has been identified 
4 Dedicated clozapine team would be highly beneficial 
5 Working within CAMHS would be helpful to know whether any such dedicated resources 
would be available to under 18s, aalthough [sic] numbers obviously very small 
6 Information/adverts/leaflets - very frequently 
7 Promotion of clozapine to patient and carers 
8 Additional staff dedicated to obtaining baseline blood tests is super important.  CT3 
doctors of min 5 years training should not be routinely phlebotomy (see RCPsych 
guildeine [sic])  
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Table 7-43 Additional comments 
 Comment 
1 Home Treatment Team accept patients for titration but the initiation or the registration is 
done by the referring team 
2 I assume that clinical psychologists are not your target population for completion of this 
survey and apologies for the regular 'don't know' responses. I do feel that, due to the 
nature of clients needing clozapine, the issue of tolerability etc is taken lightly by the 
team and more discussion in advance would improve compliance. 
3 ZTAS are paid to look after the administrative and monitoring side of Clozapine [sic], and 
for the most part, take responsibility for this. No clinician should be dissuaded from use 
of Clozapine [sic] for administrative/logistical reasons 
4 This is a disappointing questionnaire with too many leading questions 
5 There have been three sudden, and unclear deaths of patients on Clozapine [sic] in the 
team I have worked with (over 2 or so years). It is not clear to me the monitoring 
processes indicated any risk. I think there are increasingly 'unsaid' fears amongst staff 
about this medication, which are not helped by a lack of transparency about how such 
deaths are reported and what the processes are for analysing the data nationally. I think 
this is an unidentified and little spoken about 'Practitioner Attitude' I am aware of locally 
(i.e. amongst non-psychiatry members of the MDT), that I hope it is helpful to highlight in 
this survey. 
6 Caring for pts with depression, so this has been rarely a drug of choice in the area I'm 
currently working in 
7 As a Care Coordinator working in a community setting I have seen clozapine improve 
the quality of some of my service users. I have seen one client who responded so well to 
clozapine that her quality of life changed so much. Unforunately [sic] she gained approx. 
8 stone and she satopped [sic] the clozapine. She was prescribed orlistat but she wass 
[sic] unable to tolerate it.  Our team is now down to 8 members and it will be very difficult 
to commite [sic] to community clozapine tritration [sic] 
8 We have considerable experience of treating patients who did not respond to clozapine 
monotherapy and were augmented by another atypical antipsychotic medication 
9 Difficult for me to comment, as so rarely used in adolescents.  My reservation would be 
such a serious undertaking in ones so young 
10 Tricky medication requiring a lot of input in terms of monitoring physical effects, 
particularly patients in the community 
11 Having only experience of 1 -2 patients on clozapine, I am not an expert or clinician, 
being a social worker in mental health.   However, effects have been good 
12 Courier times a significant problem with a chaotic group - eg. Arrive too late and courier 
'gone' 
13 More information for SHOs RE benign ethnic neutropaenia, which can cause anxiety 
and 'amber' results for FBC 
14 I don't feel this survey is very applicable to me, especially working in an older adult ward.  
I'm not really exposed to the various problems that this survey alludes to 
15 Patient yesterday admitted described clozapine as a wonder drug for him, reduction in 
negative symptoms, clozapine 'makes me do things' 




Appendix E. Patient attitudes to clozapine: questionnaire 
 








1. Have you heard of a medication called clozapine? 
a. Yes – go to Q2 
b. No – read paragraph below to the patient 
c. Don’t know – read paragraph below to the patient 
Clozapine is an antipsychotic drug.  It is used to treat the symptoms of schizophrenia.  It 
helps to reduce things like hearing voices or seeing things that aren’t there.  It improves 
concentration and helps to make people’s thinking clearer.  It has some side effects that are 
quite common.  These include constipation, feeling sleepy, drooling, feeling dizzy when 
standing up, and a racing heart.  We can treat these if they happen.  It also has some side 
effects that are very rare but can be serious.  Clozapine can cause the levels of white blood 
cells to drop.  Because of this, before taking clozapine you have to have a blood test.  You 
then need to have your blood tested every week for the first three months.  After that it is 
every two weeks, then once a month.   For many people clozapine is the only medicine that 
works for them. 
2. Have you ever asked to take clozapine? 
a. Yes – go to Q3 
b. No – go to Q4 
c. Don’t know – go to Q4 
d. Other 
 
3. What happened? 
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4. If you were offered clozapine now, would you take it? 
a. I’d take it 
b. I wouldn’t take it 
c. I might take it 





6. You would have to have blood taken before starting clozapine.  On a scale of 0 to 4, 
how would you feel about that? 
 





I’d be slightly 
bothered but I’d 
still be willing to 
try it 
I’d be fairly 
bothered but 
I’d still be willing 
to try it 
I’d be very 
bothered but 
I’d still be 
willing to try it 
I wouldn’t try 
clozapine 
because of this 
 
Or 5. Don’t know  
Or 6. Other 
 
7. You would have to have your blood taken regularly whilst taking clozapine.  On a scale 
of 0 to 4, how would you feel about that? 
 





I’d be slightly 
bothered but I’d 
still be willing to 
try it 
I’d be fairly 
bothered but 
I’d still be willing 
to try it 
I’d be very 
bothered but 
I’d still be 
willing to try it 
I wouldn’t try 
clozapine 
because of this 
 
Or 5. Don’t know  
Or 6. Other 
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8. On a scale of 0 to 4, how much do the side effects of clozapine worry you? 
 




I’m a bit 
worried but I’d 
still be willing to 
try it 
I’m fairly 
worried but I’d 
still be willing to 
try it 
I’m very 
worried but I’d 
still be willing to 
try it 
I wouldn’t try 
clozapine 
because of the 
side effects 
 
Or 5. Don’t know 
Or 6. Other 
 
9. Are there any side effects that particularly worry you? 
 
10. In order to start clozapine, sometimes people have to be admitted to hospital for a short 
time.  If that was necessary for you, how would you feel about it? 
 





I’d be slightly 
bothered but I’d 
still be willing to 
try it 
I’d be fairly 
bothered but 
I’d still be willing 
to try it 
I’d be very 
bothered but 
I’d still be 
willing to try it 
I wouldn’t try 
clozapine 
because of this 
 
Or 5. Don’t know 
Or 6. Other 
 
11. If clozapine could be started whilst you were at home, would that make a difference? 
a. Yes 
b. No 




12. Comparing clozapine to medicines you’ve had before, how much do you think it would 
help your symptoms? 
 
0 1 2 3 4 
Clozapine 












would be about 














Or 5. Don’t know 






Appendix F. Patient attitudes to clozapine initiation: free text 
comments 
Table 7-44 Free-text responses to 'why didn’t you start the clozapine when it was offered?’ 
Comment 
I devoured it 
The voices kept going on. I did take it 
I took it a while ago.  It was a long time ago.  Everything boiled up. 
Overheated, slowed down 
I didn't want it because of the blood tests, and the changes to the blood cells 
I took it 
I can't remember 
I refused to take it 
I’m not sure 
I’m not sure 
Table 7-45 Free-text responses to follow-up question of 'why' to 'if you were offered clozapine now, would 
you take it?' 
If you were offered clozapine 
now, would you take it? 
Comment 
Yes I have a depot at the moment and it makes me feel 
deflated and flat 
It is the right thing to do 
If it would help I'd take it.  I trust the doctor's opinion - 
if they say I need it then I'll take it 
I know it would do me good.  I trust you 
I take all my medication 
It would be good for my health 
I like my current medicines 
I know what it does 
I want my mental health to recover 
I need something in addition to my current medicines 
It’s good to join in and help with taking bloods 
I would speak to the doctor 
I haven’t tried it 
Because I’ve heard of it 
No Because of the side effects 
I'm not sure what the effects might be 
I'm fine at the moment - I don't need it 
There are more negatives than positives.  The side 
effects 
The blood tests 
I only want good food and sleep 
Side effects.  I like my current medication 
The constant monitoring.  The side effects - 
salivation, drowsiness.  I don't like needles 
I don’t have symptoms therefore I don’t need it 
I don't want it 
It changes blood cells 
I'm happy with my current medication 
Blood tests 
I don't want to change my medication 
I don't need medicines 
The side effects 
I don't want it 
I don't like tablets 
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If you were offered clozapine 
now, would you take it? 
Comment 
The dose sounds too high 
I don’t want to have bloods taken 
I'm on too many medicines already 
It kills white blood cells 
I don't know much about it 
Because of the drop in white blood cells 
Because of the side effects 
I don’t know what it will do to me 
I don’t feel ill at the moment 
Maybe Just to try it 
The white cell thing sounds risky 
Don’t know I have epilepsy - only the doctors know about what 
medicines might affect it 
I wouldn't take it if it wasn't necessary for me 
I'm not sure what it is, or what it does 
Side effects.  I like my current medication 
I don’t know how it would affect me 
I don't know anything about it 
Right now I just want to get out of here 
Side effects.  Another patient said it's for women 
Other Because I'm in hospital 
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Table 7-46 Free-text responses to 'which side effects worry you the most?' 
Comment 
Dizziness - I have a head injury so I already get dizzy 
It would make me weaker 
Constipation - I already have this 
The effect on the WBC, the impact drowsiness would have on my daily life, the racing heart 
rate 
Loss of dignity 
The negative effect on my mind.  Dizziness, headaches, constipation 
Medicines are there to improve and stay positive so I'm not worried about side effects 
I haven't taken it so I can't know 
I know other people who take clozapine.  For them the psychosis is so bad the side effects 
are worth taking.  It's a balance for each individual.  Therefore if I needed clozapine I 
wouldn't care about the side effects because I would need it 
All of them.  The drooling especially 
The strength of the pill makes me worried about collapsing.  You can't miss a day of taking 
clozapine, so you are basically dependent on it 
Vomiting, memory loss, drooling.  I see other patients that drool, it means you are disabled 
Heart palpitations 
All of them 
Constipation, drowsiness 
Reduced sex drive, passing out, any physical effect 
Reduced WCC, immune system being destroyed 
Weight gain 
Reduced white cells 
Dizziness and drowsiness - I have these at the moment 
It would stop me functioning at school - I have Clopixol injection at the moment and it's 
stopping me concentrating 
Dizziness 
Dizziness 
Effect on white blood cells, increased heart rate, constipation, sleepiness 
Constipation 
Not sleeping, worrying, wanting to smoke 
The drop in white blood cells 
The drop in white blood cells 
None in particular, but generally I don't like medicines that make you feel drowsy 
Stuttering 






Table 7-47 Free-text responses to follow-up question of 'why' to 'on a scale of 0 to 4, how likely do you think 
clozapine would be to work for you?' 
Comment 
I've had drooling on amisulpride before, so I wouldn't want this to happen again.  I don't 
need clozapine.  But I recognise that if psychosis is really bad then people need clozapine 
and then for them any negative problems (having to have bloods done, the side effects, 
being admitted) are outweighed by the benefits.  So the problem is people not having any 
insight into the severity of their psychosis 
I haven't taken it so I can't really know 
The side effects.  I think clozapine would help but the side effects mean I'd prefer my 
current treatment 
I don't like changing medicines 
I don't know until I've tried it 
I'm not sure 
I only want injections - I'm old fashioned 
Risperidone works for me 
I don't know much about it.  But if it's better than other medicines I'd take it despite the side 
effects and the bloods 
I don't have hallucinations.  I don't know why I'd need to take it 
I'm homeless, so would have to come into hospital for clozapine so I wouldn't want to do 
that 
I want aripiprazole depot.  I only want to take the advice of the doctors on medication 
choice 
Side effects 
The side effects.  I already have constipation so that's worrying 
I have never tried clozapine so how would I know? 
It has certain vital elements that other medicines don't have 
I'm not sure what the effect of clozapine would be.  I don't like taking medicines 
From what I've heard from other patients, and also research I've done on the internet 
My current medicines are no good for me 
The side effects are similar to my current medicine 
Constipation 
I don't believe in any medicines 
It attacks the immune system 
The side effects - the reduced WCC means you might get viral infections 
The side effects.  Then you have to take more medicines for the side effects 
I don't know 
My body isn't used to it 
It would keep me out of hospital 
I would be worried about starting clozapine at home because side effects wouldn't be 
monitored 
Starting at home wouldn't make a difference because I'm on too many tablets already.  
Clozapine would much less helpful because it's a new drug to me 
I've never taken it; how would I know? 
It would have a sweet taste 
I trust what you say.  If you think I need clozapine, I'll take it 
It would give me more motivation 
I haven't tried clozapine.  But quetiapine has no side effects so I prefer that 
Because of the side effects 
The side effects, and if you need to be admitted to hospital 
Because of the benefits of clozapine 
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Comment 
I'm not sure 
I haven't taken clozapine so I don't know if it would be better than other medicines 
That's what it's designed to do 
We need to share the blood that we have 
I've never taken it so wouldn't know 
I haven't tried it 
Because it would help 
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Appendix G. Statistical data for chapter 5 
Figure 7-3 Scatter plot, intent to treat group, analysis method 1 
Table 7-48 Z-score for net change in days of admission post-clozapine, Intent to treat group, analysis method 
1 
 Frequency Percent Valid Percent Cumulative Percent 
Extreme Outliers 1 1.0 1.0 1.0 
Probable Outliers 4 3.9 3.9 4.9 
Potential Outliers 3 2.9 2.9 7.8 
Normal range 94 92.2 92.2 100.0 
Total 102 100.0 100.0  
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Table 7-49 Skewness and kurtosis for outcome data, Intent to treat group, analysis method 1 















N 102 102 102 102 
Mean 0.7347 -2.9848 3.9275 5.45 
Median 0.4300 3.4950 2.0450 4.00 
Std. 
Deviation 
1.19069 75.53929 4.61050 3.952 
Variance 1.418 5706.184 21.257 15.616 
Skewness 3.198 -0.937 1.582 2.083 
Std. Error of 
Skewness 
0.239 0.239 0.239 0.239 
Kurtosis 15.403 3.439 1.855 5.526 
Std. Error of 
Kurtosis 
0.474 0.474 0.474 0.474 
Range 9.37 501.30 18.58 23 
z-skewness 13.38 -3.92 6.62 8.72 
z-kurtosis 32.50 7.26 3.91 11.66 
Table 7-50 Kolmogorov-Smirnov and Shapiro-Wilk tests of normality, intent to treat group, method 1 
 Kolmogorov-Smirnov Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Net change in days of admission per 
year 
0.191 102 <0.0005 0.871 102 <0.0005 
Net change in number of admissions 
per year 
0.200 102 <0.0005 0.720 102 <0.0005 
Total number of antipsychotic 
prescriptions before clozapine 
0.222 102 <0.0005 0.794 102 <0.0005 
Clozapine theoretical delay 0.213 102 <0.0005 0.791 102 <0.0005 
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Figure 7-4 Wilcoxon signed rank test, change in days of admission per year, analysis method 1 
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Figure 7-5 Wilcoxon signed rank test, change in admissions per year, analysis method 1 
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Figure 7-6 Scatterplot, intent to treat group, analysis method 2 
Table 7-51 Z-score for net change in days of admission post-clozapine, Intent to treat group, analysis method 
2 




Extreme outliers 1 1.0 1.0 1.0 
Probable outliers 1 1.0 1.0 2.0 
Potential outliers 2 2.0 2.0 3.9 
Normal range 98 96.1 96.1 100.0 
Total 102 100.0 100.0  
Table 7-52 Paired samples t-test, intent to treat group, method 2 
 Paired Differences t df Sig. (2-

















0.34265 0.64808 0.06417 0.21535 0.46994 5.340 101 <0.0005 
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Figure 7-7 Scatter plot, intent to treat group, analysis method 3 
Table 7-53 Z-score for net change in days of admission post-clozapine, Intent to treat group, analysis method 
3 
 Frequency Percent Valid Percent Cumulative Percent 
Extreme Outliers 1 1.0 1.0 1.0 
Probable Outliers 4 3.9 3.9 4.9 
Potential Outliers 3 2.9 2.9 7.8 
Normal range 94 92.2 92.2 100.0 
Total 102 100.0 100.0  
  
 405 
















N 102 102 102 102 
Mean 3.9275 2.4234 0.7347 5.45 
Std. Error 
of Mean 
0.45651 7.54320 0.11790 0.391 
Median 2.0450 6.0850 0.4300 4.00 
Std. 
Deviation 
4.61050 76.18259 1.19069 3.952 
Variance 21.257 5803.787 1.418 15.616 




0.239 0.239 0.239 0.239 
Kurtosis 1.855 3.084 15.403 5.526 
Std. Error 
of Kurtosis 












Table 7-55 Kolmogorov-Smirnov and Shapiro-Wilk tests of normality, intent to treat group, method 3 
 Kolmogorov-Smirnov Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Net change in days of 
admission per year 
0.194 102 <0.0005 0.886 102 <0.0005 
Net change in number of 
admissions per year  
0.200 102 <0.0005 0.720 102 <0.0005 




0.222 102 <0.0005 0.794 102 <0.0005 
Clozapine theoretical 
delay 
0.213 102 <0.0005 0.791 102 <0.0005 
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Figure 7-8 Wilcoxon signed rank test, change in days of admission per year, analysis method 3 
 407 
Figure 7-9 Wilcoxon signed rank test, change in admissions per year, analysis method 3 
 408 
Figure 7-10 Scatter plot, intent to treat group, analysis method 4 
Table 7-56 Z-score for net change in days of admission post-clozapine, Intent to treat group, analysis method 
4 
 Frequency Percent Valid Percent Cumulative Percent 
Probable outliers 3 2.9 2.9 2.9 
Normal range 99 97.1 97.1 100.0 
Total 102 100.0 100.0  
Table 7-57 Paired samples t-test, intent to treat group, method 4 
 Paired Differences t df Sig. (2-

















0.73529 1.19063 0.11789 0.50143 0.96916 6.237 101 <0.0005 
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Figure 7-11 Scatter plot, intent to treat group, analysis method 5 
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Table 7-58 Z-score for net change in days of admission post-clozapine, Intent to treat group, analysis method 
5 
 Frequency Percent Valid Percent Cumulative Percent 
Extreme outliers 2 2.0 2.0 2.0 
Probable outliers 3 2.9 2.9 5.9 
Potential outliers 2 2.0 2.0 7.8 
Normal range 94 92.2 92.2 100.0 
Total 102 100.0 100.0  
Table 7-59 Skewness and kurtosis for analysis method 5 















N 102 102 102 102 
Mean 47.3139 0.7347 3.9275 5.45 
Std. Error 
of Mean 
9.18974 0.11790 0.45651 0.391 
Median 23.7350 0.4300 2.0450 4.00 
Std. 
Deviation 
92.81178 1.19069 4.61050 3.952 
Variance 8614.027 1.418 21.257 15.616 




0.239 0.239 0.239 0.239 

















Table 7-60 Kolmogorov-Smirnov and Shapiro-Wilk tests of normality, intent to treat group, method 5 
 Kolmogorov-Smirnov Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Net change in days of admission 
pre-post clozapine per year 
0.186 102 <0.0005 0.829 102 <0.0005 
Net change in number of admissions 
per year  
0.200 102 <0.0005 0.720 102 <0.0005 
Total number of antipsychotic 
prescriptions before clozapine 
0.222 102 <0.0005 0.794 102 <0.0005 
Clozapine theoretical delay 0.213 102 <0.0005 0.791 102 <0.0005 
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Figure 7-12 Wilcoxon signed rank test, change in days of admission per year, analysis method 5 
 412 
Figure 7-13 Wilcoxon signed rank test, change in admissions per year, analysis method 5 
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Figure 7-14 Q-Q plot, net change in days of admission per year, analysis method 1, clozapine continuers 
Table 7-61 Paired samples t-test, clozapine continuers group, method 1 
 Paired Differences t df Sig. (2-

















0.77313 1.21173 0.14804 0.47757 1.06870 5.223 66 <0.0005 










Figure 7-17 Q-Q plot, net change in days of admission per year, analysis method 2, clozapine continuers 
Table 7-62 Paired samples t-test, clozapine continuers group, method 2 
 Paired Differences t df Sig. (2-

















0.38940 0.53612 0.06550 0.25863 0.52017 5.945 66 <0.0005 
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Figure 7-18 Wilcoxon signed rank test, change in days of admission per year, clozapine continuers, analysis 
method 2 
 417 





Figure 7-20 Q-Q plot, net change in days of admission per year, analysis method 3, clozapine continuers 
Table 7-63 Paired samples t-test, clozapine continuers group, method 3 
 Paired Differences t df Sig. (2-

















0.77313 1.21173 0.14804 0.47757 1.06870 5.223 66 <0.0005 
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Figure 7-21 Wilcoxon signed rank test, change in days of admission per year, clozapine continuers, analysis 
method 3 
 420 




Figure 7-23 Q-Q plot, net change in days of admission per year, analysis method 4, clozapine continuers 
Table 7-64 Paired samples t-test, clozapine continuers group, method 4 
 Paired Differences t df Sig. (2-

















0.77313 1.21173 0.14804 0.47757 1.06870 5.223 66 <0.0005 
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Figure 7-24 Wilcoxon signed rank test, change in days of admission per year, clozapine continuers, analysis 
method 4 
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Figure 7-25 Wilcoxon signed rank test, change in admissions per year, clozapine continuers, analysis 
method 4 
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Figure 7-26 Q-Q plot, net change in days of admission per year, analysis method 5, clozapine continuers 
Table 7-65 Paired samples t-test, clozapine continuers group, method 5 
 Paired Differences t df Sig. (2-

















0.77313 1.21173 0.14804 0.47757 1.06870 5.223 66 <0.0005 
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Figure 7-27 Wilcoxon signed rank test, change in days of admission per year, clozapine continuers, analysis 
method 5 
 426 




Figure 7-29 Q-Q plot, net change in days of admission per year, analysis method 1, clozapine discontinuers 
Table 7-66 Paired samples t-test, clozapine discontinuers group, method 1 




















0.66286 1.16305 0.19659 0.26334 1.06238 3.372 34 0.002 
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Figure 7-30 Wilcoxon signed rank test, change in days of admission per year, clozapine discontinuers, 
analysis method 1 
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Figure 7-31 Wilcoxon signed rank test, change in admissions per year, clozapine discontinuers, analysis 




Figure 7-32 Q-Q plot, net change in days of admission per year, analysis method 2, clozapine discontinuers 
Table 7-67 Paired samples t-test, clozapine discontinuers group, method 2 




















0.25314 .82289 0.13909 -0.02953 0.53582 1.820 34 0.078 
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Figure 7-33 Wilcoxon signed rank test, change in days of admission per year, clozapine discontinuers, 
analysis method 2 
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Figure 7-34 Wilcoxon signed rank test, change in admissions per year, clozapine discontinuers, analysis 
method 2 
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Figure 7-35 Q-Q plot, net change in days of admission per year, analysis method 3, clozapine discontinuers 
Table 7-68 Paired samples t-test, clozapine discontinuers group, method 3 




















0.66286 1.16305 0.19659 0.26334 1.0624 3.372 34 0.002 
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Figure 7-36 Wilcoxon signed rank test, change in days of admission per year, clozapine discontinuers, 
analysis method 3 
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Figure 7-37 Wilcoxon signed rank test, change in admissions per year, clozapine discontinuers, analysis 
method 3 
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Figure 7-38 Q-Q plot, net change in days of admission per year, analysis method 4, clozapine discontinuers 
Table 7-69 Paired samples t-test, clozapine discontinuers group, method 4 




















0.66286 1.16305 0.19659 0.26334 1.06238 3.372 34 0.002 
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Figure 7-39 Wilcoxon signed rank test, change in days of admission per year, clozapine discontinuers, 
analysis method 4 
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Figure 7-40 Wilcoxon signed rank test, change in admissions per year, clozapine discontinuers, analysis 
method 4 
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Figure 7-41 Q-Q plot, net change in days of admission per year, analysis method 5, clozapine discontinuers 
Table 7-70 Paired samples t-test, clozapine discontinuers group, method 5 




















0.66286 1.16305 0.19659 0.26334 1.06238 3.372 34 0.002 
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Figure 7-42 Wilcoxon signed rank test, change in days of admission per year, clozapine discontinuers, 
analysis method 5 
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Figure 7-43 Wilcoxon signed rank test, change in admissions per year, clozapine discontinuers, analysis 
method 5 
Table 7-71 Linear regression model summary, change in days of admission per year, intent to treat group, 
method 1 
R R Square Adjusted R Square Std. Error of the 
Estimate 
0.054 0.003 -0.007 75.80351 
Table 7-72 ANOVA, change in days of admission per year, intent to treat group, method 1 
 Sum of 
Squares 
df Mean Square F Sig. 
Regression 1707.433 1 1707.433 0.297 .587 
Residual 574617.198 100 5746.172  
Total 576324.631 101  







B Std. Error Beta 
Constant -6.487 9.880  -0.657 0.513 
Clozapine theoretical 
delay 
0.892 1.636 0.054 0.545 0.587 
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Table 7-74 Bootstrapping for coefficients, change in days of admission per year, intent to treat group, method 
1 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant -6.487 -0.479 9.981 0.541 -26.071 11.814 
Clozapine theoretical 
delay 
0.892 0.099 1.192 0.466 -1.566 3.583 
Table 7-75 Linear regression model summary, change in number of admissions per year, intent to treat 
group, method 1 
R R Square Adjusted R Square Std. Error of the 
Estimate 
0.235 0.055 0.046 1.16307 
Table 7-76 ANOVA, change in number of admissions per year, intent to treat group, method 1 
 Sum of 
Squares 
df Mean Square F Sig. 
Regression 7.920 1 7.920 5.855 0.017 
Residual 135.272 100 1.353  
Total 143.192 101  







B Std. Error Beta 
Constant 0.973 0.152  6.420 <0.0005 
Clozapine theoretical 
delay 
-0.061 0.025 -0.235 -2.420 0.017 
Table 7-78 Bootstrapping for coefficients, change in number of admissions per year, intent to treat group, 
method 1 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.973 0.007 0.178 0.001 0.654 1.359 
Clozapine theoretical 
delay 
-0.061 -0.002 0.022 0.020 -0.110 -0.025 
Table 7-79 Linear regression model summary, change in days of admission per year, intent to treat group, 
method 2 
R R Square Adjusted R Square Std. Error of the 
Estimate 
0.095 0.009 -0.001 57.38544 
Table 7-80 ANOVA, change in days of admission per year, intent to treat group, method 2 
 Sum of 
Squares 
df Mean Square F Sig. 
Regression 2968.447 1 2968.447 0.901 0.345 
Residual 329308.882 100 3293.089  
Total 332277.329 101  
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B Std. Error Beta 
Constant 21.355 7.480  2.855 0.005 
Clozapine theoretical 
delay 
-1.176 1.238 -0.095 -
0.949 
0.345 
Table 7-82 Bootstrap for Coefficients, change in days of admission per year, intent to treat group, method 2 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 21.355 -0.114 7.554 0.007 6.556 35.420 
Clozapine theoretical 
delay 
-1.176 0.034 0.910 0.191 -3.115 0.679 
Table 7-83 Linear regression model summary, change in number of admissions per year, intent to treat 
group, method 2 
R R Square Adjusted R Square Std. Error of the 
Estimate 
0.112 0.013 0.003 0.64756 
Table 7-84 ANOVA, change in number of admissions per year, intent to treat group, method 2 





Regression 0.535 1 0.535 1.275 0.261 
Residual 41.933 100 0.419   
Total 42.468 101    







B Std. Error Beta 
Constant 0.405 0.084  4.796 <0.0005 
Clozapine theoretical 
delay 
-0.016 0.014 -0.112 -1.129 0.261 
Table 7-86 Bootstrap for Coefficients, change in number of admissions per year, intent to treat group, method 
2 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.405 -0.001 0.089 0.001 0.233 0.580 
Clozapine theoretical 
delay 
-0.016 <0.0005 0.012 0.203 -0.040 0.007 
Table 7-87 Linear regression model summary, change in days of admission per year, intent to treat group, 
method 3 
R R Square Adjusted R Square Std. Error of the 
Estimate 
0.016 < 0.0005 -0.010 76.55247 
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Table 7-88 ANOVA, change in days of admission per year, intent to treat group, method 3 
 Sum of 
Squares 
df Mean Square F Sig. 
Regression 154.441 1 154.441 0.026 0.871 
Residual 586028.025 100 5860.280  
Total 586182.465 101  







B Std. Error Beta 
Constant 1.370 9.978  0.137 0.891 
Clozapine theoretical 
delay 
0.268 1.652 0.016 0.162 0.871 
Table 7-90 Bootstrap for Coefficients, change in days of admission per year, intent to treat group, method 3 










10.371 0.884 -18.511 19.927 
Clozapine theoretical 
delay 
0.268 0.072 1.214 0.817 -2.291 2.835 
Table 7-91Linear regression model summary, change in days of admission per year, intent to treat group, 
method 3 
R R Square Adjusted R Square Std. Error of the 
Estimate 
0.235 0.055 0.046 1.16307 
Table 7-92 ANOVA, change in days of admission per year, intent to treat group, method 3 
 Sum of Squares df Mean Square F Sig. 
Regression 7.920 1 7.920 5.855 0.017 
Residual 135.272 100 1.353  
Total 143.192 101  







B Std. Error Beta 
Constant 0.973 0.152  6.420 <0.0005 
Clozapine theoretical 
delay 
-0.061 0.025 -0.235 -2.420 0.017 
Table 7-94 Bootstrap for Coefficients, change in days of admission per year, intent to treat group, method 3 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.973 -0.007 0.183 0.001 0.661 1.307 
Clozapine theoretical 
delay 
-0.061 <0.0005 0.022 0.027 -0.116 -0.021 
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Table 7-95 Linear regression model summary, change in days of admission per year, intent to treat group, 
method 4 
R R Square Adjusted R Square Std. Error of the Estimate 
0.019 <0.0005 -0.010 79.75255 
Table 7-96 ANOVA, change in days of admission per year, intent to treat group, method 4 
 Sum of Squares df Mean Square F Sig. 
Regression 237.574 1 237.574 0.037 0.847 
Residual 636046.884 100 6360.469   
Total 636284.458 101    







B Std. Error Beta 
Constant 9.284 10.395  0.893 0.374 
Clozapine theoretical 
delay 
-0.333 1.721 -0.019 -0.193 0.847 
Table 7-98 Bootstrap for Coefficients, change in days of admission per year, intent to treat group, method 4 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 9.284 -0.150 10.961 0.402 -11.374 30.498 
Clozapine 
theoretical delay 
-0.333 0.030 1.285 0.820 -3.028 2.254 
Table 7-99 Linear regression model summary, change in number of admissions per year, intent to treat 
group, method 4 
R R Square Adjusted R Square Std. Error of the Estimate 
0.235 0.055 0.046 1.16307 
Table 7-100 ANOVA, change in number of admissions per year, intent to treat group, method 4 





Regression 7.920 1 7.920 5.855 0.017 
Residual 135.272 100 1.353  
Total 143.192 101  







B Std. Error Beta 
Constant 0.973 0.152  6.420 <0.0005 
Clozapine theoretical 
delay 
-0.061 0.025 -0.235 -2.420 0.017 
Table 7-102 Bootstrap for Coefficients, change in number of admissions per year, intent to treat group, 
method 4 





BCa 95% Confidence 
Interval 
Lower Upper 





<0.0005 0.023 0.025 -0.117 -0.018 
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Table 7-103 Linear regression model summary, change in days of admission per year, intent to treat group, 
method 5 
R R Square Adjusted R Square Std. Error of the Estimate 
0.208 0.043 0.034 91.24355 
Table 7-104 ANOVA, change in days of admission per year, intent to treat group, method 5 
 Sum of Squares df Mean Square F Sig. 
Regression 37478.189 1 37478.189 4.502 0.036 
Residual 832538.572 100 8325.386   
Total 870016.761 101    







B Std. Error Beta 
Constant 63.723 11.893  5.358 <0.0005 
Clozapine theoretical 
delay 
-4.178 1.969 -0.208 -2.122 0.036 
Table 7-106 Bootstrap for Coefficients, change in days of admission per year, intent to treat group, method 
5 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 63.723 -0.099 13.325 0.002 38.464 90.419 
Clozapine theoretical 
delay 
-4.178 -0.016 1.507 0.017 -7.459 -1.210 
Table 7-107 Linear regression model summary, change in number of admissions per year, intent to treat 
group, method 5 
R R Square Adjusted R Square Std. Error of the Estimate 
0.235 0.055 0.046 1.16307 
Table 7-108 ANOVA, change in number of admissions per year, intent to treat group, method 5 
 Sum of Squares df Mean Square F Sig. 
Regression 7.920 1 7.920 5.855 0.017 
Residual 135.272 100 1.353  
Total 143.192 101  







B Std. Error Beta 
Constant 0.973 0.152  6.420 <0.0005 
Clozapine theoretical 
delay 
-0.061 0.025 -0.235 -2.420 0.017 
Table 7-110 Bootstrap for Coefficients, change in number of admissions per year, intent to treat group, 
method 5 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.973 -0.001 0.183 0.001 0.662 1.310 
Clozapine theoretical 
delay 
-0.061 -0.001 0.022 0.028 -0.113 -0.023 
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Table 7-111 Linear regression model summary, change in days of admission per year, clozapine continuers 
group, method 1 
R R Square Adjusted R Square Std. Error of the Estimate 
0.065 0.004 -0.011 62.46892 
Table 7-112 ANOVA, change in days of admission per year, clozapine continuers group, method 1 
 Sum of Squares df Mean Square F Sig. 
Regression 1068.707 1 1068.707 0.274 0.603 
Residual 253653.751 65 3902.365   
Total 254722.459 66    
Table 7-113 Linear regression coefficients, change in days of admission per year, clozapine continuers 






B Std. Error Beta 
Constant 8.776 10.304  0.852 0.398 
Clozapine theoretical 
delay 
0.876 1.674 0.065 0.523 0.603 
Table 7-114 Bootstrap for Coefficients, change in days of admission per year, clozapine continuers group, 
method 1 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 8.776 -0.092 10.489 0.422 -12.432 28.414 
Clozapine 
theoretical delay 
0.876 -0.016 1.141 0.443 -1.382 3.127 
Table 7-115 Linear regression model summary, change in number of admissions per year, clozapine 
continuers group, method 1 
R R Square Adjusted R Square Std. Error of the Estimate 
0.198 0.039 0.024 1.19719 
Table 7-116 ANOVA, change in number of admissions per year, clozapine continuers group, method 1 
 Sum of Squares df Mean Square F Sig. 
Regression 3.791 1 3.791 2.645 0.109 
Residual 93.163 65 1.433  
Total 96.954 66  
Table 7-117 Linear regression coefficients, change in number of admissions per year, clozapine continuers 






B Std. Error Beta 
Constant 0.988 0.197  5.004 <0.0005 
Clozapine theoretical 
delay 
-0.052 0.032 -0.198 -1.626 0.109 
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Table 7-118 Bootstrap for Coefficients, change in number of admissions per year, clozapine continuers 
group, method 1 





BCa 95% Confidence 
Interval 
Lower Upper 







0.031 0.140 -0.126 -0.004 
Table 7-119 Linear regression model summary, change in days of admission per year, clozapine continuers 
group, method 2 
R R Square Adjusted R Square Std. Error of the Estimate 
0.046 0.002 -0.013 47.89324 
Table 7-120 ANOVA, change in days of admission per year, clozapine continuers group, method 2 
 Sum of Squares df Mean Square F Sig. 
Regression 322.159 1 322.159 0.140 0.709 
Residual 149094.555 65 2293.762  
Total 149416.714 66  
Table 7-121 Linear regression coefficients, change in days of admission per year, clozapine continuers 






B Std. Error Beta 
Constant 26.727 7.900  3.383 0.001 
Clozapine theoretical 
delay 
-0.481 1.284 -0.046 -0.375 0.709 
Table 7-122 Bootstrap for Coefficients, change in days of admission per year, clozapine continuers group, 
method 2 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 26.727 0.525 7.603 0.002 12.496 43.851 
Clozapine 
theoretical delay 
-0.481 -0.082 0.921 0.590 -2.347 1.067 
Table 7-123 Linear regression model summary, change in number of admissions per year, clozapine 
continuers group, method 2 
R R Square Adjusted R Square Std. Error of the Estimate 
0.127 0.016 0.001 .24378 
Table 7-124 ANOVA, change in number of admissions per year, clozapine continuers group, method 2 
 Sum of Squares df Mean Square F Sig. 
Regression 0.063 1 0.063 1.059 0.307 
Residual 3.863 65 0.059  
Total 3.926 66  
Table 7-125 Linear regression coefficients, change in number of admissions per year, clozapine continuers 






B Std. Error Beta 
Constant 0.081 0.040  2.003 0.049 
Clozapine theoretical 
delay 
0.007 0.007 0.127 1.029 0.307 
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Table 7-126 Bootstrap for Coefficients, change in number of admissions per year, clozapine continuers 
group, method 2 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.081 -0.001 0.034 0.027 0.023 0.146 
Clozapine theoretical 
delay 
0.007 <0.0005 0.007 0.317 -0.004 0.021 
Table 7-127 Linear regression model summary, change in days of admission per year, clozapine continuers 
group, method 3 
R R Square Adjusted R Square Std. Error of the Estimate 
0.015 <0.0005 -0.015 63.72243 
Table 7-128 ANOVA, change in days of admission per year, clozapine continuers group, method 3 
 Sum of Squares df Mean Square F Sig. 
Regression 57.193 1 57.193 0.014 0.906 
Residual 263935.612 65 4060.548   
Total 263992.805 66    
Table 7-129 Linear regression coefficients, change in days of admission per year, clozapine continuers 






B Std. Error Beta 
Constant 16.861 10.511  1.604 0.114 
Clozapine theoretical 
delay 
0.203 1.708 0.015 0.119 0.906 
Table 7-130 Bootstrap for coefficients, change in days of admission per year, clozapine continuers, method 
3 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 16.861 -0.038 10.872 0.131 -4.907 36.290 
Clozapine 
theoretical delay 
0.203 -0.041 1.207 0.858 -2.349 2.469 
Table 7-131 Linear regression model summary, change in number of admissions per year, clozapine 
continuers group, method 3 
R R Square Adjusted R Square Std. Error of the Estimate 
0.198 0.039 0.024 1.19719 
Table 7-132 ANOVA, change in number of admissions per year, clozapine continuers group, method 3 
 Sum of Squares df Mean Square F Sig. 
Regression 3.791 1 3.791 2.645 0.109 
Residual 93.163 65 1.433  
Total 96.954 66  
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Table 7-133 Linear regression coefficients, change in number of admissions per year, clozapine continuers 






B Std. Error Beta 
Constant 0.988 0.197  5.004 <0.0005 
Clozapine theoretical 
delay 
-0.052 0.032 -0.198 -1.626 0.109 
Table 7-134 Bootstrap for coefficients, change in number of admissions per year, clozapine continuers, 
method 3 





BCa 95% Confidence 
Interval 
Lower Upper 







0.031 0.142 -0.129 -0.005 
Table 7-135 Linear regression model summary, change in days of admission per year, clozapine continuers 
group, method 4 
R R Square Adjusted R Square Std. Error of the Estimate 
0.030 0.001 -0.014 68.58996 
Table 7-136 ANOVA, change in days of admission per year, clozapine continuers group, method 4 
 Sum of Squares df Mean Square F Sig. 
Regression 276.130 1 276.130 0.059 0.809 
Residual 305797.858 65 4704.582  
Total 306073.987 66  
Table 7-137 Linear regression coefficients, change in days of admission per year, clozapine continuers 






B Std. Error Beta 
Constant 25.030 11.314  2.212 0.030 
Clozapine theoretical 
delay 
-0.445 1.839 -0.030 -0.242 0.809 
Table 7-138 Bootstrap for Coefficients, change in days of admission per year, clozapine continuers group, 
method 4 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 25.030 -0.334 12.486 0.056 -.318 48.063 
Clozapine 
theoretical delay 
-0.445 -0.012 1.403 0.760 -3.181 2.220 
Table 7-139 Linear regression model summary, change in number of admissions per year, clozapine 
continuers group, method 4 
R R Square Adjusted R Square Std. Error of the Estimate 
0.198 0.039 0.024 1.19719 
Table 7-140 ANOVA, change in number of admissions per year, clozapine continuers group, method 4 
 Sum of Squares df Mean Square F Sig. 
Regression 3.791 1 3.791 2.645 0.109 
Residual 93.163 65 1.433  
Total 96.954 66  
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Table 7-141 Linear regression coefficients, change in number of admissions per year, clozapine continuers 






B Std. Error Beta 
Constant 0.988 0.197  5.004 <0.0005 
Clozapine theoretical 
delay 
-0.052 0.032 -0.198 -
1.626 
0.109 
Table 7-142 Bootstrap for Coefficients, change in number of admissions per year, clozapine continuers 
group, method 4 





BCa 95% Confidence 
Interval 
Lower Upper 







0.031 0.153 -0.127 -0.005 
Table 7-143 Linear regression model summary, change in days of admission per year, clozapine continuers 
group, method 5 
R R Square Adjusted R Square Std. Error of the Estimate 
0.196 0.038 0.024 79.81468 
Table 7-144 ANOVA, change in days of admission per year, clozapine continuers group, method 5 
 Sum of Squares df Mean Square F Sig. 
Regression 16537.610 1 16537.610 2.596 0.112 
Residual 414074.892 65 6370.383  
Total 430612.502 66  
Table 7-145 Linear regression coefficients, change in days of admission per year, clozapine continuers 
group, method 5 
 B Std. Error Beta t Sig. 
Constant 68.574 13.165  5.209 <0.0005 
Clozapine theoretical delay -3.447 2.139 -0.196 -1.611 0.112 
Table 7-146 Bootstrap for Coefficients, change in days of admission per year, clozapine continuers group, 
method 5 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 68.574 0.438 15.849 0.003 39.831 102.445 
Clozapine 
theoretical delay 
-3.447 -0.152 1.896 0.079 -7.647 -0.431 
Table 7-147 Linear regression model summary, change in number of admissions per year, clozapine 
continuers group, method 5 
R R Square Adjusted R Square Std. Error of the Estimate 
0.198 0.039 0.024 1.19719 
Table 7-148 ANOVA, change in number of admissions per year, clozapine continuers group, method 5 
 Sum of Squares df Mean Square F Sig. 
Regression 3.791 1 3.791 2.645 0.109 
Residual 93.163 65 1.433   
Total 96.954 66    
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Table 7-149 Linear regression coefficients, change in number of admissions per year, clozapine continuers 






B Std. Error Beta 
Constant 0.988 0.197  5.004 <0.0005 
Clozapine theoretical 
delay 
-0.052 0.032 -0.198 -1.626 0.109 
Table 7-150 Bootstrap for Coefficients, change in number of admissions per year, clozapine continuers 
group, method 5 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.988 <0.0005 0.246 0.017 0.597 1.451 
Clozapine 
theoretical delay 
-0.052 -0.002 0.032 0.150 -0.127 -0.002 
Table 7-151 Linear regression model summary, change in days of admission per year, clozapine 
discontinuers group, method 1 
R R Square Adjusted R Square Std. Error of the Estimate 
0.005 <0.0005 -0.030 91.35137 
Table 7-152 ANOVA, change in days of admission per year, clozapine discontinuers group, method 1 
 Sum of Squares df Mean Square F Sig. 
Regression 7.018 1 7.018 0.001 0.977 
Residual 275387.383 33 8345.072  
Total 275394.401 34  
Table 7-153 Linear regression coefficients, change in days of admission per year, clozapine discontinuers 






B Std. Error Beta 
Constant -32.775 19.436  -1.686 0.101 
Clozapine theoretical 
delay 
0.097 3.343 0.005 0.029 0.977 
Table 7-154 Bootstrap for coefficients, change in days of admission per year, clozapine discontinuers group, 
method 1 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant -32.775 -1.958 19.209 0.109 -71.884 -1.083 
Clozapine 
theoretical delay 
0.097 0.349 2.181 0.970 -4.642 5.594 
Table 7-155 Linear regression model summary, change in number of admissions per year, clozapine 
discontinuers group, method 1 
R R Square Adjusted R Square Std. Error of the Estimate 
0.320 0.102 0.075 1.11810 
Table 7-156 ANOVA, change in number of admissions per year, clozapine discontinuers group, method 1 
 Sum of Squares df Mean Square F Sig. 
Regression 4.707 1 4.707 3.765 0.061 
Residual 41.255 33 1.250  
Total 45.961 34  
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Table 7-157 Linear regression coefficients, change in number of admissions per year, clozapine 






B Std. Error Beta 
Constant 0.943 0.238  3.964 <0.0005 
Clozapine theoretical 
delay 
-0.079 0.041 -0.320 -1.940 0.061 
Table 7-158 Bootstrap for coefficients, change in number of admissions per year, clozapine discontinuers 
group, method 1 





BCa 95% Confidence 
Interval 
Lower Upper 







0.038 0.027 -0.170 -0.031 
Table 7-159 Linear regression model summary, change in days of admission per year, clozapine 
discontinuers group, method 2 
R R Square Adjusted R Square Std. Error of the Estimate 
0.193 0.037 0.008 70.49758 
Table 7-160 ANOVA, change in days of admission per year, clozapine discontinuers group, method 2 
 Sum of Squares df Mean Square F Sig. 
Regression 6356.659 1 6356.659 1.279 0.266 
Residual 164007.010 33 4969.909  
Total 170363.669 34  
Table 7-161 Linear regression coefficients, change in days of admission per year, clozapine discontinuers 






B Std. Error Beta 




-2.918 2.580 -0.193 -1.131 0.266 
Table 7-162 Bootstrap for coefficients, change in days of admission per year, clozapine discontinuers group, 
method 2 















1.669 0.093 -6.469 -0.127 
Table 7-163 Linear regression model summary, change in number of admissions per year, clozapine 
discontinuers group, method 2 
R R Square Adjusted R Square Std. Error of the Estimate 
0.136 0.019 -0.011 0.53113 
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Table 7-164 ANOVA, change in number of admissions per year, clozapine discontinuers group, method 2 
 Sum of Squares df Mean Square F Sig. 
Regression 0.176 1 0.176 0.623 0.436 
Residual 9.309 33 0.282   
Total 9.485 34    
Table 7-165 Linear regression coefficients, change in number of admissions per year, clozapine 






B Std. Error Beta 
Constant 0.359 0.113  3.179 0.003 
Clozapine theoretical 
delay 
0.015 0.019 0.136 0.789 0.436 
Table 7-166 Bootstrap for coefficients, change in number of admissions per year, clozapine discontinuers 
group, method 2 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.359 -0.002 0.119 0.024 0.162 0.593 
Clozapine theoretical 
delay 
0.015 0.002 0.016 0.376 -0.014 0.051 
Table 7-167 Linear regression model summary, change in days of admission per year, clozapine 
discontinuers group, method 3 
R R Square Adjusted R Square Std. Error of the Estimate 
0.023 0.001 -0.030 91.53356 
Table 7-168 ANOVA, change in days of admission per year, clozapine discontinuers group, method 3 
 Sum of Squares df Mean Square F Sig. 
Regression 141.064 1 141.064 0.017 0.898 
Residual 276486.977 33 8378.393  
Total 276628.041 34  
Table 7-169 Linear regression coefficients, change in days of admission per year, clozapine discontinuers 






B Std. Error Beta 
Constant -25.284 19.475  -1.298 0.203 
Clozapine theoretical 
delay 
-0.435 3.350 -0.023 -0.130 0.898 
Table 7-170 Bootstrap for coefficients, change in days of admission per year, clozapine discontinuers group, 
method 3 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant -25.284 -1.970 19.101 0.194 -64.528 5.910 
Clozapine 
theoretical delay 
-0.435 0.304 2.154 0.842 -5.171 4.694 
Table 7-171 Linear regression model summary, change in number of admissions per year, clozapine 
discontinuers group, method 3 
R R Square Adjusted R Square Std. Error of the Estimate 
0.320 0.102 0.075 1.11810 
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Table 7-172 ANOVA, change in number of admissions per year, clozapine discontinuers group, method 3 
 Sum of Squares df Mean Square F Sig. 
Regression 4.707 1 4.707 3.765 0.061 
Residual 41.255 33 1.250  
Total 45.961 34  
Table 7-173 Linear regression coefficients, change in number of admissions per year, clozapine 






B Std. Error Beta 
Constant 0.943 0.238  3.964 <0.0005 
Clozapine theoretical 
delay 
-0.079 0.041 -0.320 -1.940 0.061 
Table 7-174 Bootstrap for coefficients, change in number of admissions per year, clozapine discontinuers 
group, method 3 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.943 0.001 0.263 0.005 0.457 1.460 
Clozapine 
theoretical delay 
-0.079 -0.005 0.037 0.026 -0.171 -0.028 
Table 7-175 Linear regression model summary, change in days of admission per year, clozapine 
discontinuers group, method 4 
R R Square Adjusted R Square Std. Error of the Estimate 
0.049 0.002 -0.028 92.82800 
Table 7-176 ANOVA, change in days of admission per year, clozapine discontinuers group, method 4 
 Sum of Squares df Mean Square F Sig. 
Regression 674.788 1 674.788 0.078 0.781 
Residual 284362.227 33 8617.037  
Total 285037.014 34  
Table 7-177 Linear regression coefficients, change in days of admission per year, clozapine discontinuers 






B Std. Error Beta 
Constant -17.783 19.750  -0.900 0.374 
Clozapine theoretical 
delay 
-0.951 3.397 -0.049 -0.280 0.781 
Table 7-178 Bootstrap for coefficients, change in days of admission per year, clozapine discontinuers group, 
method 4 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant -17.783 -0.469 20.550 0.406 -59.192 20.119 
Clozapine 
theoretical delay 
-0.951 0.140 2.323 0.662 -6.453 4.577 
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Table 7-179 Linear regression model summary, change in number of admissions per year, clozapine 
discontinuers group, method 4 
R R Square Adjusted R Square Std. Error of the Estimate 
0.320 0.102 0.075 1.11810 
Table 7-180 ANOVA, change in number of admissions per year, clozapine discontinuers group, method 4 
 Sum of Squares df Mean Square F Sig. 
Regression 4.707 1 4.707 3.765 0.061 
Residual 41.255 33 1.250  
Total 45.961 34  
Table 7-181 Linear regression coefficients, change in number of admissions per year, clozapine 






B Std. Error Beta 
Constant 0.943 0.238  3.964 <0.0005 
Clozapine 
theoretical delay 
-0.079 0.041 -0.320 -1.940 0.061 
Table 7-182 Bootstrap for coefficients, change in number of admissions per year, clozapine discontinuers 
group, method 4 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.943 0.019 0.277 0.003 0.404 1.551 
Clozapine 
theoretical delay 
-0.079 -0.007 0.041 0.031 -0.159 -0.033 
Table 7-183 Linear regression model summary, change in days of admission per year, clozapine 
discontinuers group, method 5 
R R Square Adjusted R Square Std. Error of the Estimate 
0.249 0.062 0.033 110.53921 
Table 7-184 ANOVA, change in days of admission per year, clozapine discontinuers group, method 5 
 Sum of Squares df Mean Square F Sig. 
Regression 26592.130 1 26592.130 2.176 0.150 
Residual 403224.229 33 12218.916  
Total 429816.360 34  
Table 7-185 Linear regression coefficients, change in days of admission per year, clozapine discontinuers 






B Std. Error Beta 
Constant 54.970 23.518  2.337 0.026 
Clozapine theoretical 
delay 
-5.968 4.045 -0.249 -1.475 0.150 
Table 7-186 Bootstrap for coefficients, change in days of admission per year, clozapine discontinuers group, 
method 5 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 54.970 2.912 24.807 0.046 3.113 116.499 
Clozapine theoretical 
delay 
-5.968 -0.602 2.912 0.034 -11.913 -2.213 
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Table 7-187 Linear regression model summary, change in number of admissions per year, clozapine 
discontinuers group, method 5 
R R Square Adjusted R Square Std. Error of the Estimate 
0.320 0.102 0.075 1.11810 
Table 7-188 ANOVA, change in number of admissions per year, clozapine discontinuers group, method 5 
 Sum of Squares df Mean Square F Sig. 
Regression 4.707 1 4.707 3.765 0.061 
Residual 41.255 33 1.250   
Total 45.961 34    
Table 7-189 Linear regression coefficients, change in number of admissions per year, clozapine 






B Std. Error Beta 
Constant 0.943 0.238  3.964 <0.0005 
Clozapine theoretical 
delay 
-0.079 0.041 -0.320 -1.940 0.061 
Table 7-190 Bootstrap for coefficients, change in number of admissions per year, clozapine discontinuers 
group, method 5 





BCa 95% Confidence 
Interval 
Lower Upper 
Constant 0.943 0.031 0.263 0.008 0.415 1.588 
Clozapine 
theoretical delay 
-0.079 -0.009 0.038 0.028 -0.160 -0.038 
Table 7-191 MANOVA patient demographics, intent to treat group 
 Category N 
Gender Male 64 
Female 38 
Age 20 - 29 17 
30 - 39 37 
40 - 49 38 
50 -59 8 
60 - 69 1 
70 - 79 1 









Clozapine continuer or discontinuer Continuer 67 
Discontinuer 35 
Total number of antipsychotics pre-clozapine 1 - 2 16 
3 - 5 49 
6 - 10 27 
11 + 10 
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Table 7-192 MANOVA test for equality of covariance matrices, intent to treat group 





Table 7-193 MANOVA test statistics, intent to treat group 





Intercept Pillai's Trace 0.382 5.861 2.000 19.000 0.010 
Wilks' 
Lambda 
0.618 5.861 2.000 19.000 0.010 
Hotelling's 
Trace 
0.617 5.861 2.000 19.000 0.010 
Roy's Largest 
Root 
0.617 5.861 2.000 19.000 0.010 
Gender Pillai's Trace 0.065 0.659 2.000 19.000 0.529 
Wilks' 
Lambda 
0.935 0.659 2.000 19.000 0.529 
Hotelling's 
Trace 
0.069 0.659 2.000 19.000 0.529 
Roy's Largest 
Root 
0.069 0.659 2.000 19.000 0.529 
Age Pillai's Trace 0.727 2.283 10.000 40.000 0.032 
Wilks' 
Lambda 
0.398 2.220 10.000 38.000 0.038 
Hotelling's 
Trace 
1.196 2.152 10.000 36.000 0.045 
Roy's Largest 
Root 
0.806 3.223 5.000 20.000 0.027 
Ethnicity Pillai's Trace 0.266 0.768 8.000 40.000 0.633 
Wilks' 
Lambda 
0.736 0.788 8.000 38.000 0.616 
Hotelling's 
Trace 
0.357 0.803 8.000 36.000 0.604 
Roy's Largest 
Root 
0.350 1.750 4.000 20.000 0.179 
Diagnosis Pillai's Trace 0.149 0.536 6.000 40.000 0.777 
Wilks' 
Lambda 
0.855 0.516 6.000 38.000 0.793 
Hotelling's 
Trace 
0.165 0.495 6.000 36.000 0.808 
Roy's Largest 
Root 
0.129 0.859 3.000 20.000 0.478 
Clozapine continuer or 
discontinuer 
Pillai's Trace 0.224 2.750 2.000 19.000 0.089 
Wilks' 
Lambda 
0.776 2.750 2.000 19.000 0.089 
Hotelling's 
Trace 
0.289 2.750 2.000 19.000 0.089 
Roy's Largest 
Root 
0.289 2.750 2.000 19.000 0.089 
Total number of 
antipsychotics pre-clozapine 
Pillai's Trace 0.357 1.446 6.000 40.000 0.221 
Wilks' 
Lambda 
0.674 1.381 6.000 38.000 0.247 
Hotelling's 
Trace 
0.438 1.315 6.000 36.000 0.275 
Roy's Largest 
Root 
0.272 1.815 3.000 20.000 0.177 
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Table 7-194 MANOVA Levene's test of equality of error variances, intent to treat group 
 F df1 df2 Sig. 
Net change in days of admission per year 2.432 81 20 0.014 
Net change in number of admissions per year  1.536 81 20 0.139 
Table 7-195 ANOVA summary table, intent to treat group 
Source Dependent 
Variable 





Corrected Model Net change in 
days of 
admission 
291115.477 81 3594.018 1.746 0.079 
Net change in 
number of 
admissions 
36.769 81 0.454 1.593 0.119 
Intercept Net change in 
days of 
admission 
3879.570 1 3879.570 1.885 0.185 
Net change in 
number of 
admissions  
3.163 1 3.163 11.100 0.003 
Gender Net change in 
days of 
admission 
2853.128 1 2853.128 1.386 0.253 
Net change in 
number of 
admissions  
0.182 1 0.182 0.639 0.433 
Age Net change in 
days of 
admission 
32649.207 5 6529.841 3.173 0.029 
Net change in 
number of 
admissions 
2.868 5 0.574 2.013 0.120 
Ethnicity Net change in 
days of 
admission 
2014.601 4 503.650 0.245 0.909 
Net change in 
number of 
admissions 
0.472 4 0.118 0.414 0.796 
Diagnosis Net change in 
days of 
admission 
5231.681 3 1743.894 0.847 0.484 
Net change in 
number of 
admissions 
0.367 3 0.122 0.430 0.734 
Clozapine continuer 
or discontinuer 
Net change in 
days of 
admission 
11348.115 1 11348.115 5.514 0.029 
Net change in 
number of 
admissions  
1.082 1 1.082 3.796 0.066 
Total number of 
antipsychotics pre-
clozapine 
Net change in 
days of 
admission 
7428.049 3 2476.016 1.203 0.334 
Net change in 
number of 
admissions 
1.480 3 0.493 1.732 0.193 
Residual sum of 
squares 
Net change in 
days of 
admission 









Net change in 
number of 
admissions 
5.699 20 0.285 
Total Net change in 
days of 
admission 
360850.836 102  




Total sums of 
squares 








Table 7-196 MANOVA eigenvalues, age variable, intent to treat group 
Variate Eigenvalue % of Variance Cumulative % Canonical Correlation 
1 0.105 91.4 91.4 0.309 
2 0.010 8.6 100.0 0.099 
Table 7-197 MANOVA, significance tests for variates, age variable, intent to treat group 
Test of variate(s) Wilks' Lambda Chi-square df Sig. 
1 through 2 0.896 10.672 10 0.384 
2 0.990 0.954 4 0.917 
Table 7-198 MANOVA, canonical variate correlation coefficients, age variable, intent to treat group 
 Variate 
1 2 
Net change in days of admission per year 0.996 0.090 
Net change in number of admissions per year 0.522 0.853 
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Figure 7-44 MANOVA, combined group plot, age variable, intent to treat group 
Figure 7-45 MANOVA histogram, age variable, intent to treat group 
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Table 7-199 MANOVA patient demographics, age variable combined, intent to treat group 
 Value Label N 
Age category 1 20 - 29 17 
2 30 - 39 37 
3 40 - 49 38 
4 > 50 10 
Gender 1 Male 64 
2 Female 38 
Ethnicity category 1 White 45 
2 Black 38 
3 Asian 9 
4 Mixed 7 
5 Other 3 
Diagnosis 1 F20 68 
2 F25 17 
3 F31 6 
4 Other 11 
Total number of antipsychotics pre-clozapine category 1 1 - 2 16 
2 3 - 5 49 
3 6 - 10 27 
4 11 + 10 
Clozapine continuer or discontinuer 0 Continuer 67 
1 Discontinuer 35 
Table 7-200 MANOVA test for equality of covariance matrices, age variable combined, intent to treat group 







Table 7-201 MANOVA test statistics, age variable combined, intent to treat group 





Intercept Pillai's Trace 0.413 6.671 2.000 19.000 0.006 
Wilks' Lambda 0.587 6.671 2.000 19.000 0.006 
Hotelling's Trace 0.702 6.671 2.000 19.000 0.006 
Roy's Largest 
Root 
0.702 6.671 2.000 19.000 0.006 
Age Pillai's Trace 0.553 2.545 6.000 40.000 0.035 
Wilks' Lambda 0.500 2.620 6.000 38.000 0.032 
Hotelling's Trace 0.893 2.678 6.000 36.000 0.030 
Roy's Largest 
Root 
0.752 5.014 3.000 20.000 0.009 
Gender Pillai's Trace 0.094 0.990 2.000 19.000 0.390 
Wilks' Lambda 0.906 0.990 2.000 19.000 0.390 
Hotelling's Trace 0.104 0.990 2.000 19.000 0.390 
Roy's Largest 
Root 
0.104 0.990 2.000 19.000 0.390 
Ethnicity Pillai's Trace 0.266 0.768 8.000 40.000 0.633 
Wilks' Lambda 0.736 0.788 8.000 38.000 0.616 
Hotelling's Trace 0.357 0.803 8.000 36.000 0.604 
Roy's Largest 
Root 
0.350 1.750 4.000 20.000 0.179 
Diagnosis Pillai's Trace 0.149 0.536 6.000 40.000 0.777 
Wilks' Lambda 0.855 0.516 6.000 38.000 0.793 
Hotelling's Trace 0.165 0.495 6.000 36.000 0.808 
Roy's Largest 
Root 




Pillai's Trace 0.357 1.446 6.000 40.000 0.221 
Wilks' Lambda 0.674 1.381 6.000 38.000 0.247 
Hotelling's Trace 0.438 1.315 6.000 36.000 0.275 
Roy's Largest 
Root 




Pillai's Trace 0.224 2.750 2.000 19.000 0.089 
Wilks' Lambda 0.776 2.750 2.000 19.000 0.089 
Hotelling's Trace 0.289 2.750 2.000 19.000 0.089 
Roy's Largest 
Root 
0.289 2.750 2.000 19.000 0.089 
Table 7-202 MANOVA Levene's test of equality of error variances, age variable combined, intent to treat 
group 
 F df1 df2 Sig. 
Net change in days of admission per year 2.432 81 20 0.014 
Net change in number of admissions per year 1.536 81 20 0.139 
Table 7-203 ANOVA summary table, age variable combined, intent to treat group 
Source Dependent 
Variable 





Corrected Model Net change in 
days of per year 
291115.477 81 3594.018 1.746 0.079 




36.769 81 0.454 1.593 0.119 
Intercept Net change in 
days of per year 
1907.653 1 1907.653 0.927 0.347 
Net change in 
number of 











Age Net change in 
days of per year 
30949.841 3 10316.614 5.013 0.009 




2.260 3 0.753 2.644 0.077 
Gender Net change in 
days of per year 
4186.576 1 4186.576 2.034 0.169 




0.172 1 0.172 0.603 0.447 
Ethnicity Net change in 
days of per year 
2014.601 4 503.650 0.245 0.909 




0.472 4 0.118 0.414 0.796 
Diagnosis Net change in 
days of per year 
post-clozapine) 
per year 
5231.681 3 1743.894 0.847 0.484 




0.367 3 0.122 0.430 0.734 
Total number of 
antipsychotics pre-
clozapine 
Net change in 
days of per year 
7428.049 3 2476.016 1.203 0.334 








Net change in 
days of per year 
11348.115 1 11348.115 5.514 0.029 




1.082 1 1.082 3.796 0.066 
Error Net change in 
days of per year 
41161.853 20 2058.093   




5.699 20 0.285 
Total Net change in 
days of per year 
360850.836 102  





Corrected Total Net change in 
days of per year 
332277.329 101 






Table 7-204 MANOVA eigenvalues, age variable combined, intent to treat group 
Function Eigenvalue % of Variance Cumulative % Canonical Correlation 
1 0.046 99.6 99.6 0.210 
2 <0.0005 0.4 100.0 0.013 
Table 7-205 MANOVA, significance tests for variates, age variable combined, intent to treat group 
Test of Function(s) Wilks' Lambda Chi-square df Sig. 
1 through 2 0.956 4.446 6 0.617 
2 1.000 0.017 2 0.992 
Table 7-206 MANOVA, canonical variate correlation coefficients, age variable combined, intent to treat group 
 Function 
1 2 
Net change in days of admission per year 0.969 0.246 
Net change in number of admissions per year  0.393 0.919 
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Figure 7-46 MANOVA, combined group plot, age variable combined, intent to treat group 
Figure 7-47 MANOVA histogram, age variable combined, intent to treat group 
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Table 7-207 MANOVA patient demographics, age outliers removed, intent to treat group 
 Value Label N 
Age category 1 20 - 29 17 
2 30 - 39 37 
3 40 - 49 38 
4 50 - 59 8 
Gender 1 Male 63 
2 Female 37 
Ethnicity category 1 White 44 
2 Black 37 
3 Asian 9 
4 Mixed 7 
5 Other 3 
Diagnosis 1 F20 66 
2 F25 17 
3 F31 6 
4 Other 11 
Total number of antipsychotics pre-
clozapine 
1 1 - 2 15 
2 3 - 5 48 
3 6 - 10 27 
4 11 + 10 
Clozapine continuer or discontinuer 0 Continuer 65 
1 Discontinuer 35 
Table 7-208 MANOVA test for equality of covariance matrices, age outliers removed, intent to treat group 







Table 7-209 MANOVA test statistics, age outliers removed, intent to treat group 





Intercept Pillai's Trace 0.422 6.934 2.000 19.000 0.005 
Wilks' Lambda 0.578 6.934 2.000 19.000 0.005 
Hotelling's Trace 0.730 6.934 2.000 19.000 0.005 
Roy's Largest 
Root 
0.730 6.934 2.000 19.000 0.005 
Age Pillai's Trace 0.601 2.866 6.000 40.000 0.020 
Wilks' Lambda 0.480 2.810 6.000 38.000 0.023 
Hotelling's Trace 0.915 2.745 6.000 36.000 0.027 
Roy's Largest 
Root 
0.658 4.388 3.000 20.000 0.016 
Gender Pillai's Trace 0.065 0.659 2.000 19.000 0.529 
Wilks' Lambda 0.935 0.659 2.000 19.000 0.529 
Hotelling's Trace 0.069 0.659 2.000 19.000 0.529 
Roy's Largest 
Root 
0.069 0.659 2.000 19.000 0.529 
Ethnicity Pillai's Trace 0.266 0.768 8.000 40.000 0.633 
Wilks' Lambda 0.736 0.788 8.000 38.000 0.616 
Hotelling's Trace 0.357 0.803 8.000 36.000 0.604 
Roy's Largest 
Root 
0.350 1.750 4.000 20.000 0.179 
Diagnosis Pillai's Trace 0.149 0.536 6.000 40.000 0.777 
Wilks' Lambda 0.855 0.516 6.000 38.000 0.793 
Hotelling's Trace 0.165 0.495 6.000 36.000 0.808 
Roy's Largest 
Root 




Pillai's Trace 0.357 1.446 6.000 40.000 0.221 
Wilks' Lambda 0.674 1.381 6.000 38.000 0.247 
Hotelling's Trace 0.438 1.315 6.000 36.000 0.275 
Roy's Largest 
Root 




Pillai's Trace 0.224 2.750 2.000 19.000 0.089 
Wilks' Lambda 0.776 2.750 2.000 19.000 0.089 
Hotelling's Trace 0.289 2.750 2.000 19.000 0.089 
Roy's Largest 
Root 
0.289 2.750 2.000 19.000 0.089 
Table 7-210 MANOVA Levene's test of equality of error variances, age outliers removed, intent to treat group 
 F df1 df2 Sig. 
Net change in days of admission per year 2.482 79 20 0.012 
Net change in number of admissions per year  1.568 79 20 0.128 
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Table 7-211 ANOVA test results, age outliers removed, intent to treat group 
Source Dependent 
Variable 





Corrected Model Net change in 
days of admission 
per year 
275805.019 79 3491.203 1.696 0.091 




35.721 79 0.452 1.587 0.122 
Intercept Net change in 
days of admission 
per year 
1053.818 1 1053.818 0.512 0.483 




3.076 1 3.076 10.796 0.004 
Age Net change in 
days of admission 
per year 
26783.170 3 8927.723 4.338 0.016 




2.779 3 0.926 3.251 0.043 
Gender Net change in 
days of admission 
per year 
2853.128 1 2853.128 1.386 0.253 




0.182 1 0.182 0.639 0.433 
Ethnicity Net change in 
days of admission 
per year 
2014.601 4 503.650 0.245 0.909 




0.472 4 0.118 0.414 0.796 
Diagnosis Net change in 
days of admission 
per year 
5231.681 3 1743.894 0.847 0.484 








Net change in 
days of admission 
per year 
7428.049 3 2476.016 1.203 0.334 








Net change in 
days of admission 
per year 
11348.115 1 11348.115 5.514 0.029 













Error Net change in 
days of admission 
per year 
41161.853 20 2058.093  




5.699 20 0.285  
Total Net change in 
days of admission 
per year 
340073.608 100  




52.602 100  
Corrected Total Net change in 
days of admission 
per year 
316966.872 99  




41.420 99  
Table 7-212 MANOVA eigenvalues, age outliers removed, intent to treat group 
Eigenvalue % of Variance Cumulative % Canonical Correlation 
0.056 99.2 99.2 0.230 
0.000 0.8 100.0 0.021 
Table 7-213 MANOVA, significance tests for variates, age outliers removed, intent to treat group 
Test of Function(s) Wilks' Lambda Chi-square df Sig. 
1 through 2 0.947 5.271 6 0.510 
2 1.000 0.042 2 0.979 
Table 7-214 MANOVA, canonical variate correlation coefficients, age outliers removed, intent to treat group 
 Function 
1 2 
Net change in days of admission per year 0.979 0.202 
Net change in number of admissions per year 0.422 0.907 
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Figure 7-48 MANOVA, combined group plot, age outliers removed, intent to treat group 
Figure 7-49 MANOVA histogram, age outliers removed, intent to treat group 
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Table 7-215 MANOVA patient demographics, clozapine continuers group 
 Value Label N 
Age category 1 20 - 29 9 
2 30 - 39 23 
3 40 - 49 28 
4 50 - 59 5 
Ethnicity category 1 White 29 
2 Black 23 
3 Other 13 
Gender 1 Male 36 
2 Female 29 
Diagnosis 1 F20 41 
2 F25 12 
3 Other 12 
Total number of antipsychotics pre-clozapine 1 1 - 2 12 
2 3 - 5 27 
3 6 - 10 17 
4 11 + 9 
Table 7-216 MANOVA test for equality of covariance matrices, clozapine continuers group 







Table 7-217 MANOVA test statistics, clozapine continuers group 





Intercept Pillai's Trace 0.746 17.639 2.000 12.000 <0.0005 
Wilks' 
Lambda 
0.254 17.639 2.000 12.000 <0.0005 
Hotelling's 
Trace 
2.940 17.639 2.000 12.000 <0.0005 
Roy's 
Largest Root 
2.940 17.639 2.000 12.000 <0.0005 
Age Pillai's Trace 0.689 2.276 6.000 26.000 0.067 
Wilks' 
Lambda 
0.414 2.216 6.000 24.000 0.077 
Hotelling's 
Trace 
1.166 2.138 6.000 22.000 0.089 
Roy's 
Largest Root 
0.886 3.838 3.000 13.000 0.036 
Ethnicity Pillai's Trace 0.370 1.475 4.000 26.000 0.238 
Wilks' 
Lambda 
0.636 1.523 4.000 24.000 0.227 
Hotelling's 
Trace 
0.563 1.548 4.000 22.000 0.223 
Roy's 
Largest Root 
0.546 3.546 2.000 13.000 0.059 
Gender Pillai's Trace 0.213 1.628 2.000 12.000 0.237 
Wilks' 
Lambda 
0.787 1.628 2.000 12.000 0.237 
Hotelling's 
Trace 
0.271 1.628 2.000 12.000 0.237 
Roy's 
Largest Root 
0.271 1.628 2.000 12.000 0.237 
Diagnosis Pillai's Trace 0.111 0.383 4.000 26.000 0.819 
Wilks' 
Lambda 
0.889 0.362 4.000 24.000 0.833 
Hotelling's 
Trace 
0.123 0.340 4.000 22.000 0.848 
Roy's 
Largest Root 




Pillai's Trace 0.579 1.767 6.000 26.000 0.145 
Wilks' 
Lambda 
0.501 1.650 6.000 24.000 0.177 
Hotelling's 
Trace 
0.835 1.530 6.000 22.000 0.215 
Roy's 
Largest Root 
0.535 2.317 3.000 13.000 0.123 
Table 7-218 MANOVA Levene's test of equality of error variances, clozapine continuers group 
 F df1 df2 Sig. 
Net change in days of admission per year 7.419 51 13 <0.0005 
Net change in number of admissions per year 1.608 51 13 0.175 
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Table 7-219 ANOVA test results, clozapine continuers group 
Source Dependent 
Variable 









115377.498 51 2262.304 1.400 0.259 




15.843 51 0.311 1.872 0.108 




23348.243 1 23348.243 14.451 0.002 




6.244 1 6.244 37.634 <0.0005 




15939.674 3 5313.225 3.289 0.055 




1.546 3 0.515 3.106 0.064 




542.458 2 271.229 0.168 0.847 




0.742 2 0.371 2.236 0.146 




151.311 1 151.311 0.094 0.764 




0.507 1 0.507 3.055 0.104 




529.911 2 264.955 0.164 0.850 












7125.819 3 2375.273 1.470 0.268 

















21003.425 13 1615.648  




2.157 13 0.166  




169639.109 65  




27.287 65  




136380.923 64  




18.000 64  
Table 7-220 MANOVA eigenvalues, clozapine continuers group 
Function Eigenvalue % of Variance Cumulative % Canonical Correlation 
1 0.059 92.2 92.2 0.237 
2 0.005 7.8 100.0 0.070 
Table 7-221 MANOVA, significance tests for variates, clozapine continuers group 
Test of Function(s) Wilks' Lambda Chi-square df Sig. 
1 through 2 0.939 3.817 6 0.701 
2 0.995 0.304 2 0.859 
Table 7-222 MANOVA, canonical variate correlation coefficients, clozapine continuers group 
 Function 
1 2 
Net change in days of admission per year 0.968 0.249 
Net change in number of admissions per year  0.372 0.928 
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Figure 7-50 MANOVA combined groups plot, age variable, clozapine continuers group 
Figure 7-51 MANOVA histogram, age variable. clozapine continuers group  
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Table 7-223 MANOVA patient demographics, clozapine discontinuers group 
 Value Label N 
Age 1 20 - 29 8 
2 30 - 39 14 
3 40 - 49 10 
4 50 - 59 3 
Ethnicity 1 White 15 
2 Black 14 
3 Other 6 
Gender 1 Male 27 
2 Female 8 
Diagnosis 1 F20 25 
2 F25 5 
3 Other 5 
Total number of antipsychotics pre-clozapine category 1 1 - 2 3 
2 3 - 5 21 
3 6 - 10 10 
4 11 + 1 
Table 7-224 MANOVA test for equality of covariance matrices, clozapine discontinuers group 







Table 7-225 MANOVA test statistics, clozapine discontinuers group 





Intercept Pillai's Trace 0.446 2.816 2.000 7.000 0.127 
Wilks' 
Lambda 
0.554 2.816 2.000 7.000 0.127 
Hotelling's 
Trace 
0.804 2.816 2.000 7.000 0.127 
Roy's Largest 
Root 
0.804 2.816 2.000 7.000 0.127 
Age Pillai's Trace 0.203 0.452 4.000 16.000 0.770 
Wilks' 
Lambda 
0.797 0.421 4.000 14.000 0.791 
Hotelling's 
Trace 
0.255 0.382 4.000 12.000 0.817 
Roy's Largest 
Root 
0.255 1.018 2.000 8.000 0.404 
Ethnicity Pillai's Trace 0.290 0.677 4.000 16.000 0.618 
Wilks' 
Lambda 
0.716 0.638 4.000 14.000 0.644 
Hotelling's 
Trace 
0.390 0.586 4.000 12.000 0.679 
Roy's Largest 
Root 
0.371 1.484 2.000 8.000 0.283 
Gender Pillai's Trace 0.595 5.145 2.000 7.000 0.042 
Wilks' 
Lambda 
0.405 5.145 2.000 7.000 0.042 
Hotelling's 
Trace 
1.470 5.145 2.000 7.000 0.042 
Roy's Largest 
Root 
1.470 5.145 2.000 7.000 0.042 
Diagnosis Pillai's Trace 0.617 1.784 4.000 16.000 0.181 
Wilks' 
Lambda 
0.410 1.965 4.000 14.000 0.155 
Hotelling's 
Trace 
1.372 2.058 4.000 12.000 0.150 
Roy's Largest 
Root 
1.322 5.289 2.000 8.000 0.034 
Number of antipsychotics 
pre-clozapine 
Pillai's Trace 0.265 0.610 4.000 16.000 0.661 
Wilks' 
Lambda 
0.738 0.574 4.000 14.000 0.686 
Hotelling's 
Trace 
0.351 0.527 4.000 12.000 0.718 
Roy's Largest 
Root 
0.340 1.361 2.000 8.000 0.310 
Table 7-226 MANOVA Levene's test of equality of error variances, clozapine discontinuers group 
 F df1 df2 Sig. 
Net change in days of admission per year 1.706 26 8 0.220 
Net change in number of admissions per year  1.844 26 8 0.186 
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Table 7-227 ANOVA test statistics, clozapine discontinuers group 
Source Dependent 
Variable 





Corrected Model Net change in 
days of admission 
per year 
149587.832 26 5753.378 2.215 0.122 




19.287 26 0.742 1.570 0.260 
Intercept Net change in 
days of admission 
per year 
5258.478 1 5258.478 2.025 0.193 




0.101 1 0.101 0.213 0.657 
Age Net change in 
days of admission 
per year 
3044.689 2 1522.344 0.586 0.579 




0.958 2 0.479 1.014 0.405 
Ethnicity Net change in 
days of admission 
per year 
3683.176 2 1841.588 0.709 0.521 




0.076 2 0.038 0.080 0.924 
Gender Net change in 
days of admission 
per year 
15546.102 1 15546.102 5.986 0.040 




5.557 1 5.557 11.760 0.009 
Diagnosis Net change in 
days of admission 
per year 
27296.754 2 13648.377 5.255 0.035 








Net change in 
days of admission 
per year 
1620.352 2 810.176 0.312 0.741 




0.157 2 0.079 0.166 0.850 
Error Net change in 
days of admission 
per year 
20775.837 8 2596.980  













Total Net change in 
days of admission 
per year 
170434.499 35  




25.315 35  
Corrected Total Net change in 
days of admission 
per year 
170363.669 34  




23.067 34  
Table 7-228 MANOVA eigenvalues, clozapine discontinuers group 
Function Eigenvalue % of Variance Cumulative % Canonical Correlation 
1 0.105 88.0 88.0 0.309 
2 0.014 12.0 100.0 0.119 
Table 7-229 MANOVA, significance tests for variates, clozapine discontinuers group 
Test of Function(s) Wilks' Lambda Chi-square df Sig. 
1 through 2 0.892 3.542 6 0.738 
2 0.986 0.442 2 0.802 
Table 7-230 MANOVA, canonical variate correlation coefficients, clozapine discontinuers group 
 Function 
1 2 
Net change in days of admission per year 0.998 0.065 
Net change in number of admissions per year  0.531 0.847 
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Figure 7-52 MANOVA combined groups plot, age variable, clozapine discontinuers group 
Figure 7-53 MANOVA histogram, age variable, clozapine discontinuers group  
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Table 7-231 MANOVA, eigenvalues, gender variable, clozapine discontinuers group 
Function Eigenvalue % of Variance Cumulative % Canonical Correlation 
1 0.042 100.0 100.0 0.201 
Table 7-232 MANOVA, significance tests for variates, gender variable, clozapine discontinuers group 
Test of Function(s) Wilks' Lambda Chi-square df Sig. 
1 0.960 1.318 2 0.517 




Net change in number of admissions per year  0.979 
Net change in days of admission per year 0.418 
Figure 7-54 MANOVA histogram, gender variable, clozapine discontinuers group 
Table 7-234 MANOVA, eigenvalues, diagnosis variable, clozapine discontinuers group 
Function Eigenvalue % of Variance Cumulative % Canonical Correlation 
1 0.090 72.2 72.2 0.287 
2 0.035 27.8 100.0 0.183 
Table 7-235 MANOVA, significance tests for variates, diagnosis variable, clozapine discontinuers group 
Test of Function(s) Wilks' Lambda Chi-square df Sig. 
1 through 2 0.887 3.783 4 0.436 
2 0.967 1.072 1 0.301 
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Net change in number of admissions per year 0.999 0.043 
Net change in days of admission per year 0.554 0.832 
Figure 7-55 MANOVA, combined groups plot, diagnosis variable, clozapine discontinuers group 
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Figure 7-56 MANOVA, histogram, diagnosis variable, clozapine discontinuers group 
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Appendix H. Statistical data for chapter 6 
Table 7-237 t-test, continuous variables 
 Levene's Test for 
Equality of Variances 
t-test for Equality of Means 



































 0.328 94.189 0.744 0.264 0.807 -1.337 1.866 














Table 7-238 Chi-square test, ethnicity 










4.615 4 0.329 0.335  
Likelihood Ratio 5.230 4 0.265 0.318  
Fisher's Exact 
Test 
4.758   0.298  
Linear-by-Linear 
Association 
0.274 1 0.601 0.650 0.337 0.064 
N of Valid Cases 133   
Table 7-239 Chi-square test, diagnosis 










0.012 2 0.994 1.000  
Likelihood Ratio 0.012 2 0.994 1.000  
Fisher's Exact 
Test 
0.059   1.000  
Linear-by-Linear 
Association 
0.001 1 0.982 1.000 0.542 0.094 
N of Valid Cases 133   
Table 7-240 Multiway crosstabulation table, gender x clozapine continuer or discontinuer x ethnicity 




White Gender Male Count 2a 3a 5 
Expected 
Count 
2.1 2.9 5.0 
% within 
Gender 





66.7% 75.0% 71.4% 
% of Total 28.6% 42.9% 71.4% 
Std. Residual -0.1 0.1  
Female Count 1a 1a 2 
Expected 
Count 
0.9 1.1 2.0 
% within 
Gender 





33.3% 25.0% 28.6% 
% of Total 14.3% 14.3% 28.6% 
Std. Residual 0.2 -0.1  
Total Count 3 4 7 
Expected 
Count 
3.0 4.0 7.0 
% within 
Gender 
42.9% 57.1% 100.0% 
% within 
clozapine 
100.0% 100.0% 100.0% 
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% of Total 42.9% 57.1% 100.0% 
Black British Gender Male Count 2a 3a 5 
Expected 
Count 
2.2 2.8 5.0 
% within 
Gender 





50.0% 60.0% 55.6% 
% of Total 22.2% 33.3% 55.6% 
Std. Residual -0.1 0.1  
Female Count 2a 2a 4 
Expected 
Count 
1.8 2.2 4.0 
% within 
Gender 





50.0% 40.0% 44.4% 
% of Total 22.2% 22.2% 44.4% 
Std. Residual 0.2 -0.1  
Total Count 4 5 9 
Expected 
Count 
4.0 5.0 9.0 
% within 
Gender 





100.0% 100.0% 100.0% 
% of Total 44.4% 55.6% 100.0% 
Black African Gender Male Count 9a 2a 11 
Expected 
Count 
9.7 1.3 11.0 
% within 
Gender 





60.0% 100.0% 64.7% 
% of Total 52.9% 11.8% 64.7% 
Std. Residual -0.2 0.6  
Female Count 6a 0a 6 
Expected 
Count 
5.3 0.7 6.0 
% within 
Gender 
100.0% 0.0% 100.0% 
% within 
clozapine 
40.0% 0.0% 35.3% 
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% of Total 35.3% 0.0% 35.3% 
Std. Residual 0.3 -0.8  
Total Count 15 2 17 
Expected 
Count 
15.0 2.0 17.0 
% within 
Gender 





100.0% 100.0% 100.0% 
% of Total 88.2% 11.8% 100.0% 
Caribbean Gender Male Count 3a 12a 15 
Expected 
Count 
4.5 10.5 15.0 
% within 
Gender 





50.0% 85.7% 75.0% 
% of Total 15.0% 60.0% 75.0% 
Std. Residual -0.7 0.5  
Female Count 3a 2a 5 
Expected 
Count 
1.5 3.5 5.0 
% within 
Gender 





50.0% 14.3% 25.0% 
% of Total 15.0% 10.0% 25.0% 
Std. Residual 1.2 -0.8  
Total Count 6 14 20 
Expected 
Count 
6.0 14.0 20.0 
% within 
Gender 





100.0% 100.0% 100.0% 
% of Total 30.0% 70.0% 100.0% 
British Gender Male Count 23a 11a 34 
Expected 
Count 
25.1 8.9 34.0 
% within 
Gender 
67.6% 32.4% 100.0% 
% within 
clozapine 
67.6% 91.7% 73.9% 
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% of Total 50.0% 23.9% 73.9% 
Std. Residual -0.4 0.7  
Female Count 11a 1a 12 
Expected 
Count 
8.9 3.1 12.0 
% within 
Gender 





32.4% 8.3% 26.1% 
% of Total 23.9% 2.2% 26.1% 
Std. Residual 0.7 -1.2  
Total Count 34 12 46 
Expected 
Count 
34.0 12.0 46.0 
% within 
Gender 





100.0% 100.0% 100.0% 
% of Total 73.9% 26.1% 100.0% 












% of Total 50.0% 50.0% 
Std. Residual 0.0  












% of Total 50.0% 50.0% 
Std. Residual 0.0  

















% of Total 100.0% 100.0% 












% of Total 100.0% 100.0% 
Std. Residual 0.0  












% of Total 100.0% 100.0% 
Other African Gender Male Count 4a 1a 5 
Expected 
Count 
3.8 1.3 5.0 
% within 
Gender 





66.7% 50.0% 62.5% 
% of Total 50.0% 12.5% 62.5% 
Std. Residual 0.1 -0.2  
Female Count 2a 1a 3 
Expected 
Count 
2.3 .8 3.0 
% within 
Gender 





33.3% 50.0% 37.5% 
% of Total 25.0% 12.5% 37.5% 
Std. Residual -0.2 0.3  
Total Count 6 2 8 
Expected 
Count 
6.0 2.0 8.0 
% within 
Gender 
75.0% 25.0% 100.0% 
% within 
clozapine 
100.0% 100.0% 100.0% 
 491 






% of Total 75.0% 25.0% 100.0% 
Eritraen Gender Male Count 0a 1a 1 
Expected 
Count 
0.5 0.5 1.0 
% within 
Gender 





0.0% 100.0% 50.0% 
% of Total 0.0% 50.0% 50.0% 
Std. Residual -0.7 0.7  
Female Count 1a 0a 1 
Expected 
Count 
.5 .5 1.0 
% within 
Gender 





100.0% 0.0% 50.0% 
% of Total 50.0% 0.0% 50.0% 
Std. Residual 0.7 -0.7  
Total Count 1 1 2 
Expected 
Count 
1.0 1.0 2.0 
% within 
Gender 





100.0% 100.0% 100.0% 
% of Total 50.0% 50.0% 100.0% 












% of Total 100.0% 100.0% 
Std. Residual .0  





















Gender Male Count 7a 1a 8 
Expected 
Count 
7.2 .8 8.0 
% within 
Gender 





77.8% 100.0% 80.0% 
% of Total 70.0% 10.0% 80.0% 
Std. Residual -0.1 0.2  
Female Count 2a 0a 2 
Expected 
Count 
1.8 .2 2.0 
% within 
Gender 





22.2% 0.0% 20.0% 
% of Total 20.0% 0.0% 20.0% 
Std. Residual 0.1 -0.4  
Total Count 9 1 10 
Expected 
Count 
9.0 1.0 10.0 
% within 
Gender 





100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 












% of Total 100.0% 100.0% 
Std. Residual 0.0  

















% of Total 100.0% 100.0% 
Indian Gender Male Count 0a 1a 1 
Expected 
Count 
0.7 0.3 1.0 
% within 
Gender 





0.0% 100.0% 33.3% 
% of Total 0.0% 33.3% 33.3% 
Std. Residual -0.8 1.2  
Female Count 2a 0a 2 
Expected 
Count 
1.3 .7 2.0 
% within 
Gender 





100.0% 0.0% 66.7% 
% of Total 66.7% 0.0% 66.7% 
Std. Residual 0.6 -0.8  
Total Count 2 1 3 
Expected 
Count 
2.0 1.0 3.0 
% within 
Gender 





100.0% 100.0% 100.0% 
% of Total 66.7% 33.3% 100.0% 












% of Total 50.0% 50.0% 
Std. Residual 0.0  

















% of Total 50.0% 50.0% 
Std. Residual 0.0  












% of Total 100.0% 100.0% 












% of Total 100.0% 100.0% 
Std. Residual .0  












% of Total 100.0% 100.0% 












% of Total 100.0% 100.0% 
Std. Residual 0.0  

















% of Total 100.0% 100.0% 












% of Total 100.0% 100.0% 
Std. Residual 0.0  












% of Total 100.0% 100.0% 












% of Total 100.0% 100.0% 
Std. Residual 0.0  












% of Total 100.0% 100.0% 
Total Gender Male Count 53a 40b 93 
Expected 
Count 
59.4 33.6 93.0 
% within 
Gender 





62.4% 83.3% 69.9% 
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% of Total 39.8% 30.1% 69.9% 
Std. Residual -0.8 1.1  
Female Count 32a 8b 40 
Expected 
Count 
25.6 14.4 40.0 
% within 
Gender 





37.6% 16.7% 30.1% 
% of Total 24.1% 6.0% 30.1% 
Std. Residual 1.3 -1.7  
Total Count 85 48 133 
Expected 
Count 
85.0 48.0 133.0 
% within 
Gender 





100.0% 100.0% 100.0% 
% of Total 63.9% 36.1% 100.0% 
Each subscript letter denotes a subset of clozapine continuer or discontinuer categories whose 
column proportions do not differ significantly from each other at the 0.05 level. 
Table 7-241 Multiway crosstabulation table, gender x clozapine continuer or discontinuer x diagnosis 




F20 Gender Male Count 41a 28a 69 
Expected Count 44.0 25.0 69.0 
% within Gender 59.4% 40.6% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
70.7% 84.8% 75.8% 
% of Total 45.1% 30.8% 75.8% 
Std. Residual -0.4 0.6  
Female Count 17a 5a 22 
Expected Count 14.0 8.0 22.0 
% within Gender 77.3% 22.7% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
29.3% 15.2% 24.2% 
% of Total 18.7% 5.5% 24.2% 
Std. Residual 0.8 -1.1  
Total Count 58 33 91 
Expected Count 58.0 33.0 91.0 
% within Gender 63.7% 36.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 63.7% 36.3% 100.0% 
F25 Gender Male Count 5a 6b 11 
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Expected Count 7.2 3.9 11.0 
% within Gender 45.5% 54.5% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
38.5% 85.7% 55.0% 
% of Total 25.0% 30.0% 55.0% 
Std. Residual -0.8 1.1  
Female Count 8a 1b 9 
Expected Count 5.9 3.2 9.0 
% within Gender 88.9% 11.1% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
61.5% 14.3% 45.0% 
% of Total 40.0% 5.0% 45.0% 
Std. Residual 0.9 -1.2  
Total Count 13 7 20 
Expected Count 13.0 7.0 20.0 
% within Gender 65.0% 35.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 65.0% 35.0% 100.0% 
F31 Gender Male Count 2a 3a 5 
Expected Count 3.3 1.7 5.0 
% within Gender 40.0% 60.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
33.3% 100.0% 55.6% 
% of Total 22.2% 33.3% 55.6% 
Std. Residual -0.7 1.0  
Female Count 4a 0a 4 
Expected Count 2.7 1.3 4.0 
% within Gender 100.0% 0.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
66.7% 0.0% 44.4% 
% of Total 44.4% 0.0% 44.4% 
Std. Residual 0.8 -1.2  
Total Count 6 3 9 
Expected Count 6.0 3.0 9.0 
% within Gender 66.7% 33.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 66.7% 33.3% 100.0% 
Other Gender Male Count 5a 3a 8 
Expected Count 4.9 3.1 8.0 
% within Gender 62.5% 37.5% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
62.5% 60.0% 61.5% 
% of Total 38.5% 23.1% 61.5% 
Std. Residual 0.0 0.0  
Female Count 3a 2a 5 
Expected Count 3.1 1.9 5.0 
% within Gender 60.0% 40.0% 100.0% 
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% within Clozapine 
continuer or 
discontinuer 
37.5% 40.0% 38.5% 
% of Total 23.1% 15.4% 38.5% 
Std. Residual 0.0 0.1  
Total Count 8 5 13 
Expected Count 8.0 5.0 13.0 
% within Gender 61.5% 38.5% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 61.5% 38.5% 100.0% 
Total Gender Male Count 53a 40b 93 
Expected Count 59.4 33.6 93.0 
% within Gender 57.0% 43.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
62.4% 83.3% 69.9% 
% of Total 39.8% 30.1% 69.9% 
Std. Residual -0.8 1.1  
Female Count 32a 8b 40 
Expected Count 25.6 14.4 40.0 
% within Gender 80.0% 20.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
37.6% 16.7% 30.1% 
% of Total 24.1% 6.0% 30.1% 
Std. Residual 1.3 -1.7  
Total Count 85 48 133 
Expected Count 85.0 48.0 133.0 
% within Gender 63.9% 36.1% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 63.9% 36.1% 100.0% 
Each subscript letter denotes a subset of clozapine continuer or discontinuer categories whose column 
proportions do not differ significantly from each other at the 0.05 level. 
Table 7-242 Multiway crosstabulation table, gender x clozapine continuer or discontinuer x merged ethnicity 
categories 




White Gender Male Count 25a 16a 41 
Expected Count 27.6 13.4 41.0 
% within Gender 61.0% 39.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
67.6% 88.9% 74.5% 
% of Total 45.5% 29.1% 74.5% 
Std. Residual -0.5 0.7  
Female Count 12a 2a 14 
Expected Count 9.4 4.6 14.0 
% within Gender 85.7% 14.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
32.4% 11.1% 25.5% 
% of Total 21.8% 3.6% 25.5% 
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Std. Residual 0.8 -1.2  
Total Count 37 18 55 
Expected Count 37.0 18.0 55.0 
% within Gender 67.3% 32.7% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 67.3% 32.7% 100.0% 
Black Gender Male Count 18a 19a 37 
Expected Count 21.1 15.9 37.0 
% within Gender 48.6% 51.4% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
56.3% 79.2% 66.1% 
% of Total 32.1% 33.9% 66.1% 
Std. Residual -0.7 0.8  
Female Count 14a 5a 19 
Expected Count 10.9 8.1 19.0 
% within Gender 73.7% 26.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
43.8% 20.8% 33.9% 
% of Total 25.0% 8.9% 33.9% 
Std. Residual 1.0 -1.1  
Total Count 32 24 56 
Expected Count 32.0 24.0 56.0 
% within Gender 57.1% 42.9% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 57.1% 42.9% 100.0% 
Asian Gender Male Count 2a 3a 5 
Expected Count 2.8 2.2 5.0 
% within Gender 40.0% 60.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
40.0% 75.0% 55.6% 
% of Total 22.2% 33.3% 55.6% 
Std. Residual -0.5 0.5  
Female Count 3a 1a 4 
Expected Count 2.2 1.8 4.0 
% within Gender 75.0% 25.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
60.0% 25.0% 44.4% 
% of Total 33.3% 11.1% 44.4% 
Std. Residual 0.5 -0.6  
Total Count 5 4 9 
Expected Count 5.0 4.0 9.0 
% within Gender 55.6% 44.4% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 55.6% 44.4% 100.0% 
Mixed Gender Male Count 7a 1a 8 
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Expected Count 7.2 .8 8.0 
% within Gender 87.5% 12.5% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
77.8% 100.0% 80.0% 
% of Total 70.0% 10.0% 80.0% 
Std. Residual -0.1 0.2  
Female Count 2a 0a 2 
Expected Count 1.8 0.2 2.0 
% within Gender 100.0% 0.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
22.2% 0.0% 20.0% 
% of Total 20.0% 0.0% 20.0% 
Std. Residual 0.1 -0.4  
Total Count 9 1 10 
Expected Count 9.0 1.0 10.0 
% within Gender 90.0% 10.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
Other Gender Male Count 1a 1a 2 
Expected Count 1.3 0.7 2.0 
% within Gender 50.0% 50.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
50.0% 100.0% 66.7% 
% of Total 33.3% 33.3% 66.7% 
Std. Residual -0.3 0.4  
Female Count 1a 0a 1 
Expected Count 0.7 0.3 1.0 
% within Gender 100.0% 0.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
50.0% 0.0% 33.3% 
% of Total 33.3% 0.0% 33.3% 
Std. Residual 0.4 -0.6  
Total Count 2 1 3 
Expected Count 2.0 1.0 3.0 
% within Gender 66.7% 33.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 66.7% 33.3% 100.0% 
Total Gender Male Count 53a 40b 93 
Expected Count 59.4 33.6 93.0 
% within Gender 57.0% 43.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
62.4% 83.3% 69.9% 
% of Total 39.8% 30.1% 69.9% 
Std. Residual -0.8 1.1  
Female Count 32a 8b 40 
Expected Count 25.6 14.4 40.0 
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% within Gender 80.0% 20.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
37.6% 16.7% 30.1% 
% of Total 24.1% 6.0% 30.1% 
Std. Residual 1.3 -1.7  
Total Count 85 48 133 
Expected Count 85.0 48.0 133.0 
% within Gender 63.9% 36.1% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 63.9% 36.1% 100.0% 
Each subscript letter denotes a subset of clozapine continuer or discontinuer categories whose column 
proportions do not differ significantly from each other at the 0.05 level. 
Table 7-243 Multiway crosstabulation table, gender x clozapine continuer or discontinuer x merged ethnicity 
category 




White Gender Male Count 25a 16a 41 
Expected Count 27.6 13.4 41.0 
% within Gender 61.0% 39.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
67.6% 88.9% 74.5% 
% of Total 45.5% 29.1% 74.5% 
Std. Residual -0.5 0.7  
Female Count 12a 2a 14 
Expected Count 9.4 4.6 14.0 
% within Gender 85.7% 14.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
32.4% 11.1% 25.5% 
% of Total 21.8% 3.6% 25.5% 
Std. Residual 0.8 -1.2  
Total Count 37 18 55 
Expected Count 37.0 18.0 55.0 
% within Gender 67.3% 32.7% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 67.3% 32.7% 100.0% 
Black Gender Male Count 18a 19a 37 
Expected Count 21.1 15.9 37.0 
% within Gender 48.6% 51.4% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
56.3% 79.2% 66.1% 
% of Total 32.1% 33.9% 66.1% 
Std. Residual -0.7 0.8  
Female Count 14a 5a 19 
Expected Count 10.9 8.1 19.0 
% within Gender 73.7% 26.3% 100.0% 
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% within Clozapine 
continuer or 
discontinuer 
43.8% 20.8% 33.9% 
% of Total 25.0% 8.9% 33.9% 
Std. Residual 1.0 -1.1  
Total Count 32 24 56 
Expected Count 32.0 24.0 56.0 
% within Gender 57.1% 42.9% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 57.1% 42.9% 100.0% 
Other Gender Male Count 10a 5a 15 
Expected Count 10.9 4.1 15.0 
% within Gender 66.7% 33.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
62.5% 83.3% 68.2% 
% of Total 45.5% 22.7% 68.2% 
Std. Residual -0.3 0.4  
Female Count 6a 1a 7 
Expected Count 5.1 1.9 7.0 
% within Gender 85.7% 14.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
37.5% 16.7% 31.8% 
% of Total 27.3% 4.5% 31.8% 
Std. Residual 0.4 -0.7  
Total Count 16 6 22 
Expected Count 16.0 6.0 22.0 
% within Gender 72.7% 27.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 72.7% 27.3% 100.0% 
Total Gender Male Count 53a 40b 93 
Expected Count 59.4 33.6 93.0 
% within Gender 57.0% 43.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
62.4% 83.3% 69.9% 
% of Total 39.8% 30.1% 69.9% 
Std. Residual -0.8 1.1  
Female Count 32a 8b 40 
Expected Count 25.6 14.4 40.0 
% within Gender 80.0% 20.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
37.6% 16.7% 30.1% 
% of Total 24.1% 6.0% 30.1% 
Std. Residual 1.3 -1.7  
Total Count 85 48 133 
Expected Count 85.0 48.0 133.0 
% within Gender 63.9% 36.1% 100.0% 
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% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 63.9% 36.1% 100.0% 
Each subscript letter denotes a subset of clozapine continuer or discontinuer categories whose column 
proportions do not differ significantly from each other at the 0.05 level. 
Table 7-244 Multiway crosstabulation table, gender x clozapine continuer or discontinuer x merged diagnosis 
category 




F20 Gender Male Count 41a 28a 69 
Expected Count 44.0 25.0 69.0 
% within Gender 59.4% 40.6% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
70.7% 84.8% 75.8% 
% of Total 45.1% 30.8% 75.8% 
Std. Residual -0.4 0.6  
Female Count 17a 5a 22 
Expected Count 14.0 8.0 22.0 
% within Gender 77.3% 22.7% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
29.3% 15.2% 24.2% 
% of Total 18.7% 5.5% 24.2% 
Std. Residual 0.8 -1.1  
Total Count 58 33 91 
Expected Count 58.0 33.0 91.0 
% within Gender 63.7% 36.3% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 63.7% 36.3% 100.0% 
F25 Gender Male Count 5a 6b 11 
Expected Count 7.2 3.9 11.0 
% within Gender 45.5% 54.5% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
38.5% 85.7% 55.0% 
% of Total 25.0% 30.0% 55.0% 
Std. Residual -0.8 1.1  
Female Count 8a 1b 9 
Expected Count 5.9 3.2 9.0 
% within Gender 88.9% 11.1% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
61.5% 14.3% 45.0% 
% of Total 40.0% 5.0% 45.0% 
Std. Residual 0.9 -1.2  
Total Count 13 7 20 
Expected Count 13.0 7.0 20.0 
% within Gender 65.0% 35.0% 100.0% 
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% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 65.0% 35.0% 100.0% 
Other Gender Male Count 7a 6a 13 
Expected Count 8.3 4.7 13.0 
% within Gender 53.8% 46.2% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
50.0% 75.0% 59.1% 
% of Total 31.8% 27.3% 59.1% 
Std. Residual -0.4 0.6  
Female Count 7a 2a 9 
Expected Count 5.7 3.3 9.0 
% within Gender 77.8% 22.2% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
50.0% 25.0% 40.9% 
% of Total 31.8% 9.1% 40.9% 
Std. Residual 0.5 -0.7  
Total Count 14 8 22 
Expected Count 14.0 8.0 22.0 
% within Gender 63.6% 36.4% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 63.6% 36.4% 100.0% 
Total Gender Male Count 53a 40b 93 
Expected Count 59.4 33.6 93.0 
% within Gender 57.0% 43.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
62.4% 83.3% 69.9% 
% of Total 39.8% 30.1% 69.9% 
Std. Residual -0.8 1.1  
Female Count 32a 8b 40 
Expected Count 25.6 14.4 40.0 
% within Gender 80.0% 20.0% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
37.6% 16.7% 30.1% 
% of Total 24.1% 6.0% 30.1% 
Std. Residual 1.3 -1.7  
Total Count 85 48 133 
Expected Count 85.0 48.0 133.0 
% within Gender 63.9% 36.1% 100.0% 
% within Clozapine 
continuer or 
discontinuer 
100.0% 100.0% 100.0% 
% of Total 63.9% 36.1% 100.0% 
Each subscript letter denotes a subset of clozapine continuer or discontinuer categories whose column 
proportions do not differ significantly from each other at the 0.05 level. 
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Table 7-245 Logistic regression iteration history, gender 
Iteration -2 Log likelihood Coefficients 
Constant 
Step 0 1 173.954 -0.556 
2 173.947 -0.571 
3 173.947 -0.571 
Table 7-246 Logistic regression summary statistics 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 167.134 0.050 0.068 
Table 7-247 Logistic regression classification table 
Observed Predicted 





Clozapine continuer or 
discontinuer 
Continuer 85 0 100.0 
Discontinuer 48 0 0.0 
Overall Percentage   63.9 
Table 7-248 Logistic regression equation variables 
 B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Male 1.105 0.447 6.100 1 0.014 3.019 1.256 7.255 
Constant -1.386 0.395 12.300 1 <0.0005 0.250  
Table 7-249 Logistic regression bootstrap 
 b Bootstrap 
Bias Std. Error Sig. (2-tailed) 95% Confidence Interval 
Lower Upper 
Male 1.105 0.033 0.476 0.010 0.235 2.138 
Constant -1.386 -0.030 0.417 0.001 -2.398 -0.694 
 506 


















Gender Male 1 5 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
2 6 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
3 7 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
4 8 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
5 10 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
6 14 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
7 17 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
8 18 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
9 19 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
10 21 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
11 22 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
12 25 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
13 26 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
14 32 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
15 33 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
16 34 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
17 35 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
18 36 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
19 41 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
20 42 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
21 43 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
22 44 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
23 47 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
24 48 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
25 51 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
26 52 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
27 53 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
28 54 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
29 55 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
30 56 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
31 57 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
32 59 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 



















34 63 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
35 64 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
36 65 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
37 66 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
38 68 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
39 69 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
40 70 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
41 71 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
42 73 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
43 74 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
44 75 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
45 76 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
46 77 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
47 79 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
48 80 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
49 81 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
50 82 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
51 83 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
52 84 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
53 85 0.43011 Continuer 0.00820 0.01075 -0.86874 <0.000005 -0.01907 
54 87 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
55 90 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
56 91 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
57 92 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
58 93 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
59 94 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
60 95 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
61 96 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
62 97 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
63 98 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
64 99 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
65 100 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
66 102 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 



















68 105 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
69 106 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
70 107 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
71 108 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
72 110 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
73 111 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
74 112 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
75 113 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
76 114 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
77 116 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
78 117 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
79 119 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
80 120 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
81 121 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
82 122 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
83 123 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
84 124 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
85 125 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
86 126 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
87 127 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
88 128 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
89 129 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
90 130 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
91 131 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
92 132 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
93 133 0.43011 Continuer 0.01440 0.01075 1.15109 <0.000005 0.02527 
Total n  93 93 93 93 93 93 93 
Female 1 1 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
2 2 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
3 3 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
4 4 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
5 9 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
6 11 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 



















8 13 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
9 15 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
10 16 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
11 20 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
12 23 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
13 24 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
14 27 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
15 28 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
16 29 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
17 30 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
18 31 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
19 37 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
20 38 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
21 39 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
22 40 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
23 45 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
24 46 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
25 49 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
26 50 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
27 58 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
28 60 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
29 61 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
30 67 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
31 72 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
32 78 0.20000 Continuer 0.00641 0.02500 -0.50000 -0.03205 0.03205 
33 86 0.20000 Continuer 0.10256 0.02500 2.00000 0.12821 -0.12821 
34 88 0.20000 Continuer 0.10256 0.02500 2.00000 0.12821 -0.12821 
35 89 0.20000 Continuer 0.10256 0.02500 2.00000 0.12821 -0.12821 
36 101 0.20000 Continuer 0.10256 0.02500 2.00000 0.12821 -0.12821 
37 103 0.20000 Continuer 0.10256 0.02500 2.00000 0.12821 -0.12821 
38 109 0.20000 Continuer 0.10256 0.02500 2.00000 0.12821 -0.12821 
39 115 0.20000 Continuer 0.10256 0.02500 2.00000 0.12821 -0.12821 
40 118 0.20000 Continuer 0.10256 0.02500 2.00000 0.12821 -0.12821 























Table 7-251 Kaplan-Meier survival table 
 Time 
(days) 
Status Cumulative Proportion 






Cases Estimate Std. Error 
1 1.000 Discontinued 0.992 0.007 1 132 
2 33.000 Discontinued 0.985 0.011 2 131 
3 68.000 Discontinued 0.977 0.013 3 130 
4 84.000 Discontinued 0.970 0.015 4 129 
5 92.000 Discontinued 0.962 0.016 5 128 
6 170.000 Discontinued 0.955 0.018 6 127 
7 182.000 Discontinued 0.947 0.019 7 126 
8 197.000 Discontinued 0.940 0.021 8 125 
9 203.000 Discontinued 0.932 0.022 9 124 
10 207.000 Discontinued 0.925 0.023 10 123 
11 229.000 Discontinued 0.917 0.024 11 122 
12 282.000 Discontinued 0.910 0.025 12 121 
13 367.000 Discontinued 0.902 0.026 13 120 
14 554.000 Discontinued 0.895 0.027 14 119 
15 565.000 Discontinued 0.887 0.027 15 118 
16 582.000 Discontinued 0.880 0.028 16 117 
17 584.000 Discontinued 0.872 0.029 17 116 
18 703.000 Discontinued 0.865 0.030 18 115 
19 789.000 Discontinued 0.857 0.030 19 114 
20 827.000 Discontinued 0.850 0.031 20 113 
21 833.000 Discontinued 0.842 0.032 21 112 
22 869.000 Discontinued 0.835 0.032 22 111 
23 933.000 Discontinued 0.827 0.033 23 110 
24 1012.000 Discontinued 0.820 0.033 24 109 
25 1064.000 Discontinued 0.812 0.034 25 108 
26 1120.000 Discontinued 0.805 0.034 26 107 
27 1146.000 Discontinued 0.797 0.035 27 106 
28 1160.000 Discontinued 0.789 0.035 28 105 
29 1162.000 Discontinued 0.782 0.036 29 104 
30 1215.000 Discontinued 0.774 0.036 30 103 
31 1244.000 Discontinued 0.767 0.037 31 102 
32 1266.000 Discontinued 0.759 0.037 32 101 
33 1339.000 Discontinued 0.752 0.037 33 100 
34 1421.000 Discontinued 0.744 0.038 34 99 
35 1443.000 Discontinued 0.737 0.038 35 98 
36 1457.000 Discontinued 0.729 0.039 36 97 
37 1468.000 Discontinued 0.722 0.039 37 96 
38 1610.000 Discontinued 0.714 0.039 38 95 
39 1739.000 Discontinued 0.707 0.039 39 94 
40 1774.000 Censored . . 39 93 
41 1782.000 Censored . . 39 92 
42 1783.000 Discontinued 0.699 0.040 40 91 
43 1794.000 Censored . . 40 90 
44 1827.000 Censored . . 40 89 
45 1839.000 Censored . . 40 88 
46 1849.000 Censored . . 40 87 
47 1863.000 Censored . . 40 86 
48 1865.000 Censored . . 40 85 
49 1865.000 Censored . . 40 84 
50 1866.000 Discontinued 0.691 0.040 41 83 
51 1870.000 Censored . . 41 82 
52 1905.000 Censored . . 41 81 
53 1974.000 Discontinued 0.682 0.041 42 80 




Status Cumulative Proportion 






Cases Estimate Std. Error 
55 2019.000 Censored . . 42 78 
56 2020.000 Censored . . 42 77 
57 2034.000 Censored . . 42 76 
58 2041.000 Censored . . 42 75 
59 2056.000 Discontinued 0.673 0.041 43 74 
60 2108.000 Censored . . 43 73 
61 2129.000 Censored . . 43 72 
62 2146.000 Censored . . 43 71 
63 2147.000 Censored . . 43 70 
64 2153.000 Censored . . 43 69 
65 2158.000 Censored . . 43 68 
66 2160.000 Censored . . 43 67 
67 2167.000 Censored . . 43 66 
68 2172.000 Discontinued 0.663 0.042 44 65 
69 2187.000 Censored . . 44 64 
70 2188.000 Discontinued 0.653 0.042 45 63 
71 2201.000 Censored . . 45 62 
72 2221.000 Censored . . 45 61 
73 2238.000 Censored . . 45 60 
74 2299.000 Discontinued 0.642 0.043 46 59 
75 2308.000 Censored . . 46 58 
76 2312.000 Censored . . 46 57 
77 2315.000 Censored . . 46 56 
78 2330.000 Censored . . 46 55 
79 2360.000 Censored . . 46 54 
80 2396.000 Censored . . 46 53 
81 2404.000 Censored . . 46 52 
82 2429.000 Censored . . 46 51 
83 2437.000 Censored . . 46 50 
84 2450.000 Censored . . 46 49 
85 2472.000 Discontinued 0.629 0.044 47 48 
86 2480.000 Censored . . 47 47 
87 2482.000 Censored . . 47 46 
88 2521.000 Censored . . 47 45 
89 2524.000 Discontinued 0.615 0.045 48 44 
90 2536.000 Censored . . 48 43 
91 2538.000 Censored . . 48 42 
92 2539.000 Censored . . 48 41 
93 2574.000 Censored . . 48 40 
94 2591.000 Censored . . 48 39 
95 2599.000 Censored . . 48 38 
96 2606.000 Censored . . 48 37 
97 2608.000 Censored . . 48 36 
98 2609.000 Censored . . 48 35 
99 2622.000 Censored . . 48 34 
100 2634.000 Censored . . 48 33 
101 2682.000 Censored . . 48 32 
102 2693.000 Censored . . 48 31 
103 2706.000 Censored . . 48 30 
104 2717.000 Censored . . 48 29 
105 2774.000 Censored . . 48 28 
106 2788.000 Censored . . 48 27 
107 2816.000 Censored . . 48 26 
108 2816.000 Censored . . 48 25 




Status Cumulative Proportion 






Cases Estimate Std. Error 
110 2832.000 Censored . . 48 23 
111 2836.000 Censored . . 48 22 
112 2844.000 Censored . . 48 21 
113 2859.000 Censored . . 48 20 
114 2860.000 Censored . . 48 19 
115 2880.000 Censored . . 48 18 
116 2908.000 Censored . . 48 17 
117 2924.000 Censored . . 48 16 
118 2928.000 Censored . . 48 15 
119 2951.000 Censored . . 48 14 
120 2955.000 Censored . . 48 13 
121 2990.000 Censored . . 48 12 
122 3000.000 Censored . . 48 11 
123 3018.000 Censored . . 48 10 
124 3031.000 Censored . . 48 9 
125 3031.000 Censored . . 48 8 
126 3035.000 Censored . . 48 7 
127 3061.000 Censored . . 48 6 
128 3069.000 Censored . . 48 5 
129 3092.000 Censored . . 48 4 
130 3118.000 Censored . . 48 3 
131 3148.000 Censored . . 48 2 
132 3200.000 Censored . . 48 1 
133 3207.000 Censored . . 48 0 
Table 7-252 Kaplan-Meier survival analysis, gender case summary 
Gender Total N N of Events Censored 
N Percent 
Male 93 40 53 57.0% 
Female 40 8 32 80.0% 
Overall 133 48 85 63.9% 
Table 7-253 Kaplan-Meier survival table, separated for gender 
Gender Time Status Cumulative 
Proportion 










Male 1 1.000 Discontinued 0.989 0.011 1 92 
2 33.000 Discontinued 0.978 0.015 2 91 
3 68.000 Discontinued 0.968 0.018 3 90 
4 84.000 Discontinued 0.957 0.021 4 89 
5 92.000 Discontinued 0.946 0.023 5 88 
6 170.000 Discontinued 0.935 0.025 6 87 
7 182.000 Discontinued 0.925 0.027 7 86 
8 197.000 Discontinued 0.914 0.029 8 85 
9 203.000 Discontinued 0.903 0.031 9 84 
10 229.000 Discontinued 0.892 0.032 10 83 
11 282.000 Discontinued 0.882 0.033 11 82 
12 554.000 Discontinued 0.871 0.035 12 81 
13 582.000 Discontinued 0.860 0.036 13 80 
14 584.000 Discontinued 0.849 0.037 14 79 
15 703.000 Discontinued 0.839 0.038 15 78 
16 789.000 Discontinued 0.828 0.039 16 77 
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17 827.000 Discontinued 0.817 0.040 17 76 
18 833.000 Discontinued 0.806 0.041 18 75 
19 933.000 Discontinued 0.796 0.042 19 74 
20 1012.000 Discontinued 0.785 0.043 20 73 
21 1064.000 Discontinued 0.774 0.043 21 72 
22 1120.000 Discontinued 0.763 0.044 22 71 
23 1146.000 Discontinued 0.753 0.045 23 70 
24 1160.000 Discontinued 0.742 0.045 24 69 
25 1215.000 Discontinued 0.731 0.046 25 68 
26 1244.000 Discontinued 0.720 0.047 26 67 
27 1266.000 Discontinued 0.710 0.047 27 66 
28 1339.000 Discontinued 0.699 0.048 28 65 
29 1421.000 Discontinued 0.688 0.048 29 64 
30 1443.000 Discontinued 0.677 0.048 30 63 
31 1457.000 Discontinued 0.667 0.049 31 62 
32 1468.000 Discontinued 0.656 0.049 32 61 
33 1610.000 Discontinued 0.645 0.050 33 60 
34 1739.000 Discontinued 0.634 0.050 34 59 
35 1774.000 Censored . . 34 58 
36 1783.000 Discontinued 0.623 0.050 35 57 
37 1794.000 Censored . . 35 56 
38 1827.000 Censored . . 35 55 
39 1863.000 Censored . . 35 54 
40 1865.000 Censored . . 35 53 
41 1866.000 Discontinued 0.612 0.051 36 52 
42 1905.000 Censored . . 36 51 
43 1974.000 Discontinued 0.600 0.051 37 50 
44 2019.000 Censored . . 37 49 
45 2020.000 Censored . . 37 48 
46 2034.000 Censored . . 37 47 
47 2041.000 Censored . . 37 46 
48 2056.000 Discontinued 0.587 0.052 38 45 
49 2108.000 Censored . . 38 44 
50 2129.000 Censored . . 38 43 
51 2146.000 Censored . . 38 42 
52 2147.000 Censored . . 38 41 
53 2153.000 Censored . . 38 40 
54 2158.000 Censored . . 38 39 
55 2160.000 Censored . . 38 38 
56 2172.000 Discontinued 0.571 0.053 39 37 
57 2187.000 Censored . . 39 36 
58 2201.000 Censored . . 39 35 
59 2312.000 Censored . . 39 34 
60 2315.000 Censored . . 39 33 
61 2360.000 Censored . . 39 32 
62 2437.000 Censored . . 39 31 
63 2450.000 Censored . . 39 30 
64 2482.000 Censored . . 39 29 
65 2524.000 Discontinued 0.552 0.054 40 28 
66 2536.000 Censored . . 40 27 
67 2539.000 Censored . . 40 26 
68 2574.000 Censored . . 40 25 
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69 2599.000 Censored . . 40 24 
70 2608.000 Censored . . 40 23 
71 2609.000 Censored . . 40 22 
72 2634.000 Censored . . 40 21 
73 2682.000 Censored . . 40 20 
74 2693.000 Censored . . 40 19 
75 2706.000 Censored . . 40 18 
76 2717.000 Censored . . 40 17 
77 2774.000 Censored . . 40 16 
78 2788.000 Censored . . 40 15 
79 2816.000 Censored . . 40 14 
80 2829.000 Censored . . 40 13 
81 2836.000 Censored . . 40 12 
82 2844.000 Censored . . 40 11 
83 2860.000 Censored . . 40 10 
84 2924.000 Censored . . 40 9 
85 2928.000 Censored . . 40 8 
86 2951.000 Censored . . 40 7 
87 2955.000 Censored . . 40 6 
88 3000.000 Censored . . 40 5 
89 3018.000 Censored . . 40 4 
90 3031.000 Censored . . 40 3 
91 3061.000 Censored . . 40 2 
92 3069.000 Censored . . 40 1 
93 3092.000 Censored . . 40 0 
Female 1 207.000 Discontinued 0.975 0.025 1 39 
2 367.000 Discontinued 0.950 0.034 2 38 
3 565.000 Discontinued 0.925 0.042 3 37 
4 869.000 Discontinued 0.900 0.047 4 36 
5 1162.000 Discontinued 0.875 0.052 5 35 
6 1782.000 Censored . . 5 34 
7 1839.000 Censored . . 5 33 
8 1849.000 Censored . . 5 32 
9 1865.000 Censored . . 5 31 
10 1870.000 Censored . . 5 30 
11 1989.000 Censored . . 5 29 
12 2167.000 Censored . . 5 28 
13 2188.000 Discontinued 0.844 0.059 6 27 
14 2221.000 Censored . . 6 26 
15 2238.000 Censored . . 6 25 
16 2299.000 Discontinued 0.810 0.066 7 24 
17 2308.000 Censored . . 7 23 
18 2330.000 Censored . . 7 22 
19 2396.000 Censored . . 7 21 
20 2404.000 Censored . . 7 20 
21 2429.000 Censored . . 7 19 
22 2472.000 Discontinued 0.767 0.075 8 18 
23 2480.000 Censored . . 8 17 
24 2521.000 Censored . . 8 16 
25 2538.000 Censored . . 8 15 
26 2591.000 Censored . . 8 14 
27 2606.000 Censored . . 8 13 
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28 2622.000 Censored . . 8 12 
29 2816.000 Censored . . 8 11 
30 2832.000 Censored . . 8 10 
31 2859.000 Censored . . 8 9 
32 2880.000 Censored . . 8 8 
33 2908.000 Censored . . 8 7 
34 2990.000 Censored . . 8 6 
35 3031.000 Censored . . 8 5 
36 3035.000 Censored . . 8 4 
37 3118.000 Censored . . 8 3 
38 3148.000 Censored . . 8 2 
39 3200.000 Censored . . 8 1 
40 3207.000 Censored . . 8 0 
Table 7-254 Risk estimate for discontinuing clozapine 
 Value 95% Confidence Interval 
Lower Upper 
Odds Ratio for Gender (Male / Female) 0.331 0.138 0.796 
For cohort Continuer = Continuer 0.712 0.563 0.901 
For cohort Continuer = Discontinuer 2.151 1.109 4.171 
N of Valid Cases 133   
Table 7-255 Chi-square for clozapine discontinuation risk estimate 






Pearson Chi-Square 6.421 1 0.011  
Continuity Correction 5.462 1 0.019  
Likelihood Ratio 6.812 1 0.009  
Fisher's Exact Test    0.011 0.008 
Linear-by-Linear 
Association 
6.373 1 0.012  
N of Valid Cases 133  
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